# Duggan_2005_Olanzapine for schizophrenia.

Cochrane
Library

Cochrane Database of Systematic Reviews

Olanzapine for schizophrenia (Review)

Duggan L, Fenton M, Rathbone J, Dardennes R, El-Dosoky A, Indran S

Duggan L, Fenton M, Rathbone J, Dardennes R, El-Dosoky A, Indran S. 
Olanzapine for schizophrenia. 
Cochrane Database of Systematic Reviews 2005, Issue 2. Art. No.: CD001359. 
DOI: 10.1002/14651858.CD001359.pub2.

www.cochranelibrary.com

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

T A B L E   O F   C O N T E N T S

ABSTRACT.....................................................................................................................................................................................................
PLAIN LANGUAGE SUMMARY.......................................................................................................................................................................
BACKGROUND..............................................................................................................................................................................................
OBJECTIVES..................................................................................................................................................................................................
METHODS.....................................................................................................................................................................................................
RESULTS........................................................................................................................................................................................................
DISCUSSION..................................................................................................................................................................................................
AUTHORS' CONCLUSIONS...........................................................................................................................................................................
ACKNOWLEDGEMENTS................................................................................................................................................................................
REFERENCES................................................................................................................................................................................................
CHARACTERISTICS OF STUDIES..................................................................................................................................................................
DATA AND ANALYSES....................................................................................................................................................................................
Analysis  1.1.  Comparison  1  OLANZAPINE  vs  PLACEBO,  Outcome  1  Global  effect:  1.  No  important  clinical  response  -  by  6
weeks*....................................................................................................................................................................................................
Analysis  1.2.  Comparison  1  OLANZAPINE  vs  PLACEBO,  Outcome  2  Global  effect:  2.  CGI  endpoint  score  -  by  6  weeks  (high
score=poor)*..........................................................................................................................................................................................
Analysis 1.3. Comparison 1 OLANZAPINE vs PLACEBO, Outcome 3 Global effect: 3. Needing additional benzodiazepines - by six
weeks*....................................................................................................................................................................................................
Analysis  1.4.  Comparison  1  OLANZAPINE  vs  PLACEBO,  Outcome  4  Mental  state:  1.  BPRS  total  -  by  6  weeks  (endpoint,  high
score=poor)*..........................................................................................................................................................................................
Analysis  1.5.  Comparison  1  OLANZAPINE  vs  PLACEBO,  Outcome  5  Mental  state:  2.  BPRS  total  -  by  6  weeks  (endpoint,  high
score=poor, skewed data)*...................................................................................................................................................................
Analysis 1.6. Comparison 1 OLANZAPINE vs PLACEBO, Outcome 6 Mental state: 3. PANSS total - by 6 weeks (endpoint, high
score=poor)*..........................................................................................................................................................................................
Analysis 1.7. Comparison 1 OLANZAPINE vs PLACEBO, Outcome 7 Mental state: 4. Negative symptoms - by 6 months (SANS,
endpoint, high score=poor)*................................................................................................................................................................
Analysis 1.8. Comparison 1 OLANZAPINE vs PLACEBO, Outcome 8 Mental state: 5. Negative symptoms - by 6 weeks (PANSS,
endpoint, high score=poor)*................................................................................................................................................................
Analysis 1.9. Comparison 1 OLANZAPINE vs PLACEBO, Outcome 9 Mental state: 6. Negative symptoms - by 6 weeks (skewed
data)*.....................................................................................................................................................................................................
Analysis 1.10. Comparison 1 OLANZAPINE vs PLACEBO, Outcome 10 Mental state: 7. Positive symptoms - by 6 weeks (endpoint,
high score=poor, skewed data)*..........................................................................................................................................................
Analysis 1.11. Comparison 1 OLANZAPINE vs PLACEBO, Outcome 11 Mental state: 8. Positive symptoms - by 6 weeks (PANSS
endpoint, high score=poor)*................................................................................................................................................................
Analysis 1.12. Comparison 1 OLANZAPINE vs PLACEBO, Outcome 12 Leaving the study early: 1. Any reason................................
Analysis 1.13. Comparison 1 OLANZAPINE vs PLACEBO, Outcome 13 Leaving the study early: 2. Due to lack of efficacy...............
Analysis  1.14.  Comparison  1  OLANZAPINE  vs  PLACEBO,  Outcome  14  Adverse  events:  1.  Anticholinergic  effects  -  specific
symptoms by 6 weeks *........................................................................................................................................................................
Analysis  1.15.  Comparison  1  OLANZAPINE  vs  PLACEBO,  Outcome  15  Adverse  events:  2a.  Extrapyramidal  -  needing
anticholinergic medication by 6 weeks*.............................................................................................................................................
Analysis 1.16. Comparison 1 OLANZAPINE vs PLACEBO, Outcome 16 Adverse events: 2b. Extrapyramidal - specific symptoms
by 6 weeks*...........................................................................................................................................................................................
Analysis 1.17. Comparison 1 OLANZAPINE vs PLACEBO, Outcome 17 Adverse events: 2c. Extrapyramidal - specific symptoms -
by 6 weeks (various scales, skewed data)*.........................................................................................................................................
Analysis 1.18. Comparison 1 OLANZAPINE vs PLACEBO, Outcome 18 Adverse events: 3. Gastrointestinal - sickness - nausea/
vomiting - by 6 weeks*.........................................................................................................................................................................
Analysis 1.19. Comparison 1 OLANZAPINE vs PLACEBO, Outcome 19 Adverse events: 4. Other problems - by 6 weeks*...............
Analysis 1.20. Comparison 1 OLANZAPINE vs PLACEBO, Outcome 20 Adverse events: 5. Sleep problems - by 6 weeks*...............
Analysis 1.21. Comparison 1 OLANZAPINE vs PLACEBO, Outcome 21 Adverse events: 6. Weight*..................................................
Analysis 1.22. Comparison 1 OLANZAPINE vs PLACEBO, Outcome 22 Quality of Life: 1. QLS total - by six months (endpoint, high
score=good)*.........................................................................................................................................................................................
Analysis 2.1. Comparison 2 OLANZAPINE vs PLACEBO (3 to 5 days), Outcome 1 Global effect: 1. CGI severity of illness (very short
term 3-5 days, change, high=poor)......................................................................................................................................................

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

1
2
3
3
3
6
16
20
20
22
55
102
106

106

107

107

107

108

108

108

108

109

109

109
110
111

111

111

112

112

112
113
113
114

115

i

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 2.2. Comparison 2 OLANZAPINE vs PLACEBO (3 to 5 days), Outcome 2 Global effect: 2. Relapse (very short term 3-5
days).......................................................................................................................................................................................................
Analysis 2.3. Comparison 2 OLANZAPINE vs PLACEBO (3 to 5 days), Outcome 3 Mental state: 1. PANSS total (very short term 3
to 5 days, change, high score=poor)...................................................................................................................................................
Analysis 2.4. Comparison 2 OLANZAPINE vs PLACEBO (3 to 5 days), Outcome 4 Mental state: 2. Negative symptoms (very short
term 3 to 5 days, PANSS, endpoint, high score=poor).......................................................................................................................
Analysis 2.5. Comparison 2 OLANZAPINE vs PLACEBO (3 to 5 days), Outcome 5 Mental state: 3. Positive symptoms (very short
term 3 to 5 days, PANSS 3-5 days).......................................................................................................................................................
Analysis 2.6. Comparison 2 OLANZAPINE vs PLACEBO (3 to 5 days), Outcome 6 Mental state: 4. Depression (very short term 3
to 5 days, MADRS, change, high score=poor)......................................................................................................................................
Analysis 2.7. Comparison 2 OLANZAPINE vs PLACEBO (3 to 5 days), Outcome 7 Mental state: 5. Mental state (very short term 3
to 5 days, MMSE, high score=poor)......................................................................................................................................................
Analysis 2.8. Comparison 2 OLANZAPINE vs PLACEBO (3 to 5 days), Outcome 8 Leaving the study early. Any reason - by 5 days.....
Analysis  2.9.  Comparison  2  OLANZAPINE  vs  PLACEBO  (3  to  5  days),  Outcome  9  Adverse  events:  1.  Anticholinergic  effects  -
headache (very short term 3 to 5 days,)*............................................................................................................................................
Analysis 2.10. Comparison 2 OLANZAPINE vs PLACEBO (3 to 5 days), Outcome 10 Adverse events: 2. Gastrointestinal (very short
term 3 to 5 days,)*................................................................................................................................................................................
Analysis 3.1. Comparison 3 OLANZAPINE vs TYPICAL ANTIPSYCHOTICS, Outcome 1 Death: deaths during study or within 30 days
of study discontinuation.......................................................................................................................................................................
Analysis  3.2.  Comparison  3  OLANZAPINE  vs  TYPICAL  ANTIPSYCHOTICS,  Outcome  2  Global  effect:  1.  No  important  clinical
response - by 6-8 weeks.......................................................................................................................................................................
Analysis  3.3.  Comparison  3  OLANZAPINE  vs  TYPICAL  ANTIPSYCHOTICS,  Outcome  3  Global  effect:  2.  No  important  clinical
response - by 12 weeks........................................................................................................................................................................
Analysis  3.4.  Comparison  3  OLANZAPINE  vs  TYPICAL  ANTIPSYCHOTICS,  Outcome  4  Global  effect:  3.  No  important  clinical
response by 9 months..........................................................................................................................................................................
Analysis 3.5. Comparison 3 OLANZAPINE vs TYPICAL ANTIPSYCHOTICS, Outcome 5 Global effect: 4. Relapse/hospitalisation by
52 weeks*...............................................................................................................................................................................................
Analysis  3.6.  Comparison  3  OLANZAPINE  vs  TYPICAL  ANTIPSYCHOTICS,  Outcome  6  Global  effect:  5.  CGI  total  (endpoint,
high=poor).............................................................................................................................................................................................
Analysis  3.7.  Comparison  3  OLANZAPINE  vs  TYPICAL  ANTIPSYCHOTICS,  Outcome  7  Global  effect:  6.  CGI  severity  of  illness
(endpoint, high=poor, skewed data)...................................................................................................................................................
Analysis  3.8.  Comparison  3  OLANZAPINE  vs  TYPICAL  ANTIPSYCHOTICS,  Outcome  8  Mental  state:  1.  Needing  additional
benzodiazepines - by 12 weeks...........................................................................................................................................................
Analysis 3.9. Comparison 3 OLANZAPINE vs TYPICAL ANTIPSYCHOTICS, Outcome 9 Mental state: 2. BPRS total by 3 months
(endpoint, high score=poor).................................................................................................................................................................
Analysis 3.10. Comparison 3 OLANZAPINE vs TYPICAL ANTIPSYCHOTICS, Outcome 10 Mental state: 3. BPRS total (endpoint, high
score=poor, skewed data)....................................................................................................................................................................
Analysis 3.11. Comparison 3 OLANZAPINE vs TYPICAL ANTIPSYCHOTICS, Outcome 11 Mental state: 4. PANSS total (endpoint,
high score=poor)...................................................................................................................................................................................
Analysis  3.12.  Comparison  3  OLANZAPINE  vs  TYPICAL  ANTIPSYCHOTICS,  Outcome  12  Mental  state:  5.  Negative  symptoms
(PANSS, endpoint, high score=poor)...................................................................................................................................................
Analysis  3.13.  Comparison  3  OLANZAPINE  vs  TYPICAL  ANTIPSYCHOTICS,  Outcome  13  Mental  state:  6.  Negative  symptoms
(various scales, endpoint, high score=poor, skewed data)................................................................................................................
Analysis 3.14. Comparison 3 OLANZAPINE vs TYPICAL ANTIPSYCHOTICS, Outcome 14 Mental state: 7. Positive symptoms - 8
weeks (BPRS, endpoint, high score=poor)..........................................................................................................................................
Analysis  3.15.  Comparison  3  OLANZAPINE  vs  TYPICAL  ANTIPSYCHOTICS,  Outcome  15  Mental  state:  8.  Positive  symptoms
(PANSS, endpoint, high score=poor)...................................................................................................................................................
Analysis  3.16.  Comparison  3  OLANZAPINE  vs  TYPICAL  ANTIPSYCHOTICS,  Outcome  16  Mental  state:  9.  Positive  symptoms
(various scales, endpoint, high score=poor, skewed data)................................................................................................................
Analysis  3.17.  Comparison  3  OLANZAPINE  vs  TYPICAL  ANTIPSYCHOTICS,  Outcome  17  Mental  state:  10.  Depression  (MADRS,
endpoint, high score=poor, skewed data)...........................................................................................................................................
Analysis 3.18. Comparison 3 OLANZAPINE vs TYPICAL ANTIPSYCHOTICS, Outcome 18 Mental state: 11. Anxiety - by 14 weeks
(HAMA, endpoint, high score=poor, skewed data)..............................................................................................................................
Analysis 3.19. Comparison 3 OLANZAPINE vs TYPICAL ANTIPSYCHOTICS, Outcome 19 Mental state: 12. Subjective Well-Being
Under Neuroleptic Scale - by 6 weeks (high score=...........................................................................................................................
Analysis 3.20. Comparison 3 OLANZAPINE vs TYPICAL ANTIPSYCHOTICS, Outcome 20 Leaving the study early: 1a. Any reason.....

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

115

115

116

116

116

117

117
117

117

126

127

128

128

128

129

129

129

130

130

131

131

132

132

133

133

134

134

134

135

ii

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 3.21. Comparison 3 OLANZAPINE vs TYPICAL ANTIPSYCHOTICS, Outcome 21 Leaving the study early: 1b. Any reason
(Peto Odds ratio)...................................................................................................................................................................................
Analysis 3.22. Comparison 3 OLANZAPINE vs TYPICAL ANTIPSYCHOTICS, Outcome 22 Leaving the study early: 2. Due to lack of
efficacy...................................................................................................................................................................................................
Analysis 3.23. Comparison 3 OLANZAPINE vs TYPICAL ANTIPSYCHOTICS, Outcome 23 Adverse events: 1. Anticholinergic effects
- specific symptoms - by 6 to 12 weeks*.............................................................................................................................................
Analysis 3.24. Comparison 3 OLANZAPINE vs TYPICAL ANTIPSYCHOTICS, Outcome 24 Adverse events: 2a. Extrapyramidal - ESRS
- by 6 weeks (endpoint, high score=poor)...........................................................................................................................................
Analysis  3.25.  Comparison  3  OLANZAPINE  vs  TYPICAL  ANTIPSYCHOTICS,  Outcome  25  Adverse  events:  2b.  Extrapyramidal  -
needing additional anticholinergic medication*................................................................................................................................
Analysis  3.26.  Comparison  3  OLANZAPINE  vs  TYPICAL  ANTIPSYCHOTICS,  Outcome  26  Adverse  events:  2c.  Extrapyramidal  -
specific symptoms*...............................................................................................................................................................................
Analysis  3.27.  Comparison  3  OLANZAPINE  vs  TYPICAL  ANTIPSYCHOTICS,  Outcome  27  Adverse  events:  2d.  Extrapyramidal  -
specific symptoms (various scales, endpoint, skewed data)*...........................................................................................................
Analysis 3.28. Comparison 3 OLANZAPINE vs TYPICAL ANTIPSYCHOTICS, Outcome 28 Adverse events: 2e. Extrapyramidal - Van
Putten - by 6 weeks (endpoint, skewed data)....................................................................................................................................
Analysis  3.29.  Comparison  3  OLANZAPINE  vs  TYPICAL  ANTIPSYCHOTICS,  Outcome  29  Adverse  events:  2f.  Extrapyramidal  -
DIEPSS scale - by 8 weeks (endpoint, skewed data)..........................................................................................................................
Analysis 3.30. Comparison 3 OLANZAPINE vs TYPICAL ANTIPSYCHOTICS, Outcome 30 Adverse events: 3. Requiring propranolol
- by 12 weeks.........................................................................................................................................................................................
Analysis 3.31. Comparison 3 OLANZAPINE vs TYPICAL ANTIPSYCHOTICS, Outcome 31 Adverse events: 4. Adverse drug reaction,
requiring dose reduction or additional medication - by 8 weeks......................................................................................................
Analysis  3.32.  Comparison  3  OLANZAPINE  vs  TYPICAL  ANTIPSYCHOTICS,  Outcome  32  Adverse  events:  5.  Gastrointestinal  -
specific symptoms*...............................................................................................................................................................................
Analysis 3.33. Comparison 3 OLANZAPINE vs TYPICAL ANTIPSYCHOTICS, Outcome 33 Adverse events: 6. Other problems*.........
Analysis 3.34. Comparison 3 OLANZAPINE vs TYPICAL ANTIPSYCHOTICS, Outcome 34 Adverse events: 7. Sleep problems*.........
Analysis 3.35. Comparison 3 OLANZAPINE vs TYPICAL ANTIPSYCHOTICS, Outcome 35 Adverse events: 8. Sleep problems by 6
weeks (LSEQ).........................................................................................................................................................................................
Analysis  3.36.  Comparison  3  OLANZAPINE  vs  TYPICAL  ANTIPSYCHOTICS,  Outcome  36  Adverse  events:  9.  Sleep  problems,
Behaviour following waking - by 6 weeks (skewed data)..................................................................................................................
Analysis  3.37.  Comparison  3  OLANZAPINE  vs  TYPICAL  ANTIPSYCHOTICS,  Outcome  37  Adverse  events:  10.  Weight  average
increase*................................................................................................................................................................................................
Analysis  3.38.  Comparison  3  OLANZAPINE  vs  TYPICAL  ANTIPSYCHOTICS,  Outcome  38  Adverse  events:  11.  Weight:  average
increase - by 12 weeks (change data)*................................................................................................................................................
Analysis 3.39. Comparison 3 OLANZAPINE vs TYPICAL ANTIPSYCHOTICS, Outcome 39 Adverse events: 12. Weight: gain.............
Analysis 3.40. Comparison 3 OLANZAPINE vs TYPICAL ANTIPSYCHOTICS, Outcome 40 Adverse events: 13. Weight decrease - by
12 weeks................................................................................................................................................................................................
Analysis  3.41.  Comparison  3  OLANZAPINE  vs  TYPICAL  ANTIPSYCHOTICS,  Outcome  41  Adverse  events:  14.  Plasma  prolactin
levels, endpoint 6 weeks......................................................................................................................................................................
Analysis 3.42. Comparison 3 OLANZAPINE vs TYPICAL ANTIPSYCHOTICS, Outcome 42 Quality of life: endpoint - by 6 to 12 weeks
(high score=good, skewed data)..........................................................................................................................................................
Analysis 3.43. Comparison 3 OLANZAPINE vs TYPICAL ANTIPSYCHOTICS, Outcome 43 Drug compliance: DAI-30, mean change
- by 22 weeks (skewed data)................................................................................................................................................................
Analysis 4.1. Comparison 4 OLANZAPINE vs TYPICAL ANTIPSYCHOTICS FOR PEOPLE WITH TREATMENT RESISTANT ILLNESS,
Outcome 1 Global effect: 1. No important clinical response - by 8 weeks........................................................................................
Analysis 4.2. Comparison 4 OLANZAPINE vs TYPICAL ANTIPSYCHOTICS FOR PEOPLE WITH TREATMENT RESISTANT ILLNESS,
Outcome 2 Global effect: 2. CGI total - by 8 weeks (endpoint, high score=poor).............................................................................
Analysis 4.3. Comparison 4 OLANZAPINE vs TYPICAL ANTIPSYCHOTICS FOR PEOPLE WITH TREATMENT RESISTANT ILLNESS,
Outcome 3 Mental state: 1. BPRS total - by 8 weeks (endpoint score, high score=poor).................................................................
Analysis 4.4. Comparison 4 OLANZAPINE vs TYPICAL ANTIPSYCHOTICS FOR PEOPLE WITH TREATMENT RESISTANT ILLNESS,
Outcome 4 Mental state: 2. Negative symptoms - 8 weeks (SANS, endpoint, high score=poor, skewed data)................................
Analysis 4.5. Comparison 4 OLANZAPINE vs TYPICAL ANTIPSYCHOTICS FOR PEOPLE WITH TREATMENT RESISTANT ILLNESS,
Outcome 5 Mental state: 3. Positive symptoms by 8 weeks (BPRS, endpoint, high score=poor).....................................................
Analysis 4.6. Comparison 4 OLANZAPINE vs TYPICAL ANTIPSYCHOTICS FOR PEOPLE WITH TREATMENT RESISTANT ILLNESS,
Outcome 6 Leaving the study early: 1. Any reason.............................................................................................................................

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

136

137

137

139

139

140

142

143

143

144

144

144

145
146
147

147

148

148

149
149

149

150

150

152

152

152

152

153

153

iii

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 4.7. Comparison 4 OLANZAPINE vs TYPICAL ANTIPSYCHOTICS FOR PEOPLE WITH TREATMENT RESISTANT ILLNESS,
Outcome 7 Leaving the study early: 2. Due to lack of efficacy..........................................................................................................
Analysis 4.8. Comparison 4 OLANZAPINE vs TYPICAL ANTIPSYCHOTICS FOR PEOPLE WITH TREATMENT RESISTANT ILLNESS,
Outcome 8 Adverse events: 1. Anticholinergic effects - specific symptoms - by 8 weeks................................................................
Analysis 4.9. Comparison 4 OLANZAPINE vs TYPICAL ANTIPSYCHOTICS FOR PEOPLE WITH TREATMENT RESISTANT ILLNESS,
Outcome 9 Adverse effects: 2a. Extrapyramidal - specific symptoms - by 8 weeks..........................................................................
Analysis 4.10. Comparison 4 OLANZAPINE vs TYPICAL ANTIPSYCHOTICS FOR PEOPLE WITH TREATMENT RESISTANT ILLNESS,
Outcome 10 Adverse effects: 2b. Extrapyramidal - specific symptoms - by 8 weeks (various scales, endpoint, high=poor, ske.......
Analysis 4.11. Comparison 4 OLANZAPINE vs TYPICAL ANTIPSYCHOTICS FOR PEOPLE WITH TREATMENT RESISTANT ILLNESS,
Outcome 11 Adverse effects: 3. Gastrointestinal - nausea / vomiting - by 8 weeks..........................................................................
Analysis 4.12. Comparison 4 OLANZAPINE vs TYPICAL ANTIPSYCHOTICS FOR PEOPLE WITH TREATMENT RESISTANT ILLNESS,
Outcome 12 Adverse events: 4. Sleep problems - by 8 weeks...........................................................................................................
Analysis 5.1. Comparison 5 OLANZAPINE vs ATYPICAL ANTIPSYCHOTICS, Outcome 1 Death..........................................................
Analysis 5.2. Comparison 5 OLANZAPINE vs ATYPICAL ANTIPSYCHOTICS, Outcome 2 Global effect: 1. No clinically important
response.................................................................................................................................................................................................
Analysis 5.3. Comparison 5 OLANZAPINE vs ATYPICAL ANTIPSYCHOTICS, Outcome 3 Global effect: 2. Relapse/hospitalisation
by 52 weeks...........................................................................................................................................................................................
Analysis 5.4. Comparison 5 OLANZAPINE vs ATYPICAL ANTIPSYCHOTICS, Outcome 4 Global effect: 3. CGI total by 3 -12 months
(endpoint, high score=poor).................................................................................................................................................................
Analysis  5.5.  Comparison  5  OLANZAPINE  vs  ATYPICAL  ANTIPSYCHOTICS,  Outcome  5  Mental  state:  1a.  Needing  addtional
benzodiazepines....................................................................................................................................................................................
Analysis 5.6. Comparison 5 OLANZAPINE vs ATYPICAL ANTIPSYCHOTICS, Outcome 6 Mental state: 1b. Needing antidepressants
by 2 years...............................................................................................................................................................................................
Analysis  5.7.  Comparison  5  OLANZAPINE  vs  ATYPICAL  ANTIPSYCHOTICS,  Outcome  7  Mental  state:  2.  No  important  clinical
response (decrease in PANSS total score)...........................................................................................................................................
Analysis  5.8.  Comparison  5  OLANZAPINE  vs  ATYPICAL  ANTIPSYCHOTICS,  Outcome  8  Mental  state:  3.  No  important  clinical
response (decrease in BPRS total score).............................................................................................................................................
Analysis  5.9.  Comparison  5  OLANZAPINE  vs  ATYPICAL  ANTIPSYCHOTICS,  Outcome  9  Mental  state:  4.  BPRS  total  at  8  weeks
(endpoint, high score=worse)..............................................................................................................................................................
Analysis 5.10. Comparison 5 OLANZAPINE vs ATYPICAL ANTIPSYCHOTICS, Outcome 10 Mental state: 5. BPRS total at 3-12 months
(endpoint, high score=poor, skewed data).........................................................................................................................................
Analysis 5.11. Comparison 5 OLANZAPINE vs ATYPICAL ANTIPSYCHOTICS, Outcome 11 Mental state: 6. PANSS total (endpoint,
high score=poor)...................................................................................................................................................................................
Analysis  5.12.  Comparison  5  OLANZAPINE  vs  ATYPICAL  ANTIPSYCHOTICS,  Outcome  12  Mental  state:  7.  Negative  symptoms
(PANSS, endpoint, high score=poor)...................................................................................................................................................
Analysis  5.13.  Comparison  5  OLANZAPINE  vs  ATYPICAL  ANTIPSYCHOTICS,  Outcome  13  Mental  state:  8.  Negative  symptoms
(various scales, endpoint, high score=poor, skewed data)................................................................................................................
Analysis  5.14.  Comparison  5  OLANZAPINE  vs  ATYPICAL  ANTIPSYCHOTICS,  Outcome  14  Mental  state:  9.  Negative  symptoms
change data at 6 months (SANS, high score=poor)............................................................................................................................
Analysis  5.15.  Comparison  5  OLANZAPINE  vs  ATYPICAL  ANTIPSYCHOTICS,  Outcome  15  Mental  state:  10.  Positive  symptoms
(PANSS, endpoint, high score=poor)...................................................................................................................................................
Analysis  5.16.  Comparison  5  OLANZAPINE  vs  ATYPICAL  ANTIPSYCHOTICS,  Outcome  16  Mental  state:  11.  Positive  symptoms
(various scales, endpoint, high score=poor, skewed data)................................................................................................................
Analysis 5.17. Comparison 5 OLANZAPINE vs ATYPICAL ANTIPSYCHOTICS, Outcome 17 Mental state: 12. Depression - by 8 weeks
(Hamilton or MADRS rating scale, high score=poor, skewed data)....................................................................................................
Analysis 5.18. Comparison 5 OLANZAPINE vs ATYPICAL ANTIPSYCHOTICS, Outcome 18 Mental state: 13. Depression - by 18 weeks
(MADRS, high score=poor, skewed data).............................................................................................................................................
Analysis 5.19. Comparison 5 OLANZAPINE vs ATYPICAL ANTIPSYCHOTICS, Outcome 19 Leaving the study early: 1. Any reason.....
Analysis 5.20. Comparison 5 OLANZAPINE vs ATYPICAL ANTIPSYCHOTICS, Outcome 20 Leaving the study early: 2. Due to lack
of efficacy...............................................................................................................................................................................................
Analysis 5.21. Comparison 5 OLANZAPINE vs ATYPICAL ANTIPSYCHOTICS, Outcome 21 Adverse events: 1. Anticholinergic effects
- specific symptoms..............................................................................................................................................................................
Analysis 5.22. Comparison 5 OLANZAPINE vs ATYPICAL ANTIPSYCHOTICS, Outcome 22 Adverse events: 2a. Extrapyramidal -
needing anticholinergic medication....................................................................................................................................................
Analysis 5.23. Comparison 5 OLANZAPINE vs ATYPICAL ANTIPSYCHOTICS, Outcome 23 Adverse events: 2b. Extrapyramidal -
any..........................................................................................................................................................................................................

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

153

154

155

155

155

156

165
165

166

166

166

167

167

168

169

169

169

170

170

170

171

171

172

172

172
173

174

176

177

iv

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 5.24. Comparison 5 OLANZAPINE vs ATYPICAL ANTIPSYCHOTICS, Outcome 24 Adverse events: 2c. Extrapyramidal -
parkinsonism ESRS (endpoint, high score=poor, skewed data)........................................................................................................
Analysis 5.25. Comparison 5 OLANZAPINE vs ATYPICAL ANTIPSYCHOTICS, Outcome 25 Adverse events: 2d. Extrapyramidal -
specific symptoms................................................................................................................................................................................
Analysis 5.26. Comparison 5 OLANZAPINE vs ATYPICAL ANTIPSYCHOTICS, Outcome 26 Adverse events: 3. Treatment emergent
adverse events -by 4 to 8 weeks..........................................................................................................................................................
Analysis 5.27. Comparison 5 OLANZAPINE vs ATYPICAL ANTIPSYCHOTICS, Outcome 27 Adverse events: 4. Other:.......................
Analysis 5.28. Comparison 5 OLANZAPINE vs ATYPICAL ANTIPSYCHOTICS, Outcome 28 Adverse events: 8. Simpson and Angus
Scale - by 2 months (endpoint, high score=poor, skewed data)........................................................................................................
Analysis 5.29. Comparison 5 OLANZAPINE vs ATYPICAL ANTIPSYCHOTICS, Outcome 29 Adverse events: 9. Yale Brown Obsessive
Compulsive Scale - by 6 weeks (endpoint, high score=poor, skewed da..........................................................................................
Analysis 5.30. Comparison 5 OLANZAPINE vs ATYPICAL ANTIPSYCHOTICS, Outcome 30 Adverse events: 10. Sleep problems.......
Analysis 5.31. Comparison 5 OLANZAPINE vs ATYPICAL ANTIPSYCHOTICS, Outcome 31 Adverse events: 6. Weight gain..............
Analysis 5.32. Comparison 5 OLANZAPINE vs ATYPICAL ANTIPSYCHOTICS, Outcome 32 Adverse events: 7. Weight gain..............
Analysis 5.33. Comparison 5 OLANZAPINE vs ATYPICAL ANTIPSYCHOTICS, Outcome 33 Adverse events: 8. Weight - by 8 weeks
(change data).........................................................................................................................................................................................
Analysis 5.34. Comparison 5 OLANZAPINE vs ATYPICAL ANTIPSYCHOTICS, Outcome 34 Quality of life: 1. QOL total - by 3 to 12
months(endpoint, high score=good)...................................................................................................................................................
Analysis 5.35. Comparison 5 OLANZAPINE vs ATYPICAL ANTIPSYCHOTICS, Outcome 35 Quality of life: 2. QLS total by 3 to 12
months (endpoint, high score=good)..................................................................................................................................................
Analysis  5.36.  Comparison  5  OLANZAPINE  vs  ATYPICAL  ANTIPSYCHOTICS,  Outcome  36  Service  outcome:1.  Discharged  from
hospital - by 8 weeks............................................................................................................................................................................
Analysis 5.37. Comparison 5 OLANZAPINE vs ATYPICAL ANTIPSYCHOTICS, Outcome 37 Service outcome: 2. Hospitalisation for
imminent risk of suicide - by 2 years..................................................................................................................................................
Analysis 5.38. Comparison 5 OLANZAPINE vs ATYPICAL ANTIPSYCHOTICS, Outcome 38 Service outcome: 3. Increase in level of
surveillance - by two years...................................................................................................................................................................
Analysis 6.1. Comparison 6 OLANZAPINE vs ATYPICAL ANTIPSYCHOTICS FOR PEOPLE WITH TREATMENT RESISTANT ILLNESS,
Outcome 1 Death - by 18 weeks..........................................................................................................................................................
Analysis 6.2. Comparison 6 OLANZAPINE vs ATYPICAL ANTIPSYCHOTICS FOR PEOPLE WITH TREATMENT RESISTANT ILLNESS,
Outcome 2 Global effect: No clinically important response - by 18 weeks.......................................................................................
Analysis 6.3. Comparison 6 OLANZAPINE vs ATYPICAL ANTIPSYCHOTICS FOR PEOPLE WITH TREATMENT RESISTANT ILLNESS,
Outcome 3 Mental state: 1. No important clinical response - by 18 weeks (20% decrease in PANSS).............................................
Analysis 6.4. Comparison 6 OLANZAPINE vs ATYPICAL ANTIPSYCHOTICS FOR PEOPLE WITH TREATMENT RESISTANT ILLNESS,
Outcome 4 Mental state: 2. BPRS total - by 18 weeks (endpoint, high score=poor, skewed data)...................................................
Analysis 6.5. Comparison 6 OLANZAPINE vs ATYPICAL ANTIPSYCHOTICS FOR PEOPLE WITH TREATMENT RESISTANT ILLNESS,
Outcome 5 Mental state: 3. PANSS total - by 18 weeks (endpoint, high score=poor).......................................................................
Analysis 6.6. Comparison 6 OLANZAPINE vs ATYPICAL ANTIPSYCHOTICS FOR PEOPLE WITH TREATMENT RESISTANT ILLNESS,
Outcome 6 Mental state: 4. Negative symptoms - by 18 weeks (BPRS, endpoint, high score=poor, skewed data).........................
Analysis 6.7. Comparison 6 OLANZAPINE vs ATYPICAL ANTIPSYCHOTICS FOR PEOPLE WITH TREATMENT RESISTANT ILLNESS,
Outcome 7 Mental state: 5. Negative symptoms - by 18 weeks (PANSS, endpoint, high score=poor).............................................
Analysis 6.8. Comparison 6 OLANZAPINE vs ATYPICAL ANTIPSYCHOTICS FOR PEOPLE WITH TREATMENT RESISTANT ILLNESS,
Outcome 8 Mental state: 6. Positive symptoms - by 18 weeks (BPRS, endpoint, high score=poor, skewed data)...........................
Analysis 6.9. Comparison 6 OLANZAPINE vs ATYPICAL ANTIPSYCHOTICS FOR PEOPLE WITH TREATMENT RESISTANT ILLNESS,
Outcome 9 Leaving the study early. Any reason.................................................................................................................................
Analysis 6.10. Comparison 6 OLANZAPINE vs ATYPICAL ANTIPSYCHOTICS FOR PEOPLE WITH TREATMENT RESISTANT ILLNESS,
Outcome 10 Leaving the study early. due to lack of efficacy - by 18 weeks.....................................................................................
Analysis 6.11. Comparison 6 OLANZAPINE vs ATYPICAL ANTIPSYCHOTICS FOR PEOPLE WITH TREATMENT RESISTANT ILLNESS,
Outcome 11 Adverse events: 1. HAS - by 18 weeks (change, high score=poor)................................................................................
Analysis 6.12. Comparison 6 OLANZAPINE vs ATYPICAL ANTIPSYCHOTICS FOR PEOPLE WITH TREATMENT RESISTANT ILLNESS,
Outcome 12 Adverse events: 2. AIMS - by 18 weeks (change, high score=poor)...............................................................................
Analysis 6.13. Comparison 6 OLANZAPINE vs ATYPICAL ANTIPSYCHOTICS FOR PEOPLE WITH TREATMENT RESISTANT ILLNESS,
Outcome 13 Adverse events: 3. Simpson and Angus Scale - by 18 weeks (change, high score=poor).............................................
Analysis 6.14. Comparison 6 OLANZAPINE vs ATYPICAL ANTIPSYCHOTICS FOR PEOPLE WITH TREATMENT RESISTANT ILLNESS,
Outcome 14 Adverse events: 4. Anticholinergic effects - by 18 weeks..............................................................................................
Analysis 6.15. Comparison 6 OLANZAPINE vs ATYPICAL ANTIPSYCHOTICS FOR PEOPLE WITH TREATMENT RESISTANT ILLNESS,
Outcome 15 Adverse events: 5. Extrapyramidal - by 18 weeks..........................................................................................................

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

177

178

179

179
184

184

184
185
186
187

187

187

187

188

188

191

191

192

192

192

193

193

193

193

194

194

194

195

195

196

v

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 6.16. Comparison 6 OLANZAPINE vs ATYPICAL ANTIPSYCHOTICS FOR PEOPLE WITH TREATMENT RESISTANT ILLNESS,
Outcome 16 Adverse events: Other - by 18 weeks.............................................................................................................................
Analysis 7.1. Comparison 7 OLANZAPINE vs ATYPICAL ANTIPSYCHOTICS FOR FIRST EPISODE, Outcome 1 Mental state: 1. No
important clinical response - by 6 weeks (50% decrease in PANSS total score)...............................................................................
Analysis 7.2. Comparison 7 OLANZAPINE vs ATYPICAL ANTIPSYCHOTICS FOR FIRST EPISODE, Outcome 2 Adverse events: 1.
Extrapyramidal - needing anticholinergic medication - by 6 weeks..................................................................................................
Analysis 7.3. Comparison 7 OLANZAPINE vs ATYPICAL ANTIPSYCHOTICS FOR FIRST EPISODE, Outcome 3 Adverse events: 2.
Exprapyramidal - any - by 6 weeks......................................................................................................................................................
Analysis 7.4. Comparison 7 OLANZAPINE vs ATYPICAL ANTIPSYCHOTICS FOR FIRST EPISODE, Outcome 4 Adverse events: 3.
Anticholinergic effects - rhinitis - by 6 weeks.....................................................................................................................................
Analysis 7.5. Comparison 7 OLANZAPINE vs ATYPICAL ANTIPSYCHOTICS FOR FIRST EPISODE, Outcome 5 Adverse events: 4.
hyperprolactinaemia - by 6 weeks......................................................................................................................................................
ADDITIONAL TABLES....................................................................................................................................................................................
WHAT'S NEW.................................................................................................................................................................................................
HISTORY........................................................................................................................................................................................................
CONTRIBUTIONS OF AUTHORS...................................................................................................................................................................
DECLARATIONS OF INTEREST.....................................................................................................................................................................
SOURCES OF SUPPORT...............................................................................................................................................................................
NOTES...........................................................................................................................................................................................................
INDEX TERMS...............................................................................................................................................................................................

197

199

200

200

200

200

201
202
202
202
203
203
203
203

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

vi

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

[Intervention Review]

Olanzapine for schizophrenia

Cochrane Database of Systematic Reviews

Lorna Duggan1, Mark Fenton2, John Rathbone3, Roland Dardennes4, Ahmed El-Dosoky5, Saroja Indran6

1Kneeswork House Hosptial, Herts, UK. 2Database of Uncertainties about the Effects of Treatments (DUETs), National Institute for Health
and Clinical Excellence, Manchester, UK. 3HEDS, ScHARR, The University of Sheffield, Sheffield, UK. 4Clinique des Maladies Mentales et de
l'Encephale, Universite Rene Descartes (Paris V), Paris, France. 5The Behman Hospital, Cairo, Egypt. 6Department of Psychiatry, Faculty
of Medicine, University Kebangsaan Malaysia, Kuala Lumpur, Malaysia

Contact: Lorna Duggan, Kneeswork House Hosptial, Partnership in Care, Bassingbourn, Herts, SG8 5JP, UK. lornaduggan@yahoo.co.uk,
lorna.duggan@partnershipsincare.co.uk.

Editorial group: Cochrane Schizophrenia Group.
Publication status and date: Edited (no change to conclusions), published in Issue 1, 2013.

Citation:  Duggan L, Fenton M, Rathbone J, Dardennes R, El-Dosoky A, Indran S. Olanzapine for schizophrenia. Cochrane Database of
Systematic Reviews 2005, Issue 2. Art. No.: CD001359. DOI: 10.1002/14651858.CD001359.pub2.

Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Background

A B S T R A C T

Olanzapine is an atypical antipsychotic reported to be effective without producing disabling extrapyramidal adverse effects associated
with older, typical antipsychotic drugs.

Objectives

To  determine  the  clinical  effects  and  safety  of  olanzapine  compared  with  placebo,  typical  and  other  atypical  antipsychotic  drugs  for
schizophrenia and schizophreniform psychoses.

Search methods

We  updated  the  first  search  [Biological  Abstracts  (1980-1999),  The  Cochrane  Library  (Issue  2,  1999),  EMBASE  (1980-1999),  MEDLINE
(1966-1999), PsycLIT (1974-1999) and The Cochrane Schizophrenia Group's Register (October 2000)] in October 2004 using the Cochrane
Schizophrenia's Group's register of trials. We also searched references of all included studies for further trials, and contacted relevant
pharmaceutical companies and authors.

Selection criteria

We included all randomised clinical trials comparing olanzapine with placebo or any antipsychotic treatment for people with schizophrenia
or schizophreniform psychoses.

Data collection and analysis

We  independently  extracted  data  and,  for  homogeneous  dichotomous  data,  calculated  the  random  effects  relative  risk  (RR),  the  95%
confidence intervals (CI) and the number needed to treat (NNT) on an intention-to-treat basis. For continuous data we calculated weighted
mean differences.

Main results

Fifty five trials are included (total n>10000 people with schizophrenia). Attrition from olanzapine versus placebo studies was >50% by
six weeks, leaving interpretation of results problematic. Olanzapine appeared superior to placebo at six weeks for the outcome of 'no
important clinical response' (any dose, 2 RCTs n=418, RR 0.88 CI 0.8 to 0.1, NNT 8 CI 5 to 27). Although dizziness and dry mouth were reported
more frequently in the olanzapine-treated group, this did not reach statistical significance. The olanzapine group gained more weight.

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

1

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

When compared with typical antipsychotic drugs, data from several small trials are incomplete. With high attrition in both groups (14
RCTs, n=3344, 38% attrition by six weeks, RR 0.81 CI 0.65 to 1.02) the assumptions included in all data are considerable. For the short
term outcome of 'no important clinical response', olanzapine seems as effective as typical antipsychotics (4 RCTs, n=2778, RR 0.90 CI 0.76
to 1.06). People allocated olanzapine experienced fewer extrapyramidal adverse effects than those given typical antipsychotics. Weight
change data for the short term are not statistically significant but results between three to 12 months suggest a clinically important average
gain of four kilograms for people given olanzapine (4 RCTs, n=186, WMD 4.62, CI 0.6 to 8.64).

Twenty three percent of people in trials of olanzapine and other atypical drugs left by eight weeks; 48% by three to12 months (11 RCTs,
n=1847, RR 0.91 CI 0.82 to 1.00). There is little to choose between the atypicals, although olanzapine may cause fewer extrapyramidal
adverse  effects  than  other  drugs  in  this  category.  Olanzapine  produces  more  weight  gain  than  other  atypicals  with  some  differences
reaching conventional levels of statistical significance (1 RCT, n=980, RR gain at 2 years 1.73 CI 1.49 to 2.00, NNH 5 CI 4 to 7). There are very
few data for people with first episode illness (1 RCT, duration 6 weeks, n=42). For people with treatment-resistant illness there were no
clear differences between olanzapine and clozapine (4 RCTs, n=457).

Authors' conclusions

The large proportion of participants leaving studies early in these trials makes it difficult to draw firm conclusions on olanzapine's clinical
effects. For people with schizophrenia it may offer antipsychotic efficacy with fewer extrapyramidal adverse effects than typical drugs, but
more weight gain. There is a need for further large, long-term randomised trials with more comprehensive data.

P L A I N   L A N G U A G E   S U M M A R Y

Olanzapine for schizophrenia

Since  the  early  1950s  the  mainstay  of  treatment  for  schizophrenia  has  been  the  typical  antipsychotics  such  as  chlorpromazine  and
haloperidol. Although they are effective in controlling voices and delusions for many people with schizophrenia, they have a smaller effect
on symptoms such as apathy and social withdrawal. They also have disabling adverse effects such as tremor, stiffness and slowing of
movement. The newer drugs, such as olanzapine, are reputed to have fewer adverse motor effects and are as effective, if not more so,
than the older drugs. This review examines the randomised controlled trials of olanzapine compared with placebo, typical and atypical
antipsychotic drugs.

Most of the studies in this review were either sponsored by or run by the pharmaceutical companies responsible for the marketing of these
drugs. Olanzapine seems to be an effective antipsychotic that produces less adverse effects for movement. It does however tend to cause
more weight gain than the older drugs. Its effectiveness appears similar to other atypical drugs and it is not markedly beneficial for apathy,
demotivation and social withdrawal.

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

2

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

B A C K G R O U N D

M E T H O D S

Antipsychotic  drugs  have  been  the  mainstay  of  treatment  for
schizophrenia since the 1950s. These conventional antipsychotics
are  largely  effective  against  the  'positive'  symptoms  such  as
fixed  false  beliefs  (delusions)  and  perceptions  without  a  cause
(hallucinations).  They  seem  relatively  ineffective  against  the
'negative' symptoms of schizophrenia (apathy, slowing and paucity
of movement and thought). It is believed that the conventional or
'typical' antipsychotics exert their antipsychotic effect by blocking
specific  sites  in  the  brain  (dopamine  D2  receptors  -  Seeman
1987).  However,  this  D2  blockade  is  also  responsible  for  the
occurrence of extrapyramidal symptoms, such as stiffness, tremor,
repetitive movements (parkinsonism), that may contribute to poor
compliance with medication.

The  search  for  antipsychotic  agents  to  manage  both  'positive'
and  'negative'  symptoms  has  produced  a  class  of  drugs  called
'atypical' antipsychotics. These compounds, including olanzapine,
are  purported  to  have  addressed  the  limitations  of  traditional
antipsychotics by promising better efficacy and/or adverse effect
profiles (McEwan 1993, Anonymous 1997).

research  suggests 

the  pathophysiology  of

Technical background
Recent 
that 
schizophrenia  is  likely  to  be  heterogeneous  and  may  involve
neurotransmitter systems other than D2 receptors. Tamminga 1998,
Lieberman 1998 suggested that the addition of 5-HT2 antagonists,
for  example  ritanserin,  to  traditional  anti  dopamine-D2  drug
therapy improved negative symptoms and attenuate pre-existing
drug-induced extrapyramidal effects (Tamminga 1998, Lieberman
1998).

Olanzapine,  a  thienobenzodiazepine  derivative,  is  an  'atypical'
antipsychotic  showing  affinity  at  D1-D5,  serotinergic  (5HT2,3,6),
muscarinic (subtypes 1-5), adrenergic (alpha 1-2) and histaminergic
(H1) binding sites (Conley 1998, Tollefson 1997(HGAJ), Reus 1997,
Anonymous 1997). It is structurally similar to clozapine but has a
slightly  different  binding  site  affinity.  It  is  weaker  than  clozapine
as an alpha-1 and alpha-2 adrenergic agonist relative to D2, D4 or
5HT2a antagonism.

O B J E C T I V E S

The  primary  objective  of  this  review 
is  to  determine  the
clinical  effects  of  olanzapine  compared  with  placebo,  typical
antipsychotic agents, and other atypical antipsychotics, for treating
schizophrenia and related psychoses.

As secondary objectives, we also investigated:
1.  whether  people  with  schizophrenia  described  as  'treatment
resistant'  differed  in  their  treatment  response  from  those  whose
illness was not classified as such
2.  whether  people  having  predominantly  negative  symptoms  of
schizophrenia  were  more  responsive  to  olanzapine  than  those
without this classification
3. whether people experiencing their first episode of a psychotic
illness differed in response from those with a previous history.

Criteria for considering studies for this review

Types of studies

We included all relevant randomised controlled trials. Where a trial
was  described  as  'double-blind',  but  it  was  only  implied  that  the
study  was  randomised,  these  trials  were  included  in  a  sensitivity
analysis.  If  there  was  no  substantive  difference  within  primary
outcomes  (see  types  of  outcome  measures)  when  these  'implied
randomisation'  studies  were  added,  then  they  were  included  in
the final analysis. If there was a substantive difference, only clearly
randomised  trials  were  used  and  the  results  of  the  sensitivity
analysis  described  in  the  text.  Quasi-randomised  studies,  such
as  those  allocating  by  using  alternate  days  of  the  week,  were
excluded.

Types of participants

included 

schizophrenia 

people  with 

other
We 
types  of  schizophrenia-like  psychoses  (schizophreniform  and
schizoaffective  disorders).  There 
is  no  clear  evidence  that
the  schizophrenia-like  psychoses  are  caused  by  fundamentally
different  disease  processes  or  require  different  treatment
approaches (Carpenter 1994).

and 

Types of interventions

1. Olanzapine: any dose
2. Any other antipsychotic agent, divided into typical and atypical
3. Placebo.

Types of outcome measures

Outcomes  were  divided  into  short-term  (less  than  three  months)
medium term (three to 12 months) and long term (over one year).

Primary outcomes

1. Clinical response
1.1 No clinically significant response in global state - as defined by
each of the studies

Secondary outcomes

1. Death, by suicide or natural causes

2. Leaving the study early

3. Clinical response
3.1 Average score/change in global state
3.2 No clinically significant response on psychotic symptoms - as
defined by each of the studies
3.3 Average score/change on psychotic symptoms
3.4  No  clinically  significant  response  on  positive  symptoms  -  as
defined by each of the studies
3.5 Average score/change in positive symptoms
3.6  No  clinically  significant  response  on  negative  symptoms  -  as
defined by each of the studies
3.7 Average score/change in negative symptoms
3.8 Use of additional medication (other than anticholinergics) for
psychiatric symptoms

4. Extrapyramidal adverse effects
4.1 Incidence of use of antiparkinson drugs

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

3

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

4.2  No  clinically  significant  extrapyramidal  adverse  effects  -  as
defined by each of the studies
4.3 Average score/change in extrapyramidal adverse effects

2.5. We searched MEDLINE (Jan 1966 - September 1999) using the
Cochrane Schizophrenia Group's phrase for randomised controlled
trials and schizophrenia (see Group search strategy) combined with
the phrase:

5. Other adverse effects, general and specific

6. Service utilization outcomes
6.1 Hospital admission
6.2 Days in hospital

7. Economic outcomes

8. Quality of life/satisfaction with care for either recipients of care
or carers
8.1. Significant change in quality of life/satisfaction - as defined by
each of the studies
8.2 Average score/change in quality of life/satisfaction

Search methods for identification of studies

Electronic searches

1. Electronic searching for update (October 2004)

1.1.  We  searched  the  Cochrane  Schizophrenia  Group's  Register
(October 2004) with the phrase:

[olanzapine*  or  Zyprexa*  in  title  or  *olanzapine*  or  *zyprexa*
in  abstract,  index  terms  of  REFERENCE]  or  [olanzapine*  in
interventions of STUDY]

The  Schizophrenia  Groups  trials  register  is  based  on  regular
searches  of  BIOSIS  Inside;  CENTRAL;  CINAHL;  EMBASE;  MEDLINE
and  PsycINFO;  the  hand  searching  of  relevant  journals  and
conference proceedings, and searches of several key grey literature
sources. A full description is given in the Group's module.

2. Details of previous searches:

2.1.  We  searched  the  Cochrane  Schizophrenia  Group's  Register
(October 2000) using the phrase:

[and (zyprex* or olanzapine*)]

2.6. We searched PsycLIT (Jan 1974 - June 1999) using the Cochrane
Schizophrenia  Group's  phrase  for  randomised  controlled  trials
and schizophrenia (see Group search strategy) combined with the
phrase:

[and (zyprex* or olanzapine*)]

3. Conference abstracts:
3.1  the  American  Psychiatric  Association  (1998)  conference,
XXIst  Collegium  Internationale  Neuro-psychopharmacologicum
(Glasgow, Scotland - July 1998)

3.2  the  11th  European  College  of  Neuropsychopharmacology
Congress (Paris, France, October 31 - November 4, 1998)

3.3 We searched the World Psychiatric Association (1999) Abstracts
of the XI World Congress of Psychiatry (Hamburg, Germany - August
6-11, 1999) using the phrase:

[olanzapine and randomi*]

Searching other resources

1. Reference lists
We searched all references of articles selected for further relevant
trials.

2. Authors of studies
We  contacted  authors  of  studies  when  necessary  to  clarify  data,
and requested additional studies.

3. Pharmaceutical company
We contacted Eli Lilly to obtain unpublished data and unpublished
trials.

[zyprex* or olanzapine* or #42 = 427]

Data collection and analysis

(#42 is the field within this Register in which each intervention is
coded and 427 is olanzapine.)

2.2.  We  searched  the  Cochrane  Library  (June  1999)  using  the
phrase:

[zyprex* or olanzapine*]

2.3.  We  searched  biological  Abstracts  (Jan  1980  -  June  1999)
using the Cochrane Schizophrenia Group's phrase for randomised
controlled  trials  and  schizophrenia  (see  Group  search  strategy)
combined with the phrase:

[and (zyprex* or olanzapine*)]

2.4. We searched EMBASE (Jan 1980 - July 1999) using the Cochrane
Schizophrenia  Group's  phrase  for  randomised  controlled  trials
and schizophrenia (see Group search strategy) combined with the
phrase:

[and  (zyprex*  or  olanzapine*  or  explode  "OLANZAPINE"/  all
subheadings)]

[For  definitions  of  terms  used  in  this,  and  other  sections,  please
refer to the Glossary]

1. Selection of studies
We  (LD,  MF)  independently  inspected  all  reports  of  identified
studies.  It  was  usually  possible  to  resolve  any  disagreement  by
consensus;  however,  where  doubt  remained  we  acquired  the
full  article.  We  independently  decided  whether  these  met  the
review  criteria.  No  blinding  to  the  names  of  authors,  institutions
and  journal  of  publication  took  place.  Again,  we  resolved  any
disagreements  by  consensus.  When  this  proved  impossible,  we
sought further information and, in the interim, added these trials
to  the  'Awaiting  assessment'  list.  LD,  MF  and  JR  independently
inspected  citations  from  the  subsequent  updated  search  (2004)
and identified relevant abstracts. We obtained and inspected full
reports of the abstracts meeting the review criteria.

2. Assessment of methodological quality
We  allocated  trials  to  three  quality  categories,  as  described  in
the  Cochrane  Collaboration  guidelines  (Alderson  2004).  We  only
included trials in Category A or B in the review.

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

4

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

3. Data management
3.1 Data extraction
We  independently  extracted  data  and  resolved  disagreement
by  discussion.  When  this  was  not  possible  we  sought  further
information from trial authors.

3.2 Intention to treat analysis
Where  possible  we  analysed  data  on  an  intention-to-treat  basis
and  assumed  that  those  who  had  not  been  accounted  for  had
the less positive outcome. This rule did not include the outcome
of  'death'.  We  tested  this  assumption  with  a  sensitivity  analysis.
For  continuous  data  it  is  impossible  to  manage  the  data  in  this
way therefore we presented 'completer' data. Where feasible, we
converted continuous scores to dichotomous data.

If,  for  a  given  outcome,  more  than  50%  of  the  total  numbers
randomised were not accounted for, we did not present results as
such  data  are  impossible  to  interpret  with  authority.  If,  however,
more than 50% of those in one arm of a study were lost, but the
total loss was less than 50%, we marked data with '*' to indicate the
result may well be prone to bias.

4. Data analysis
4.1 Binary data
When  summation  was  appropriate,  with  binary  outcomes  such
as  improved/not  improved,  we  calculated  the  relative  risk  (RR)
statistic  with  a  95%  confidence  interval  (CI)  and  used  a  random
effects model. In addition, as a measure of efficiency, we estimated
the number needed to treat (NNT) or the number needed to harm
(NNH) from the pooled totals.

4.2 Continuous data
4.2.1 Normally distributed data
Continuous  data  on  clinical  and  social  outcomes  are  often  not
normally  distributed.  To  avoid  the  pitfall  of  applying  parametric
tests to non-parametric data, we applied the following standards
to  all  data  before  inclusion:  (a)  standard  deviations  and  means
were reported in the paper or were obtainable from the authors;
(b) when a scale started from the finite number zero, the standard
deviation,  when  multiplied  by  two,  was  less  than  the  mean  (as
otherwise the mean is unlikely to be an appropriate measure of the
centre of the distribution, (Altman 1996); (c) if a scale started from
a positive value (such as PANSS which can have values from 30 to
210) the calculation described above was modified to take the scale
starting point into account. In these cases skew is present if 2SD>(S-
Smin), where S is the mean score and Smin is the minimum score.
Endpoint scores on scales often have a finite start and end point
and  these  rules  can  be  applied  to  them.  When  continuous  data
are  presented  on  a  scale  which  includes  a  possibility  of  negative
values  (such  as  change  on  a  scale),  it  is  difficult  to  tell  whether
data  are  non-normally  distributed  (skewed)  or  not.  Skewed  data
are presented in the 'Other data' tables rather than included in the
analysis.

For  change  data  (endpoint  minus  baseline),  the  situation  is  even
more  problematic.  In  the  absence  of  individual  patient  data
it  is  impossible  to  know  if  data  are  skewed,  though  this  is
likely.  After  consulting  the  ALLSTAT  electronic  statistics  mailing
list,  we  presented  change  data  in  order  to  summarise  available
information. In doing this, it was assumed either that data were not
skewed or that the analyses could cope with the unknown degree
of skew. Again, without individual patient data it is impossible to
test this assumption. Where both change and endpoint data were

Cochrane Database of Systematic Reviews

available for the same outcome category, we have presented only
endpoint  data.  We  acknowledge  that  by  doing  this,  much  of  the
published change data could have been excluded, but argue that
endpoint  data  is  more  clinically  relevant  and  that  if  change  data
were to be presented along with endpoint data, it would be given
undeserved  equal  prominence.  We  contacted  authors  of  studies
that only reported change for endpoint figures.

4.2.2 Summary statistic
For  continuous  outcomes  we  estimated  a  weighted  mean
difference  (WMD)  between  groups.  Again  this  was  based  on  the
random  effects  model,  as  this  takes  into  account  any  differences
between  studies  even  if  there  is  no  statistically  significant
heterogeneity.  We  did  not  consider  continuous  data  presented
without  use  of  summary  statistics  (i.e.  mean,  SD,  SE,  median,
interquartile range), although we noted the existence of these data
in the text.

4.2.3 Valid Scales
Many rating scales are available to measure outcomes in mental
health  trials  (Marshall  2000).  These  scales  vary  in  quality  and
many are poorly validated. It is generally accepted that measuring
instruments  should  have  the  properties  of  reliability  (the  extent
to  which  a  test  effectively  measures  anything  at  all)  and  validity
(the  extent  to  which  a  test  measures  that  which  it  is  supposed
to measure). Before publication of an instrument, most scientific
journals insist that its reliability and validity be demonstrated to the
satisfaction of referees. As a minimum standard, we excluded data
from unpublished rating scales. In addition, the rating scale should
be either: (i) a self report; or (ii) completed by an independent rater
or relative. More stringent standards for instruments may be set in
future editions of this review.

Continuous  data  may  be  presented  from  different  scales,  rating
the  same  outcome.  In  this  event,  we  presented  all  data  without
summation and inspected the general direction of effect.

4.2.4 Conversion to a common metric
To  facilitate  comparison  between  trials,  we  converted  variables
(such as days in hospital) that could be reported in different metrics
(mean days per year, per week or per month) to a common metric
(e.g. mean days per month).

4.3 Cluster trials
Studies  increasingly  employ  'cluster  randomisation'  (such  as
randomisation by clinician or practice) but analysis and pooling of
clustered data poses problems. Firstly, authors often fail to account
for  intra  class  correlation  in  clustered  studies,  leading  to  a  'unit
of  analysis'  error  (Divine  1992)  whereby  p  values  are  spuriously
low, confidence intervals unduly narrow and statistical significance
overestimated.  This  causes  type  I  errors  (Bland  1997,  Gulliford
1999).

Where  clustering  was  not  accounted  for  in  primary  studies,  we
presented  the  data  in  a  table,  with  a  (*)  symbol  to  indicate
the  presence  of  a  probable  unit  of  analysis  error.  In  subsequent
versions of this review we will seek to contact first authors of studies
to obtain intra class correlation co-efficients of their clustered data
and to adjust for this by using accepted methods (Gulliford 1999).
Where clustering has been incorporated into the analysis of primary
studies,  we  will  also  present  these  data  as  if  from  a  non-cluster
randomised study, but adjusted for the clustering effect.

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

5

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

We have sought statistical advice and have been advised that the
binary data as presented in a report should be divided by a 'design
effect'. This is calculated using the mean number of participants per
cluster (m) and the intra-class correlation co-efficient (ICC) Design
effect = 1+(m-1)*ICC (Donner 2002). If the ICC was not reported it
was assumed to be 0.1 (Ukoumunne 1999).

5. Investigation for heterogeneity
Firstly,  we  considered  all  the  included  studies  within  any
comparison  to  judge  clinical  heterogeneity.  We  then  visually
inspected  the  graphs  to  investigate  the  possibility  of  statistical
heterogeneity  and  supplemented  this  using,  primarily,  the  I-
squared  statistic.  This  provides  an  estimate  of  the  percentage
of  variability  due  to  heterogeneity  rather  than  to  chance  alone.
Where  the  I-squared  estimate  was  greater  than  or  equal  to  75%,
we  interpreted  this  as  indicating  the  presence  of  high  levels  of
heterogeneity (Higgins 2003). If inconsistency had been high, data
would  not  have  been  summated,  but  we  would  have  presented
them separately and investigated reasons for heterogeneity.

6. Addressing publication bias
We  entered  all  data  from  all  identified  and  selected  trials  into
a  funnel  graph  (trial  effect  against  trial  size)  in  an  attempt  to
investigate the likelihood of overt publication bias (Egger 1997).

7. General
Where  possible,  we  entered  data  in  such  a  way  that  the  area  to
the left of the line of no effect indicated a favourable outcome for
olanzapine.

R E S U L T S

Description of studies

For  substantive  descriptions  of  studies  please  see  Included  and
Excluded studies tables.

1. Excluded studies
When this review was first undertaken we excluded a total of over
160  studies.  Of  these,  more  than  60  were  excluded  because  they
were not randomised trials, including nine open-label, single-arm
studies  supplied  by  Eli  Lilly.  Nine  were  review  articles  and  one
reported validity data for a questionnaire. Twelve studies did not
include people with schizophrenia. More than 70 studies presented
outcomes that were not usable. One study was originally excluded
(Conley  2001)  following  the  withdrawal  of  the  study  by  Janssen-
Cilag. Amended data have now been presented and are included
(Conley 2001). For the 2004 update, even fewer studies were added
to  the  excluded  studies  due  to  the  increasing  specificity  of  the
Cochrane Schizophrenia register of controlled trials.

2. Awaiting assessment
No studies are waiting assessment.

3. Ongoing studies
Eight  RCTs  comparing  olanzapine  with  other  antipsychotics
are  ongoing  (Centorrino  2001,  Hirsch  2000,  Krakowski  2001,
Ramamurthy  2000a,  Reveley  2000,  Reynolds  2003,  Singh  2000b,
Turner 2002).

Cochrane Database of Systematic Reviews

schizophrenia, schizophreniform and schizoaffective disorders. All
included  studies  are  reported  as  randomised  and  all  but  16  are
described  as  double  blind.  In  almost  half  of  the  studies,  Eli  Liiy
(the  pharmaceutical  company  that  produces  olanzapine)  carried
out  randomisation  at  the  individual  investigation  sites;  Janssen-
Cilag undertook randomisation in the Conley 2001 study. For the
remaining included studies, no additional information is available.

4.1 Length of trials
Schizophrenia is a lifelong illness that affects young people. Thirty
one  studies  presented  data  on  'short-term'  follow-up  (less  than
three months). Three of these acute phase studies (Beasley 1996a
(HGAD),  Beasley  1997  (E003),  Tomlinson  1997(HGAJ))  lasted  six
weeks with 'responders' entering a 46-week extension. Tomlinsons
(HGDY)  study  was  the  shortest  trial  (three  to  five  days)  following
abrupt discontinuation of cocaine. Twenty three studies fell into the
'medium term' (three to 12 months) category and only two trials
(Jones  1998  (P022),  Meltzer  (Intercept))  fulfilled  our  criterion  for
'long-term' (more than one year). The included trials of treatment
resistant patients provided only short-term and medium-term data.

4.2 Participants
All but eleven studies included participants with operationalised
diagnoses (Chang 2003, Chen 2003, Jakovljevic1999 HGCH, Jones
1998  (P022),  Kern  2001,  Lecrubier  1999,  Littrell  1999,  McQuade
2003,  Namjoshi  2002,  Ritchie  2003,  Wang  2002)  by  Diagnostic
and  Statistical  Manual  (APA  1994)  or  The  International  Statistical
Classification  of  Diseases  and  Related  Health  Problems  (ICD-10).
The participants in all studies bar one were diagnosed as suffering
from schizophrenia, although twelve studies also included people
with  schizoaffective  disorder  and  schizophreniform  psychosis.
Wang 2003 used CLMD-3 (Chinese Classification of Mental Disorders
Version  3).  HGCQ  (Turkey)  2000  did  not  mention  the  diagnosis
but  Eli  Lilly  listed  the  study's  participants  as  suffering  from
'schizophrenia  and  related  psychoses'  and  hence  it  is  included.
As  Beasley  1996a  (HGAD)  only  allowed  women  of  'childbearing
potential' to enter after approximately two-thirds of the enrolment
had  been  completed  the  participants  were  predominantly  male.
Svestka 2003 recruited only women.

The  participants  in  Tollefson  1997(HGAJ)  were  less  severely  ill
than  was  generally  seen  in  the  other  studies  (mean  BPRS  score
at  baseline  in  the  olanzapine  group:  Tollefson  1997(HGAJ)  -
33.1,  Beasley  1996a  (HGAD)  -  42.6,  Beasley  1997  (E003)  -  42.3,
Jakovljevic1999  HGCH  -  43.7).  This  large  study  also  contained
a  large  number  of  people  who  were  intolerant  of  their  current
medication.

Four  studies  selected  people  whose  illness  was  described  as
resistant  to  treatment  (Beuzen  1998  (HGCF),  Bitter  2004  (HGCK),
Conley 1998, Kelly 2003). All used different definitions of treatment
resistance  and  treatment  intolerance  as  set  out  in  the  included
studies table.

4.3 Setting
Twenty  two  trials  took  place  in  both  inpatient  and  outpatient
settings. Eighteen used an inpatient design and only five studies an
outpatient setting. Eleven studies did not report the setting.

4. Included studies
Fifty  five  studies  are  included  in  the  October  2004  update
and  this  represents  an  additional  26  studies  since  the  2003
update.  These  55  studies  randomised  over  10000  people  with

4.4 Study size
Tollefson  1997(HGAJ)  was  by  far  the  largest  study  (1996
participants) whilst Kelly 2003 was the smallest study, randomising
only 13 people. Seventeen studies had fewer than fifty participants,

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

6

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

eleven  had  between  50  and  100  participants,  24  studies  had
between 100 and 400 participants and four randomised more than
four hundred people. There were no cluster trials.

4.5 Intervention
The trialists gave olanzapine in a wide range of doses from 1mg/day
to 50 mg/day. Beasley 1996b (HGAP) used 1 mg/day stating that this
was equivalent to a placebo. Beasley 1997 (E003), however, started
with the same assertion but altered this during the study. Because
of this we stopped using 1mg/day as additional placebo data.

The  comparators  were  placebo,  chlorpromazine,  haloperidol,
fluphenazine,  flupentixol,  perphenazine,  clozapine,  amisulpride,
sonepiprazole.
zisprasidone,  aripiprazole  and 
risperidone, 
it  was
that 
recently  announced 
(Pharmacia  Corporation 
discontinuing  the  development  of  the  atypical  antipsychotic
sonepiprazole (PNU 101387)).

4.6 Outcomes
4.6.1 Improvement - Definition of improvement often consisted of a
20-40% reduction in BPRS or PANSS scores. For treatment resistant
participants,  the  lower  level  of  change  in  mental  state  scores
was  considered  as  an  improvement.  Individual  papers  reported
different  cut  offs  for  improvement.  Pragmatic  outcomes  were
reported in Meltzer (InterSept) (suicide attempt, death by suicide,
change in hospital status etc.).

Studies often dichotomised their overall measure of efficacy from
continuous scales (BPRS, PANSS). This dichotomising is welcome
as data begins to become clinically understandable. It is, however,
wasteful of time and effort, if a simple yes/no question on clinical
efficacy  would  suffice  rather  than  hundreds  of  BPRS  and  PANSS
questions. The validity of dichotomising is unclear.

Seven studies supplied by Eli Lilly, present data for loss to follow
up and adverse effects. As far as we understand, effects on global
functioning and mental state are not currently available, even to the
funding company. We have contacted Eli Lilly to ascertain exactly
what outcomes were recorded in addition to those for which data
are available, but have not received a response to date. However,
additional data is included in this update from three studies HGCQ
(Turkey) 2000, HGDV (Morocco) 1999 and Loza 1999 (HGDT).

4.6.2 Adverse effects - Many studies sponsored by pharmaceutical
companies  reported  data  only  when  the  differing  incidence
was  statistically  significant.  The  authors  regarded  these  data  as
potentially  misleading,  as  chance  events  were  likely  to  be  given
prominence and equally frequent adverse effects to be ignored. Eli
Lilly provided published and unpublished adverse event data from
the COSTART terms. These have been included in this version of the
review.

4.6.3  Outcome  scales  -  Details  of  scales  that  provided  usable
data  are  shown  below.  Reasons  for  exclusion  of  data  from  other
instruments are given under 'Outcomes' in the 'Included studies'
section.

4.6.3.1 Global state scales
4.6.3.1.1 Clinical Global Impression Scale - CGI Scale (Guy 1976)
This  is  used  to  assess  both  severity  of  illness  and  clinical
improvement,  by  comparing  the  conditions  of  the  person
standardised  against  other  people  with  the  same  diagnosis.  A

Cochrane Database of Systematic Reviews

seven-point scoring system is usually used with low scores showing
decreased severity and/or overall improvement.

4.6.3.2 Mental state scales
4.6.3.2.1 Brief Psychiatric Rating Scale - BPRS (Overall 1962)
This  is  used  to  assess  the  severity  of  abnormal  mental  state.
The  original  scale  has  16  items,  but  a  revised  18-item  scale  is
commonly  used.  Each  item  is  defined  on  a  seven-point  scale
varying from 'not present' to 'extremely severe', scoring from 0-6 or
1-7. Scores can range from 0-126, with high scores indicating more
severe symptoms. Four studies extracted the BPRS scores from the
PANSS Beasley 1996b (HGAP), Beasley 1997 (E003), Tollefson 1997,
COSTART 1990, Tran 1997 (HGBG). We have not found any validation
of this method of extracting scores.

4.6.3.2.2  Hamilton  Rating  Scale  for  Depression  -  HDRS  (Hamilton
1960)
This  instrument  is  designed  to  be  used  only  on  people  already
diagnosed  as  suffering  from  an  affective  disorder  of  depressive
type. It is used for quantifying the results of an interview, and its
value depends entirely on the skill of the interviewer in eliciting the
necessary information. The scale contains 17 variables measured
on either a five or a three-point rating scale, the latter being used
where quantification of the variable is either difficult or impossible.
Among  the  variables  are:  depressed  mood,  suicide,  work  and
loss of interest, retardation, agitation, gastro-intestinal symptoms,
general  somatic  symptoms,  hypochondriasis,  loss  of  insight,  and
loss of weight. It is useful to have two raters independently scoring
the  person  at  the  same  interview.  The  scores  of  the  person  are
obtained by summing the scores of the two physicians. High scores
indicate greater severity of depressive symptoms.

4.6.3.2.3 Hamilton Anxiety Rating Scale - HAMA (Hamilton 1969)
The Hamilton Anxiety Scaleis a rating scale developed to quantify
the severity of anxiety symptomatology, often used in psychotropic
drug  evaluation.  It  consists  of  14  items,  each  defined  by  a  series
of  symptoms.  Each  item  is  rated  on  a  5-point  scale,  ranging
from  0  (not  present)  to  4  (severe).  The  14  items  consist  of:
Anxious  Mood,  Tension,  Fears,  Insomnia,  Intellectual,  Depressed
Mood,  Somatic  Complaints  (Muscular),  Somatic  Complaints
(Sensory),  Cardiovascular  Symptoms,  Respiratory  Symptoms,
Gastrointestinal  symptoms,  Genitourinary  symptoms,  Autonomic
Symptom and Behaviour at Interview.

4.6.3.2.4 Mini Mental State Examination - MMSE (Folstein 1975)
This clinician-administered clinical evaluation assesses cognition
in  five  areas:  orientation, 
immediate  recall,  attention  and
calculation, delayed recall, and language. The test takes 15 minutes
to administer and the score ranges from 0 (severe impairment) to
30 (normal).

4.6.3.2.5 Positive and Negative Syndrome Scale - PANSS (Kay 1986)
This schizophrenia scale has 30 items, each of which can be defined
on  a  seven-point  scoring  system  varying  from  1  -  absent  to  7  -
extreme. It can be divided into three sub-scales for measuring the
severity  of  general  psychopathology,  positive  symptoms  (PANSS-
P), and negative symptoms (PANSS-N). A low score indicates lesser
severity.

4.6.3.2.6  Scale  for  the  Assessment  of  Negative  Symptoms  -  SANS
(Andreasen 1983)
This six-point scale gives a global rating of the following negative
symptoms; alogia, affective blunting, avolition-apathy, anhedonia-

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

7

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

asociality and attention impairment. Higher scores indicate more
symptoms.

4.6.3.2.7  Montgomery  Asberg  Depression  Rating  Scale  -  MADRS
(Montgomery 1979)
A  65-item  comprehensive  psychopathology  scale  was  used  to
identify  the  17  most  commonly  occurring  symptoms  in  primary
depressive illness. Ratings are based on 10 items, with higher scores
indicating more symptoms.

4.6.3.2.7  Subjective  Well-being  on  Neuroleptics  Scale  -  SWN  (de
Haan 2002a)
The  SWN  is  an  instrument  to  measure  the  subtle  subjective
changes, such as restrictions in emotionality, the clarity of thinking
and  spontaneity  that  are  often  referred  to  as  'pharmacogenic
depression' or the 'neuroleptic induced deficit syndrome'.

4.6.3.3 Adverse effects scales
4.6.3.3.1 Abnormal Involuntary Movement Scale - AIMS (Guy 1976)
This has been used to assess tardive dyskinesia, a long-term, drug-
induced movement disorder and short-term movement disorders
such as tremor.

4.6.3.3.2  Association  for  Methodology  and  Documentation  in
Psychiatry (AMDP-5 1981)
This is a 40-item adverse event questionnaire.

4.6.3.3.3 Barnes Akathisia Scale - BAS (Barnes 1989)
The  scale  comprises  items  rating  the  observable,  restless
movements that characterise akathisia, a subjective awareness of
restlessness, and any distress associated with the condition. These
items are rated from 0 - normal to 3 - severe. In addition, there is an
item for rating global severity (from 0 - absent to 5 - severe). A low
score indicates low levels of akathisia.

4.6.3.3.4 COSTART Terms (COSTART 1990)
This is a list drawn up by the US Food and Drug Administration in
order to help consistent description of adverse reactions. It is not a
scoring system. Eighteen studies reported usable data.

4.6.3.3.5  Drug-Induced  Extrapyramidal  Symptom  Scale  -  DIEPSS
(Inada 1996)
This  is  a  nine  item  scale  used  to  assess  the  extrapyramidal
syndromes parkinsonism, akathisia, dystonia and dyskinsia.

4.6.3.3.6 Extrapyramidal Symptom Rating Scale - ESRS (Chouinard
1980)
This  consists  of  a  questionnaire  relating  to  parkinsonian
symptoms (nine items), a physician's examination for parkinsonism
and  dyskinetic  movements  (eight  items),  and  a  clinical  global
impression of tardive dyskinesia. High scores indicate severe levels
of movement disorder.

4.6.3.3.7 Hillside Akathisia Scale - HAS (Fleischhacker 1989)
The  Hillside  Akathisia  Scale  (HAS)  has  two  subjective  and  three
objective items for which anchored rating points are provided.

4.6.3.3.8 Simpson Angus Scale - SAS (Simpson 1970)
This  ten-item  scale,  with  a  scoring  system  of  0-4  for  each
item,  measures  drug-induced  parkinsonism,  a  short-term  drug-
induced  movement  disorder.  A  low  score  indicates  low  levels  of
parkinsonism.

Cochrane Database of Systematic Reviews

4.6.3.3.9  UKU  Side  Effects  Rating  Scale  -  UKU-SERS  (Lingjaerde
1987)
The  UKU  rates  four  major  topics:  psychological  side  effects  (10
items),  neurological  side  effects  (eight  items),  autonomic  side
effects  (11  items)  and  other  side  effects  (19  items).  Each  item  is
defined  by  means  of  a  four-point  scale  where  zero  means  not/
doubtfully present. Scoring range is 0-144.

4.6.3.3.10  Leeds  Sleep  Evaluation  Questionaire  -  LSEQ  (Parrott
1980)
The SEQ is a simple 10 item bipolar VAS type questionnaire that
can  be  used  to  evaluate  sedative  effects  in  psychotropic  drugs.
Four areas are tapped 1) sleep onset, 2) quality of sleep, 3) ease of
awakening and 4) integrity of morning behaviour. The SEQ has been
factor analysed and four factors were identified, 1) getting asleep,
2)  perceived  sleep  quality,  3)  awakening  and  4)  early  morning
behaviour. A high score indicates improvement.

4.6.3.4 Quality of life scales
4.6.3.4.1 Quality of Life Scale (Lehman 1983)
This  standardised  assessment  includes  areas  such  as  living
situation, leisure activities, relationships and finances. This is rated
on a seven-point scale, with higher scores indicating a better quality
of life.

4.6.3.4.2 Quality of Life Scale - QLS (Carpenter 1984)
This semi-structured interview is administered and rated by trained
clinicians. It contains 21 items rated on a seven-point scale based
on  the  interviewer's  judgement  of  patient  functioning.  A  total
QLS  and  four  sub-scale  scores  are  calculated,  with  higher  scores
indicating less impairment.

4.6.3.5 Satisfaction
4.6.3.5.1 Van Putten Scale
This  is  designed  to  measure  patient  satisfaction  with  treatment.
This was used in the HGCQ (Turkey) 2000 study. A fuller description
of this scale is being sought.

4.6.3.5.2 Drug Attitude Inventory - DAI-30 (Hogan 1983)
This is a self-report 30-item scale for assessing patient satisfaction
with antipsychotic treatment in-patients with schizophrenia. This
inventory is designed to measure the person's subjective responses
to medications as well as values and attitudes toward illness and
health. Higher scores indicate a more favourable attitude towards
antipsychotic  drug  treatment.  A  positive  total  final  score  means
a positive subjective response (compliant). A negative total score
means a negative subjective response (non-compliant).

5. Missing outcomes
Only  Beasley  1996a  (HGAD),  Meltzer  (InterSept)  and  Namjoshi
2002 reported hospital admission data. No useful data about daily
functioning,  such  as  'employed'  or  'trouble  with  the  police',  or
satisfaction  with  care  was  reported.  Eli  Lilly  provided  economic
data  and  this  will  be  incorporated  into  further  updates  of  the
review. Six studies reported mortality data.

Risk of bias in included studies

1. Randomisation
Reporting of randomisation seemed poor in the published papers.
As  studies  have  shown  that  poor  reporting  of  randomisation
increases the odds of presenting 'significant' outcomes (Chalmers
1983,  Schulz  1995)  this  was  brought  to  the  attention  of  the
companies  responsible  for  the  trials  (Eli  Lilly  and  Janssen-Cilag).

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

8

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

They  have  since  provided  full  reports  of  randomisation  and  the
studies now fall into quality category A (adequate concealment of
allocation). Eli Lilly randomised using computer-generated blocks,
for investigative sites or investigator and concealed randomisation
from the investigators. Janssen-Cilag used a randomisation ratio of
1:1 using the minimisation technique of Pocock and Simon (Pocock
1975) and a dynamic randomisation procedure stratified by body
mass index (BMI), PANSS total and ESRS scores.

2. Blinding to interventions and outcomes
Again authors poorly reported their blinding procedures with only
(Conley 1998) clearly describing adequate precautions. Eli Lilly and
Janssen-Cilag  supplied  us  with  details  of  blinding  that  we  have
included in the 'Included studies' table. Several studies gave people
a medication kit containing their medication of allocation in a form
that  was  not  clearly  different  from  the  comparison  drug  or  used
identical capsules (Conley 2001). No study tested blinding. He 2003
and Meltzer (InterSept) were not blind.

3. Follow-up
The numbers leaving the study early were high, albeit comparable
to trials of other atypical antipsychotics (Fabre 1995, Hunter 2003,
Srisurapanont 2004, Thornley 2003). The majority of trials that had
been published in peer reviewed journals described the participant
disposition  well,  clearly  informing  the  reader  as  to  individual
reasons  for  withdrawal  from  the  study.  Studies  that  had  been
presented as posters or presentations often did not include data on
the follow-up of participants, leaving the reader uninformed as to
the whereabouts of the participants.

Nearly  all  the  studies  stated  that  they  analysed  their  data  on
an  intention-to-treat  basis  using  the  last  observation  carried
forward. This practice may well overestimate any treatment effect.
Once  participants  leave  a  study,  unless  the  trialists  continue  to
follow  and  collect  data,  assumptions  have  to  be  made  about
outcome.  As  many  people  left  these  studies  early,  the  results  do
incorporate  considerable  assumptions  (see  'Results',  'Discussion'
and 'Implications for research'). Eli Lilly kindly provided drop out
data from their trials.

In  this review those leaving the studies early were classified as a
'bad outcome' and analysed accordingly (except for the outcome
of  death).  Whatever  the  management  of  lost  data,  interpretation
of results with large degrees of attrition must be undertaken with
caution.  Where  greater  than  50%  of  those  randomised  were  lost
to  follow  up,  outcomes  are  marked  with  '*'  in  order  to  draw  the
attention  of  the  reader  to  the  'prone  to  bias'  footnote  in  the
graphical display of results.

Effects of interventions

1. The search
We found more than 800 citations using the search strategies and
55 studies for inclusion. Twenty six of these are additional studies in
the 2004 update. Eli Lilly identified 11 randomised controlled trials,
four of which were unpublished data on file. We found many trials
reported as presentations at conferences or meetings with the full
report being published in an academic journal (Table 1). There is a
close correlation between study size and number of presentations.
If regression analysis of the data in Table 1 is undertaken on a log-
graph the least-squares line makes a close fit (R2=0.92). For every 10
people that are randomised in an olanzapine versus typical drugs
comparison there is a report. A study of 10 could be predicted to

Cochrane Database of Systematic Reviews

merit a report, of 100-110 presentations and of 1000-1100 reports.
Considering the likely under-identification of presentations of the
larger  studies  this  pattern  of  comprehensive  dissemination  does
not  seem  too  unlikely.  Janssen-Cilag  withdrew  data  from  Conley
2001  in  April  1999,  due  to  site  irregularities.  It  has  now  been
published and is included in this review.

2. COMPARISON 1. OLANZAPINE versus PLACEBO
Five  trials  used  placebo  groups  in  their  comparisons  (Beasley
1996a  (HGAD),  Beasley  1996b  (HGAP),  Corrigan  2004,  Lecrubier
1999, Tollefson 1999(HGDY)). Tollefson 1999(HGDY) is so short term
(duration  five  days)  that  we  have  reported  data  in  a  separate
comparison. The loss to follow up in the other four studies is such
that most data within this comparison is marked with '*' and 'prone
to bias' in the graphical presentations. The degree of assumption
within these data is very great and must be interpreted with a high
degree of caution. Tollefson 1999(HGDY) was the only trial to have
small numbers of people leaving, but this trial lasted for just five
days.

2.1 Global effect
2.1.1 No important clinical response
The trialists defined 'no important clinical response' as the number
of  people  per  treatment  group  who  did  not  present  at  least  a
40%  reduction  in  psychotic  symptoms  measured  by  any  scale.
Olanzapine was superior to placebo at six weeks (any dose, 2 RCTs,
n=418,  RR  0.88  CI  0.8  to  0.1,  NNT  8  CI  5  to  27).  When  analysed
by dose, greatest effect occurred at 15 mg/day olanzapine (1 RCT
n=137, RR 0.74 CI 0.6 to 0.1, NNT 5 CI 3 to 42), was smaller for 10 mg/
day (2 RCTs, n=232, RR 0.8 CI 0.7 to 0.1, NNT 7 CI 4 to 40) and lost in
the single study that reported data on 5 mg/day (1 RCT, n=133, RR
0.94 CI 0.7-1.2) and 1 mg/day (1 RCT, n=102, RR 0.98 CI 0.9 to 1.1).

2.1.2  Change  in  overall  state  as  measured  at  endpoint  by  CGI
(Clinical Global Impression)
CGI  continuous  data  shows  a  significant  difference  in  favour  of
olanzapine (2 RCTs, n=230, WMD (weighted mean difference) -0.53,
CI -0.89 to -0.17).

2.1.3 Needing additional benzodiazepines
At  six  weeks,  similar  proportions  of  each  group  had  received
benzodiazepines  as  an  additional  medication  (2  RCTs,  n=418,  RR
0.96 CI 0.9 to 1.1).

2.2 Mental state
2.2.1 Total scores
At six weeks global measures of mental state favoured olanzapine
over placebo. Both non-skewed BPRS total and PANSS total data
favoured olanzapine (by about seven points on BPRS (1 RCT, n=98,
MD -6.86 CI -12.3 to -1.38) and 12 points (1 RCT, n=98, MD -12.43 CI
-22.54to -2.32) on PANSS. Beasley 1996a (HGAD) reported skewed
data for the BPRS scale. These are not graphically displayed.

2.2.2 Negative/positive sub-scores
The SANS, a scale specifically designed and validated for reporting
negative  symptoms  showed  no  difference  in  olanzapine  and
placebo groups (1 RCT, n=94, MD -0.50, CI -2.87 to 1.87). The PANSS
negative  sub-scale  score  was  also  equivocal.  Skewed  data  from
the  negative  sub-scores  of  the  BPRS  and  SANS  tended  to  favour
olanzapine but differences were not significant.

Positive  symptoms  were  measured  using  sub-scores  of  the  BPRS
and PANSS. Skewed data from the former are difficult to interpret

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

9

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

but  one  study  reported  PANSS  data  that  suggest  a  statistically
significant advantage for olanzapine of four points (n=98, MD -4.0
CI -7.10 to -0.90).

2.3 Leaving the study early
2.3.1 Any reason
In  the  short  term  (six  weeks),  the  levels  of  attrition  reported
by  Beasley  1996a  (HGAD),  Beasley  1996b  (HGAP)  were  similarly
high, olanzapine (52%) placebo (53%). Pooling the data favoured
olanzapine (3 RCTs, n=598, RR 0.86 CI 0.75 to 0.98, NNT 14 CI 8 to 95).
Nevertheless, these attrition rates are considerable. Beasley 1996a
(HGAD) reported a maintenance phase. This study counted people
as  'dropouts'  if  they  were  ineligible,  or  eligible  and  unwilling,  to
continue the study medication beyond the acute phase (six weeks).
At  the  start  of  the  maintenance  phase,  153/198  of  those  taking
olanzapine and 55/68 had left the study (RR 0.96 CI 0.8 to 1.1). At
52 weeks only 17 people on olanzapine and two on placebo were
continuing within their allocated groups (RR 0.94 CI 0.9 to 1.0). The
data at six months are equivocal from Lecrubier 1999.

2.3.2 Due to lack of efficacy
Participants taking olanzapine were significantly less likely to leave
studies  early  due  to  lack  of  efficacy  at  six  weeks  (RR  0.61  CI  0.43
to 0.89, NNT 7 CI 5 to124). Lecrubier 1999 data at six months are
equivocal. At one year those who entered the maintenance phase
of the original six-week acute phase study (Beasley 1996a (HGAD)),
however, were significantly less likely to leave the study early due
to lack of efficacy (n=58, RR 0.41 CI 0.2 to 0.9, NNT 3 CI 2 to 52).

2.4 Adverse effects
We  did  not  agree  with  some  of  the  trialists'  criteria  for  adverse
events. For example 'exacerbation of schizophrenia' is classed as
adverse event in Beasley 1996b (HGAP). This is reported as 'lack of
efficacy' in this review and strengthens the assertion that adding
those  who  left  the  study  early  to  the  adverse  outcome  may  be
justified. In these trials, adverse events needed to reach a frequency
of at least 10% or be statistically significant before being reported.
As  a  result  of  this,  less  common,  but  possibly  important  adverse
effects were not reported.

2.4.1 Anticholinergic effects
Beasley  1996a  (HGAD)  reported  that  dry  mouth  and  dizziness,
especially,  were  more  frequent  in  the  olanzapine  treated  group,
although  neither  difference  reached  conventional 
levels  of
statistical significance.

2.4.2 Extrapyramidal effects
The need for anticholinergic medication, used as a proxy-measure
for extrapyramidal adverse effects, was the same in those allocated
to  olanzapine  and  those  taking  placebo  (n=418,  RR  0.90  CI  0.3
to  2.8).  Scales  that  provide  normally  distributed  data  measured
akathisia,  dyskinesia  and  parkinsonism.  Againthere  are  no  clear
differences between groups.

2.4.3 Other effects
In the doses used within these studies, olanzapine did not clearly
increase nausea or vomiting, problems with sedation or agitation,
hostility  and  withdrawal.  Again,  it  is  debatable  that  these  should
be  reported  as  treatment  emergent  adverse  effects.  Weight  was
increased  by  six  weeks  in  the  olanzapine  group  but  not  to  a
statistically significant extent (2 RCTs, n=227, WMD 3.6kg CI -1.2 to
8.4) and at six months there was no clear difference in weight gain.

Cochrane Database of Systematic Reviews

2.5 Quality of life
Hamilton  1998  recorded,  but  did  not  report,  usable  quality  of
life data from Beasley 1996a (HGAD). Lecrubier 1999, however, did
present  some  useful  information  suggesting  that  the  olanzapine
group  did  report  a  higher  quality  of  life  than  those  allocated
placebo.  This  did  not  reach  conventional  levels  of  statistical
significance (n=80, MD 8.2 CI -2.5 to 18.9).

2.6 Missing outcomes
Data were collected regarding inpatient or outpatient status, but
again they reported no data. No study reported mortality, cognitive
functioning, satisfaction with treatment, cost effectiveness, social
functioning or self-harm.

3. COMPARISON 2. OLANZAPINE versus PLACEBO (three to five days)

Tollefson 1999(HGDY) reported very short-term data and it did not
seem reasonable to synthesize these with the data presented above
in  comparison  number  one  as  these  record  outcomes  at  about
six weeks. It appears to be a switching study from a group taking
clozapine to either olanzapine or placebo.

3.1 Global effect
Tollefson  1999(HGDY)  did  not  achieve  conventional  levels  of
statistical significance for the outcome of change in the CGI severity
scale (n=106, MD -0.23 CI -0.52 to 0.06). However, for the outcome
of  relapse  at  five  days,  they  did  find  a  difference  in  favour  of
olanzapine,  although  we  are  unclear  what  a  relapse  at  five  days
means (n=106, RR 0.13 CI 0.02 to 0.96).

3.2 Mental state
For the outcome of change in PANSS total scores at five days, results
favour olanzapine (n=106, MD -5.23 CI -9.98 to -0.48), however, on
positive and negative symptoms, results were equivocal. Tollefson
1999(HGDY)  reported  improvement  on  change  scores  using  the
MADRS for those taking olanzapine at five days (n=106, MD -4.52 CI
-6.99 to -2.05), but found no difference on the MMSE.

3.3 Leaving the study early. Any reason
Equivocal results for leaving the study early are reported in this very
short term study (n=105, RR 0.38 CI 0.11 to 1.34).

3.4 Adverse events
Equivocal  five  day  results  for  headache  and  gastrointestinal
adverse events are reported.

4. COMPARISON 3. OLANZAPINE versus TYPICAL ANTIPSYCHOTICS

trials 

compared  olanzapine  with 

typical
Twenty  nine 
antipsychotics.  Altamura  1999  (HGBQ),  Avasthi  2001,  Barak  2002,
Beasley 1996a (HGAD), Beasley 1997 (E003), Bernardo 2001 (HGDD),
Chaudhry  2003,  de  Haan  2003,  Esel  2001,  Ishigooka  2001,  Jones
1998  (P022),  Lieberman  2003  (HGDH,  Malyarov  1999,  Namjoshi
2002;  Rosenheck  2003(HGFI),  Tollefson  1997(HGAJ),  HGCJ  (Hong
Kong), HGCU (Taiwan) 1998, HGFH (Korea) 1998, used haloperidol
as the comparator, while Chang 2003, Conley 1998, He 2003, Loza
1999  (HGDT),  HGDV  (Morocco)  1999,  HGCQ  (Turkey)  2000  used
chlorpromazine. Jakovljevic1999 HGCH compared olanzapine with
fluphenazine, HGBJ (Finland) with perphenazine and HGBL 1997,
flupentixol.  Lima  2003  (HGHS)  compared  olanzapine  with  typical
antipsychotics  decided  upon  by  the  clinicians  involved  (mainly
haloperidol or chlorpromazine).

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

10

4.1 Death

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

For the outcome of death, data were reported in only one study
(Ishigooka 2001) and supplied by Eli Lilly for (Beasley 1997 (E003)
and Tollefson 1997(HGAJ)). Death from 'all causes' was not more
likely in either group (2 RCTs, n=2427, RR 1.84 CI 0.48 to 7.11). Death
from suicide and accidental injury (3 RCTs, n=2609, RR 1.28 CI 0.17
to 9.70), 'other causes' (2 RCTs, n=2427, RR 1.48 CI 0.15 to 14.22) and
cause 'unknown' (1 RCT, n=1996, RR 0.16 CI 0.01 to 4.04) were all
equally likely whether allocated to olanzapine or the typical drug.

4.2 Global effect
4.2.1 No important clinical response
Data  relevant  to  this  outcome  are  not  available  for  many  of  the
studies  listed  above  (see  'Description  of  studies').  At  six  to  eight
weeks,  Beasley  1996a  (HGAD),  Beasley  1997  (E003)  and  Tollefson
1997(HGAJ)  defined  'important  clinical  response'  as  those  who
presented  at  least  a  40%  reduction  in  psychotic  symptoms  as
measured  by  any  scale.  Conley  1998,  for  the  treatment  resistant
participants, defined 'important clinical response' as at least a 20%
reduction in mental state ratings. The large Tollefson 1997(HGAJ)
trial  dominates  heterogeneous  results  for  'any  dose  olanzapine',
but  if  random  effects  relative  risk  is  calculated,  there  is  no  clear
difference  between  the  typical  drugs  and  olanzapine  for  this
outcome  (4  RCTs,  n=2778,  RR  0.93  CI  0.85  to  1.01,  Chi  square
21.8, df=3). In an earlier version of this review, we calculated the
effect size using Peto Odds and a fixed effect model produced an
unequivocal result favouring olanzapine (Peto OR 0.6 CI 0.5 to 0.7,
NNT  7  CI  5.3  to  8.8,  Chi-square  13.5,  df  3).  The  random  effects
relative risk data, especially in the presence of heterogeneity and
common events, are likely to be the more reliable (see 'Discussion').
Data  relating  to  specific  doses  do  not  show  differences  between
olanzapine  and  typical  drugs.  At  12  weeks  Lieberman  2003
(HGDH)  reports  equivocal  data  (n=263,  RR  0.82  CI  .64  to  1.06).  At
nine  months  Lima  2003  (HGHS)  also  defined  'important  clinical
response'  as  those  who  presented  at  least  a  40%  reduction  in
psychotic symptoms on the PANSS (n=197, RR 0.85 CI 0.69 to 1.05),
or a endpoint CGI score of </=2, (n=197, RR 0.82, CI 0.67 to 1.00).

4.2.2 Relapse/rehospitalisation
Only  Beasley  1996a  (HGAD)  and  Namjoshi  2002  reported
hopitalisation rates which were higher in the olanzapine arm, but
the drop outs in the olanzapine arm were >50% and prone to bias
and data are heterogeneous (I-squared 96%).

4.2.3 Clinical Global Impression endpoint score
In the short term, endpoint data do favour olanzapine over typical
drugs  (9  RCTs,  n=2503,  WMD  -0.31  CI  -0.57o  -0.06)  as  do  three  to
twelve month data (5 RCTs, n=411, WMD -0.46 CI -0.83 to -0.09).

4.3 Mental state
4.3.1 Needing additional medication
Less  people 
olanzapine 
benzodiazepines than those taking haloperidol (3 RCTs, n=2526, RR
0.91 CI 0.85 to 0.96, NNT 17 CI 10 to 37).

additional

required 

taking 

4.3.2 Total scores
Bernardo  2001  (HGDD),  Chang  2003,  Conley  1998,  Esel  2001,
Ishigooka 2001 and Loza 1999 (HGDT) presented endpoint data for
BPRS  total  scores  that  were  equivocal  between  olanzapine  and
typical antipsychotics (6 RCTs, n=397, WMD 0.00 CI -3.38 to 3.38).
Much of the skewed BPRS data, presented in 'Other data' tables,
are  also  equivocal.  PANSS  total  scores  however,  clearly  favour
olanzapine.  Outcomes  reported  for  the  short  and  medium  term
significantly favour olanzapine (8 RCTs, n=2427, WMD -6.04 CI -11.11

Cochrane Database of Systematic Reviews

to  -.96;  6  RCTs  n=563,  WMD  -8.48  CI  -13.84  to  -3.12  respectively).
Longer-term  data  are  again  equivocal  but  are  based  on  small
numbers (n=44, Jones 1998 (P022)).

4.3.3 Negative symptoms
PANSS  negative  sub-score  data  are  consistently  in  favour  of
olanzapine (short term 4 RCTs, n=2297, WMD -1.20 CI -2.37 to -0.02;
medium term 5 RCTs, n=408, WMD -2.11 CI -3.34 to -0.88; long term
1 RCT, n=44 MD -4.75 CI -8.10 to -1.40). When measured using BPRS
negative sub-scores and the SANS, all data still favoured olanzapine
although  the  clinical  significance  of  these  data  is  not  clear  (see
Discussion).

4.3.4 Positive symptoms
When  olanzapine  was  compared  with  typicals  and  rated  using
the  BPRS  positive  symptom  sub-score  trialists  found  no  clear
difference (short term, 2 RCTs, n=110, WMD -0.97 CI -2.21 to 0.28)).
PANSS  positive  sub-score  rating  in  the  short  term  was  in  favour
of olanzapine (4 RCTs, n=2297, WMD -1.03 CI -1.63 to -0.43). In the
medium  term  however,  this  was  not  continued  (3  RCTs  ,  n=334,
WMD  -2.20  CI  -5.42  to  1.02  respectively).  Long-term  study  data
(Jones  1998  (P022)  were  not  significant.  Skewed  data  tended  to
favour olanzapine.

4.3.5 Depression
Avasthi 2001, Tollefson 1997(HGAJ), HGCU (Taiwan) 1998 and HGCJ
(Hong Kong) rated depression using the Montgomery and Asberg
Depression Scale. All data are skewed but tend to be moderately in
favour of olanzapine. They are reported in 'Other data' tables.

4.3.6 Subjective well being
No difference was found between the two groups in this small study
(de Haan 2003).

4.4 Leaving the study early
4.4.1 Any reason
The  results  for  this  outcome  (at  four  to  eight  weeks)  vary  in
terms  of  whether  they  are  statistically  significant  depending  on
the  statistical  test  applied  to  them.  The  conservative  random
effects relative risk suggests that the difference is not statistically
significant (14 RCTs, n=3344, RR 0.81 CI 0.65 to 1.02). If, however, a
Peto odds ratio is employed, the results are statistically significant
(14  RCTs,  n=3344,  OR  0.54  CI  0.46  to  0.63,  NNT  8  CI  6  to  10).  We
suggest  that  the  conservative  approach,  in  this  high  event  rate
group, is more likely to be accurate (see 'Discussion'). In any event,
by four/eight weeks, 34% in the olanzapine group had dropped out
compared to 45% in the comparator groups. By three to 12 months,
significantly fewer people had left the olanzapine group (11 RCTs,
n=1084,  RR  0.79  CI  0.65  to  0.95).  Beyond  12  months  the  findings
were again equivocal (n=2738, RR 0.93 CI 0.86 to1.02). At this stage
83% of those originally allocated to olanzapine had left versus 90%
randomised to typical drugs.

4.4.2 Due to lack of efficacy
When  lack  of  efficacy  is  cited  as  reason  for  attrition  there  is
a  difference  at  three  to  12  months  in  favour  of  those  taking
olanzapine (6 RCTs, n=482 RR 0.57 CI 0.34 to 0.96, NNT 16 CI 11 to
167). However, there is no difference between olanzapine and other
drugs up to 8 weeks and over 12 months.

4.5 Adverse effects
4.5.1 Anticholinergic effects - specific symptoms

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

11

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Fewer people taking olanzapine experienced orthostatic changes
(2  RCTs,  n=82,  RR  0.13  CI  0.1  to  0.4)  and  hypersalivation  (4  RCTs,
n=2636, RR 0.37 CI 0.20 to 0.71), than those on typical drugs. Other
effects  such  as  blurred  vision,  constipation,  dry  mouth,  dizziness
and urination difficulties were equivocal.

4.5.2 Extrapyramidal effects
Beasley  1997  (E003),  Conley  1998  and  Tollefson  1997(HGAJ)
report  on  the  incidence  of  any  extrapyramidal  event.  Results
favour  olanzapine  (3  RCTs,  n=2511,  RR  0.41  CI  0.28  to  0.60).
Heterogeneous ESRS data (Chi squared=57.25 df=2) was equivocal
(4 RCTs, n=139, WMD -3.62 CI -8.11 to 0.87). Those taking olanzapine
required  less  anticholinergic  medication  compared  with  those
taking  haloperidol  at  six  to  12  weeks  (4  RCTs,  n=2957,  RR  0.28
CI  0.21  to  0.38,  NNT  3  CI  3  to  4),  and  by  three  to  12  months
(n=276,  RR  0.55  CI  0.35  to  0.86,  NNT  8  CI  6  to  24).  Data  on
a  whole  series  of  specific  extrapyramidal  symptoms  favours
olanzapine. Participants taking olanzapine experienced less acute
dystonia,  akathisia,  bradykinesia,  hypertonia,  hypokinesia,  new
onset  parkinsonism,  rigidity,  and  tremor  than  people  allocated
to  haloperidol.  For  the  outcomes  of  dyskinetic  movements  and
choreoathetosis  data  were  equivocal.  Interestingly,  in  the  single
study  (Conley  1998)  with  chlorpromazine  as  the  comparator  and
reporting data for this outcome, the superiority of olanzapine is less
convincing. Lieberman 2003 (HGDH) reports that fewer participants
on  olanzapine  required  propranolol.  Continuous  albeit  skewed
rating-scale  data  for  akathisia,  dyskinesia  and  parkinsonism  all
favour  olanzapine  but  the  statistical  or  clinical  significance  is
unclear (see 'Discussion'). Bernardo 2001 (HGDD) provided skewed
data  for  the  Simpson  and  Angus  Scale  and  the  Barnes  Akathisia
Scale  which  are  not  reported,  due  to  the  large  SD's.  Ishigooka
2001 reported extrapyramidal data from the DIEPSS scale; all were
skewed and are shown in 'Other Data' tables.

4.5.3 Other adverse effects
Ishigooka 2001 reported equivocal data for adverse drug reactions
which required dose reduction or additional medication. Data from
Ishigooka  2001  for  the  outcome  of  anorexia  favoured  olanzapine
(n=182,  RR  0.26  CI  0.09  to  0.74).  Tollefson  1997(HGAJ)  reported
that people taking olanzapine had an increase in appetite (n=1996,
RR  1.65  CI  1.35  to  2.01,  NNH  10  CI  7  to15).  Reports  of  nausea
were equivocal while data on vomiting favoured olanzapine over
haloperidol (n=1996, RR 0.59 CI 0.45 to 0.78).

Cochrane Database of Systematic Reviews

RCTs, n=428, RR 1.78 CI 1.44 to 2.19, NNH 6 CI 4 to 11), but most
authors did not specify the criteria used for weight increase. One
study reported this to be any weight increase >= 7%. Ishigooka 2001
also reported on weight loss with equivocal results (p=0.06). Weight
changes reported beyond 12 months were equivocal (1 RCT, Jones
1998 (P022)).

4.5.3.3  Other  effects  -  One  study  reported  treatment  emergent
agitation,  hostility  and  withdrawn  behaviour  (Beasley  1996a
(HGAD))  and  found  no  differences  between  olanzapine  and
haloperidol.  Also,  Beasley  1996a  (HGAD)  reported  equivocal
data  for  gastrointestinal  disturbances  for  the  olanzapine  and
haloperidol  groups.  One  study,  HGCQ  (Turkey)  2000,  reported
on  rash  with  equivocal 
for  both  olanzapine  and
finding 
chlorpromazine. Avasthi 2001 reported equivocal data for asthenia.
Ishigooka  2001  reported  abnormal  gait  which  appeared  less
common in the olanzapine group (n=182, RR 0.11 CI 0.3 to 0.5 NNH 6
CI 6 to 10). Esel 2001 reports laboratory results for prolactin levels at
6 weeks in favour of olanzapine (n=29, MD -15.01 CI -17-94 to -12.08).

4.6 Quality of life
Beasley  1996a  (HGAD)  and  Tollefson  1997(HGAJ)  both  reported
data on quality of life in a form that we could not use in this review.

4.7 Economic outcomes
Three  studies  reported  cost  data,  however,  none  were  in  a
usable  form  (Jones  1998  (P022),  Namjoshi  2002  and  Rosenheck
2003(HGFI).

4.8 Missing outcomes
No  data  are  reported  for  social  functioning,  employment  status,
death and family satisfaction with care.

5.  COMPARISON  4.  OLANZAPINE  versus  TYPICAL  ANTIPSYCHOTIC
FOR THOSE WITH TREATMENT RESISTANT ILLNESS

Conley  1998,  compared  olanzapine  with  chlorpromazine 
in
hospitalised treatment resistant patients in an eight-week trial and
Altamura 1999 (HGBQ) compared olanzapine with haloperidol in a
14  week  trial,  defining  non-responders  according  to  Breier  1994;
essentially those with treatment resistant illnesses. Many outcomes
were not reported by Altamura 1999 (HGBQ). All participants were
inpatients in Conley 1998, however, Altamura 1999 (HGBQ) did not
describe the setting of the study.

4.5.3.1  Drowsiness  -  There  is  no  suggestion  of  a  problem  of
insomnia with olanzapine. However, those taking typicals are more
likely  to  be  drowsy  than  those  on  olanzapine,  (6  RCTs,  n=2636,
RR  0.82  CI  0.73  to  0.93,  NNH  18  CI  12  to  57).  Continuous  data  on
the Leeds Sleep Evaluation Questionnaire were equivocal between
those on olanzapine and chlorpromazine.

5.1 Global effect
5.1.1 No important clinical response
Conley 1998 defined this as the number of people per group who
did  not  present  at  least  a  20%  reduction  in  psychotic  symptoms
measured  by  any  scale.  At  eight  weeks  thee  was  no  difference
reported between the two groups (n=84, RR 0.93 CI 0.85 to 1.01).

4.5.3.2 Weight changes - This update of the review contains some
new data on weight changes. Twenty of 29 studies report weight
data in various ways, not all of them amenable to comparison. Data
for the short term are inconclusive (8 RCTs, n=2455, WMD 0.81kg CI
-0.56 to 2.18) but the three to 12 month results suggest an average
gain of four kilograms (4 RCTs, n=186, WMD 4.62, CI 0.6 to 8.64). Two
studies,  Barak  2002  and  Lieberman  2003  (HGDH),  report  change
data suggesting an increase in weight of 3.44 Kgs at three months
(2  RCTS,  n=283,  WMD  3.44  CI  2.57  to  4.31).  Five  studies  (Avasthi
2001, Chaudhry 2003, Ishigooka 2001, Lieberman 2003 (HGDH), He
2003) report heterogeneous results for weight gain (medium term)
which  was  significantly  higher  for  those  receiving  olanzapine  (5

5.1.2 CGI (Clinical Global Impression)
No difference between groups was apparent in Conley 1998 (n=81,
MD -0.10 CI -0.49 to 0.29).

5.2 Mental state
5.2.1 Total score
Conley  1998  reported  no  discernible  difference  between  the
olanzapine  and  chlorpromazine  groups  on  the  total  score  of  the
BPRS (n=84, MD -2.80 CI -8.43 to 2.83).

5.2.2 Negative symptoms

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

12

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Skewed  SANS  data  favoured  olanzapine  but  there  were  only  0.9
points  difference  between  groups  and  the  statistical  and  clinical
significance were unclear.

5.2.3 Positive symptoms
Parametric  BPRS  positive  sub-scale  ratings  favoured  olanzapine
but not to a degree that was statistically significant (n=84, MD -1.30
CI -2.90 to 0.30).

5.3 Leaving the study early
5.3.1 Any reason
No  differences  between  those  allocated  olanzapine  and  people
taking  either  chlorpromazine  or  haloperidol  were  apparent
(Altamura 1999 (HGBQ) and Conley 1998).

5.3.2 Due to lack of efficacy
No difference was reported between the groups in the two trials.

5.4 Adverse events
Essentially  the  data  for  adverse  effects  reflect  those  already
presented  for  the  larger  comparison  between  olanzapine  and
typical antipsychotic drugs for those whose illness is not treatment
resistant.

5.4.1 Anticholinergic effects
Conley 1998 reported fewer people on olanzapine experienced dry
mouth (RR 0.52 CI 0.3 to 0.8, NNH 3 CI -6.3 to -1.8). Blurred vision,
dizziness and palpitations were equivocal. Orthostatic changes (1
RCT, n=84, RR 0.13 CI 0.13 to 0.35, NNT 3CI 2 to 3) and dry mouth
(1 RCT, n=84, RR 0.52 CI 0.3 to 0.8, NNT 3 CI 3 to 7) both favoured
olanzapine to chlorpromazine.

5.4.2 Extrapyramidal events
In Conley 1998 fewer people taking olanzapine experienced 'any
extrapyramidal  effects'  (n=84,  RR  0.57  CI  0.3  to1.0)  or  dyskinetic
movements  (n=84,  RR  0.10  CI  0.01  to  0.5,  NNH  3  CI  -5.5  to  -2.1).
Skewed  data  from  both  the  Barnes  Akathisia  Scale  and  Simpson
and  Angus  (parkinsonism)  Scale  were  uninformative  but  did  not
highlight clear differences between groups.

5.4.3 Other adverse events
Those  allocated  to  olanzapine  and  chlorpromazine  reported
similar rates of nausea/vomiting and difficulty in getting to sleep or
drowsiness. Altamura 1999 (HGBQ) (n=47) reported body weight at
the end of the 14 week study. No suggestion of a difference between
those randomised to olanzapine and those allocated haloperidol
were seen at this time (MD 0.35kg CI -9.7 to 10.4).

Cochrane Database of Systematic Reviews

2002,  Ritchie  2003,  Simpson  2004,  Svestka  2003,  Thomas  1998
(HGBU),  Tran  1997  (HGBG),  Wang  2002,  Wang  2003).  Thirteen
trials compared olanzapine with risperidone, eight with clozapine,
two  with  amisulpiride,  two  with  aripiprazole  and  one  each  with
sonepiprazole and zisprasidone. Some of the trials relate to those
with treatment resistant illness (Beuzen 1998 (HGCF), Bitter 2004
(HGCK),  Kelly  2003  and  Naber  2001  (HGBF)),  people  in  their  first
episode (Svestka 2003) and the elderly (Jeste 2003, Ritchie 2003).

6.1 Death
Unpublished data from Beuzen 1998 (HGCF) and Conley 2001 did
not  reveal  deaths  in  either  group.  Three  other  studies  reported
mortality  data;  one  whose  primary  aim  was  to  measure  if
olanzapine vs clozapine prevented death (Meltzer (InterSept)), and
two reporting on interventions in older people (Jeste 2003, Ritchie
2003).  No  statistical  difference  was  detected  between  the  two
groups  (any  cause,  5  RCTs,  n=1778,  RR  0.70  CI  0.31  to  1.60;  by
suicide, 1 RCT, n=980, RR 1.67 CI 0.40 to 6.94).

6.2 Global
6.2.1 Global effect
No difference was found for the outcome of no important clinical
response  (as  measured  by  CGI,  or  by  Kane  1988  criteria),  when
olanzapine was compared to other atypicals at eight weeks or three
months, (7 RCTs).

6.2.2 Relapse/rehospitalisation
Namjoshi  2002  and  Meltzer  (InterSept)  were  the  only  studies  to
provide data on rehospitalisation, however the Meltzer (InterSept)
data relates to this being used as a rescue intervention to prevent
suicide and is reported in this comparison as a service outcome (no
40  see  later).  By  12  months  the  number  of  people  rehospitalised
was significantly higher in the risperidone group (n=278, RR 0.49 CI
0.31 to 0.79, NNT 7 CI 5 to 16; Namjoshi 2002).

6.2.3 CGI endpoint score
Pooled results from three trials are equivocal (3 RCTs, n=570, WMD
0.00 CI -0.20 to 0.19).

6.3 Mental state
6.3.1 Needing additional benzodiazepines
Pooled  data  at  six  to  eight  weeks,  and  by  eighteen  weeks,
shows  similar  numbers  of  participants  receiving  olanzapine  or
other  atypicals  (clozapine,  risperidone  or  ziprasidone)  required
additional  benzodiazepines.  At  two  years,  Meltzer  (InterSept)
reports a barely significant result in favour of clozapine (n=980, RR
1.11 CI 1.01 to 1.22, NNH 16 8 to 167).

5.4.4 Missing outcomes
No  data  were  reported  on  quality  of  life,  social  functioning,
employment, death and harm, cognitive functioning, satisfaction
with  treatment  and  cost  effectiveness.  Trials  supplied  no  clear
data on the use of additional medication but Conley 1998 stated
"no difference between the groups in the amount and duration of
lorazepam use during the study".

6.3.2 Needing an antidepressant by two years
Meltzer  (InterSept)  reports  on  data  from  two  years  that  more
participants on olanzapine needed an antidepressant than people
allocated  clozapine,  however,  this  did  not  reach  statistical
significance  (n=980,  RR  1.12  CI  0.99  to  1.27).  The  same  study
reported  antidepressants  being  used  as  a  rescue  intervention  to
prevent suicide (n=980, RR 2.20 CI 1.21 to 4.00, NNH 26 CI 11 to 145).

6. COMPARISON 5. OLANZAPINE versus ATYPICAL ANTIPSYCHOTICS

Twenty  seven 
trials  compared  olanzapine  with  atypical
antipsychotics  (Beuzen  1998  (HGCF),  Bitter  2004  (HGCK),  Casey
2003,  Chan  2003,  Chen  2003,  Conley  2001,  Corrigan  2004,  de
Haan  2002,  Jeste  2003,  Jones  1998  (P022),  Kelly  2003,  Kern
2001,  Lecrubier  1999,  Littrell  1999,  Malyarov  1999,  Martin  2002,
McQuade 2003, Meltzer (InterSept), Naber 2001 (HGBF), Namjoshi

6.3.3 No important clinical response (20 and 40% decrease in PANSS
total score; 20 and 40% decrease in BPRS total score)
Short  term  data  from  four  studies  (Chen  2003,  Conley  2001,
Jeste  2003,  Wang  2003)  were  equivocal  for  the  olanzapine  and
atypical groups (risperidone or clozapine). The criterion for clinical
improvement  was  20%  to  25%  or  more  reduction  in  total  PANSS
score. Svestka 2003 used a 50% reduction in total PANSS score over

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

13

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

six  weeks  in  people  who  were  experiencing  their  first  episode  of
psychosis. Results are again equivocal. Medium term outcomes by
(Beuzen 1998 (HGCF), Bitter 2004 (HGCK) and (Tran 1997 (HGBG)),
favoured  olanzapine  to  the  other  atypical  antipsychotic  groups
(clozapine and risperidone, 3 RCTs, n=669, RR 0.89 CI 0.81 to 0.99,
NNT 13 CI 8 to 139) using a 40% or more cut off point. BPRS data
at six weeks from Simpson 2004 and Wang 2002 did not distinguish
between the two groups.

6.3.3 Total endpoint scores
BPRS endpoint data from the clozapine (Beuzen 1998 (HGCF) and
risperidone (Tran 1997 (HGBG), Thomas 1998 (HGBU) comparisons
were  skewed  and  difficult  to 
interpret.  All  findings  favour
olanzapine  but  by  very  minimal  differences.  Wang  2002  reports
a  statistical  significance  on  BPRS  endpoint  score  in  favour  of
olanzapine (n=61, MD -1.60 CI -2.96 to -0.24). Martin 2002 reported
equivocal  BPRS  end-point  data  for  the  medium  term  (n=377)
between olanzapine and amisulpride. PANSS total scores, at three
to  12  months  are  heterogeneous  (Chi  squared  37.44  df=4),  and
equivocal  (5  RCTs,  n=715,  WMD  3.01  CI  -5.74  to  11.76).  Twelve
months data are also equivocal (n=42 MD 1.86 CI -9.08 to 12.8).

6.3.4 Negative symptoms
No  difference  was  seen  between  olanzapine  and  risperidone  at
eight  weeks  (n=278,  MD  0.20  CI  -1.1  to  1.5).  Endpoint  PANSS
negative  sub-scale  scores  are  similar  between  atypicals  at  3-12
months  (4  RCTs,  n=593,  WMD  -1.52  CI  -2.08  to  5.13)  and  over
12  months  (n=42,  MD  -0.20  CI  -3.76  to  3.36).  Lecrubier  1999
(amisulpiride)  reported  endpoint  SANS  scores  as  identical.  Other
skewed data support the parametric findings.

6.3.5 Positive symptoms
Both  skewed  BPRS  and  SANS  data  and  parametric  PANSS
positive symptom scores do not suggest any differences between
olanzapine and other atypical antipsychotics.

6.3.6 Depression
We  entered  skewed  data  from  the  HAM-D  (Conley  2001)  and
MADRS (Martin 2002) in 'Other data' tables, and they do not suggest
any  difference  between  those  taking  olanzapine,  risperidone  or
amisulpiride.

6.4 Leaving the study early
6.4.1 Any reason
There was no difference in the numbers of people leaving the study
early for either short, medium or long-term studies. By eight weeks,
21% of those taking olanzapine had left the study, compared to 25%
taking the other atypicals. By three to 12 months, this had increased
to 46% and 52% respectively.

6.4.2 Due to lack of efficacy
There was no notable difference between atypical drugs.

6.5 Adverse effects
6.5.1 Anticholinergic effects - specific symptoms
Statistically significant differences were found for the outcomes of
constipation by six to eight weeks (2 RCTs, n=247, RR 0.47 CI 0.25 to
0.89, NNH 9 CI 7 to 44), 18 weeks (n=180, RR 0.35 CI 0.15 to 0.85, NNT
9 CI 7 to 36) and by two years (n=980, RR 0.45 CI 0.34 to 0.60, NNT 7
CI 6 to 10). No difference was detected for the outcome of dizziness
at six to eight, or by 18 weeks, however, at two years, less people
on olanzapine experienced dizziness (n=480, RR 0.51 CI 0.40 to 0.66,
NNH 8 CI 6 to 11), did not report a problem with libido (n=66, RR 0.78

Cochrane Database of Systematic Reviews

CI 0.61 to 0.99, NNT 5 CI 3 to 110). At all time points, those taking
olanzapine experienced less salivation (6 weeks, n=121, RR 0.02 CI
0.00 to 0.36, NNT 3 CI 3 to 5; by 18 weeks, 2 RCTs, n=330, RR 0.32 CI
0.15 to 0.67, NNT 4 CI 3 to 8; by 2 years, n=980, RR 0.17 CI 0.13 to 0.23,
NNT 3 CI 3 to 3) and urinary incontinence (n=980, RR 0.45 CI 0.27 to
0.77, NNT 21 CI 16 to 49) and salivation (3 RCTs, n=1192, RR 0.20 CI
0.06 to 0.63, NNT 3 CI 3 to 7). Participants taking olanzapine were
more likely to experience dry mouth by two years (n=490, RR 1.51
CI 1.02 to 2.55, NNH 12 CI 7 to 715). Data for vision abnormalities at
eight weeks and rhinitis were equivocal.

6.5.2 Extrapyramidal effects
6.5.2.1 Needing additional anticholinergic medication
At  both  eight  to  12  weeks  and  three  to  12  months,  significantly
fewer  people  taking  olanzapine  had  received  anticholinergic
medication compared to those taking comparators, (4 RCTs, n=923,
RR 0.64 CI 0.46 to 0.91, NNT 7 CI 5 to 27; 2 RCTs, n=519, RR 0.56 CI
0.4 to 0.79, NNH 9 CI 7 to 18) respectively.

6.5.2.2 Any extrapyramidal symptoms
Dichotomised  data  show  no  difference  at  eight  weeks  (4  RCT's,
n=657,  RR  0.76  CI  0.54  to  1.08),  however  at  three  to  12  months,
fewer participants taking olanzapine reported any extrapyramidial
symptoms (n=339, RR 0.6 CI 0.41 to 0.88, NNT 9 CI 6 to 27).

6.5.2.3 Parkinsonism
Skewed data from two studies using the ESRS (Conley 2001, Jones
1998 (P022)), when pooled, gave equivocal results, as does Martin
2002 which uses the SAS.

6.5.2.4 Specific extrapyramidal symptoms
Beuzen  1996  (HGCE)  and  Tran  1997  (HGBG)  reported  only
those adverse events that were statistically significantly different
between  groups,  whereas  Conley  2001  only  reported  those
occurring  in  10%  of  either  group.  Beuzen  1998  (HGCF)  reported
results at a 5% incidence. Rates were similar for akathisia (by three
to  12  months,  4  RCTs,  n=924,  RR  0.98  CI  0.64  to  1.49),  dyskinetic
movements  (2  RCTs,  n=519,  RR  0.99  CI  0.40  to  2.46),  restlessness
(n=122,  RR  1.00  CI  0.15  to  6.87)  and  tremor  (2  RCTs,  n=297,  RR
0.54 CI 0.15 to 1.91). Akathisia at two years however appears more
prevalent  in  those  who  have  taken  olanzapine  (n=980,  RR  1.63
CI1.07 to 2.48, NNH 27 CI 12 to 239). The incidence of parkinsonism
appeared less in the olanzapine group (1 RCT, n=339, RR 0.58 CI 0.36
to 0.94, NNH 11 CI 6 to 75).

6.5.2.3 Other adverse effects
Treatment  emergent  adverse  events  were  less  common  in  the
olanzapine group (3 RCTs, n=569, RR 0.9 CI 0.82 to 0.98, NNT 13 CI
8 to 64).

There was no difference between those on olanzapine and those
on comparators in levels of asthenia at siz to eight weeks and 18
to 52 weeks. However at two years, those taking olanzapine were
less likely to have asthenia than those on clozapine (n=980, RR 0.51
CI 0.32 to 0.82, NNT 21 CI 15 to 56), or low white cell counts by two
years (n=980, RR 0.44 CI 0.25 to 0.76, NNT 23 CI 17 to 53), but not
at four or 18 to 26 weeks. People in the olanzapine group were also
less likely to have dyspepsia at two years (n=980, RR 0.69 CI 0.50 to
0.95, NNT 22 CI 14 to 134), headache at four to eight weeks (4 RCTs,
n=677, RR 0.72 CI 0.54 to 0.96, NNT 15 CI 9 to 100), hyperlactinaemia
by six weeks (n= 42, RR 0.24 CI 0.10 to 0.58, NNT 2 CI 2 to 3), nausea
at  18  to  26  weeks  and  two  years  (n=435,  RR  0.27  CI  0.09  to  0.75,
NNT 10 CI 8 to 2; n=980, RR 0.67 CI 0.49 to 0.90, NNT 17 CI 11 to 56),

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

14

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

tachycardia at six weeks (n= 122, RR 0.06 CI 0.01 to 0.40, NNT 4 CI
4 to 6) and vomiting at two years (n= 980, RR 0.61 CI 0.45 to 0.83,
NNT 15 CI 11 to 33). The longest study, Meltzer (InterSept), found
no difference between groups for the outcome of diabetes mellitus
at two years. Equivocal results were reported for agitation, anxiety,
fever,  flu  syndrome,  increase  in  SGPT,  increase  in  transaminase,
sweating, tooth disorder and postural hypotension.

6.5.3 Sleep problems
No  statistical  differences  were  reported  in  the  trials  between
olanzapine  and  risperidone  at  six  to  eight  weeks  for  insomnia
or  somnolence.  At  18  to  26  weeks,  people  on  olanzapine  had
less  insommia  (n=255,  RR  0.34  CI  0.20  to  0.60,  NNT  5  CI  4  to  8),
whilst those on olanzapine at two years were more likely to suffer
greater  insomnia  (n=980,  RR  1.57  CI  1.28  to  1.93,  NNH  9  CI  6  to
18). At 18 to 26 weeks, there was no difference for the outcome of
somnolence, whilst at two years, people on olanzapine experienced
less somnolence (n=980, RR 0.57 CI 0.48 to 0.67, NNT 5 CI 5 to 7).

6.5.4 Weight
Differences  in  weight  in  the  short  and  medium  term  were
equivocal.  However,  at  two  years,  significantly  more  participants
had gained weight on olanzapine than clozapine (1 RCT, n=980, RR
1.73  CI  1.49  to  2.00,  NNH  5  CI  4  to  7).  End  point  data  reported  in
three trials at three to 12 months, and one study at over 12 months
were equivocal. However, change data in the short term revealed
an  increase  in  weight  for  those  taking  olanzapine  compared  to
comparator (3 RCTs, n= 463, WMD 1.42 CI 0.62 to 2.23).

6.5.5 Other
A single study (de Haan 2002) reported equivocal skewed data at
six weeks for the outcome of obsessive compulsive disorder.

6.6 Quality of life
Lecrubier  1999,  Thomas  1998  (HGBU)  and  Tran  1997  (HGBG)
employed two continuous data scales relating to quality of life and
results were equivocal at three to 12 months

6.7 Service outcomes
Martin 2002 reported equivocal data for discharged from hospital
(short  term:  two  months).  Meltzer  (InterSept)  reported  equivocal
results for an increase in levels of surveillance for those who were
suicidal. Those taking olanzapine were more likely to be admitted
to hospital as a rescue intervention than those on clozapine at two
years (n=980, RR 1.28 CI 1.02 to 1.61, NNH 18 CI 9 to 251).

6.7 Missing data
No  data  were  reported  on  additional  medication  (other
than  anticholinergics  or  benzodiazepines),  social  functioning,
employment  status,  cognitive  functioning  and  cost  effectiveness.
Data  on  satisfaction  with  treatment  were  provided  by  the  Drug
Awareness Inventory, but has yet to be included as we are still trying
to identify the validity of the measure and its meaning.

7. COMPARISON 6. OLANZAPINE versus ATYPICAL ANTIPSYCHOTICS
FOR PEOPLE WITH TREATMENT RESISTANT ILLNESS

Four  trials  compare  olanzapine  to  clozapine  for  people  whose
illness were resistant to treatment (Beuzen 1998 (HGCF), Bitter 2004
(HGCK), Kelly 2003, Naber 2001 (HGBF).

7.1 Death
Unpublished data supplied by the trialists of Beuzen 1998 (HGCF)
reveal no deaths in either group (n=180).

Cochrane Database of Systematic Reviews

7.2 Global effect - No important response
Beuzen 1998 (HGCF) and Bitter 2004 (HGCK) used two criteria for
improvement when comparing olanzapine with clozapine (CGI and
Kane  1988  criteria).  Results  from  both  favour  neither  drug  at  18
weeks.

7.3 Mental state
7.3.1 No important clinical response (20% reduction in PANSS total
score)
There is no clear difference between olanzapine and clozapine (2
RCTs, n=330, RR 1.0 CI 0.68 to 1.49).

7.3.2 Total score
Beuzen  1998  (HGCF)  reports  BPRS  and  PANSS  total  endpoint
scores. BPRS data are skewed and therefore problematic to present
by  graph,  but  do  not  suggest  a  clear  difference  between  groups.
PANSS total scores are equivocal (n=176, MD 0.03 CI -8.07 to 8.13).

7.3.3 Negative symptoms
When  skewed  negative  sub-scores  are  extracted  from  the  BPRS,
no  differences  between  olanzapine  and  clozapine  are  revealed.
PANSS negative sub-scores are parametric and also show no clear
differences (1 RCT, n=176, MD -0.75 CI -2.9 to 1.4).

7.3.4 Positive symptoms
Positive  symptoms  sub-scores  of  the  BPRS  are  also  skewed  and
uninformative. Data are equivocal.

7.4 Leaving the study early
7.4.1 Any reason
Data are equivocal at eight weeks and by three to 12 months almost
half had left both groups.

7.4.2 Due to lack of efficacy
Data  from  Beuzen  1998  (HGCF)  and  Bitter  2004  (HGCK)  are
equivocal.

7.5 Adverse effects
7.5.1 Anticholinergic effects
Results  for  salivation  are  equivocal.  Constipation  is  less  of
a  problem  for  people  taking  olanzapine  compared  with  those
allocated clozapine (1 RCT, n=180, RR 0.35 CI 0.15 to 0.85, NNT 9 CI
7 to 38).

7.5.2 Extrapyramidal effects
Mean  data  from  the  HAS  and  the  AIMS  and  the  SAS  do  not
demonstrate a difference between groups, neither do the data on
akathisia.

7.5.3 Other
Those on olanzapine suffer less nausea (n=180, RR 0.10 CI 0.01 to
0.77, NNT 11 CI 10 to 40) and somnolence (2 RCTs, n=310, RR 0.54
CI 0.32 to 0.88, NNT 10 CI 7 to 38) compared with clozapine. Results
are equivocal for the outcomes of agitation, anxiety, asthenia, back
pain,  decrease  in  white  blood  cells,  fever,  flu  syndrome,  postural
hypotension, sweating, tooth disorder, vomiting and weight gain.

8. COMPARISON 7. OLANZAPINE versus ATYPICAL ANTIPSYCHOTICS
FOR FIRST EPISODE

One six week trial (Svestka 2003) with 42 females is included in this
comparison.

8.1 Global effect - No important response

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

15

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Equivocal data from this one small study are reported.

8.2 Adverse events
8.2.1 Anticholinergic effects
Less people taking olanzapine complained of rhinitis (n=42, RR 0.13
CI 0.02 to 0.91, NNT 4 CI 3 to 30).

8.2.2 Extrapyramidal - needing anticholinergic medication
Fewer  participants  taking  olanzapine  required  anticholinergic
medication (n=42, RR .38 CI 0.17 to 0.89, NNT 3 CI 2 to 15).

8.2.3 Extrapyramidal - any report
People taking risperidone reported more extrapyramidal adverse
events (n=42, RR 0.4 CI 0.19 to 0.83, NNT 3 CI 2 to 9).

8.2.4 Hyperprolactineamia
Hyperprolactineamia  was  more  common  in  people  taking
risperidone (n=42, RR 0.24 CI 0.10 to 0.58, NNT 2 CI 2 to 3).

D I S C U S S I O N

1. Applicability of results
The  largest  trials  were  multi-centre  and  conducted  primarily
within  the  western  world,  although  smaller  studies  have  been
reported from countries such as Morocco and Taiwan. Participants
had operationally diagnosed disorders in the main uncomplicated
by co-morbidity. The large Tollefson 1997(HGAJ) study, dominant
within  the  important  olanzapine  versus  typical  antipsychotics
comparison,  however,  appeared  more  representative  of  day-to-
day  practice  because  those  with  co-morbid  disorders  were  not
excluded. More of the recently included studies come from China,
Korea,  and  east  Europe,  with  less  originating  from  the  USA  and
the  UK.  Meltzer  (InterSept)  is  the  longest  study  (two  years),  and
uses outcomes based on more real world relevance to people with
schizophrenia and clinicians alike. The inclusion criteria were more
closely matched to those seen in clinical practice than in previous
research trials. We welcome the inclusion of many more trials from
China  and  are  seeking  further  information  on  a  number  of  these
trials so we can include additional outcomes. Data which have been
included from these trials show a marked difference in the ability
of  their  participants  to  remain  in  the  studies  compared  with  the
high  attrition  rates  seen  in  the  west.  To  summarise  we  get  some
impression of change over time with the setting, participants and
outcomes of trials becoming slightly more like everyday practice.

2. Reporting of adverse event data
Most  trials  only  reported  adverse  events  if  their  incidence  was
either  statistically  significant  or  had  a  frequency  of  10%  or
greater  which  results  in  rare  adverse  effects  being  ignored.  If
this policy had been implemented rigorously in other drug trials,
the agranulocytosis of clozapine and ocular problems associated
with thioridazine would have gone unreported. Eli Lilly has kindly
provided  us  with  unpublished  COSTART  adverse  event  data  for
many of the studies and so we are able to report more adverse effect
data than is seen in the final reports of the studies. It is, however
still very problematic that the >10% frequency rule for reporting of
adverse effects is still used as a device in these influential trials.

3. Limited data
A  great  deal  of  global  effect/mental  state  data  are  missing  from
the  studies  supplied  by  Eli  Lilly  and  we  have  been  informed  that
rights to these data are not available even to the company. Efforts
have  been  made  to  contact  authors  to  acquire  the  necessary

Cochrane Database of Systematic Reviews

information for inclusion in this review. It is frustrating that despite
considerable  investment  in  clinical  trials,  data  are  so  limited  on
tolerability, social functioning, employment, death, legal problems,
cognitive functioning and satisfaction. In addition, data on hospital
admission,  outpatient/day  hospital  visits  seems  to  have  been
collected  by  several  studies  but  only  reported  in  a  useable  form
in one study, Beasley 1996a (HGAD). We find it surprising that a
compound worth in excess of $3.69bn per year (Sellers 2003) is so
successful even though there is a lack of important data for people
with schizophrenia, their families and professional carers.

4. The search
Researchers have studied a remarkably successful dissemination
of  results  through  academic  presentations  both  at  conferences
and  in  journals.  It  is  likely  that  even  the  hundreds  of  citations  to
included  studies  within  this  review  represent  only  a  proportion
of presentations of these trials. Understandably the larger studies
have attracted more publications or conference presentations. We
have found no evidence of an attempt to conceal the fact that the
hundreds of presentations relate to a limited number of studies but
inclusion of the unique company trial codes in each presentation
would have helped piece together the few sausages from the very
thinly sliced salami.

Sponsorship or involvement with a pharmaceutical company was
apparent  in  38  of  the  55  included  studies  (69%).  Although  high,
this figure may be an underestimate, as in many reports, potential
conflicts  of  interest  or  acknowledgements  were  not  recorded.
Sponsorship  of  trials  by  the  pharmaceutical  industry  continues
to  cause  concern  (Offerhaus  2004)  and  the  continued  need  for
independent research is advocated (Hoadley 2004).

5. COMPARISON 1: OLANZAPINE versus PLACEBO
At  the  end  of  these  trials  the  extent  of  those  who  had  'dropped
out'  (olanzapine  52%,  placebo  53%)  was  of  such  a  magnitude
that  all  results,  except  for  those  of  'leaving  the  study  early',  are
overly full of assumptions making it impossible to reach a confident
interpretation.

5.1 Global effect
This outcome is based on only two studies. Beasley 1996a (HGAD),
a study that did not extrapolate BPRS from the PANSS, gives 75%
of  the  weighting  to  the  final  result.  The  fact  that  approximately
eight  people  have  to  be  treated  with  olanzapine,  as  compared
with  placebo,  in  order  for  one  person  to  improve  at  six  weeks  is
encouraging of olanzapines' antipsychotic properties. However, it
would be more reassuring if this finding was based on more direct
measures of all participants and was sustained in the long term. The
CGI continuous data also favour olanzapine. Clinical interpretation
of a weighted mean difference of -0.523 is, however, problematic.
When analysed by dose, the effect was only seen with the 15 mg/
day and 10 mg/day olanzapine groups.

5.2 Mental state
5.2.1 Total scores
Change  in  total  BPRS  and  PANSS  scores  favour  olanzapine  over
placebo.  However,  interpretation  of  an  average  change  of  seven
BPRS points or 12 in the PANSS scoring is problematic, especially
considering  that  over  50%  of  data  are  'last-observation-carried-
forward',where the trialists assume that the person remains stable
after  their  last  rating.  These  scales  also  do  not  produce  'interval'
data (so a 20% decline from 100 to 80 is not the same clinically as

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

16

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

a 20% decline from a score of 50 to 40). These scales dont report
clinically meaningful outcomes.

to be looking for major change in mental state/behaviour in those
diagnosed as acutely ill.

5.2.2 Negative/positive sub-scores
The  same  applies  to  the  negative  and  positive  sub-scores  as
measured with the BPRS and PANSS. The SANS data, for negative
symptoms, were equivocal and other information sheds doubt on
olanzapine's advantage over placebo for these difficult symptoms.

Incomplete data from ratings of positive symptoms suggest some
effect for olanzapine. It is, however, unclear how to use these data
to inform those with schizophrenia or their carers.

5.3 Leaving the study early
There  was  great  attrition  from  these  studies.  Over  a  six-week
period, fewer of those given olanzapine left the study early (52%)
than  those  given  placebo  (53%),  NNT  14  CI  8  to  95,  but  the
numbers  are  still  high.  Even  if  this  result  is  secondary  to  clinical
improvement, such a degree of loss must suggest that there was
some factor within the design of the study that was unacceptable
to  participants.  By  one  year  almost  everyone  had  left  the  key
study in this area (Beasley 1996a (HGAD)) making any other data
impossible  to  interpret.  When  lack  of  efficacy  is  cited  as  the
reason for attrition, data are supportive of olanzapine's short term
antipsychotic effects.

5.4 Adverse effects
Olanzapine has anticholinergic adverse effects, causing dry mouth
and  dizziness,  but  this  is  not  significantly  more  apparent  than
placebo  from  analysis  of  the  current  data  in  this  review.  Specific
extrapyramidal symptoms (akathisia and tremor) appeared higher
in the olanzapine group, although this did not reach statistical or,
probably, clinical significance. This is supported by the similar use
of  anticholinergic  medication  in  the  two  groups.  In  addition  all
scale  data  relating  to  movement  disorders  showed  no  important
differences  between  olanzapine  and  placebo.  Data  on  nausea/
vomiting  and  sleepiness  are  equivocal,  but  all  are  based  on
information that makes a great deal of assumptions.

Data  supplied  by  Eli  Lilly  show  that  weight  increases  with
olanzapine,  even  in  short  studies,  although  this  did  not  reach
conventional  levels  of  statistical  significance  (at  six  weeks  WMD
3.58kg CI -1.18 to 8.34). Nearly four kilograms in six weeks would
probably be of clinical significance.

5.5 Quality of life
It  is  unfortunate  that  Beasley  1996a  (HGAD)  did  not  fully  report
quality  of  life  data  (Hamilton  1998).  What  limited  data  there  are
come  from  Lecrubier  1999.  The  data  are  interesting  and  should
encourage Eli Lilly to find more powerful data for dissemination.

5.6 Missing outcomes
Data were collected regarding inpatient or outpatient status, but,
again,  the  published  reports  do  not  tell  us  the  results.  This  must
undermine confident use of olanzapine.

6. COMPARISON 2. OLANZAPINE verus PLACEBO (three to five days)

6.1 Global effect
It is difficult to know what to make of many of the outcomes in this
very short term study on a population taking clozapine. One could
surmise  that  this  is  a  treatment  resistant  or  treatment  intolerant
group  as  they  were  switched  from  clozapine  to  olanzapine.
(Clozapine is only licensed in this group.) It would be unreasonable

6.2 Mental state
PANSS total scores at five days favours olanzapine, however, the
clinical  significance  of  a  mean  difference  of  -5.23  on  this  scale  is
unclear,  and  results  of  the  positive  and  negative  subscales  were
equivocal.  We  find  the  utility  of  the  MMSE  for  a  group  of  people
acutely ill with schizophrenia puzzling. Depression scores favoured
olanzapine.

6.3 Leaving the study early
Unsurprisingly, few dropped out of this very short study.

6.4 Adverse events
Olanzapine-treated participants reported similar levels of adverse
events as those taking placebo.

6.5 Missing outcomes
The single trial did not report on hospitalisation status or quality
of life.

7. COMPARISON 3: OLANZAPINE versus TYPICAL ANTIPSYCHOTICS

7.1 Death
Only one study reported this important outcome. Eli Lilly supplied
us with data from a further two trials. Results indicate there is no
substantive difference in the numbers of people who have died due
to  suicide,  accidental  injury  or  other  causes  between  olanzapine
and other typical antipsychotic.

7.2 Global effect
From data presented in this review there are no clear differences
between  olanzapine  and  typical  drugs  for  the  outcome  of  'no
important  clinical  response  at  six  to  eight  weeks'.  Using  odds
ratios does make a statistically significant difference, but in these
heterogeneous  data,  random  effects  relative  risk  analyses  are
advisable.  The  latter  makes  the  result  not  statistically  significant
and this is still true at twelve weeks and nine months.

CGI  endpoint  data 
antipsychotics both at six weeks and at three to twelve months.

favours  olanzapine  over 

the 

typical

7.3 Mental state
People taking olanzapine required less additional benzodiazepines
than  those  taking  typical  drugs  implying  that  they  are  less
disturbed as a result of taking the olanzapine.

Scale  derived  data  differs  in  the  presented  outcomes.  BPRS  did
not  favour  the  olanzapine  group  when  compared  with  typical
antipsychotics (n=397), but more powerful PANSS data do favour
olanzapine. Gains are an average of a decline of six PANSS points
in the short term and medium term. The clinical relevance of these
scores remains unclear. Whether the PANSS is an interval scale, with
a six-point decline having the same clinical meaning for someone
who started with a score of 70, as for a person whose initial rating
was 30, is not explained by the trials.

Both positive and negative symptom PANSS-derived data favours
olanzapine, which underlines the impression that olanzapine is at
least  as  effective  an  antipsychotic  as  typical  drugs.  Montgomery
and Asberg Depression Scale data were skewed and with the data
provided in the studies, clinical interpretation of these scale data is
not possible.

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

17

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

less 

leave

likely  to 

7.4 Leaving the study early
People  allocated  to  olanzapine  were 
the  study  than  those  taking  typical  antipsychotics;  the  results
being  statistically  significant  or  not  dependent  on  the  analysis
undertaken.  We  suggest  the  most  conservative  random  effects
relative risk is more applicable (and only statistically significant at
three to twelve months). At four to eight weeks 34% of those taking
olanzapine and 45% of those taking a typical antipsychotic had left,
and beyond 52 weeks, this had risen to 83% and 90% respectively.
Such  attrition  makes  interpretation  of  all  the  other  data  virtually
impossible. These data suggest that clinicians should be confident
that all but a few of those given olanzapine will still be taking their
medication at the end of a year, provided the same study conditions
apply.

Supporting the unclear general effects, results for the comparison
of olanzapine versus typical drugs, when lack of efficacy is cited as
reason for attrition there are no differences between groups except
at three to 12 months where olanzapine is favoured.

7.5 Adverse effects
Current data pertaining to anticholinergic adverse effects, suggests
that  olanzapine  causes  less  hypersalivation  and  orthostatic
changes  than  typical  drugs.  Other  effects  such  as  dry  mouth,
dizziness,  palpitations,  constipation,  dry  mouth  and  urination
difficulties were as common as they were with the older drugs.

Data  on  a  series  of  specific  extrapyramidal  symptoms  favours
olanzapine  -  especially  when  compared  to  haloperidol.  Within
the  chlorpromazine  comparison  the  differences  were 
less
marked.  Heterogeneous  rating  scale  data  do  not  suggest  that
extrapyramidal effects are less marked with olanzapine, but clinical
interpretation  of  these  heterogeneous  data  is  not  possible.  We
view  the  use  of  additional  anticholinergic  medication  as  a  more
useful marker of extrapyramidal effects (both for those taking the
antipsychotics  and  their  carers)  and  this  is  lower  in  those  taking
olanzapine than the typical drugs.

More  people  treated  with  olanzapine  reported  an  increase  in
appetite  compared  to  those  taking  conventional  antipsychotics.
This  supports  clinical  experience.  The  data  on  weight  gain  is
equivocal  in  the  short-term  studies  and  shows  a  statistically
significant difference in the medium term, with those on olanzapine
gaining more weight. Jones 1998 (P022), a small study, is equivocal
regarding weight gain in the long-term and may be an example of
a Type II Error.

7.6 Quality of life
It is disappointing that large and important studies, such as Beasley
1996a (HGAD) and Tollefson 1997(HGAJ), report data on quality of
life in a form that is not possible to use in this review. We hope that
further collaboration with Eli Lilly will shed light on these data.

7.7 Economic outcomes
Statistical  significance  favours  olanzapine  for  cost  effectiveness,
but again no usable data are provided to support this claim.

7.8 Cognitive function
Jones 1998 (P022) reported data on cognitive functioning that are
not possible to use in this review. As this topic gains interest, it is
likely that more data will be forthcoming in future studies.

7.9 Missing outcomes

Cochrane Database of Systematic Reviews

Conclusions cannot be drawn for outcomes of social functioning or
satisfaction for this popular commonly used drug.

8. COMPARISON 4. OLANZAPINE versus TYPICAL ANTIPSYCHOTICS
FOR PEOPLE WITH TREATMENT RESISTANT ILLNESS

Both Conley 1998 and Altamura 1999 (HGBQ) compared olanzapine
with  typical  antipsychotics  (chlorpromazine  and  haloperidol
respectively)  in  people  whose  illnesses  were  rated  as  treatment
resistant.  Olanzapine  has  been  marketed  as  being  structurally
similar  to  clozapine;  a  drug  with  efficacy  in  treatment  resistant
patients  (Wahlbeck  1999).  The  effects  of  olanzapine  in  this  sub-
group of people with schizophrenia are important. Although both
studies focused on treatment-resistant participants, who would, by
definition, have long-standing illness, the studies were classified as
short-term (Conley 1998) and medium-term Altamura 1999 (HGBQ).
Altamura 1999 (HGBQ) did not describe the setting of the study.

8.1 Global effect
Conley  1998  defined  'no  important  clinical  response'  as  the
number  of  people  per  group  who  did  not  present  at  least  a  20%
reduction in psychotic symptoms measured by any scale. At eight
weeks  there  was  no  difference  between  the  two  groups.  The
continuous measure (Clinical Global Impression) corroborated this
finding.  It  appears  that  olanzapine  has  similar  global  effects  to
typical  antipsychotics  on  those  with  treatment  resistant  illness
but  this  may  reflect  a  Type  II  Error  and  these  findings  require
replication.

8.2 Mental state
In keeping with the equivocal result for 'global effect', mental state
measures (total BPRS, SANS, positive symptom sub-score BPRS) do
not appear significantly different.

8.3 Leaving the study early
Similar  numbers  of  people  left  the  studies  early  for  'any  reason'
and due to 'lack of efficacy', although rates were less than for those
with non-treatment-resistant illness. This may reflect the severity
of their illness, and the likelihood that they are inpatients.

8.4 Adverse events
Data  were  only  available  from  Conley  1998  on  the  outcome  of
anticholinergic  effects,  where  more  people  on  chlorpromazine
experienced  dry  mouth.  It  is  clear,  however,  that  olanzapine  has
important anticholinergic effects, as the incidence of blurred vision
and  dizziness  was  similar  in  both  groups.  More  people  taking
chlorpromazine experienced orthostatic changes and palpitations
than those on olanzapine.

For  extrapyramidal  events  again  data  were  only  available  from
Conley  1998  where  fewer  people  taking  olanzapine  experienced
these symptoms. Until the findings of this trial are replicated, it is
inadvisable to draw definitive conclusions regarding the incidence
of movement disorders in relation to olanzapine. Much of the scale
data were uninformative.

In  this  small  study  (Conley  1998),  olanzapine  was  no  less
sedating  than  chlorpromazine  although  the  results  suggested
that,  with  larger  numbers,  and  more  power  and  precision,  the
experimental drug might have shown significantly less drowsiness
than chlorpromazine. Data on weight gain were only available from
the  Altamura  1999  (HGBQ)  medium-term  study.  Although  when
comparing  baseline  weights  with  endpoint  weight,  those  taking

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

18

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

olanzapine gained weight whilst those on haloperidol did not, this
did not reach statistical significance. Data relating to the question
of  weight  gain  remain  limited  but  none  suggest  that  olanzapine
causes weight to decrease.

8.5 Missing outcomes
No  quality  of  life  data  or  cost  effectiveness  data  are  reported.
Conclusions  cannot  be  drawn  for  the  outcomes  of  social
functioning, employment status, death and cognitive functioning
or family satisfaction.

9. COMPARISON 5. OLANZAPINE versus ATYPICAL ANTIPSYCHOTICS

Twenty  seven  studies  compared  olanzapine  with  atypical
antipsychotics. These trials contained a mix of patient populations
including  first  episode  (Siesta  2003)  and  elderly  people  (Jeste
2003,  Ritchie  2003),  whereas  Tran  1997  (HGBG)  excluded  people
whose  illness  was  'treatment  resistant'  and  Jones  1998  (P022)
studied  'stable,  early  phase  outpatients'.  Four  studies  included
only treatment-resistant participants (Beuzen 1998 (HGCF), Bitter
2004  (HGCK),  Kelly  2003  and  Naber  2001  (HGBF))  and  used
clozapine, a drug effective in this group (Wahlbeck 1999). Thomas
1998  (HGBU)  did  not  expand  on  description  further  than  DSM-
IV  criteria,  whereas  Lecrubier  1999  described  the  participants  as
suffering from 'primarily negative symptoms'. Martin 2002 utilised
amisulpride as the comparator antisychotic, and randomised both
inpatients and outpatients.

9.1 Death
Again this important outcome is poorly reported. There were no
significant differences in deaths reported in any study. Within well-
conducted trials there are likely to be fewer deaths than amongst
people with the same condition who are not part of a controlled
study.

9.2 Global effect
At this point there are no clear differences between olanzapine and
other atypicals for CGI data or clinical response. Data from a single
study does suggest that rehospitalisation is lower for those given
olanzapine when compared with risperidone.

9.3 Mental state
In the short and medium term similar proportions on olanzapine
and other atypicals required additional benzodiazepines, however,
by  two  years  more  people  taking  olanzapine  required  additional
benzodiazepines 
two  years
antidepressants had been used more frequently in the olanzapine
treated group.

those  on  clozapine.  At 

than 

When mental state percentage improvements were used to classify
response  there  was  no  difference  between  olanzapine  and  other
atypicals. In the short term however, medium term data favoured
olanzapine.

Endpoint data from ratings scales reveal inconsistencies with the
majority  of  comparisons  being  equivocal.  Olanzapine  does  not
appear  to  be  any  different  to  the  other  atypical  antipsychotics
on the outcome measured by mental state rating scales. Negative
symptoms  were  not  clearly  more  amenable  to  olanzapine  than
other drugs of the atypical class.

9.4 Leaving the study early
This was a prevalent behaviour in both groups for all time periods
with 49% lost in the olanzapine group and 56% in the comparator

Cochrane Database of Systematic Reviews

group by 12 months. Nevertheless attrition of such a degree must
draw  into  question  the  external  validity  of  all  other  data.  Similar
proportions left due to lack of efficacy of trials.

9.5 Adverse effects
Some  anticholinergic  effects  appear  less  prevalent  in  the
olanzapine treated group (constipation, hypersalivation) whereas
dry mouth is more of a problem for those taking olanzapine.

taking  olanzapine 

received  anticholinergic
Fewer  people 
medication  compared  to  those  taking  other  atypicals.  At  eight
weeks  similar  proportions  in  the  two  groups  had  complained  of
any extrapyramidal event, however, by three to 12 months this was
more apparent in those taking other atypicals. New occurrences of
parkinsonism  were  fewer  in  the  olanzapine  group.  At  three  to  12
months akathisia was similar in the two groups, by two years it was
higher in the olanzapine treated group.

Treatment emergent effects were less common in the olanzapine
group.

Data  reported  at  two  years  by  Meltzer  (InterSept)  revealed  lower
rates  of  dyspepsia,  asthenia,  nausea,  vomiting  and  reduction  in
white blood cell count in people taking olanzapine compared with
those allocated to clozapine.

Sleep  problems  reveal  inconsistencies  with  both  insomnia  and
somnolence being side effects.

Weight gain appears to be more of a problem with olanzapine than
other atypicals, although dichotomous data reached conventional
levels of statistical significance only at two years. By eight weeks
those taking olanzapine had gained significantly more weight than
those taking other atypicals.

9.6 Quality of life
No difference is apparent between atypicals and olanzapine on two
continuous measures of quality of life. It is good to see an attempt
to  measure  this  elusive  but  important  issue.  However,  simple
outcomes such as 'gaining employment' or 'avoiding trouble with
the police' or 'feeling that life has improved in quality' may have
resulted in more comprehensible information.

9.7 Service outcomes
Those  people  taking  olanzapine  in  the  Meltzer  (InterSept)  study
required  significantly  more  admissions  to  hospital  and  increased
levels  of  surveillance  to  maintain  their  safety  compared  to  the
clozapine group.

9.8 Missing data
Social  function  outcomes  were  absent  as  were  data  relating
to  harm,  cognitive  functioning  and  cost  effectiveness.  Data  on
satisfaction with treatment were provided by the Drug Awareness
Inventory, but has yet to be included while we try to identify validity
and meaning.

COMPARISON 

10. 
ATYPICAL
ANTIPSYCHOTICS  FOR  PEOPLE  WITH  TREATMENT  RESISTANT
ILLNESS

OLANZAPINE 

versus 

6. 

As  olanzapine's  structural  similarity  to  clozapine  is  cited  in
marketing, the authors decided to incorporate a comparison with
clozapine for people whose illness is treatment resistant.

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

19

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

10.1 Death
Again this important outcome was not reported. That no deaths
occurred  in  this  trial  (Beuzen  1998  (HGCF))  of  180  participants  is
reassuring  but  longer-term  real-world  studies  are  needed  before
any firm conclusions can be drawn.

10.2 Global effect
No  differences  on  global  effect  as  measured  by  the  CGI  or  Kane
1988 criteria were apparent, although this may be a Type II Error
because of the small sample size. It is nevertheless interesting that
there are no clear differences between olanzapine and clozapine in
a treatment-resistant group of people for this outcome but more
data are needed.

10.3 Leaving the study early
At 18 weeks (medium term) similar numbers had left the study early
(46%). Olanzapine, in the context of a randomised trial, is just as
acceptable or unacceptable as clozapine.

10.4 Adverse events
Constipation,  nausea  and  somnolence  are  less  of  a  problem  for
those on olanzapine compared with clozapine.

10.5 Missing data
Again, no data were reported relating to social functioning, quality
of life or cost effectiveness.

COMPARISON 

11. 
7. 
ANTIPSYCHOTICS FOR PEOPLE WITH FIRST EPISODE

OLANZAPINE 

versus 

ATYPICAL

One small study of women with first episode of illness was included
(Svestka 2003) and compared olanzapine with risperidone.

11.1 Global effect
Equivocal data from this one small study are reported.

11.2 Adverse events
Fewer  participants  taking  olanzapine  required  anticholinergic
medication or reported any extrapyramidal adverse events.

Hyperprolactineamia  was  more  common 
risperidone though the clinical significance of this is unclear.

in  people  taking

A U T H O R S '   C O N C L U S I O N S

Implications for practice

1. For people with schizophrenia
For  people  with  less  severe  schizophrenia,  olanzapine  offers
antipsychotic efficacy with fewer movement disorders. If the illness
is  more  severe,  then  there  is  little  to  choose  between  any  of  the
typical  or  atypical  drugs  except  on  the  issue  of  adverse  effects
such as parkinsonism. Olanzapine is effective in reducing negative
symptom  scores  on  a  mental  state  rating  scale,  but  the  clinical
relevance  of  this  result  is  unclear.  These  findings  alone  may  be
enough  to  support  people  with  schizophrenia  trying  olanzapine
before the typical antipsychotic drugs. Olanzapine's propensity to
cause weight gain may, however, be unacceptable to many.

2. For clinicians
The  very  great  losses  to  follow  up  make  recommendations
difficult.  In  these  trials  most  people  given  olanzapine  stopped
taking the drug within six months to one year. Global impression
suggests that 10-15 mg/day of olanzapine is antipsychotic, being

Cochrane Database of Systematic Reviews

better  than  placebo,  but,  for  people  with  severe  illness,  when
compared  with  typicals  and  atypicals  there  is  little  difference
for  the  same  outcome.  On  one  sub-scale  score,  of  one  mental
state  rating  scale,  olanzapine  shows  superiority  over  typical
antipsychotics  for  negative  symptoms.  This  result  is  difficult  to
interpret clinically. Such findings need replication in large simple
studies  and  should  not  form  the  evidence  base  of  treatment
recommendations.  Olanzapine  may  have  fewer  extrapyramidal
effects  than  chlorpromazine  and  haloperidol  and,  perhaps,  than
risperidone. Despite poor data regarding the effects of olanzapine
on weight, it does seem to encourage rapid weight gain. However,
it  is  unclear  as  to  whether  this  weight  gain  continues  while  the
person  is  taking  olanzapine  and  if  the  weight  is  lost  if  the  drug
is  stopped.  Currently  not  enough  data  relating  to  those  with
treatment-resistant schizophrenia are available to draw definitive
conclusions.

3. For managers/policy makers
Olanzapine  is  expensive  when  compared  with  the  typical
antipsychotics.  For  people  making  cost-effectiveness  and  cost-
utility  decisions,  there  is  little  useful  trial-derived  data  to  help
decision making.

Implications for research

1. General
Clear and strict adherence to the CONSORT statement (Moher 2001)
for  all  outcomes  would  have  resulted  in  this  review  being  more
informative. Denominator data were not always clearly presented
and some results were described as 'significant' or not, but raw data
were not reported (Beasley 1996a (HGAD), Tollefson 1997(HGAJ)).

2. Specific
2.1 Trial identifiers
The  authors  have  had  to  inspect  a  very  great  number  of
presentations of the few trials included in this review and there are
likely to be more that we have not yet discovered. Using specific
trial  identifiers,  within  the  multiple  publications,  would  greatly
decrease confusion over identification of the source trial.

longer,  conducted  and  reported

2.2 More studies
Additional  well  planned, 
randomised  controlled  trials  are  needed  that  address  important,
relevant  outcomes.  Conflict  free  funding  is  justified.  High-quality
trial-derived data relating to hospital admission, satisfaction with
care,  family  burden,  employment,  and  important  adverse  effects
such  as  weight  gain  are  lacking.  Dichotomous,  clinically  useful
data relating to mental state and behaviour need replication and
expansion.  Useful  cost-effectiveness  data  needs  to  be  a  research
priority.

A C K N O W L E D G E M E N T S

The reviewers would like to thank:

Charles M Beasley Jr for prompt and willing assistance in supplying
extra  data,  and  George  Duggan  and  Rosie  Fenton  for  patience
beyond the call of duty.

Eli Lilly and their contact person, Anne-Marie Crawford, have been
exceedingly  helpful  in  identifying  and  supplying  extra  data  from
unpublished trials, and clarifying any questions we have had about
data.

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

20

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Janssen-Cilag  and  their  contact,  Clive  Rogers,  for  supplying
additional data.

We  would  like  to  express  our  gratitude  to  trialists  who  have
responded  to  the  many  requests  for  information,  and  provided
printed copies of articles or additional data.

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

21

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

R E F E R E N C E S

References to studies included in this review

Altamura 1999 (HGBQ) {published and unpublished data}

Altamura AC, Eli Lilly Data Compilers. HGBQ - Olanzapine
verus haloperidol in partial responder schizophrenic patients.
Supplied by Eli Lilly 2000.

Altamura AC, Velona I, Curreli R, Bravi D. Olanzapine
in the treatment of paranoid schizophrenia. European
Neuropsychopharmacology 1999;9(Suppl 5):S297.

*  Altamura AC, Velona I, Curreli R, Mundo E, Bravi D. Is
olanzapine better than haloperidol in resistant schizophrenia?
A double-blind study in partial responders. International
Journal of Psychiatry in Clinical Practice 2002;6(2):107-11.
[EMBASE&#160; 2002201401; CN-00443300.]

Avasthi 2001 {published data only}

Avasthi A, Kulhara P, Kakkar N. Olanzapine in the treatment of
schizophrenia: an open label comparitive trial from North India.
Indian Journal of Psychiatry 2001;43(3):257-63.

Barak 2002 {published data only}

Barak Y, Shamir E, Zemishlani H, Mirecki I, Toren P, Weizman R.
Olanzapine vs. haloperidol in the treatment of elderly chronic
schizophrenia patients. Progress in Neuro-Psychopharmacology
& Biological Psychiatry 2002;26:1199-202. [MEDLINE: 22339706;
PMID 12452546]

Beasley 1996a (HGAD) {published and unpublished data}

*  *Beasley CM Jr, Tollefson G, Tran P, Satterlee W, Sanger T,
Hamilton S. Olanzapine versus placebo and haloperidol: acute
phase results of the North American double-blind olanzapine
trial. Neuropsychopharmacology 1996;14:111-23.

Baker R W, Julier B, Stauffer V. Manic-like symptoms in
schizophrenic patients treated with olanzapine, haloperidol and
placebo. 7th World Congress of Biological Psychiatry; 2001 Jul
1-6; Berlin, Germany. 2001; Vol. 2, issue Suppl. 1.

Baker RW, Ames D, Umbricht DSG, Chengappa KNR,
Schooler NR. Obsessive-compulsive symptoms in schizophrenia
- a comparison of olanzapine and placebo. Psychopharmacology
Bulletin 1996;32:89-93.

Beasley CM Jr, Tollefson GD, Tran PV. Safety of olanzapine.
Journal of Clinical Psychiatry 1997;58(Suppl 10):13-7.

Beasley CM, Sayler ME, Kiesler GM, Potvin JH, Sanger TM,
Tollefson GD. The influence of pharmacotherapy on self-
directed and externally-directed aggression in schizophrenia.
Schizophrenia Research 1998;29(1-2):28.

Beasley CM, Tollefson GD, Beuzen JN, Dellva MA, Sanger TM,
Paul S. Acute and long-term results of the North American
double-blind Olanzapine trial. Schizophrenia - Breaking
down the Barriers, 4th International Conference; October 6-9;
Vancouver; BC, Canada. 1996.

Crawford AM, Beasley CM, Tollefson GD. Olanzapine - impact
of an atypical antipsychotic candidate on prolactin release.

American Psychiatric Association, 149th Annual Meeting; May
4-9. 1996.

Crawford AM, Beasley CM, Tollefson GD. The acute and
long-term effect of olanzapine compared with placebo and
haloperidol on serum prolactin concentration. 10th European
College of Neuropsychopharmacology Congress; Sep 13-17;
Vienna, Austria. 1997.

Crawford AM, Beasley CM, Tollefson GD. The acute and
long-term effect of olanzapine compared with placebo and
haloperidol on serum prolactin concentrations. Journal of the
European College of Neuropsychopharmacology 1997;9:P2016.
[[NR692]]

Dellva MA, Tran P, Tollefson GD, Wentley AL, Beasley CM Jr.
Standard olanzapine versus placebo and ineffective-dose
olanzapine in the maintenance treatment of schizophrenia.
Psychiatric Services 1997;48:1571-7.

Edgell ET, Hamilton SH, Revicki DA, Genduso LA, Tollefson GD.
Costs of olanzapine treatment compared with haloperidol
for schizophrenia: results from a randomized clinical trial.
Proceedings of XXIst Collegium Internationale Neuro-
psychopharmacologicum; July 12-16; Glasgow, Scotland, UK.
1998.

Hamilton SH, Revicki DA, Genduso LA, Beasley CM Jr.
Olanzapine versus placebo and haloperidol: quality of life
and efficacy results of the North American double-blind trial.
Neuropsychopharmacology 1998;18:41-9.

Martin C, Genduso L, Revicki D, Hamilton S, Tran P, Beasley C.
Quality of life outcomes of olanzapine, a new atypical
antipsychotic agent. Schizophrenia Research 1996;18(2,3):130.
[CSG NO. 4087]

Perry PJ, Lund BC, Sanger T, Beasley. Olanzapine Plasma
consentrations and Clinical Response: Acute Phase Results
of the North American Olanzapine Trial. Journal of Clinical
Psychopharmacology 2001;21(1):14-20.

Revicki D, Genduso L. Effect of Olanzapine on deficit syndrome
symptoms in chronic schizophrenia. 8th European College of
Neuropsychopharmacology Congress; Sep 30 - Oct 4; Venice;
Italy. 1995.

Sanger T, Tollefson GD. A controlled study on the course
of primary and secondary negative symptoms. American
Psychiatric Association, 150th Annual Meeting; San Diego; CA,
USA. 1997.

Sanger T, Tollefson GD, Lieberman JA, Tohen M. Olanzapine
versus haloperidol in the treatment of first-episode psychosis.
American Psychiatric Association. 150th Annual Meeting; San
Diego; CA, USA. 1997.

Satterlee WG, Beasley CM, Tollefson GD, Moore N, Tran PV.
Preclinical and clinical observations of olanzapine (a new
antipsychotic). Psychopharmacology Bulletin 1994;30:638.

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

22

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Street J, Dellva M, Tamura R, Sanger T, Tollefson G. A
comparison of extrapyramidal syndromes between olanzapine
and placebo in schizophrenia. 9th Congress of the European
College of Neuropsychopharmacology, Amsterdam, The
Netherlands. 1996. [CSG NO. 3727]

Tollefson GD, Sanger TM, Beasley CM. The course of primary and
secondary negative symptoms in a placebo- and comparator-
controlled trial of the atypical antipsychotic olanzapine. 9th
European College of Neuropsychopharmacology Congress; Sep
21-25; Amsterdam; The Netherlands. 1996.

Street JS, Dellva MA, Tamura RN, Sanger T, Tollefson GD.
Comparison of extrapyramidal syndromes between olanzapine
and placebo in schizophrenia. American Psychiatric
Association, 149th Annual Meeting; May 4-9. 1996.

Street JS, Dellva MA, Tamura RN, Sanger T, Tollefson GD.
Comparison of extrapyramidal syndromes between olanzapine
and placebo in schizophrenia. XXth Collegium Internationale
Neuro-psychopharmacologicum; June 23-27; Melbourne;
Australia. 1996.

Street JS, Dellva MA, Tamura RN, Sanger T, Tollefson GD.
Comparison of extrapyramidal syndromes between olanzapine
and placebo in schizophrenia. Xth World Congress of Psychiatry;
August 23-28; Madrid; Spain. 1996.

Tollefson GD. The value of atypical antipsychotic medications.
American Psychiatric Association, 150th Annual Meeting; San
Diego; CA, USA. 1997.

Tollefson GD. Update on new atypical antipsychotics. 8th
European College of Neuropsychopharmacology Congress; Sep
30-Oct 4; Venice; Italy. 1995.

Tollefson GD, Beasley CM Jr, Tamura RN, Tran PV, Potvin JH.
Blind, controlled, long-term study of the comparative
incidence of treatment-emergent tardive dyskinesia with
olanzapine or haloperidol. American Journal of Psychiatry
1997;154(9):1248-54.

Tollefson GD, Beasley CM, Tran PV, Sanger T. Olanzapine: an
exciting atypical antipsychotic the clinical experience. 8th
European College of Neuropsychopharmacology Congress; Sep
30-Oct 4; Venice; Italy. 1995.

Tollefson GD, Sanger TM. Negative symptoms: a path analytic
approach to a double-blind, placebo and haloperidol controlled
clinical trial with olanzapine. American Journal of Psychiatry
1997;154:466-74.

Tollefson GD, Sanger TM, Beasley CM. The course of primary
and secondary negative symptoms in a controlled trial
with Olanzapine. XXth Collegium Internationale Neuro-
psychopharmacologicum; June 23-27; Melbourne; Australia.
1996.

Tollefson GD, Sanger TM, Beasley CM. The course of primary
and secondary negative symptoms in a controlled trial with
olanzapine. American Psychiatric Association, 149th Annual
Meeting; May 4-9. 1996.

Tollefson GD, Sanger TM, Beasley CM. The course of primary
and secondary negative symptoms in a controlled trial with
olanzapine. Schizophrenia Research (Special Issue - The VIth
International Congress on Schizophrenia Research; April 12-16;
Colorado Springs; CO, USA) 1997;24:192.

Tollefson GD, Sanger TM, Beasley CM, Tran PV. A double-blind,
controlled comparison of the novel antipsychotic olanzapine
versus haloperidol or placebo on anxious and depressive
symptoms accompanying schizophrenia.. Biological Psychiatry
1998;43(11):803-10. [CSG NO. 4252]

Tran P, Beasley C, Tollefson G, Beuzen J, Dellva M, Sanger T,
Paul S. Acute and long-term results of the North American
double-blind olanzapine trial. 8th European College of
Neuropsychopharmacology Congress. Sep 30-Oct 4, Venice,
Italy. 1995.

Tran PV, Beasley CM, Tollefosn GD, Sanger T, Satterlee WG.
Clinical efficacy and safety of olanzapine, a new atypical
antipsychotic agent. Neuropsychopharmacology
1994;10(Supp):267S. [MEDLINE: 21122407]

Tran PV, Beasley CM, Tollefson GD, Beuzen JN, Holman SL,
Sanger TM, Satterlee WG. Olanzapine: a promising atypical
antipsychotic agent. Schizophrenia Research 1995;15(1,2):169.
[CSG NO. 4030]

Tran PV, Dellva MA, Tollefson GD, Wentley AL, Beasley C Jr.
Oral olanzapine versus oral haloperidol in the maintenance
treatment of schizophrenia and related psychoses. British
Journal of Psychiatry 1998;172:499-505.

Williamson DJ, Tran PV, Beasley CM Tollefson GD, Sanger T,
Satterlee WG. Clinical efficacy and safety of olanzapine, a new
atypical antipsychotic agent. Journal of Psychopharmacology
1995;9(3):A47. [MEDLINE: 21122407]

Williamson DJ, Tran PV, Beasley CM, Satterlee WG, Sanger T,
Paul S, Tollefson GD. Additional clinical experience
with olanzapine, an atyical antipsychotic. Journal of
Psychopharmacology 1995;9(3):A47.

Wood AJ, Beasley CM, Tollefson GD, Tran PV.
Efficacy of olanzapine in the positive and negative
symptoms of schizophrenia. 7th European College of
Neuropsychopharmacology Congress; 1994 Oct 16-21;
Jerusalem, Israel. 1994:224-5. [MEDLINE: 21122407]

Beasley 1996b (HGAP) {published and unpublished data}

*  *Beasley Jr CM, Sanger T, Satterlee W, Tollefson G, Tran P,
Hamilton S. Olanzapine versus placebo - results of a double-
blind, fixed-dose olanzapine trial. Psychopharmacology
1996;124:159-67.

Baker R W, Julier B, Stauffer V. Manic-like symptoms in
schizophrenic patients treated with olanzapine, haloperidol and
placebo. 7th World Congress of Biological Psychiatry; 2001 Jul
1-6; Berlin, Germany. 2001.

Baker RW, Ames D, Umbricht DS, Chengappa KN, Schooler NR.
Obsessive-compulsive symptoms in schizophrenia: a
comparison of olanzapine and placebo. Psychopharmacology
Bulletin 1996;32(1):89-93.

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

23

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Beasley C, Tran P, Satterlee W, Tollefson G, Lu Y, Kuntz A,
Bradley P, Paul S. Olanzapine versus placebo, results of the
United-States double-blind olanzapine trial. XXth Collegium
Internationale Neuro-psychopharmacologicum; June 23-27;
Melbourne; Australia. 1996.

Beasley CM Jr, Dellva MA, Tamura RN, Morgenstern H,
Glazer WM, Ferguson K, Tollefson GD. A randomized, double-
blind comparison of the incidence of tardive dyskinesia during
long-term treatment with olanzapine or haloperidol. British
Journal of Psychiatry 1999;174:23-30.

Beasley CM Jr, Tollefson G, Tran P, Satterlee W, Sanger T,
Hamilton S & the Olanzapine HGAD study group. Olanzapine
versus placebo and haloperidol: acute phase results
of the North American double-blind olanzapine trial.
Neuropsychopharmacology 1996;14(2):111-23.

Beasley CM Jr, Tollefson GD, Tran PV. Safety of olanzapine.
Journal of Clinical Psychiatry 1997;58(Suppl 10):13-7.

Beasley CM, Sayler ME, Kiesler GM, Potvin JH, Sanger TM,
Tollefson GD. The influence of pharmacotherapy on self-
directed and externally-directed aggression in schizophrenia.
Schizophrenia Research 1998;29(1-2):28.

Crawford AMK, Beasley CM Jr, Tollefson GD. The acute and
long-term effect of olanzapine compared with placebo and
haloperidol on serum prolactin concentrations. Schizophrenia
Research 1997;26:41-54.

Dellva MA, Tran PV, Tollefson GD, Wentley AL, Beasley CM Jr.
Standard-dose oral olanzapine versus placebo/ineffective dose
olanzapine in the maintenance treatment of schizophrenia.
Psychiatric Services 1997;48(12):1571-7.

Hamilton, S H, Revicki, D A, Genduso, L A, Beasley. C M J.
Olanzapine versus placebo and haloperidol: quality of life
and efficacy results of the North American double-blind trial.
Neuropsychopharmacology 1998;18:41-9.

Jones B, Crawford AMK, Beasley CM Jr, Tollefson GD. The acute
and long-term effect of olanzapine compared with placebo and
haloperidol on serum prolactin concentrations. Schizophrenia
Research 1998;29(1-2):204-5.

Perry PJ, Sanger T, Beasley C. Olanzapine plasma
concentrations and clinical response in acutely ill
schizophrenic patients. Journal of Clinical Psychopharmacology
1997;17(6):472-7. [MEDLINE: 98073127]

Satterlee W, Beasley C, Sanger T, Tollefson G. Additional
clinical experience with olanzapine, an atypical antipsychotic.
Schizophrenia Research 1995;15(1,2):163. [CSG NO. 4033]

Street J, Dellva M, Tamura R, Sanger T, Tollefson G. A
comparison of extrapyramidal syndromes between olanzapine
and placebo in schizophrenia. 9th Congress of the European
College of Neuropsychopharmacology, Amsterdam, The
Netherlands. 1996. [CSG NO. 3727]

Street JS, Dellva MA, Tamura RN, Sanger T, Tollefson GD.
Comparison of extrapyramidal syndromes between Olanzapine
and placebo in schizophrenia. XXth Collegium Internationale

Cochrane Database of Systematic Reviews

Neuro-psychopharmacologicum; June 23-27; Melbourne;
Australia. 1996.

Street JS, Dellva MA, Tamura RN, Sanger T, Tollefson GD.
Comparison of extrapyramidal syndromes between olanzapine
and placebo in schizophrenia. American Psychiatric
Association, 149th Annual Meeting; May 4-9. 1996.

Street JS, Dellva MA, Tamura RN, Sanger T, Tollefson GD.
Comparison of extrapyramidal syndromes between olanzapine
and placebo in schizophrenia. Xth World Congress of Psychiatry;
Aug 23-28; Madrid; Spain. 1996.

Street JS, Tamura R, Sanger T, Tollefson G. Long-term
treatment-emergent dyskinetic symptoms in patients treated
with olanzapine and haloperidol. Psychopharmacology Bulletin
1996;32(3):522.

Tamura RN, Beasley CM, Dellva MA, Glazer WM, Morgenstern H,
Tollefson GD. What is the differential risk of tardive dyskinesia
with the novel antipsychotic olanzapine?. Schizophrenia
Research 1998;29(1-2):176.

Tollefson G, Beasley C, Tran P, Sanger T. Olanzapine: an exciting
atypical antipsychotic the clinical experience. 8th European
College of Neuropsychopharmacology Congress; Sep 30-Oct 4;
Venice; Italy. 1995.

Tollefson GD, Beasley CM, Tamura RN, Tran PV, Potvin JH. Blind,
controlled, long-term study of the comparative incidence of
treatment-emergent tardive dyskinesia with olanzapine or
haloperidol. American Journal of Psychiatry 1997;154:1248-54.

Tollefson GD, Sanger TM. Negative symptoms: a path-analytic
approach to the double-blind, placebo and haloperidol
controlled clinical trial experience with olanzapine. American
Journal of Psychiatry 1997;154:466-74.

Tollefson GD, Sanger TM, Beasley CM. The course of primary
and secondary negative symptoms in a controlled trial with
olanzapine. Schizophrenia Research 1997;24:191.

Tran PV, Dellva MA, Tollefson GD, Beasley CM Jr, Potvin JH,
Kiesler GM. Extrapyramidal symptoms and tolerability of
olanzapine versus haloperidol in the acute treatment of
schizophrenia. Journal of Clinical Psychiatry 1997;58:205-11.

Williamson DJ, Tran PV, Beasley CM Tollefson GD, Sanger T,
Satterlee WG. Clinical efficacy and safety of olanzapine, a new
atypical antipsychotic agent. Journal of Psychopharmacology
1995;9(3):A47.

Wright P, Tollefson GD, Beasley CM, Tamura RN, Tran PV,
Potvin JII. A blinded, controlled, long-term study of the
comparative incidence of treatment-resistant tardive dyskinesia
with olanzapine or haloperidol. Schizophrenia Research
1998;29(1-2):206.

Beasley 1997 (E003) {published and unpublished data}

*  *Beasley CM Jr, Hamilton SH, Crawford AM, Dellva MA,
Tollefson GD, Tran PV, Blin O, Beuzen JN. Olanzapine versus
haloperidol: acute phase results of the international double-
blind olanzapine trial. European Neuropsychopharmacology
1997;7:125-37.

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

24

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Baker R W, Julier B, Stauffer V. Manic-like symptoms in
schizophrenic patients treated with olanzapine, haloperidol and
placebo. 7th World Congress of Biological Psychiatry; 2001 Jul
1-6; Berlin, Germany. 2001, issue Suppl. 1.

Beasley CM Jr, Dellva MA, Tamura RN, Morgenstern H,
Glazer WM, Ferguson K, Tollefson GD. A randomized, double-
blind comparison of the incidence of tardive dyskinesia during
long-term treatment with olanzapine or haloperidol. British
Journal of Psychiatry 1999;174:23-30.

Beasley CM Jr, Tollefson GD, Tran PV. Safety of olanzapine.
Journal of Clinical Psychiatry 1997;58(Suppl 10):13-7.

Beasley CM, Sayler ME, Kiesler GM, Potvin JH, Sanger TM,
Tollefson GD. The influence of pharmacotherapy on self-
directed and externally-directed aggression in schizophrenia.
Schizophrenia Research 1998;29(1-2):28.

Dellva MA, Tran P, Tollefson GD, Wentley AL, Beasley CM Jr.
Standard olanzapine versus placebo and ineffective-dose
olanzapine in the maintenance treatment of schizophrenia.
Psychiatric Services 1997;48:1571-7.

Edgell ET, Hamilton SH, Revicki DA, Genduso LA, Tollefson GD.
Costs of olanzapine treatment compared with haloperidol
for schizophrenia: results from a randomized clinical trial.
Proceedings of XXIst Collegium Internationale Neuro-
psychopharmacologicum; 1998 July 12-16; Glasgow, Scotland,
UK. 1998.

Nemeroff CB. Quality of life and new antipsychotics. Xth World
Congress of Psychiatry; August 23-28; Madrid, Spain. 1996.

Revicki D, Genduso L. Olanzapine versus haloperidol therapy
for chronic schizophrenia: impact on deficit syndrome. 8th
European College of Neuropsychopharmacology Congress; Sep
30-Oct 4; Venice; Italy. 1995.

Street JS, Tamura R, Sanger T, Tollefson G. Long-term
treatment-emergent dyskinetic symptoms in patients treated
with olanzapine and haloperidol. Psychopharmacology Bulletin
1996;32(3):522.

Tamura RN, Beasley CM, Dellva MA, Glazer WM, Morgenstern H,
Tollefson GD. What is the differential risk of tardive dyskinesia
with the novel antipsychotic olanzapine?. Schizophrenia
Research 1998;29(1-2):176.

Tollefson GD, Beasley CM Jr, Tamura RN, Tran PV, Potvin JH.
Blind, controlled, long-term study of the comparative
incidence of treatment-emergent tardive dyskinesia with
olanzapine or haloperidol. American Journal of Psychiatry
1997;154(9):1248-54.

Tran P, Beasley C, Tollefson G, Crawford A, Dellva M, Gusman S,
Wood A. Acute and long-term results of the dose ranging
double-blind olanzapine trial. XXth Collegium Internationale
Neuro-psychopharmacologicum; June 23-27; Melbourne,
Australia. 1996.

Tran PV, Beasley CM, Tollefson GD, Beuzen JN, Holman SL,
Sanger TM, Satterlee WG. Olanzapine:a promising atypical

Cochrane Database of Systematic Reviews

antipsychotic agent. Schizophrenia Research 1995;15(1,2):169.
[CSG NO. 4030]

Tran PV, Dellva MA, Tollefson GD, Beasley CM Jr, Potvin JH,
Kiesler GM. Extrapyramidal symptoms and tolerability of
olanzapine versus haloperidol in the acute treatment of
schizophrenia. Journal of Clinical Psychiatry 1997;58(5):205-11.

Tran PV, Dellva MA, Tollefson GD, Wentley AL, Beasley C Jr.
Oral olanzapine versus oral haloperidol in the maintenance
tratement of schizophrenia and related psychoses. British
Journal of Psychiatry 1998;172:499-505.

Wright P, Tollefson GD, Beasley CM, Tamura RN, Tran PV,
Potvin JII. A blinded, controlled, long-term study of the
comparative incidence of treatment-resistant tardive dyskinesia
with olanzapine or haloperidol. Schizophrenia Research
1998;29(1-2):206.

Bernardo 2001 (HGDD) {published data only}

Bernardo M, Parellada E, Lomena F, Catafau AM, Font M,
Gomez JC, Lopez-Carrero C, Gutierrez F, Pavia J, Salamero M.
Double-blind olanzapine vs. haloperidol D2 dopamine receptor
blockade in schizophrenic patients: a baseline-endpoint.
Psychiatry Research 2001;107:87-97. [MEDLINE: 21421538]

Beuzen 1998 (HGCF) {published and unpublished data}

*  *Beuzen JN, Birkett M, Kiesler G, Wood A. Olanzapine
versus clozapine in resistant schizophrenic patients - results
of an international double-blind randomised clinical trial.
Proceedings of XXIst Collegium Internationale Neuro-
psychopharmacologicum; 1998 July 12-16; Glasgow, Scotland,
UK. 1998.

Beasley CM, Beuzen JN, Birkett MA. [Olanzapine versus
clozapine: an international double-blind study in the treatment
of patients with treatment-resistent schizophrenia]. NCDEU,
Boca Raton, FL, USA. 1999.

Beasley CM, Beuzen JN, Birkett MA. Olanzapine versus
Clozapine: an international double-blind study in the treatment
of patients with treatment-resistent schizophrenia. World
Psychiatric Association. Hamburg, Germany. 1999.

Beasley CM, Beuzen JN, Birkett MA. Olanzapine versus
clozapine: an international double-blind study in the treatment
of patients with treatment-resistent schizophrenia. American
College of Neuropsychopharmacology Annual Meeting, Hawaii,
USA. 1998.

Beasley CM, Beuzen JN, Birkett MA. Olanzapine versus
clozapine: an international double-blind study in the treatment
of patients with treatment-resistent schizophrenia. American
Psychiatric Association Meeting. Washington, DC, USA. 1999.

Beuzen JN, Birkett MA, Kiesler GM. An investigation of subgroup
effects in a study of olanzapine versus clozapine in the
treatment of resistant schizophrenic patients. European
Neuropsychopharmacology. 1998, issue Suppl 2:S226-7.
[MEDLINE: 21122407]

David SR, Meehan KM, Sutton VK, Taylor CC. Treatment of
negative symptoms with olanzapine in comparison with

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

25

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

other novel antipsychotic agents. International Journal of
Neuropsychopharmacology 2000;3(Suppl 1):s140. [MEDLINE:
2003063779; PMID 22476629]

Dossenbach M, Bitter I, Slabber M, Pretorius J, Bartko GY,
Banics Z, Martenyi F. Olanzapine versus clozapine in patients
nonresponsive or intolerant to standard acceptable treatment
for schizophrenia. 153rd Annual Meeting of the American
Psychiatric Association; 2000 May 13-18; Chicago, USA. 2000.

Dossenbach M, Bitter I, Slabber M, Pretorius J, Bartko GY,
Banics Z, Martenyi F. Olanzapine versus clozapine in patients
nonresponsive or intolerant to standard acceptable treatment
for schizophrenia. 155th Annual Meeting of the American
Psychiatric Association; 2002 May 18-23; Philadelphia, PA, USA.
2002.

Dossenbach M, Slabber M, Martenyi F, Bartko G, Bitter I.
Olanzapine vs. clozapine in patients non responsive or
intolerant to standard acceptable treatment of schizophrenia.
11th World Congress of Psychiatry; 1999 Aug 6-11; Hamburg,
Germany. 1999:148.

Jean-Noel B, Wood AJ, Kiesler GM, Birkett M, Tollefson GD.
Olanzapine vs. clozapine: an international double blind study in
the treatment of resistant schizophrenia. 11th World Congress
of Psychiatry; 1999 Aug 6-11; Hamburg, Germany. 1999:143.

treatment with valporate in hospitalized patients with acute
schizophrenia: a double-blind, multi-center study. 155th Annual
Meeting of the American Psychiatric Association; 2002 May
18-23; Philadelphia, PA, USA. 2002.

Chan 2003 {published data only}

Chan HY, Chen CH, Chen JJ, Sun HJ, Chiu H-J, Chang CJ. A
comparison of olanzapine and risperidone for the schizophrenic
patients intolerance of neuroleptic-induced extrapyramidal
syndromes (eps). Journal of the European College of
Neuropsychopharmacology 2003;13(4):S316. [P.2.084]

Chang 2003 {published data only}

Chang Fa wei, Wang Chang hong, Zhao Zheng. Clinical effects
of olanzapine vs chlorpromazine in treating positive symptoms
of schizophrenia. Chinese Journal of New Drugs and Clinical
Remedies 2003;22(06):357-59. [MEDI0306]

Chaudhry 2003 {published data only}

Chaudhry HR, Kongsakon R, Ignacio JC, Raza SB, Leynes MCR,
Hasanah CI, Chan B, Onate P, Brnabic AJM, Lowry AJ,
Buenaventura R. Quality of life and clinical outcomes for
asian outpatients with schizophrenia: a double-blind
randomised comparison of olanzapine and haloperidol.
Journal of the European College of Neuropsychopharmacology
2003;13(4):S309. [P.2.069]

Tollefson GD, Birkett MA, Kiesler GM, Wood AJ, Lilly Resistant
Schizophrenia Study Group. Double-blind comparison of
olanzapine versus clozapine in schizophrenic patients clinically
eligible for treatment with clozapine. Biological Psychiatry
2001;49(1):52-63. [MEDLINE: 21093232]

Chen 2003 {published data only}

Chen Fei, Liang Ligui, Zhu Xianghua. A control study of
elderly patients with schizophrenia treated with olanzapine
or clozapine. Journal of Clinical Psychological Medicine
2003;13(05):298-99. [MEDI0312]

Bitter 2004 (HGCK) {published data only}

Conley 1998 {published data only}

*  *Bitter I, Dossenbach MRK, Brook S, Feldman PD, Metcalfe S,
Gagiano CA, Furedi J, Bartko G, Janka Z, Banki CM, Kovacs G,
Breier A. Olanzapine versus clozapine in treatment-resistant
or treatment-intolerant schizophrenia. Progress in Neuro-
Psychopharmacology and Biological Psychiatry 2004;28:173-180.
[MEDLINE: 14687871; EMBASE 2003516387]

Bitter I, Brook S, Dossenbach M, Janka Z, Banki CsM,
Selemani S, Grundy S, Martenyi F. Olanzapine versus clozapine
in patients non-responsive or intolerant to standard acceptable
treatment of schizophrenia. Journal of the European College of
Neuropsychopharmacology 1999;9:S288. [MEDLINE: 21040726;
Lilly study possible stands alone]

Casey 2003 {published data only}

*  *Casey DE, Daniel DG, Wassef AA, Tracy KA, Wozniak P,
Sommerville KW. Effect of divalproex combined with olanzapine
or risperidone in patients with an acute exacerbation of
schizophrenia. Neuropsychopharmacology 2003;28:182-92.
[MEDLINE: 22384754; PMID 12496955]

*  *Conley RR, Tamminga CA, Bartko JJ, Richardson C, Peszke M,
Lingle J, Hegerty J, Love R, Gounaris C, Zaremba S. Olanzapine
compared with chlorpromazine in treatment-resistant
schizophrenia. American Journal of Psychiatry 1998;155:914-20.

Conley R, Gounaris C. Demographic differences in olanzapine
responders with therapy-refractory schizophrenia.
Schizophrenia Research ( The VIth International Congress on
Schizophrenia Research;1997 April 12-16; Colorado Springs; CO,
USA 1997;24 Suppl.:189.

Conley RR, Tamminga CA, Beasley C. Olanzapine vs
chlorpromazine in therapy-refractory schizophrenia.
Schizophrenia Research (The VIth International Congress on
Schizophrenia Research; 1997 April 12-16; Colorado Springs; CO,
USA ) 1997;24 Suppl.:189.

Conley RR, Tamminga CA, Beasley C. Olanzapine vs.
Chlorpromazine in Treatment-Resistant. Biological Psychiatry
1997;41:1S-120S.

Citrome L, Casey DE, Daniel DG, Wozniak P, Kochan LD,
Tracy KA. Adjunctive divalproex and hostility among patients
with schizophrenia receiving olanzapine or risperidone.
Psychiatric Services 2004;55(3):290-4.

Conley RR, Tamminga CA, Beasley C, Maryland Study Group.
Olanzapine vs. chlorpromazine in treatment-resistant
schizophrenia. Biological Psychiatry 1997;41:73S. [MEDLINE:
2003063779; PMID 22476629]

Citrome LL, Daniel DG, Wassef AA, Tracy KA, Wozniak P,
Casey DE. Antipsychotic monotherapy versus combination

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

26

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Kelly DL, Conley RR, Tamminga CA. Differential olanzapine
plasma concentrations by sex in a fixed-dose study.
Schizophrenia Research 1999;40(2):101-104. [CSG NO. 4333]

Richardson C, Conley R. Olanzapine response in schizophrenic
subjects with neuroleptic resistant disorganization.
Schizophrenia Research (The VIth International Congress on
Schizophrenia Research; 1997 April 12-16; Colorado Springs; CO,
USA ) 1997;24 Suppl.:191.

Conley 2001 {published and unpublished data}

Berry SA, Martinez RA, Gudelsky GA, Mahmoud R, Myers J.
Serum prolactin levels in schizophrenia. Schizophrenia
Research (8th International Congress on Schizophrenia
Research; 2001 Apr 28 - May 2; British Columbia, Canada). 2001,
issue 1-2 Suppl:280-1. [MEDLINE: 21040726; Probably Not Eli
Lilly]

Berry SA, Martinez RA, Gudelsky GA, Myers JE, Mahmoud RA.
Serum prolactin in schizophrenia. 39th Annual Meeting of the
American College of Neuropsychopharmacology; 2000; Dec
10-14; San Juan; Puerto Rico. 2000.

Brecher M. Risperidone versus olanzapine in the treatment
of patients with schizophrenia or schizoaffective
disorder. 11th Congress of The European College of
Neuropsychopharmacology; 1998 Oct 31- Nov 4; Paris, France.
1998.

Brecher M. Risperidone versus olanzapine in the treatment
of patients with schizophrenia or schizoaffective disorder.
Proceedings of XXIst Collegium Internationale Neuro-
psychopharmacologicum; 1998 July 12-16; Glasgow, Scotland,
UK. 1998.

Conley R, et al. Risperidone vs. Olanzapine in patients with
schizophrenia and schizo-affective disorder. International Drug
Therapy Newsletter 2000;35(10):77-8.

Conley RR. Risperidone versus olanzapine in patients with
schizophrenia and schizoaffective psychosis [Risperidon versus
olanzapin bei patienten mit schizophrenie und schizoaffektiven
psychosen]. Nervenheilkunde 2000;19(5):110-2.

Conley RR, Brecher M, The Risperidone/Olanzapine Study
Group. Riasperidone versus olanzapine in patients with
schizophrenia or schizoaffective disorders. European College of
Neurpsychopharmacology Meeting; 1998 October 31-November
4; Paris, France. 1998.

Conley RR, Brecher MB Olanzapine-Risperidone Study Group.
Risperidone versus olanzapine in the treatment of patients
with schizophrenia or schizoaffective disorder. 152nd Annual
Meeting of the American Psychiatric Association; 1999 May
15-20; Washington, USA. 1999. [MEDLINE: 97055970]

*  Conley RR, Mahmoud R. A randomized double-blind study of
risperidone and olanzapine in the treatment of schizophrenia
or schizoafftective disorder. American Journal of Psychiatry
2001;158:765-74.

Conley RR, Mahmoud R. Efficacy of Risperidone versus
Olanzapine in the treatment of patients with schizophrenia or

Cochrane Database of Systematic Reviews

schizoaffective disorder. 13th Congress of the European College
Neuropsychopharmacology, Munich, September 9-13. 2000.

Conley RR, Mahmoud R. Risperidone and Olanzapine in people
with schizophrenia or schizoaffective disorder: a randomised
double-blind study. Poster supplied by Company.

Conley RR, Mahmoud R. Risperidone vs olanzapine in patients
with schizophrenia & schizoaffective disorder. 40th Annual
Meeting of the New Clinical Drug Evaluation Unit (NCDEU); 2000
May 30 - Jun 2; Boca Raton, Florida. 2000. [N0146103028]

Conley RR, Mahmoud R and the Risperidone Study Group.
Risperidone versus olanzapine in patiens with schizophrenia
and schizoaffective disorder. 10th Biennial Winter Workshop on
Schizophrenia; 1998 Feb 5-11; Davos; Switzerland. 2000.

Conley RR, Mahmoud R, Risperidone Study Group.
Risperidone vs. olanzapine in patients with schizophrenia and
schizoaffective disorder. Biological Psychiatry 2000;47:32S.
[MEDLINE: 2003063779; PMID 22476629]

Conley RR, Mahmoud R, and the Risperidone Study Group.
Efficacy of Risperidone versus olanzapine in the treatment of
patients with schizophrenia or schizoaffective disorder. 22nd
CINP Congress, July 9-13 Brussels, Belgium. 2000.

Conley RR, Mahmoud RA. Risperidone versus olanzapine in
patients with schizophrenia and schizoaffective disorder. 153rd
Annual Meeting of the American Psychiatric Association; 2000
May 13-18; Chicago, USA. 2000.

Conley RR, Mahmoud RA. Risperidone versus olanzapine in
patients with schizophrenia and schizoaffective disorder. 155th
Annual Meeting of the American Psychiatric Association; 2002
May 18-23; Philadelphia, PA, USA. 2002.

Harvey P, Meltzer H, Green M. Risperidone Cogntive Effects in
Schizophrenia and Schizoaffective patients. International Drug
Therapy Newsletter 2001 August;36(8):59.

Harvey P, Meltzer HY, Green MP. Cognitive effects of risperidone
versus olanzapine in patients with schizophrenia or
schizoaffective disorder. 7th World Congress of Biological
Psychiatry; 2001 Jul 1-6; Berlin, Germany. 2001, issue Suppl. 1.

Harvey PD. Cognitive effects of risperidone and olanzapine
in patients with schizophrenia. 52nd Institute on Psychiatric
Services; 2000 Oct 25-29; Philadelphia, USA. 2000.

Harvey PD. Cognitive effects of risperidone and olanzapine in
patients with schizophrenia or schizoaffective disorder. 153rd
Annual Meeting of the American Psychiatric Association; 2000
May 13-18; Chicago, USA. 2000.

Lasser RA, Lao L, Gharabawi G. Smokers and nonsmokers
equally affected by olanzapine-induced weight gain: Metabolic
implications. Schizophrenia Research. 2004; Vol. 66, issue
2-3:163-7. [MEDLINE: 15061249; EMBASE 2004015909]

Mahmoud R, Harvey PD, Meltzer HY, Green MF. Cognitive effects
of risperidone and olanzapine in patients with schizophrenia
or schizoaffective disorder. Schizophrenia Research (8th
International Congress on Schizophrenia Research; 2001 Apr 28

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

27

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

- May 2; British Columbia, Canada). 2001, issue 1-2 Suppl:236-7.
[MEDLINE: 21040726]

Research (Abstracts of the 11th Biennial Winter Workshop on
Schizophrenia). Elsevier Science B.V, 2002, issue 3 Suppl.1:179.

Mahmoud RA. Assessment of symptoms Affecting Quality of Life
and Patient Satisfaction with Antipsychotic Drugs: New insights
for a Trial of Risperidone/Olanzapine. 52 Annual Meeting of the
American Psychiatric Association, Washington D.C., USA, MAy
15-20. 1999.

Martinez, RA, Berry SA, Gudelsky GA, Myers JE, Mahmoud RA.
serum prolacin levels in schizophrenia. 155th Annual meeting if
the American Psychiatric Association, May 18-23. 2002.

Myers J, Mahmoud R, Berry S, Conley R. Risperidone versus
Olanzapine for the Treatment of Mood Symptoms in Patients
with Schizophrenia and Schizoaffective Disorder. Bipolar
Disorders (4th International Conference on Bipolar Disorder,
Pittsburgh, Pennsylvania, USA, June 14-6, 2001. 2001, issue
Suppl 1:49. [MEDLINE: 22039781]

Myers JE, Mahmoud R, Berry S, Conley RR. Risperidone versus
olanzapine for the treatment of mood symptoms in patients
with schizophrenia and schizoaffective disorder. European
Neuropsychopharmacology (Abstracts of the 14th Congress of
the European College of Neuropsychopharmacology; 2001 Oct
13-17; Istanbul, Turkey). 2001, issue 3:254.

Myers JE, Mahmoud RA, Berry SA, Conley RR. Risperidone
versus olanzapine for the treatment of mood symptoms in
patients with schizophrenia and schizoaffective disorder. 155th
Annual Meeting of the American Psychiatric Association; 2002
May 18-23; Philadelphia, PA, USA. 2002.

Robinson G, Wheeler A, Byrd J, Visser S. Longer-term effects of
switching from typical to atypical antipsychotics in patients
with stable schizophrenia. Journal of the European College of
Neuropsychopharmacology. 2000, issue Suppl 3:S291.

Corrigan 2004 {published data only}

Corrigan MH, Gallen CC, Bonura ML, Merchant KM.
Effectiveness of the selective D4 antagonist sonepiprazole in
schizophrenia: a placebo-controlled trial. Biological Psychiatry
2004;55(5):445-51. [EMBASE: 2004123114]

de Haan 2002 {published data only}

de Haan L, Beuk N, Hoogenboom B, Dingemans P, Linszen D.
Obsessive-compulsive symptoms during treatment with
olanzapine and risperidone: a prospective study of 113 patients
with recent-onset schizophrenia or related disorders. Journal of
Clinical Psychiatry 2002;63:104-7. [MEDLINE: 21862916]

de Hann 2003 {published data only}

*  de Haan L, van Bruggen M, Lavalaye J, Booij J, Dingemans PM,
Linszen D. Subjective experience and D2 receptor occupancy in
patients with recent-onset schizophrenia treated with low-dose
olanzapine or haloperidol: a randomized, double-blind study.
American Journal of Psychiatry 2003;160:303-9. [MEDLINE:
22449968; PMID 12562577]

de Haan L, van-Bruggen M, Lavalaye J, Booij J, Dingemans P,
Linszen D. Subjective experience and d2 receptor occupancy in
patients with schizophrenia, treated with low dose olanzapine
or haloperidol; a randomized double-blind study. Schizophrenia

Esel 2001 {published and unpublished data}

Esel E, Basturk M, Saffet Gonul A, Kula M, Tayfun Turan M,
Yabanoglu I, Sofuoglu S. Effects of olanzapine and haloperidol
on serum prolactin levels in male schizophrenic patients.
Psychoneuroendocrinology 2001;26(6):641-7. [MEDLINE:
21297964]

He 2003 {published data only}

He Jin, An Qinghua. A comparative trial of olanzapine versus
chlorpromazine in the treatment of schizophrenia. Shandong
Archires of Psychiatry 2003;16(02):78-80. [MEDI0307]

HGBJ (Finland) {unpublished data only}

Eli Lilly. Data on file. Data supplied to the Cochrane
Schizophrenia Group 1999.

Naukkarinen H, Rimon R, Katila H, Riihikangas R, Heikkila L.
Olanzapine and perhenazine in schizophrenia. Schizophrenia
Research 2000;41(1):190. [CSG NO. 4504]

HGBL 1997 {unpublished data only}

Dittmann RW, Geuppert MS, Diehl A, Hubrich P, Maraz,
Gattaz WF. Olanzapine versus flupentixol in the treatment of
inpatients with schizophrenia: a randomised double-blind
trial. Schizophrenia Research (8th International Congress on
Schizophrenia Research; 2001 Apr 28 - May 2; British Columbia,
Canada). 2001, issue 1-2 Suppl:225.

Eli Lilly. Data on file. Data supplied to the Cochrane
Schizophrenia Group 1999.

HGCJ (Hong Kong) {published and unpublished data}

Tran PV, Beasley CM, Tollefson GD, Creanga D, Zhang F, Wang J,
Vangala S, Cousins L. Clinical experience with olanzapine in
patients of African, Asian, and Hispanic descent. Meeting of the
American Psychiatric Association. Washington, DC, USA. 1999.

Tran PV, Beasley CM, Tollefson GD, Creanga D, Zhang F, Wang J,
Vangala S, Cousins L. Clinical experience with olanzapine
in patients of African, Asian, and Hispanic descent. World
Psychiatric Association; Hamburg, Germany. 1999.

Tran PV, Cousins LM, Creanga D, Tollefson GD, Vangala S,
Wang J, Zhang F. Clinical experience with olanzapine in patients
of African, Asian, and Hispanic descent. ACNP. Hawaii, USA.
1998.

Tran PV, Creanga D, Zhang F, Wang J, Vangala S, Cousins L,
Tollefson GD. Clinical experience with olanzapine in ethnic
subgroups. NCDEU. Boca Raton, FL, USA. 1999.

Tran PV, Zhang F, Hwu HG, Liehmak F. Efficacy and safety study
comparing olanzapine versus haloperidol in the treatment of
Chinese patients with schizophrenia in Taiwan and Hong Kong.
APA Annual Meeting, May 15-20, Washington, DC. 1999. [CSG NO.
4118]

Vangala S, Zhang F, Tran P, Sze S. Efficacy and safety study
comparing olanzapine versus haloperidol in the treatment
of Chinese patients with schizophrenia in Hong Kong.

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

28

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Proceedings of XXIst Collegium Internationale Neuro-
psychopharmacologicum; July 12-16; Glasgow, Scotland, UK.
1998.

Zhang F, Tran PV, Taylor C, Hwu GH, Chen YS, Chang WH,
Cheng J, Wang A, Chang S, Sze S, Chen RYK, Dunn E, Lieh
Mak F. Efficacy and safety study comparing olanzapine
versus haloperidol in the treatment of Chinese patients with
schizophrenia in Taiwan and Hong Kong. World Psychiatric
Association; Hamburg, Germany. 1999.

HGCQ (Turkey) 2000 {unpublished data only}

Eli Lilly, Company. Study F1D-VI-HGCQ Olanzapine Versus
Chlorpromazine in Turkey. Unpublished Document Internal to
Eli-lilly 2000:1-560.

Kostakoglu E, Alptekin K, Kivicik BB, Martenyi F, Tunca Z,
Gogus A, Dossenbach M. [Sleep quality and early morning
wakefulness of schizophrenia patients treated with
olanzapine compared to chlorpromazine]. Errata, European
Neuropsychopharmacology. 2000; Vol. 10, issue Suppl 3.

Mraz K, Gogus A, Tunca Z, Martenyi F, Dossenbach M.
Olanzapine versus chlorpromazine in Turkey. Schizophrenia
Research (Abstracts of the Winter Workshop on Schizophrenia;
2000 Feb Davos; Switzerland). 2000.

HGCU (Taiwan) 1998 {published and unpublished data}

Tran PV, Creanga D, Zhang F, Wang J, Vangala S, Cousins L,
Tollefson GD. Clinical experience with olanzapine in ethnic
subgroups. NCDEU. Boca Raton, FL, USA. 1999.

Tran PV, Zhang F, Hwu HG, Liehmak F. Efficacy and safety study
comparing olanzapine versus haloperidol in the treatment of
Chinese patients with schizophrenia in Taiwan and Hong Kong.
American Psychiatric Association Annual Meeting; 1999 May
15-20; Washington DC; USA. 1999. [CSG NO. 4118]

Zhang F, Tran PV, Taylor C, Hwu GH, Chen YS, Chang WH,
Cheng J, Wang A, Chang S, Sze S, Chen RYK, Dunn E, Lieh
Mak F. Efficacy and safety study comparing olanzapine
versus haloperidol in the treatment of Chinese patients with
schizophrenia in Taiwan and Hong Kong. World Psychiatric
Association. Hamburg, Germany. 1999.

HGDV (Morocco) 1999 {unpublished data only}

Eli Lilly. Study HGDV Olanzapine (Versus Chlorpromazine
in Morocco). Unpublished Document Internal to Eli-lilly
2001:1-512.

*  HGDV/Moroco. Data on file. Data supplied to the Cochrane
Schizophrenia Group 1999.

HGFH (Korea) 1998 {unpublished data only}

*  HGFH Korea. Data on file. Data supplied to the Cochrane
Schizophrenia Group 1999.

Ishigooka 2001 {published data only}

*  *Ishigooka J, Hirotsu C, Kurihara M, Inada T, Miura S.
Olanzapine versus haloperidol in the treatment of patients with
chronic schizophrenia: results of the japan multi-center double-
blind olanzapine trial. Psychiatry and Clinical Neurosciences
2001;55(4):403-14.

Cochrane Database of Systematic Reviews

Inada T, Beasley CM, Yoko T, Walker D. Extrapyramidal symptom
profiles assessed with the Drug-Induced Extrapyramidal
Symptom Scale: comparison with Western scales in the
clinical double-blind studies of schizophrenic patients treated
with either olanzapine or haoperidol. International Clinical
Psychopharmacology 2003;18:39-48.

Inada T, Miura S. Favorable eps profiles of olanzapine measured
by the diepss: predictive validity of this scale to differentiate the
eps profiles of atypical antipsychotic drugs from conventional
antipsychotic drugs in the clinical trial. International Journal of
Neuropsychopharmacology 2000;3(Suppl 1):S147.

Inada T, Yagi G, Miura S. Extrapyramidal symptom profiles in
Japanese patients with schizophrenia treated with olanzapine
or haloperidol. Schizophrenia Research 2002;57(2-3):227-38.

Jakovljevic1999 HGCH {published and unpublished data}

Dossenbach M, Friedel P, Jakovljevic M, Hotujac L, Folnegovic V,
Uglesic B, Dodig G. Olanzapine versus fluphenazine - six
weeks' treatment of acute schizophrenia. 10th ECNP Congress;
September 13 - 17; Vienna; Austria. 1997.

Dossenbach M, Jakovljevic M, Folnegovi V, Uglesic B, Dodig G,
Friedel P, Hotujac L. Olanzapine versus fluphenazine - six weeks
of treatment of anxiety symptoms during acute schizophrenia.
Schizophrenia Research 1998;29(1-2):203.

Ferenc M, Dossenbach M, Jakovljevic M, Metcalfe S. Predictive
value of early anti anxiety effect on the acute antipsychotic
outcome: a comparison of fluphenazine and olanzapine. 153rd
Annual Meeting of the American Psychiatric Association; 2000
May 13-18; Chicago, USA. 2000.

*  Jakovljevic M, Dossenbach MRK. Olanzapine versus
fluphenazine in the acute (six-week) treatment of
schizophrenia. Psychiatric Danubina 1999;11(1-2):3-10.

Ljubin T, Milas DZ, Mimica N, Folnegovic Smalc V, Makaric G. A
preliminary study of the comparative effects of olanzapine and
fluphenazine on cognition in schizophrenic patients. Human
Psychopharmacology 2000;15(7):513-9.

Martenyi F, Dossenbach M, Jakovljevic M, Metcalfe S. Predictive
value of early anti-anxiety effect on the acute-antipsychotic
outcome:a comparison of fluphenazine and olanzapine.
Schizophrenia Research 2000;41(1 - Suppl.):191. [CSG NO. 4506]

Martin C, Genduso L, Revicki D, Hamilton S, Tran P, Beasley C.
Quality of life outcomes of olanzapine, a new atypical
antipsychotic agent. Schizophrenia Research 1996;18(2,3):130.
[CSG NO. 4087]

Mimica N, Dossenbach M, Friedel P, Folnegovic-Smalc V,
Makaric G, Jakovljevic M, Uglesic B. Olanzapine compared
to fluphenazine in the treatment of acute schizophrenia.
Schizophrenia Research 1998;29(1-2):150.

Schausberger B, Dossenbach M, Hotujac L, Folnegovic-
Smalc V, Uglesic B, Jakovljevic M. Impact of olanzapine
versus fluphenazine on patient's drug acceptance during
acute treatment of schizophrenia. European College of
Neuropsychopharmacology. London, England, UK. 1999.

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

29

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Tran PV, Jakovljevic M, Tollefson GD, Crawford AM,
Dossenbach M, Friedel P, Hotujac L, Folnegoiv V, Uglesic B,
Dodig G. Olanzapine versus fluphenazine: treatment of
acute schizophrenic symptomatology and anxiety. Biological
Psychiatry 1998;43:109S.

Tran PV, Tollefson GD, Crawford AM, Dossenbach M, Friedel P,
Folnegovic V, Jaklovljevic M. Olanzapine versus fluphenazine in
schizophrenia. 151st Annual Meeting of American Psychiatric
Association; May 30-June 4; Toronto, ON, Canada. 1998.

Jeste 2003 {published data only}

*  *Jeste DV, Barak Y, Madhusoodanan S, Grossman D,
Gharabawi G. International Multisite Double-Blind Trial of the
Atypical Antipsychotics Risperidone and Olanzapine in 175
Elderly Patients with Chronic Schizophrenia. American Journal
of Geriatric Psychiatry 2003;11(6):638-647.

Harvey PD, Napolitano JA, Mao L, Gharabawi G. Comparative
effects of risperidone and olanzapine on cognition in elderly
patients with schizophrenia or schizoaffective disorder. Int J
Geriatr Psychiatry 2003;18(9):820-9.

Jeste D, Madhusoodanan S, Barak Y, Martinez RA, Mahmoud R,
Kershaw P. Risperidone and olanzapine in elderly patients with
schizophrenia and schizopaffective disorder. International
Psychogeriatrics 2003;13(2):295s. [N0546099389]

Jeste DV, Madhusoodanan S, Barak F, Martinez RA. Risperidone
versus olanzapine in elderly patients with schizophrenia. 154th
Annual Meeting of the American Psychiatric Association; 2001
May 5 - 10; New Orleans, USA. Marathon Multimedia, 2001.
[MEDLINE: 21200321]

Jeste DV, Madhusoodanan S, Barak F, Martinez RA. Risperidone
versus olanzapine in elderly patients with schizophrenia. 155th
Annual Meeting of the American Psychiatric Association; 2002
May 18-23; Philadelphia, PA, USA. 2002. [NR754 Thursday, May
10, 12:00 p.m.-2:00 p.m]

Lasser RA, Mao L, Gharabawi G. Smokers and nonsmokers
equally affected by olanzapine-induced weight gain: Metabolic
implications. Schizophrenia Research 2004;66(2-3):163-7.

Jones 1998 (P022) {published and unpublished data}

Canadian Cognition and Outcome Study Group.
Neuropsychological change in early phase schizophrenia over
twelve months of treatment with olanzapine, risperidone or
haloperidol. Schizophrenia Research 1998;29:132-3.

David SR, Purdon S, Jones BD, Stip E, Labelle A, Breier AF,
Tollefson GD, Kutcher SP, Maclaren C, Hadrava V, Thompson PM,
Leblanc. Olanzapine versus risperidone versus haloperidol
in early illness schizophrenia. Education improves outcomes
in MDD. 152nd Annual Meeting of the American Psychiatric
Association; 1999 May 15-20; Washington, USA. 1999. [MEDLINE:
97055970]

Jones B. Olanzapine versus risperidone and haloperidol in the
treatment of schizophrenia. 151st Annual Meeting of American
Psychiatric Association; May 30-June 4; Toronto; ON, Canada.
1998.

Cochrane Database of Systematic Reviews

Jones B. Treatment of cognitive deficits with antipsychotic
drugs. Neurobiology of Aging (Abstracts of 6th International
Conference on Alzheimer's Disease and Related Disorders; 1998
Jul 18-23; Amsterdam, the Netherlands). 1998, issue 4S:S152-3.

Jones B, Tollefson G. Olanzapine versus risperidone and
haloperidol in the treatment of schizophrenia. Schizophrenia
Research 1998;29:150-1.

Purdon SE, Jones B, Labelle A, Addington D, Tollefson G.
A multicentre comparison of olanzapine, risperidone, and
haloperidol on working memory, new learning, and delayed
recall of verbal and nonverbal materials in early-phase
schizophrenia over a 12-month prospective double-blind
clinical trial. Schizophrenia Research (Abstracts of The 7th
International Congress on Schizophrenia Research; 1999 Apr
17-21; Santa Fe, USA). 1999:150. [MEDLINE: 20137242]

Purdon SE, Jones BD, Stip E, Labelle A, Addington D, David SR,
Breier A, Tollefson GD. Neuropsychological change in early
phase schizophrenia during 12 months of treatment with
olanzapine, risperidone, or haloperidol. The Canadian
Collaborative Group for research in schizophrenia.. Archives of
General Psychiatry 2000;57(3):249-58. [CSG NO. 4548]

Purdon SE, Jones BDW, Stip E, Labelle A, Addington D, Breier A,
Tollefson GD, and the Canadian Collaborative Group for
Research on Cognition in Schizophrenia. Olanzapine versus
haloperidol versus risperidone in early illness schizophrenia.
Unpublished typescript 2001.

Purdon SE, Jones BDW, Stip E, Labelle A, Addington Dm
Breier A, Tollefson GD. Olanzapine versus haloperidol versus
risperidone in early illness schizophrenia. Unpublished data on
file 2001. [MEDLINE: 21122407]

Purdon SE, Woodward N, Lindborg SR, Stip E. Procedural
learning in schizophrenia after 6 months of double-blind
treatment with olanzapine, risperidone, and haloperidol.
Psychopharmacology 2003;169(3-4):390-7. [PMID 12827347]

Sharma T. Atypical antipsychotics and cognition in
schizophrenia. Archives of General Psychiatry 2002;59(6):571-2.
[MEDLINE: 22039781]

Woodward ND, Purdon SE, David SR, Stip E. Procedural learning
over six months double blind treatment with haloperidol,
risperidone or olanzapine. Schizophrenia Research (8th
International Congress on Schizophrenia Research; 2001 Apr 28
- May 2; British Columbia, Canada). 2001, issue 1-2 Suppl:125.
[MEDLINE: 21040726]

Kelly 2003 {published data only}

Conley RR, Kelly DL, Richardson CM, Tamminga CA, Carpenter
Jr WT. The Efficacy of High-Dose Olanzapine Versus Clozapine
in Treatment-Resistant Schizophrenia: A Double-Blind,
Crossover Study [letter]. Journal of Clinical Psychopharmacology
2003;23(6):668-71. [MEDLINE: 14624201; EMBASE 2003477898]

*  Kelly DL, Conley RR, Richardson CM, Tamminga CA, Carpenter
Jr WT. Adverse effects and laboratory parameters of high-dose
olanzapine vs. clozapine in treatment-resistant schizophrenia.
Annals of Clinical Psychiatry 2003;15(3-4):181-6. [EMBASE:
2004064601]

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

30

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Kern 2001 {published data only}

*  *Kern RS, Cornblatt B, Carson WH, Dunbar G, Ali M, Ingenito G,
Green MF. An open-label comparison of the neurocognitive
effects of aripiprazole versus olanzapine in patients with stable
psychosis. Schizophrenia Research 2001;1-2:234. [MEDLINE:
21083242]

Carson W, Cornblatt B, Saha A, Ali M, Kern R, Green M.
Neurocognitive benefits of aripiprazole versus olanzapine
in stable psychosis. Journal of the European College of
Neuropsychopharmacology 2002;Supplement 3:S291.

Cornblatt B, Kern RS, Carson WH, Ali MW, Luo X,
Green M. Neurocognitive effects of aripiprazole versus
olanzapine in stable psychosis. International Journal of
Neuropsychopharmacology 2002;Suppl. 1:s185.

Cornblatt B, Kern RS, Carson WH, Stock E, Ali M, Ingenito G,
Green MF. Neurocognitive effects of aripiprazole versus
olanzapine in patients with stable psychosis. Journal of
Psychopharmacology 2002;16(3):A15.

Cornblatt B, Kern RS, Carson WH, Stock E, Ali M, Ingenito G,
Green MF. Neurocognitive effects of aripiprazole versus
olanzapine in patients with stable psychosis. Schizophrenia
Research 2002;3(Suppl. 1):27. [MEDLINE: 21185887]

Dubitsky GM, Harris R, Laughren T, Hardeman S. Abilify
(aripiprazole) tablets, medical review part 3. www.fda.gov/
cder/foi/nda/2002/21-436_Abilify.htm. U.S. Food and Drug
Administration CDER, 2002:111-175.

Kern RS, Cornblatt B, Carson WH, Stock E, Saha AR, Ali MW,
Ingenito G, Green MF. Neurocognitive effects: aripiprazole vs
olanzapine in stable psychosis. European Psychiatry 2002;suppl
1:104s.

Lecrubier 1999 {published and unpublished data}

*  Lecrubier Y, Bouhassira M, Olivier V, Lancrenon S,
Crawford AM. Olanzapine versus amisulpride and placebo
in the treatment of negative symptoms and deficit states of
chronic schizophrenia. European Neuropsychopharmacology
1999;9(Suppl 5):S288.

Lieberman 2003 (HGDH {published data only}

*  *Lieberman JA, Tollefson G, Tohen M, Green AI, Gur RE,
Kahn R, McEvoy J, Perkins D, Sharma T, Zipursky R, Wei H,
Hamer RM, HGDH Study= Group. Comparative efficacy and
safety of atypical and conventional antipsychotic drugs in
first-episode psychosis: a randomized, double-blind trial of
olanzapine versus haloperidol. American Journal of Psychiatry
2003;160(8):1396-404. [MEDLINE: 22781564; PMID 12900300]

Breier A, Keefe RS, Young CA, Purdon SE, Gold JM, Davis KL.
A one-year double-blind comparison of the neurocognitive
efficacy of olanzapine, risperidone, and haloperidol in patients
with schizophrenia. Schizophrenia Research 2003;60:274-5.
[EMBASE 2003496187]

Breier AF, Zipursky RB, Perkins DO, Addington JM, Tohen MF,
David SR, McGlashan TH. A trial of olanzapine versus pbo in
the prodrome: protocol and baseline sample. 155th Annual
Meeting of the American Psychiatric Association; 2002 May

18-23; Philadelphia, PA, USA. 2002. [Lilly study possible stands
alone not published]

Centorrino F, Hamer RM, Tohen M, Lieberman JA. Drug
attitudes and treatment adherence in a clinical trial comparing
haloperidol and olanzapine in first episode schizophrenia.
Schizophrenia Research 2003;60:277. [EMBASE: 2003241517]

Green A, Tohen M, Strakowski SM, Lieberman JA, Glick D,
Clarke SW. Comorbid substance use disorder and first episode
schizophrenia: acute effects of olanzapine versus haloperidol.
Schizophrenia Research (8th International Congress on
Schizophrenia Research; 2001 Apr 28 - May 2; British Columbia,
Canada). 2001, issue 1-2 Suppl:230. [MEDLINE: 21040726]

Green A, Tohen MF, Hamer RM, Strakowski SM, Lieberman JA,
Glick ICWS, GDH Research Group. First episode schizophrenia-
related psychosis and substance use disorders: acute response
to olanzapine and haloperidol. Schizophrenia Research. 2004;
Vol. 66, issue 2-3:125-35. [PMID 15061244]

Kahn RS, Lieberman JA, Charles C, Sharma T, Zipursky RB,
Gur R, Tohen M, Green AI, McEvoy JP, Perkins DO, Hamer RM,
Nemeroff CB, Tollefson GD. Antipsychotic treatment
effects on progression of brain pathomorphology in first
episode schizophrenia. Journal of the European College of
Neuropsychopharmacology 2003;13(4):S336. [P.2.131]

Keefe R, McEvoy J, Vaughn A. Source monitoring improvement
in patients with schizophrenia. Schizophrenia Research
(Abstracts of the 11th Biennial Winter Workshop on
Schizophrenia). Elsevier Science B.V, 2002, issue 3 Suppl.1:196.

Keefe R, Seidman LJ, Christensen B, Hamer RM, Yurgelun-
Todd D, Lewine R, Sitskoorn M, Sharma T, Tohen M,
Lieberman JA. Neurocognitive effects of olanzapine and low-
dose haloperidol: A two-year treatment study in first episode
psychosis. Schizophrenia Research. 2003; Vol. 60:289-90.
[EMBASE: 2003241517]

Keefe RS, Seiden LJ, Christensen B, Yurgelun-Todd DA,
Lewine RR, Sitskoorn M, Sharma T, Clark WS, Sanger TM,
Tohen M, Lieberman JA. Treatment of neurocognitive deficits
with olanzapine or low-dose haloperidol in first episode
psychosis. 39th Annual Meeting of the American College of
Neuropsychopharmacology; 2000; Dec 10-14; San Juan; Puerto
Rico. 2000.

Keefe RS, Seidman LJ, Hamer RM, Todd DY, Christensen B,
Sitskoorn MM, Lieberman JA. Neurocognition after two years
olanzapine or low-dose haldol in fe psychosis. 156th Annual
Meeting of the American Psychiatric Association; 2003 May
17-22; San Francisco, USA. 2003. [[NR576]]

Keefe RS, Seidman LJ, Hamer RM, Todd DY, Christensen B,
Sitskoorn MM, Lieberman JA. Neurocognition after two years
olanzapine or low-dose haldol in fe psychosis. 156th Annual
Meeting of the American Psychiatric Association; 2003 May
17-22; San Francisco, USA. 2003. [[NR576]]

Lieberman J, Charles HC, Sharma T, Zipursky R, Kahn R,
Gur R, Tohen M, Green AI, McEvoy J, Perkins D. Antipsychotic
treatment effects on progression of brain pathomorphology

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

31

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

in first episode schizophrenia. Schizophrenia Research
2003;60:293. [EMBASE: 2003241517]

Lieberman J, Sanger T, Tohen M, First Episode Collaborative
Study Group. Olanzapine and haloperidol treatment of first
epiode schizophrenia and schizoaffective disorder: 12 week
outcome of a two year randomized double blind trial. 2nd
International Conference on Early Psychosis; 2000 Mar 31 - Apr
2, New York, USA. 2000. [PsycINFO 2004-13151-011]

Lieberman J, Tohen M, McEvoy J, Sanger T, Keefe R, Charles C,
Clark S, Brier A, Tollefson G. Olanzapine versus haldoperidol in
the treatment of first episode phychosis. 39th Annual Meeting of
the American College of Neuropsychopharmacology; 2000; Dec
10-14; San Juan; Puerto Rico. 2000.

Lieberman JA. Research gaps and current research initiatives to
improve the treatment of schizophrenia. 156th Annual Meeting
of the American Psychiatric Association; 2003 May 17-22; San
Francisco, USA. 2003. [[SYMPOSIUM]No. 28]

Lieberman JA, Schneider LS, McEroy J, Pariot P, Stroup S,
Adiao J, Lebowitz BD. Effectiveness trials of antipsychotic drugs.
155th Annual Meeting of the American Psychiatric Association;
2002 May 18-23; Philadelphia, PA, USA. 2002.

Lieberman JA, Schneider LS, McEroy J, Pariot P, Stroup S,
Adiao J, Lebowitz BD. Effectiveness trials of antipsychotic drugs.
Annual Meeting of the American Psychiatric Association; 2001
May 5-10; LA, USA. Marathon Multimedia, 2001. [MEDLINE:
21093232]

Lieberman JA, Stroup TS. Schizophrenia, VI: Treatments.
American Journal of Psychiatry 2003;160(10):1748. [PMID
14514482]

Lieberman JA, Charles C, Sharma T, Zipursky RB, Hamer RM,
Tollefson GD. Effect of olanzapine versus haloperidol on brain
pathomorphology in first-episode psychosis. 156th Annual
Meeting of the American Psychiatric Association; 2003 May
17-22; San Francisco, USA. 2003. [[NR740]]

McEvoy J, Lieberman JA, Perkins D, Hamer RM, Sharma T,
Zipursky R, Kahn R, Gur R, Centorrino F, Glick I. Long-term
efficacy and safety of atypical and conventional antipsychotic
drugs in first episode schizophrenia. Schizophrenia Research.
2003; Vol. 60:313. [EMBASE: 2003241517]

McEvoy JP, Lieberman JA, Perkins DO, Hamer RM, Sharma T,
Zipursky RB. Long-term olanzapine treatment versus
haloperidol in first-episode psychosis. 156th Annual Meeting
of the American Psychiatric Association; 2003 May 17-22; San
Francisco, USA. 2003. [[NR207]]

Sharma T. The acute and long-term efficacy of olanzapine in
first-episode psychotic disorders: a randomised double-blind
comparison with haloperidol. National Research Register 2000.

Sharma T, Kumari V, Hughes C, Soni W, Mehrotra R, Binneman B.
Cognitive effects of clozapine and olanzapine in patients with
chronic schizophrenia. Schizophrenia Research (Abstracts of
the 11th Biennial Winter Workshop on Schizophrenia). Elsevier
Science B.V, 2002, issue 3 Suppl.1:195.

Cochrane Database of Systematic Reviews

Sharma T, Lieberman JA, McEvoy JP, Perkins DO, Hamer RM,
Zipursky RB, Kahn RS, Gur RE, Centorrino F, Glick I, Green AI,
Nemeroff CB, Rothschild AJ, Strakowski SM, Tohen M,
Tollefson GD. Long-term efficacy and safety of atypical and
conventional antipsychotic drugs in first episode schizophrenia.
Journal of the European College of Neuropsychopharmacology
2003;13(4):S134. [S.14.05]

Stroup TS, McEvoy JP, Swartz MS, Byerly MJ, Glick ID, Canive JM,
McGee MF, Simpson GM, Stevens MC, Lieberman JA. The
National Institute of Mental Health Clinical Antipsychotic Trials
of Intervention Effectiveness (CATIE) project: Schizophrenia
trial design and protocol development. Schizophrenia Bulletin.
2003; Vol. 29, issue 1:15-31. [EMBASE 2003292851]

Zipursky R, Gu H, Green AI, Centorrina F, Glick I, Perkins DO,
McEvoy J, Sharma T, Gur R, Strakowski SM. Clinical correlates
of weight gain in first episode psychosis patients treated with
olanzapine. Schizophrenia Research 2003;60:372. [EMBASE:
2003241517]

Zipursky RB, Hongbin G, Green AI, Centorrina F, Glick ID,
Lieberman JA. Clinical correlates of weight gain in first-episode
patients on olanzapine. 156th Annual Meeting of the American
Psychiatric Association; 2003 May 17-22; San Francisco, USA.
2003. [[NR563]]

Lima 2003 (HGHS) {published and unpublished data}

*  Lima MS, Mari JJ, Costa AMN, Alexandrini N, Filho SR,
Oliverira IR, Hotopf M. Quality of life of patients with
schizophrenia: A Randomised, Naturalistic, Controlled Trial
Comparing Olanzapine with Typical Antipsychotics in Brazil. Eli
Lilly and Company.

Lima MS, de Jesus Mari J, Costa AMN, Alexandrini N, Filho SR,
de Oliveira IR, Hotopt M. Quality of life of patients with
schizophrenia: a randomized, naturalistic, controlled trial
comparing olanzapine with typical antipsychotics in Brazil.
156th Annual Meeting of the American Psychiatric Association;
2003 May 17-22; San Francisco, USA. 2003. [N0146103028]

Mari JD, Lima MS, costa AN, Alexandrini N, Filho SR,
de Oliveira IR. A nine month naturalistic randomized controlled
trial comparing olanzapine and conventional antipsychotics for
schizophrenia and related disorders. Schizophrenia Research
2003;60:294. [EMBASE: 2003241517]

Mari JdJ, Lima MS, Costa AMN, Alexandrini N, Filho SR,
de Oliveira IR. Olanzapine versus conventional antipsychotics:
long-term risk of tardive dyskinesia. 156th Annual Meeting of
the American Psychiatric Association; 2003 May 17-22; San
Francisco, USA. 2003. [[NR254]]

Littrell 1999 {published data only}

Littrell KH. Patients switched from depot antipsychotics to oral
risperidone or olanzapine:an open-label randomized trial. APA
Annual Meeting, May 15-20, 1999, Washington, DC. 1999. [CSG
NO. 4111]

Loza 1999 (HGDT) {published and unpublished data}

Eli-Lilly unpublished document. HGDT Olanzapine Versus
Chlorpromazine in Egypt. Unpublished Document Internal to
Eli-lilly 2001:1-513.

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

32

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Loza N, El-Dosoky AM, Okasha TA, Khalil AH, Hasan NM,
Dossenbach M, Kratky P, Okasha A. Olanzapine compared
to chlorpromazine in acute schizophrenia. European
Neuropsychopharmacology 1999;9(Suppl 5):S291.

Malyarov 1999 {published data only}

Malyarov S, Dzub G. Comparative assessment of the positive
and negative symptom dynamics in schizophrenic patients
treated with atypical antipsychotics or haloperidol. Journal
of the European College of Neuropsychopharmacology.
1999:S296. [MEDLINE: 21040726]

Martin 2002 {published data only}

Fleurot O, Martins S, Loo H, Peuskens J, Rein W. Amisulpride vs
olanzapine in schizophrenia. Preliminary results on short-term
analysis. European Psychiatry (11th Association of European
Psychiatrists Congress, 2002 4-8th May, Stockholm, Sweden).
2002, issue Suppl 1:107s. [data now published my Martin]

Martin S, Loo H, Peuskens J, Rein W, Fleurot O. A six-month,
double-blind, controlled trial in schizophrenic patients
comparing amisulpride and olanzapine. Preliminary results on
short-term analysis. European Neuropsychopharmacology: The
Journal of the European College of Neuropsychopharmacology
2002;12(Supplement 3):S329.

*  Martin S, Loo H, Peuskens J, Thirumalai S, Giudicelli A,
Fleurot O, Rein W. A Double-blind, randomised, comparative
trial of amisulpride versus olanzapine in the treatment of
Schizophrenia: short-term results at two months. Current
Medical Research and Opinion 2002;18(6):355-62. [MEDLINE:
22039781]

Martin SD, Loo H, Peuskens J, Rein W, Fleurot O. A six-
month, double-blind, controlled trial in schizophrenic
patients comparing amisulpride and olanzapine. Preliminary
results on short-term analysis. International Journal of
Neuropsychopharmacology (Abstracts of the 23rd Congress of
the Collegium Internationale Neuro-Psychopharmacologicum;
2002 Jun 23-27; Montreal, Canada). 2002, issue Suppl 1:S119.

Mortimer A. A six month international controlled trial of the
therapeutic activity of amisulpride 200 to 800mg/day versus
olanzapine 5 to 20 mg/day in patients with schizophrenic
disorders' (The solianol study). National Research Register 2002;
Vol. 1. [N0084096619]

Mortimer A. A six month international controlled trial of the
therapeutic activity of amisulpride 200 to 800mg/day versus
olanzapine 5 to 20 mg/day in patients with schizophrenic
disorders' (The solianol study). National Research Register 2002;
Vol. 1. [N0084096619]

Mortimer A, Martin S, Loo H, Peuskens J. SOLIANOL Sudy
Group. A double-blind, randomized comparative trial of
amisulpride versus olanzapine for 6 months in the treatment
of schizophrenia. International Clinical Psychopharmacology
2004;19(2):63-9.

McQuade 2003 {unpublished data only}

Dubitsky GM, Harris R, Laughren T, Hardeman S. Abilify
(aripiprazole) tablets, medical review part 3. www.fda.gov/

Cochrane Database of Systematic Reviews

cder/foi/nda/2002/21-436_Abilify.htm. U.S. Food and Drug
Administration CDER, 2002:111-175.

*  McQuade RD, Jody DN, Kujawa MJ, Carson WH, Iwamoto T,
Archibald DG, et al. Long-term weight effects of aripiprazole vs.
olanzapine. 156th Annual Meeting of the American Psychiatric
Association; 2003 May 17-22; San Francisco, USA 2003.

Meltzer (InterSept) {published data only}

*  *Meltzer HY, Alphs L, Green AI, Altamura AC, Anand R,
Bertoldi A, Bourgeois M, Chouinard G, Islam MZ, Kane J,
Krishnan R, Lindenmayer JP, Potkin S, International
Suicide Prevention Trial Study Group. Clozapine treatment
for suicidality in schizophrenia: International Suicide
Prevention Trial (InterSePT).. Archives of General Psychiatry
2003;60(1):82-91.

Glick ID, Zaninelli R, Hsu C, Young FK, Weiss L, Gunay I, Kumar V.
Patterns of concomitant psychotropic medication use during
a 2-year study comparing clozapine and olanzapine for the
prevention of suicidal behavior.. Journal of Clinical Psychiatry
2004;65(5):679-85.

Kane J, Alphs LD, Meltzer HY, Green AI, Hsu C, Anand R, Young F,
Fahy T. The relationship between clinical response and changes
in weight for clozapine and olanzapine-treated patients.
International Journal of Neuropsychopharmacology (Abstracts
of the 23rd Congress of the Collegium Internationale Neuro-
Psychopharmacologicum; 2002 Jun 23-27; Montreal, Canada).
2002, issue Suppl 1:S171.

Kerwin R. A prospective randomised international parallel-
group comparison of clozapine versus olanzapine in the
reduction of suicide attempts in patients with schizophrenia
and schizoaffective disorder at risk for suicide. National
Research Register (N0042002860). 2000. [MEDLINE: 21040726]

Meltzer H. Decreasing suicide in schizophrenia: the intersept
study. European Psychiatry (11th Association of European
Psychiatrists Congress, 2002 4-8th May, Stockholm, Sweden).
2002, issue Suppl 1:26s.

Meltzer HY. Reducing risk of suicide in schizophrenia. Journal
of the European College of Neuropsychopharmacology
2003;13(4):S163. [S.25.03]

Meltzer HY. Reducing suicidality in schizophrenia and
schizoaffective disorder. 156th Annual Meeting of the American
Psychiatric Association; 2003 May 17-22; San Francisco, USA.
2003. [[INDUSTRY-SUPPORTED SYMPOSIUM]No. 27C]

Meltzer HY. Treatment of suicide in schizophrenia. Annuals of the
New York Academy of Sciences 2001;932:44-58.

Meltzer HY, Alphs L, Anand AR, Islam MZ, Potkin SG. The
intersept trial: reduced suicidality with clozapine treatment.
155th Annual Meeting of the American Psychiatric Association;
2002 May 18-23; Philadelphia, PA, USA. 2002.

Meltzer HY, Baldessarini RJ. Reducing the risk for suicide in
schizophrenia and affective disorders. Journal of Clinical
Psychiatry 2003;64(9):1122-9. [PMID 14628990]

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

33

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Meltzer HY, Baldessarini RJ. Reducing the risk for suicide in
schizophrenia and affective disorders. Journal of Clinical
Psychiatry 2003;64(9):1122-9. [PMID 14628990]

Mortimer A. Randomised prospective parallel group comparison
of clozapine vs olanzapine in the reduction of suicidality in
patients with schizophrenia/schizoaffective disorder. National
Research Register 2002; Vol. 1. [N0084096631]

Potkin SG, Alphs L, Hsu C, Krishn n K, Ranga Rama, Anand R,
Young FK, Meltzer H, Green A. Predicting Suicidal Risk in
Schizophrenic and Schizoaffective Patients in a Prospective
Two-Year Trial. Biological Psychiatry 2003;54(4):444-52.
[PsycINFO 2003-88046-005]

Young F, Meltzer H, Alphs L, Anand R, Green A, Potkin S, Kane J,
Krishnan R, Islam Z, Hsu C, Martin S. The intersept study:
reduced suicidal behavior in schizophrenic clozapine-treated
patients. International Journal of Neuropsychopharmacology
(Abstracts of the 23rd Congress of the Collegium Internationale
Neuro-Psychopharmacologicum; 2002 Jun 23-27; Montreal,
Canada). 2002, issue Suppl 1:S77.

Naber 2001 (HGBF) {published data only}

Bender S, Balcar A, Dittmann-Schall U, Klimke A, Riedel M,
Vorbach U, Kuehn KU, Lambert M, Dittmann RW, Naber D.
Effects of olanzapine versus clozapine on executive functions in
schizophrenia. Schizophrenia Research (Abstracts of the 11th
Biennial Winter Workshop on Schizophrenia). Elsevier Science
B.V, 2002, issue 3 Suppl.1:194. [Probably Not Elli Lilly study]

Dittmann-Balcar A, Bender S, Schall U, Klimke A, Mueller N,
Vorbach U, Kuehn KU, Dittmann RW, Naber D. Effects of
olanzapine versus clozapine on executive functions in
schizophrenia. Schizophrenia Research 2003;60:131. [EMBASE:
2003241517]

*  Naber D, Bandelow B, Bender S, Klimke A, Ku"hn K,
Lambert M, Lemmer W, Dittmann M, Riedel ER. Subjective
well-being under neuroleptic treatment with olanzapine
versus clozapine: first results from a double-blind clinical trial
using the swn self-rating scale. Schizophrenia Research (8th
International Congress on Schizophrenia Research; 2001 Apr 28
- May 2; British Columbia, Canada). 2001, issue 1-2 Suppl:240.

Naber D, Degner D, Bender S, Klimke A, Kuhn KU, Lambert M,
Lemmer W, Riedel M, Vorbach EU, Dittmann RW. Olanzapine
vs. clozapine: findings on subjective well-being from a double-
blind clinical trial. Schizophrenia Research (Abstracts of the
11th Biennial Winter Workshop on Schizophrenia). Elsevier
Science B.V, 2002, issue 3 Suppl.1:176.

Namjoshi 2002 {unpublished data only}

Namjoshi M, Young C, Huang L, Edgell ET, Breier A. Conical
and quality-of-life outcomes associated with olanzapine,
risperidone, and haloperidol treatment in patients with
schizophrenia: results from a US random study. International
Journal of Neuropsychopharmacology (Abstracts of the
23rd Congress of the Collegium Internationale Neuro-
Psychopharmacologicum; 2002 Jun 23-27; Montreal, Canada).
2002, issue Suppl 1:S127.

Cochrane Database of Systematic Reviews

Namjoshi M, Young CA, Huang L, Edgell E, Breier A. Cost-
effectiveness of olanzapine compared to risperidone and
haloperidol in the treatment of patients with schizophrenia:
Results from a U.S. randomized controlled trial. Schizophrenia
Research 2003;60:296. [N0146099645]

Namjoshi M, Young CA, Huang L, Edgell E, Breier A. Cost-
effectiveness of olanzapine compared to risperidone and
haloperidol in the treatment of patients with schizophrenia:
results from a U.S. randomized controlled trial. Schizophrenia
Research International Congress on Schizophrenia Research,
March29-April 2, 2003, Colorado Springs, CO. 2003. [EMBASE
2003496187]

*  Namjoshi M, Young Cm, Huang L, Edgell ET, Breier A.
Hospitalization rates associated with olanzapine, risperidone,
and haloperidol treatment in patients with schizophrenia:
Results from a U.S. randomized controlled trial. European
Neuropsychopharmacology: The Journal of the European
College of Neuropsychopharmacology. 2002, issue Supplement
3:S315.

Ritchie 2003 {published data only}

Ritchie CW, Chiu E, Harrigan S, Hall K, Hassett A,
Macfarlane SMM, O'Connor DW, Opie J, Ames D. The impact
upon extra-pyramidal side effects, clinical symptoms and
quality of life of a switch from conventional to atypical
antipsychotics (risperidone or olanzapine) in elderly patients
with schizophrenia. International Journal of Geriatric Psychiatry
2003;18(5):432-40. [MEDLINE: 22650960; PMID 12766921]

Rosenheck 2003(HGFI) {published data only}

Davis L, Sheikh J, Rosenheck R, Frecska E, Douyon R, Evans D,
Smith-Gamble V, Herz L, Grabowski J, Jasty V, Smelson D,
Graeber D, Allan E, Corwin J, Dunn L, Kwon K, Caroff S,
Gurklis JA. To determine if olanzapine is more cost effective
than haloperidol for the treatment of schizophrenia. / The
clinical and economic impact of olanzapine in the treatment
of schizophrenia. National Institutes of Health (http://
www.clinicaltrials.gov/ accessed 16th Feb 2001). 2001.

Glazer WM. Effectiveness and cost of olanzapine and
haloperidol in the treatment of schizophrenia: A randomized
controlled trial. JAMA 2004;291(9):1064-5. [PsycINFO
2004-11623-005]

*  Rosenheck R, Perlick D, Bingham S, Liu-Mares W, Collins J,
Warren S, Leslie D, Allan E, Campbell EC, Caroff S, Corwin J,
Davis L, Douyon R, Dunn L, Evans D, Frecska E, Grabowski J,
Graeber D, Herz L, Kwon K, Lawson W, Mena F, Sheikh J,
Smelson D, Smith-Gamble V. Effectiveness and cost of
olanzapine and haloperidol in the treatment of schizophrenia: a
randomized controlled trial. JAMA 2003;290(20):2693-702.

Simpson 2004 {published data only}

Fryburg DA, O'Sullivan RL, Siu C, Simpson G. Insulin resistance
in olanzapine and ziprasidone treated subjects: interim results
of a double-blind controlled six-week trial. 39th Annual Meeting
of the American College of Neuropsychopharmacology; 2000;
Dec 10-14; San Juan; Puerto Rico. 2000.

Glick ID, Fryburg D, O'Sullivan RL, Siu C, Simpson G.
Ziprasidone's benefits versus olanzapine regarding weight

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

34

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

and insulin resistance. European Neuropsychopharmacology
(Abstracts of the 14th Congress of the European College of
Neuropsychopharmacology; 2001 Oct 13-17; Istanbul, Turkey).
2001, issue 3:273.

Harvey P, Simpson GM, Loebel A. Ziprasidone vs olanzapine
for cognitive function in schizophrenia. European
Neuropsychopharmacology: The Journal of the European College
of Neuropsychopharmacology 2002;17(Supplement 3):S293.

O'Sullivan R, Fryburg D, Siu C, Simpson G. Insulin resistance in
olanzapine and ziprasidone treated subjects: interim results of a
double-blind controlled six-week trial. Schizophrenia Research
(8th International Congress on Schizophrenia Research; 2001
Apr 28 - May 2; British Columbia, Canada). 2001, issue 1-2
Suppl:241.

Simpson G, Horne RL, Weiden PJ, Pigott T Bari M, Romano SJ.
Ziprasidone vs olanzapine in schizophrenia: a double-blind
trial. European Psychiatry (11th Association of European
Psychiatrists Congress, 2002 4-8th May, Stockholm, Sweden).
2002, issue Suppl 1:101s.

Simpson G, O'Sullivan RL, Siu C. Ziprasidone vs olanzapine
in schizophrenia: results of a double-blind trial. European
Neuropsychopharmacology (Abstracts of the 14th Congress of
the European College of Neuropsychopharmacology; 2001 Oct
13-17; Istanbul, Turkey). 2001, issue 3:274.

Simpson G, Weiden P, Pigott T, Romano SJ, Siu C. Ziprasidone
versus olanzapine in patients with recent-onset schizophrenia.
3rd International Conference on Early Psychosis; 2002 Sep
26-28; Copenhagen, Denmark. 2002:70.

Simpson G, Weiden P, Pigott T, Romano Sol, Siu C. Ziprasidone
vs olanzapine in schizophrenia: results of a 6-month,
double-blind continuation study. International Journal of
Neuropsychopharmacology (Abstracts of the 23rd Congress of
the Collegium Internationale Neuro-Psychopharmacologicum;
2002 Jun 23-27; Montreal, Canada). 2002, issue Suppl 1:S124.

*  Simpson GM, Glick ID, Weoden PJ, Romano SJ, Siu CO.
Randomized, controlled, double-blind multicenter comparison
of the efficacy and tolerability of ziprasidone and olanzapine
in acutely ill inpatients with schizophrenia or schizoaffective
disorder. American Journal of Psychiatry 2004;161(10):1837-47.

Simpson GM, O'Sullivan RR, Horne RL, Weiden P, Bari MA,
Pigott T, Siu C. Ziprasidone vs olanzapine in schizophrenia. 7th
World Congress of Biological Psychiatry; 2001 Jul 1-6; Berlin,
Germany. 2001, issue Suppl. 1.

Cochrane Database of Systematic Reviews

Thomas 1998 (HGBU) {published and unpublished data}

Grainger, D, Gureje O, Lambert T, Tran PV, Andersen SW.
Olanzapine versus risperidone in the management of
schizophrenia: a randomized, double-blind study in Australia
and New Zealand. World Psychiatric Association Annual
Meeting. 1999;Hamburg, Germany, August 6-11. 1999.
[MEDLINE: 21122407]

Gregor K, Gureje O, Lambert T, Grainger D, Tran PV,
Andersen SW, and the Australasian Olanzapine Study Group.
Olanzapine versus risperidone in the management of
schizophrenia: a randomized, double-blind study in Australia
and New Zealand. World Psychiatric Association. Hamburg,
Germany. August 1999.

Gureje O, Catts S, Fraser A, Hustig H, Keks N, Lambert Y,
McGrath J, Miles W, Thomas A, Grainger D, Andersen S,
Tollefson G. Olanzapine versus risperidone in the treatment of
schizophrenia and related psychotic disorders. XXIst Collegium
Internationale Neuro-psychopharmacologicum. Glasgow,
Scotland, UK. July 12-16, 1998.

Gureje O, Lambert T, Grainger D, Tran PV, Andersen SW.
Olanzapine versus risperidone in the management of
schizophrenia: a randomized, double-blind study in
Australia and New Zealand. 21st Congress of the Collegium
Internationale Neuro-psychopharmacologicum; 1998 Jul 12-16;
Glasgow, Scotland. 1998. [MEDLINE: 21122407; published now
(Thomas HGBU) Gureje]

*  Gureje O, Miles W, Keks N, Grainger D, Lambert T, McGrath J,
Tran P, Catts S, Fraser A, Hustig H, Andersen S, Crawford AM.
Olanzapine vs risperidone in the management of schizophrenia:
a randomized double-blind trial in Australia and New Zealand.
Schizophrenia Research 2003;61(2-3):303-14.

Thomas A, Grainger D, Andersen S, Tollefson G. Olanzapine
versus risperidone in the treatment of schizophrenia
and related psychotic disorders. Schizophrenia Research
1998;29(1-2):147.

Tollefson 1997(HGAJ) {published and unpublished data}

Alan B, Hamilton SH. Comparative efficacy of olanzapine and
haloperidol for patients with treatment resistant schizophrenia.
11th World Congress of Psychiatry; 1999 Aug 6-11; Hamburg,
Germany. 1999:144.

Almond S, O'Donnell O. Cost analysis of the treatment of
schizophrenia in the UK: a comparison of olanzapine and
haloperidol. Pharmacoeconomics 1998;13(5 part 2):575-88.

Simpson GM, Weiden P, Pigott T, Romano SJ, Siu C. Ziprasidone
versus olanzapine in schizophrenia: six-month continuation
study. Schizophrenia Research 2003;60:303. [EMBASE:
2003241517]

Andersen S, Cohen L, Goldstein J, Tohen M, Tollefson G. Sex
and neuroendocrine differences in response to treatment with
olanzapine: a preliminary analysis. Schizophrenia Research
1998;29(1-2):186-7.

Svestka 2003 {published data only}

Svestka J, Synek O, Zourkova A. A double-blind comparison of
olanzapine and quetiapine in treatment of acute exacerbations
of schizophrenic or schizoaffective disorders. Journal
of the European College of Neuropsychopharmacology
2003;13(4):S291. [P.2.031]

Andersen SW, Tollefson GD, Sanger T. Depressive signs and
symptoms in schizophrenia:a prospective blinded trial of
olanzapine and haloperidol. APA Annual Meeting; May 15-20;
Washington DC; USA. 1999. [CSG NO. 4125]

Baker R W, Julier B, Stauffer V. Manic-like symptoms in
schizophrenic patients treated with olanzapine, haloperidol and

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

35

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

placebo. 7th World Congress of Biological Psychiatry; 2001 Jul
1-6; Berlin, Germany. 2001, issue Suppl. 1.

Neurpsychopharmacology Meeting; October 31-November 4;
Paris; France. 1998.

Beasley C, Tran P, Beuzen JN, Tamura R, Dellva MA, Bailey J,
Krueger J, Tollefson G. Olanzapine versus haloperidol: long-
term results of the multi-center international trial. XXth
Collegium Internationale Neuro-psychopharmacologicum; June
23-27; Melbourne; Australia. 1996.

Beasley CM. Safety of Olanzapine. Journal of Clinical Psychiatry
Monograph 1997;15(2):19-21.

Beasley CM Jr, Tollefson GD, Tran PV. Safety of olanzapine.
Journal of Clinical Psychiatry 1997;58(Suppl 10):13-7.

Beasley CM, Sayler ME, Kiesler GM, Potvin JH, Sanger TM,
Tollefson GD. The influence of pharmacotherapy on self-
directed and externally-directed aggression in schizophrenia.
Schizophrenia Research 1998;29(1-2):28.

Beasley CM, Tollefson GD, Dellva MA, Tamura R, Glazer WM,
Morgenstern H. The differential risk of tardive dyskinesia with
olanzapine. 151st Annual Meeting of American Psychiatric
Association; May 30 - June 4; Toronto; ON, Canada. 1998.

Brecher M. Risperidone versus olanzapine in the treatment
of patients with schizophrenia or schizoaffective disorder.
Proceedings of XXIst Collegium Internationale Neuro-
psychopharmacologicum; July 12-16; Glasgow; Scotland, UK.
1998.

Breier A, Berg PH. The psychosis of schizophrenia:Prevalence,
response to atypical antipsychotics, prediction of outcome.
Biological Psychiatry 1999;46(3):361-4. [CSG NO. 4342]

Breier A, Hamilton SH. Comparative efficacy of olanzapine and
haloperidol with treatment-resistant schizophrenia. Biological
Psychiatry 1999;45(4):403-11.

Breier AF, Hamilton SH. Comparative efficacy of olanzapine and
haloperidol for patients with treatment-resistant schizophrenia.
APA Annual Meeting, May 15-20, 1999, Washington, DC. 1999.

Burns PR, Reams SG, Sanger TM, Beasley CM Jr. Olanzapine
in the treatment of elderly patients with schizophrenia and
related psychotic disorders. 9th Biennial Winter Workshop
on Schizophrenia, February 7-13, 1998-Davos, Switzerland.
1998:ABSTRACT REF:PT07052. [CSG NO. 3963]

Burns PR, Reams SG, Sanger TM, Beasley CMJr. Olanzapine
in the treatment of elderly patients with schizophrenia and
related psychotic disorders. Proceedings of XXIst Collegium
Internationale Neuro-psychopharmacologicum. Glasgow,
Scotland, UK. July 12-16, 1998.

Cohen LS, Goldstein JM, Lee H, Tohen M, Andersen S,
Tollefson GD. Sex and neuroendocrine differences following
treatment with typical and atypical antipsychotics. 151st
Annual Meeting of American Psychiatric Association. Toronto,
ON, Canada. May 30-June 4, 1998.

Conley RR, Brecher M, The Risperidone/Olanzapine Study
Group. Riasperidone versus olanzapine in patients with
schizophrenia or schizoaffective disorders. European College of

Crawford AM, Gomez JC, Beasley CM, Tollefson GD. Olanzapine
versus haloperidol: analysis of schizophrenic patients from the
multi-center international trial. Journal of the European College
of Neuropsychopharmacology 1997;7:2015.

Crawford AMK//Gomez JC//Beasley CM Jr//Tollefson GD.
Olanzapine versus haloperidol: analysis of schizophrenic
patients from the multi-center international trial. Journal of the
European College of Neuropsychopharmacology 1997;7:P.2.015.
[EMBASE&#160; 2002184411; CN-00443250.]

David S, Crawford AM, Breier A. Prolactin levels in olanzapine
versus typical and atypical antipsychotics. European
Neuropsychopharmacology 1998;8(Suppl 2):S229.

David S, Crawford AM, Breier A. Prolactin levels in olanzapine
versus typical and atypical antipsychotics. Schizophrenia
Research 1998;29(1-2):153.

Dellva M, Satterlee W, Tran P, Beasley C, Greaney M, Tollefson G.
Extrapyramidal symptoms and tolerability of olanzapine
versus haloperidol in acute treatment. 9th Congress of the
European College of Neuropsychopharmacology, Amsterdam,
The Netherlands. 1996. [CSG NO. 3906]

Dellva MA, Beasley CM, Kuntz AJ, Tamura RN, Glazer WM,
Morgenstern H, Tollefson GM. What is the differential risk of
tardive dyskinesia with the novel antipsychotic olanzapine?.
11th Annual Meeting of the American Association for Geriatric
Psychiatry; San Diego; California. 1998. [CSG NO. 2922]

Dellva MA, Beasley CM, Tamura RN, Tollefson GD. What is
the differential risk of tardive dyskinesia with the novel
antipsychotic olanzapine?. Proceedings of XXIst Collegium
Internationale Neuro-psychopharmacologicum; July 12-16;
Glasgow; Scotland, UK. 1998.

Dellva MA, Tran P, Tollefson GD, Wentley AL, Beasley CM Jr.
Standard olanzapine versus placebo and ineffective-dose
olanzapine in the maintenance treatment of schizophrenia.
Psychiatric Services 1997;48:1571-7.

Edgell ET, Hamilton SH, Revicki DA, Genduso LA, Tollefson GD.
Costs of olanzapine treatment compared with haloperidol
for schizophrenia: results from a randomized clinical trial.
Proceedings of XXIst Collegium Internationale Neuro-
psychopharmacologicum; July 12-16; Glasgow; Scotland, UK.
1998.

Gilmore J, Kinon BJ, Basson BR, Tollefson GD. Effect of long
term olanzapine treatment on weight change in schizophrenia.
International Journal of Neuropsychopharmacology
2000;3(Suppl 1):S155.

Gilmore J, Kinon BJ, Basson BR, Tollefson GD. Effect of long
term olanzapine treatment on weight change in schizophrenia.
Journal of the European College of Neuropsychopharmacology
2000;10(Suppl 3):S305.

Gilmore JA, Kinon BJ, Zhao Z, Barber B. Improvement in quality
of life and depressive symptoms in schizophrenic patients is

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

36

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

associated with robust acute treatment response of olanzapine
versus haloperidol. Schizophrenia Research (Abstracts of the
11th Biennial Winter Workshop on Schizophrenia). Elsevier
Science B.V, 2002, issue 3 Suppl.1:177.

Gilmore JA, Kinon BJ, Zhao Z, Barber B. Rigorous criteria for
treatment response differentiated efficacy of olanzapine versus
haloperidol in patients with schizophrenia. Schizophrenia
Research (Abstracts of the 11th Biennial Winter Workshop on
Schizophrenia). Elsevier Science B.V, 2002, issue 3 Suppl.1:177.

Glazer WM, Johnstone BM. Pharmacoeconomic evaluation of
antipsychotic therapy for schizophrenia. Journal of Clinical
Psychiatry 1997;58(Suppl 10):50-4.

Gomez JC, Crawford AM. Superior efficacy of olanzapine over
haloperidol: analysis of patients with schizophrenia from a
multicenter international trial. Journal of Clinical Psychiatry
2001;62(Suppl 2):6-11. [MEDLINE: 21122407]

Grainger D, Hamilton SH, Genduso LA, Revicki DA.
Medical resource use and work and social outcomes for
olanzapine compared with haloperidol in the treatment of
schizophrenia. 21st Congress of Collegium Internationale
Neuro-psychopharmacologicum; Glasgow; Scotland, UK. 1998.
[CSG NO. 3607,ABSTRACT REF:PT07058]

Gregor K J, Hamilton S H, Edgell E T. Functional Outcomes
in Schizophrenia: A European Comparison of Olanzapine
and Haloperidol. Schizophrenia Research (10th Biennial
Winter Workshop on Schizophrenia; 2000 Feb 5-11; Davos,
Switzerland). 2000, issue 1:189.

Gregor K, Hamilton S, Edgell E. Functional outcomes in
schizophrenia: a European comparison of olanzapine and
haloperidol. 11th World Congress of Psychiatry; 1999 Aug 6-11;
Hamburg, Germany. 1999:152.

Gregor KJ, Allicar MP, Lilliu H, Bouhassira M, Le Pen C. An
economic comparison of olanzapine versus haloperidol in the
treatment of schizophrenia in France. Schizophrenia Research
2000;41(Number 1 - Special Issue):189-190.

Gregor KJ, Allicar MP, Lilliu H, Olivier V, Le Pen C, Gavart S. An
economic comparison of olanzapine versus haloperidol in the
treatment of schizophrenia in France. International Journal of
Neuropsychopharmacology 2000;3(Suppl 1):S161.

Gregor KJ, Hamilton SH, Edgell ET. Functional outcomes
in schizophrenia: a European comparison of olanzapine
and haloperidol. Journal of the European College of
Neuropsychopharmacology 1999;9(Suppl 1):S11.

Gregor KJ, Hamilton SH, Edgell ET. Functional outcomes
in schizophrenia: a European comparison of olanzapine
and haloperidol. Journal of the European College of
Neuropsychopharmacology 1999;9(Suppl 1):S11.

Gregor KJ, Hamilton SH, Edgell ET. Functional outcomes
in schizophrenia: a European comparison of olanzapine
and haloperidol. Journal of the European College of
Neuropsychopharmacology 1999;9:S289. [MEDLINE: 21040726]

Cochrane Database of Systematic Reviews

Hamilton S, Breier A, David S. Comparative efficacy of
olanzapine and haloperidol for patients with treatment
resistant schizophrenia. 11th Congress of The European College
of Neuropsychopharmacology; 1998 Oct 31- Nov 4; Paris,
France. 1998.

Hamilton S, Revicki D, Genduso LA, Tollefson GD. Cost
of olanzapine treatment compared with haloperidol for
schizophrenia: results from a randomized clinical trial. 151st
Annual Meeting of American Psychiatric Association; May 30-
June 4; Toronto; ON, Canada. 1998.

Hamilton SH, Breier A, David S. Comparative efficacy
of olanzapine and patients with treatment-resistant
schizophrenia. European Neuropsychopharmacology
1998;8(Suppl 2):S228.

Hamilton SH, Edgell ET, Revicki DA, Breier A. Functional
outcomes in schizophrenia: A comparison of olanzapine
and haloperidol in a European sample. International Clinical
Psychopharmacology 2000;15(5):245-55. [MEDLINE: 20445222]

Hamilton SH, Edgell ET, Revicki LA, Genduso LA, Tollefson G.
Clinical and economic outcomes of olanzapine compared
with haloperidol for schizophrenia: results from a randomized
clinical trial. European Neuropsychopharmacology 1998;8(Suppl
2):S236.

Hamilton SH, Genduso LA, Haley JC, Revicki DA. Medical
resource use and socioeconomics in the treatment of
schizophrenia: olanzapine compared with haloperidol. 10th
European College of Neuropsychopharmacology Congress; Sep
13-17; Vienna; Austria. 1997.

Hamilton SH, Genduso LA, Revicki DA. Medical resource use
and work and social outcomes for olanzapine compared
with haloperidol in the treatment of schizophrenia and other
psychotic disorders. Schizophrenia Research 1998;29(1-2):148-9.

Hamilton SH, Revicki DA, Edgell ET, Genduso LA, Tollefson G.
Clinical and economic outcomes of olanzapine compared with
haloperidol for schizophrenia - results from a randomised
clinical trial. Pharmacoeconomics 1999;15(5):469-80.

Hamilton SH, Revicki DA, Genduso LA, Tollefson GD. Costs
of olanzapine treatment compared with haloperidol for
schizophrenia: results from a randomized clinical trial.
Schizophrenia Research 1998;29(1-2):149.

Javor K, Kinon BJ, Gilmore J. Continued improvement in quality
of life despite weight change during olanzapine treatment.
Schizophrenia Research (8th International Congress on
Schizophrenia Research; 2001 Apr 28 - May 2; British Columbia,
Canada). 2001, issue 1-2 Suppl:233. [MEDLINE: 21040726]

Johnstone BM, Obenchain RL, Croghan TW, Tunis SL,
Kniesner TJ. To evaluate the cost-effectiveness of olanzapine
compared to haloperidol for schizophrenia. 151st Annual
Meeting of American Psychiatric Association; May 30-June 4;
Toronto; ON, Canada. 1998.

Johnstone BM, Obenchain RL, Edgell ET, Croghan TW, Tunis SL,
Kniesner TJ. Intent-to-treat analysis of repeated measures
data from a randomized clinical trial comparing the cost and

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

37

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

effectiveness of treatment for schizophrenia with olanzapine or
haloperidol. European Neuropsychopharmacology 1998;8(Suppl
2):S235.

Kinon B, Basson B, Tollefson GD. Gender specific prolactin
olanzapine versus haloperidol in schizophrenia. American
Psychiatric Association, Toronto, Canada MAy 30- June 4. 1998.

Kinon BJ, Basson B, Szymanski K, Tollefson GD. Predictors
of weight gain during olanzapine treatment. European
Neuropsychopharmacology 1998;8(Suppl 2):S220.

Kinon BJ, Basson BR, Gilmore JA, Tollefson GD. Long-term
olanzapine treatment: Weight change and weight-related
health factors in schizophrenia. Journal of Clinical Psychiatry
2001;62(2):92-100.

Kinon BJ, Basson BR, Tollefson GD. Effect of long-term
olanzapine treatment on weight change in schizophrenia.
Schizophrenia Research 2000;41(Number 1 - Special
Issue):195-196. [CSG NO. 4511]

Kinon BJ, Basson MS, Tollefson GD. Gender-specific prolactin
response to treatment with olanzapine vs. haloperidol in
schizophrenia. Poster presented at the 9th Biennial European
Winter Workshop on Schizophrenia; 1998 February 7-13, Davos,
Switzerland. 1998. [CSG NO. 3325]

Kinon BJ, Gilmore JA, Gottschalk LA. Continued improvement
in quality of life despite weight change during olanzapine
treatment. 39th Annual Meeting of the American College of
Neuropsychopharmacology; 2000; Dec 10-14; San Juan; Puerto
Rico. 2000.

Kinon BJ, Milton DR, Hill AL. Effective resolution of acute
presentation of behavioral agitation and positive psychotic
symptoms in schizophrenia with olanzapine. International
Journal of Neuropsychopharmacology 2000;3(Suppl 1):S154.

Kinon BJ, Roychowdhury SM, Milton DR, Hill AL. Effective
resolution with olanzapine of acute presentation of behavioral
agitation and positive psychotic symptoms in schizophrenia.
Journal of Clinical Psychiatry 2001;62(Suppl 2):17-21.

Kuntz AJ, Sanger TM, Beasley CM. Olanzapine in the treatment
of elderly patients with schizophrenia and related psychotic
disorders. 11th Annual Meeting of the American Association for
Geriatric Psychiatry, San Diego, California. 1998. [CSG NO. 2920]

Lane LM, Burns PR, Reamse SC, Sanger TM, Beasley CM Jr.
Olanzapine in the treatment of elderly patients with
schizophrenia and related psychotic disorders. European
Neuropsychopharmacology 1998;8(Suppl 2):S225.

Le Pen C, Lilliu H, Allicar M P, Olivier V, Gregor KJ. An economic
comparison of olanzapine versus haloperidol in the treatment
of schizophrenia in France. Encephale 1999;25(4):281-286. [CSG
NO. 4412]

Lu Y, Sanger T, Beasley C, Tran P, Tollefson, G. Olanzapine in
the treatment of schizoaffective disorder. 9th Congress of the
European College of Neuropsychopharmacology; Amsterdam;
The Netherlands. 1996. [CSG NO. 2807]

Cochrane Database of Systematic Reviews

Mallinckrodt C H, David S R, Burns P R, Breier A. Long-Term
Efficiacy and Safety of Olanzapine in Patients with Inadequate
Initial Response to Haloperidol or Olanzapine. Schizophrenia
Research (7th International Congress on Schizophrenia
Research, 1999 Apr 17-21, Santa Fe, New Mexico, USA).
1999:288.

Mallinckrodt C, David S, Burns P, Breier A. Long-term efficacy
and safety of olanzapine in patients with inadequate
initial response to haloperidol or olanzapine. European
Neuropsychopharmacology 1998;8(Suppl 2):S228.

Martin C. Impact of olanzapine on quality of life in
schizophrenia. 8th Congress of the Association of European
Psychiatrists; Jul 7-12; London; England, UK. 1996.

Martin C, Genduso L, Revicki D, Hamilton S, Tran P, Beasley C.
Impact of olanzapine on patient quality of life in schizophrenia.
Xth World Congress of Psychiatry; August 23-28; Madrid; Spain.
1996.

Meehan KM, David SR, Taylor CC, Sutton VK. Change in
extrapyramidal symptoms with olanzapine in comparison
with other antipspychotic agents. Schizophrenia Research
2000;41(1):192.

Naber D. Evidence of efficacy of neuroleptics in effective
versus negative symptoms. 10th European College of
Neuropsychopharmacology Congress; Sep 13-17; Vienna;
Austria. 1997.

Patel B, Kurtz DL, Callaghan JT, Beasley CM Jr, Bergstrom RF.
Effect of smoking and gender on population pharmacokinetics
of olanzapine. American Psychiatric Association, 149th Annual
Meeting; May 4-9. 1996.

Pilowsky LS, Busatto GF, Taylor M, Costa DC, Sharma T,
Sigmundsson T, Ell PJ, Nohria V, Kerwin RW. Dopamine D2
receptor occupancy in vivo by the novel atypical antipsychotic
olanzapine - a 123I IBZM single photon emission tomography
(SPET) study. Psychopharmocology 1996;124:148-53.

Reams SG, Sanger TM, Beasley CM Jr. Olanzapine in the
treatment of elderly patients with schizophrenia and related
psychotic disorders. Schizophrenia Research 1998;29(1-2):151-2.

Revicki D, Genduso LA, Hamilton SL, Martin C, Reblando J,
Tran PV. Quality of life outcomes for olanzapine and haloperidol
treatment for schizophrenia and related psychotic disorders.
American Psychiatric Association, 149th Annual Meeting; May
4-9. 1996.

Revicki D, Haley J, Hamilton S, et al. Quality of life outcomes
for olanzapine and haloperidol treatment for schizophrenia
and other psychotic disorders:results of an international
randomized clinical trial. Quality of Life Research 1997;6:708.
[CSG NO. 4596]

Revicki DA. Quality of life and re-integration of chronically
ill patients. 9th Congress of the Association of European
Psychiatrists; Copenhagen. 1998:Abstract number:Lilly-SAT1-5.
[CSG NO. 3806]

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

38

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Revicki LA, Genduso LA, Hamilton SH, Beasley CM Jr.
Olanzapine versus haloperidol in the treatment of
schizophrenia, schizoaffective and schizophreniform disorders.
Quality of life outcomes of a randomized clinical trial. Quality of
Life Research 1999;8:417-26.

Sanger T, Lieberman J, Tohen M, Grundy S, Beasley C Jr,
Tollefson G. Olanzapine versus haloperidol treatment in first-
episode psychosis. European Neuropsychopharmacology
1998;8(Suppl 2):S228-9.

Sanger T, Lieberman JA, Tohen M, Tollefson GD. Olanzapine
versus haloperidol in the treatment of first episode psychosis.
Proceedings of XXIst Collegium Internationale Neuro-
psychopharmacologicum; July 12-16; Glasgow; Scotland, UK.
1998.

Sanger T, Lieberman JA, Tohen M, Tollefson GD. Olanzapine
versus haloperidol in the treatment of psychosis. 151st Annual
Meeting of American Psychiatric Association; May 30-June 4;
Toronto; ON, Canada. 1998.

Sanger T, Tollefson GD, Lieberman JA, Tohen M. Olanzapine
versus haloperidol in the treatment of first-episode psychosis.
American Psychiatric Association, 150th Annual Meeting; San
Diego; CA, USA. 1997.

Sanger TM, Lieberman JA, Tohen M, Starr Grungy PH, Beasley C-
Jr, Tollefson GD. Olanzapine versus haloperidol treatment
in first-episode psychosis. American Journal of Psychiatry
1999;156:79-87.

Sanger TM, Lieberman JA, Tohen M, Tollefson GD. Olanzapine
versus haloperidol treatment of first-episode psychosis.
Schizophrenia Research 1998;29(1-2):151.

Satterlee W, Beaasley C, Sanger T, Tran P, Tollefson G.
OLANZAPINE, A NEW "ATYPICAL" ANTIPSYCHOTIC. Schizophrenia
Research 1995;15(1,2):163. [CSG NO. 4032]

Satterlee WG, Beasley CM, Tran PV, Tamura RN, Krueger JA,
Tollefson GD. Olanzapine versus haloperidol - results of a
large multi-center international trial. American Psychiatric
Association, 149th Annual Meeting; May 4-9. 1996.

Satterlee WG, Beasley CM, Tran PV, Tamura RN, Krueger JA,
Tollefson GD. Olanzapine versus haloperidol in a large
international trial. Xth World Congress of Psychiatry; August
23-28; Madrid; Spain. 1996.

Street JS, Tamura R, Sanger T, Tollefson G. Long-term
treatment-emergent dyskinetic symptoms in patients treated
with olanzapine and haloperidol. Psychopharmacology Bulletin
1996;32(3):522.

Tamura RN, Beasley CM, Dellva MA, Glazer WM, Morgenstern H,
Tollefson GD. What is the differential risk of tardive dyskinesia
with the novel antipsychotic olanzapine?. Schizophrenia
Research 1998;29(1-2):176.

Tohen M, Sanger T, Tollefson GD. Gender differences in the
response of olanzapine versus haloperidol in the treatment of
first-episode psychosis. American Psychiatric Association, 150th
Annual Meeting; San Diego; CA, USA. 1997.

Cochrane Database of Systematic Reviews

Tohen M, Sanger T, Tollefson GD, McElroy SL. Olanzapine versus
haloperidol in the treatment of schizoaffective bipolar patients.
American Psychiatric Association, 150th Annual Meeting. San
Diego, CA, USA. 1997.

Tohen M, Sanger T, Tollefson GD, McElroy SL. Olanzapine versus
haloperidol in the treatment of schizoaffective bipolar patients.
American Psychiatric Association, 150th Annual Meeting; San
Diego; CA, USA. 1997.

Tohen MF, Zhang F, Sanger TM, Gannon KS, Tollefson GD.
Olanzapine versus haloperidol in schizoaffective bipolar
disorder:a repeated-measures analysis. APA Annual Meeting,
May 15-20, Washington, DC. 1999. [CSG NO. 4113]

Tollefson G, Beasley C, Tran P, Sanger T. Olanzapine: an exciting
atypical antipsychotic: the clinical experience. 8th European
College of Neuropsychopharmacology Congress; Sep 30-Oct 4;
Venice; Italy. 1995.

Tollefson GD. Olanzapine: A Novel Antipsychotic with a broard
spectrum profile. Neuropsychopharmacology 1994;10(3S):S189.

*  Tollefson GD, Beasley CM, Tran PV, Street JS, Krueger JA,
Tamura RN, Graffeo KA, Thieme ME. Olanzapine versus
haloperidol in the treatment of schizophrenia and
schizoaffective and schizophreniform disorders: results of an
international collaborative trial. American Journal of Psychiatry
1997;154:457-65.

Tollefson GD, Lu Y. Comorbid mood disturbance
in schizophrenia. 9th European College of
Neuropsychopharmacology Congress; Sep 21-25; Amsterdam;
The Netherlands. 1996.

Tunis SL, Croghan TW, Heilman DK, Johnston BM,
Obenchain RL. Reliability, validity, application of the Medical
Outcomes Study 36-Item Short-Form Health Survey (SF-36)
in schizophrenic patients treated with olanzapine versus
haloperidol. Medical Care 1999;37(7):678-91. [CSG NO. 4586]

Wright P, Tollefson GD, Beasley CM, Tamura RN, Tran PV,
Potvin JII. A blinded, controlled, long-term study of the
comparative incidence of treatement-emergent tardive
dyskinesia with olanzapine or haloperidol. Schizophrenia
Research 1998;29(1-2):206. [EMBASE&#160; 2002184411;
CN-00443250.]

Tollefson 1997 Conti {published data only}

Basson B, Kinon BJ, Gilmore JA, Taylor CC, Tollefson GD,
Czekalla J. Factors influencing weight change in patients with
schizophrenia treated with olanzapine verus haloperidol
or risperidone. Journal of Psychopharmacology 2000;14(3
Suppl):A60. [MEDLINE: 2003063779; PMID 22476629]

Beasley CM. Safety of olanzapine. Journal of Clinical Psychiatry
1997;15(2):19-21. [MEDLINE: 14687871; EMBASE 2003516387]

Goldstein JM, Cohen LS, Horton NJ, Lee H, Andersen S, Tohen M,
Crawford A, Tollefson G. Sex differences in clinical response to
olanzapine compared with haloperidol.. Psychiatry Research
2002;110(1):27-37. [MEDLINE: &#160;22004166; CENTRAL
CN-00389114]

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

39

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Jaton LA, Kinon BJ, Rotelli MD, Kaiser C, Kollack-Walker S.
Differential rate of weight gain present among patients treated
with olanzapine. Schizophrenia Research 2003;60:S357.
[MEDLINE: 14687871; EMBASE 2003516387]

Tollefson GD, Sanger TD, Lieberman JA. Olanzapine versus
haloperidol in the treatment of first episode psychosis.
Biological Psychiatry 1997;41:73S. [MEDLINE: 2003063779; PMID
22476629]

Kennedy JS, Jeste D, Kaiser CJ, Golsham S, Maguire GA,
Tollefson G, Sanger T, Bymaster FP, Kinon BJ, Dossenbach M,
Gilmore JA, Breier A. Olanzapine vs haloperidol in
geriatric schizophrenia: analysis of data from a double-
blind controlled trial. International Journal of Geriatric
Psychiatry 2003;18:1013-20. [MEDLINE: 14618553; PsycINFO
2003-10341-008; EMBASE 2003491563]

Tollefson G, Beasley C, Tran P, Dellva MA, Krueger J, Tamura R.
Olanzapine versus haloperidol: acute results of the multicenter
international trial. Psychopharmacology Bulletin 1996;32(3):401.

Tollefson GD. A blinded trial on the course and relationship of
depressive symptoms in schizophrenia. Proceedings of XXIst
Collegium Internationale Neuro-psychopharmacologicum; July
12-16; Glasgow; Scotland, UK. 1998.

Tollefson GD. Treatment consideration for comorbid mood
disorders in schizophrenic patients. Sixth World Congress of
Biological Psychiatry; June 22-27; Nice; France. 1997.

Tollefson GD, Sanger TM. Anxious-depressive symptoms in
schizophrenia:a new treatment target for pharmacotherapy?.
Schizophrenia Research 1999;35 Suppl:S13-21. [CSG NO. 4574]

Tollefson GD, Sanger TM, Andersen SW. Depressive
signs and symptoms in schizophrenia: a prospective
blinded trial of olanzapine and haloperidol. European
Neuropsychopharmacology 1998;8(Suppl 2):225.

Tollefson GD, Sanger TM, Andersen SW. Depressive
signs and symptoms in schizophrenia: a prospective
blinded trial of olanzapine and haloperidol. European
Neuropsychopharmacology. 1998, issue Suppl 2:225. [MEDLINE:
21122407]

Tollefson GD, Sanger TM, Andersen SW. Depressive signs and
symptoms in schizophrenia:a prospective blinded trial of
olanzapine and haloperidol. 11th Congress of the European
College of Neuropsychopharmacology; Paris; France. 1998. [CSG
NO. 3368]

Tollefson GD, Beasley CM Jr, Tamura RN, Tran PV, Potvin JH.
Blind, controlled, long-term study of the comparative
incidence of treatment-emergent tardive dyskinesia with
olanzapine or haloperidol. American Journal of Psychiatry
1997;154(9):1248-54.

Tollefson GD, Sanger TM, Leiberman JA. Olanzapine versus
haloperidol in the treatment of first episode psychosis.
Schizophrenia Research (Special Issue) - The VIth International
Congress on Schizophrenia Research, Colorado Springs, CO, USA
April 12-16, 1997;24:193.

Tollefson GD, Beasley CM, Tran PV, Tamura RN, Sanger TM,
Wood A, Beuzen JN. Olanzapine versus haloperidol: results of
the multi-center international trial. Schizophrenia Research
1996;18(2-3):131.

Tollefson GD, Lu Y. A blinded trial on the course and relationship
of depressive symptoms in schizophrenia. American Psychiatric
Association, 150th Annual Meeting; San Diego; CA, USA. 1997.

Tollefson GD, Lu Y. Comorbid mood disturbance in
schizophrenia. Schizophrenia Research 1997;24:191.

Tollefson GD, Lu Y. Comorbid mood disturbance in
schizophrenia. Schizophrenia Research (Special Issue) - The VIth
International Congress on Schizophrenia Research, Colorado
Springs, CO, USA April 12-16, 1997;24:192.

Tollefson GD, Lu Y. Comorbid mood disturbance in
schizophrenia. XXth Collegium Internationale Neuro-
psychopharmacologicum; June 23-27; Melbourne; Australia.
1996.

Tollefson GD, Lu Y, Sanger TM, Beasley CM, Tran PV. Olanzapine
in the treatment of schizoaffective disorder. Schizophrenia
Research 1997;24(1-2):192-3.

Tollefson GD, Lu Y, Sanger TM, Beasley CM, Tran PV. Olanzapine
in the treatment of schizoaffective disorder. Schizophrenia
Research (Special Issue) - The VIth International Congress on
Schizophrenia Research, Colorado Springs, CO, USA April 12-16,
1997;24:192.

Tollefson GD, Sanger TM, Lieberman JA. Olanzapine versus
haloperidol in the treatment of first-epsiode psychosis.
Schizophrenia Research 1997;24:193.

Tollefson GD, Sanger TM, Lu Y, Thieme ME. Depressive signs
and symptoms in schizophrenia: a prospective blinded trial
of olanzapine and haloperidol. Archives of General Psychiatry
1998;55(3):250-8.

Tollefson GD, Tran PV, Hamilton S, Kuntz A. Olanzapine versus
risperidone in the treatment of psychosis. Preliminary report.
Biological Psychiatry 1997;41:20S. [N0146103028]

Tran P, Beasley C, Street J, Tamura R, Dellva MA, Graffeo K,
Krueger J, Tollefson G. Olanzapine versus haloperidol: acute
results of the multi-center international trial. XXth Collegium
Internationale Neuro-psychopharmacologicum; June 23-27;
Melbourne; Australia. 1996.

Tran P, Dellva M, Tamura R, Krueger J, Beasley C,
Tollefson G. Olanzapine versus haloperidol:Results of the
international trial. 9th Congress of the European College of
Neuropsychopharmacology; Amsterdam; The Netherlands.
1996. [CSG NO. 3730]

Tran P, Lu Y, Sanger T, Beasley C, Tollefson G. Olanzapine in
the treatment of schizoaffective disorder. 21st Congress of the
Collegium Internationale Neuro-psychopharmacologicum; 1998
Jul 12-16; Glasgow, Scotland. 1998. [MEDLINE: 97055970]

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

40

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Tran P, Lu Y, Sanger T, Beasley C, Tollefson G. Olanzapine in the
treatment of schizoaffective disorder. Psychopharmacology
Bulletin 1996;32(3):527. [N0146103028]

Tran P, Lu Y, Sanger T, Beasley C, Tollefson G. Olanzapine in the
treatment of schizoaffective disorder. Psychopharmacology
Bulletin 1996;32(3):527.

Tran P, Lu Y, Sanger T, Beasley C, Tollefson G. Olanzapine in the
treatment of schizoaffective disorder. Schizophrenia Research
1998;29(1-2):151.

Tran P, Sanger TM, Satterlee W, Beasley CJ, Tamura RN,
Tollefson GD. Olanzapine vs haloperidol - results of a large
multi-centre international trial. Schizophrenia 1996: Breaking
down the Barriers, 4th International Conference; October 6-9;
Vancouver; BC, Canada. 1996.

Tran PV, Dellva MA, Beasley CM Jr, Satterlee WG, Cousins LM,
Tollefson GD. Clinical experience with long-term continuation
treatment with olanzapine. 149th Annual Meeting of the
American Psychiatric Association; 1996 May 4-9; New York, USA.
1996. [MEDLINE: 97055970]

Tran PV, Dellva MA, Tollefson GD, Beasley CM Jr, Potvin JH,
Kiesler GM. Extrapyramidal symptoms and tolerability of
olanzapine versus haloperidol in the acute treatment of
schizophrenia. Journal of Clinical Psychiatry 1997;58:205-11.

Tran PV, Dellva MA, Tollefson GD, Wentley AL, Beasley C Jr.
Oral olanzapine versus oral haloperidol in the maintenance
treatment of schizophrenia and related psychoses. British
Journal of Psychiatry 1998;172:499-505.

Tran PV, Tollefson GD, Creanga D, Zhang F, Wang J, Vangala S,
Cousins L. Clinical experience with olanzapine in patients
of African, Asian, and Hispanic descent. World Psychiatric
Association; Hamburg; Germany. 1999.

Tran PV, Tollefson GD, Sanger TM, et al. Olanzapine versus
haloperidol in the treatment of schizoaffective disorder:
acute and long-term therapy. British Journal of Psychiatry
1999;174:15-22.

Tunis SL, Croghan TW, Heilman DK. Validity of SF36 for severely
mentally ill patients. 151st Annual Meeting of American
Psychiatric Association; May 30-June 4; Toronto; ON, Canada.
1998.

Cochrane Database of Systematic Reviews

with olanzapine or haloperidol. Schizophrenia Research
1998;29(1-2):206.

Zhang F, Tohen M, Gannon KS, Breier A. Olanzapine versus
haloperidol: assessment of cognitive function in patients with
schizoaffective disorder, bipolar type. Journal of the European
College of Neuropsychopharmacology. 1999:S247. [MEDLINE:
21040726]

Zhang F, Tohen M, Sanger T, Gannon KS, Tollefson GD, Breier A.
Olanzapine versus haloperidol in schizoaffective disorder,
bipolar type: a˜repeated measures analysis. Journal of the
European College of Neuropsychopharmacology 1999;9:S246.
[MEDLINE: 21040726]

Tollefson 1999(HGDY) {published and unpublished data}

Burns P, Tollefson GD, Dellva MA, Mattler CA, Kinon BJ,
Grundy SL. A controlled, double-blind investigation of the
clozapine discontinuation syndrome with conversion to either
olanzapine or placebo. Presented at the 2nd Annual Meeting of
the College of Psychiatric and Neurologic Pharmacists. March
25-28, Lake Tahoe, NV, USA. 1999.

Dellva MA, Tollefson GD, Mattler CA, Kinon BJ, Grundy SL.
A controlled, double-blind investigation of the clozapine
discontinuation syndrome with conversion to either olanzapine
or placebo. Presented at the ICSR. April 17-21, Sante Fe, NM,
USA. 1999.

Mallinckrodt C, David S, Burns P, Breier A. Long term efficacy
and safety of olanzapine in patients with inadequate initial
response to haloperidol or olanzapine. 11th Congress of the
European College of Neuropsychopharmacology, Paris, France.
1998. [CSG NO. 3360]

Tollefson GD, Dellva MA, Mattler CA, Kinon BJ, Grundy SL.
A controlled, double-blind investigation of the clozapine
discontinuation syndrome with conversion to either olanzapine
or placebo. European Neuropsychopharmacology 1998;8(Suppl
2):229.

Tollefson GD, Mattler CA, Dellva MA, et al. Controlled, double-
blind investigation of clozapine discontinuation syndrome and
switching with conversion to either olanzapine or placebo.
Journal of Clinical Psychopharmacology Accepted 1998, due to
be published October 1999.

Tran 1997 (HGBG) {published and unpublished data}

*  Tunis SL, Johnstone BM, Gibson PJ, Loosbrock DL, Dulisse BK.
Changes in perceived health and functioning as a cost-
effectiveness measure for olanzapine versus haloperidol
treatment of schizophrenia. Journal of Clinical Psychiatry
1999;60 Suppl 19:38-45. [CSG NO. 4244]

*  *Tran PV, Hamilton SH, Kuntz AJ, Potvin JH, Andersen SW,
Beasley C Jr, Tollefson GD. Double-blind comparison
of olanzapine versus risperidone in the treatment of
schizophrenia and other psychotic disorders. Journal of Clinical
Psychopharmacology 1997;17:407-18.

Williamson D, Beasley C, Tran P, Tamura N, Sanger T,
Tollefson G. Olanzapine versus haloperidol: results of the multi-
center international trial. 8th Congress of the Association of
European Psychiatrists; Jul 7-12; London; England, UK. 1996.

Wright P, Tollefson GD, Beasley CM, Tamura RN, Tran PV,
Potvin JII. A blinded, controlled, long-term study of the
comparative incidence of treatment-resistant tardive dyskinesia

Ahmed S, Zhang F, Lindborg S, Tohen M, Breier A. A comparison
of olanzapine versus risperidone on improvement in negative
symptoms and emotional discomfort in patients with
schizophrenia. Schizophrenia Research 2003;60:270. [EMBASE:
2003241517]

Ahmed S, Zhang F, Walker D, Beglinger L, Earley WR, Tran PV.
Olanzapine versus risperidone for treatment of negative
symptoms in schizophrenia. 156th Annual Meeting of the

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

41

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

American Psychiatric Association; 2003 May 17-22; San
Francisco, USA. 2003. [[NR247]]

Basson B, Kennedy J, Tollefson G, Tran, Beasley C, Bymaster F.
The comparative anti muscarinic like adverse event profiles
of olanzapine and risperidone treatment in patients with
schizophrenia spectrum psychosis. 11th World Congress of
Psychiatry; 1999 Aug 6-11; Hamburg, Germany. 1999:142.

Basson B, Kinon BJ, Gilmore JA, Taylor CC, Tollefson GD,
Czekalla J. Factors influencing weight change in patients with
schizophrenia treated with olanzapine verus haloperidol
or risperidone. Journal of Psychopharmacology 2000;14(3
Suppl):A60. [MEDLINE: 2003063779; PMID 22476629]

David S, Crawford AM, Breier A. Prolactin levels in olanzapine
versus typical and atypical antipsychotics. European
Neuropsychopharmacology 1998;8(Suppl 2):S229.

David S, Crawford AM, Breier A. Prolactin levels in olanzapine
versus typical and atypical antipsychotics. Schizophrenia
Research 1998;29(1-2):153.

David SR, Meehan KM, Sutton VK, Taylor CC. Treatment of
negative symptoms with olanzapine in comparison with
other novel antipsychotic agents. International Journal of
Neuropsychopharmacology 2000;3(Suppl 1):s140. [MEDLINE:
2003063779; PMID 22476629]

Edgell ET, Andersen SW, Grainger D, Wang J. Resource use and
quality of life of olanzapine compared with risperidone: results
from an international randomized clinical trial. XXIst Collegium
Internationale Neuro-psychopharmacologicum. Glasgow,
Scotland, UK. July 12-16, 1998.

Edgell ET, Andersen SW, Johnstone BM, Dulisse B,
Revicki D, Breier A. Olanzapine versus risperidone:
a prospective comparison of clinical and economic
outcomes in schizophrenia. International Journal of
Neuropsychopharmacology 2000;3(Suppl 1):S92.

Edgell ET, Andersen SW, Johnstone BM, Dulisse B, Revicki D,
Breier A. Olanzapine versus risperidone: a prospective
comparison of clinical and economic outcomes in
schizophrenia. Pharmacoeconomics 2000;18(6):567-79.
[MEDLINE: 21119401]

Edgell ET, Grainger DL, Andersen SW, Wang J. Resource use
and quality of life associated with olanzapine compared with
risperidone. 151st Annual Meeting of American Psychiatric
Association. Toronto, ON, Canada. May 30-June 4, 1998.

Feldman PD, Kaiser CJ, Kennedy JS, Sutton VK, Tran PV,
Tollefson GD, Zhang F, Breier A. Comparison of risperidone
and olanzapine in the control of negative symptoms of
chronic schizophrenia and related psychotic disorders in
patients aged 50 to 65 years. Journal of Clinical Psychiatry
2003;64(9):998-1004. [MEDLINE: 14628974; EMBASE
2003383256]

Grainger D, Edgell ET, Andersen SW, Wang J. Resource use
and QOL of olanzapine compared with risperidone: results
from an international randomized clinical trial. European
Neuropsychopharmacology 1998;8(Suppl 2):S225-6.

Cochrane Database of Systematic Reviews

Grainger D, Edgell ET, Andersen SW, Wang J. Resource use
and QOL of olanzapine compared with risperidone: results
from an international randomized clinical trial. European
Neuropsychopharmacology 1998;8(Suppl 2):S225-6. [MEDLINE:
21122407]

Grainger D, Edgell ET, Andersen SW, Wang J. Resource use and
quality of life of olanzapine compared with risperidone:Results
from an international randomized clinical trial. 11th Congress
of the European College of Neuropsychopharmacology, Paris,
France. 1998. [CSG NO. 3342]

Kennedy J, Basson B, Tran P, Beasley C, Bymaster F, Breier A.
The comparative anti-muscarinic-like adverse event profiles
of olanzapine and risperidone treatment in patients with
schizophrenia spectrum psychosis. 39th Annual Meeting of the
New Clinical Drug Evaluation Unit, Boca Raton, FL, USA, June
1-4, 1999. 1999:89. [EMBASE&#160; 2002184411; CN-00443250.]

Kennedy JS, Basson BR, Tran PV, Beasley CM, Bymaster FP,
Tollefson GD. The comparative anti-muscarinic-like adverse
event profiles of olanzapine and risperidone treatment in
patients with schizophrenia spectrum psychosis. APA Annual
Meeting, May 15-20, 1999, Washington, DC. 1999. [CSG NO. 4110]

Kinon B, Basson B, Tollefson GD. Gender-Specific Prolactin
Response to Treatment with Olanzapine Versus Risperidone
in Schizophrenia. 1998 Annual Meeting of the American
Psychiatric Association, Toronto, Ontario, Canada. 1998:NR449.
[CSG NO. 3586]

Kinon B, Basson B, Tollefson GD. Gender-specific prolactin
response to treatment with olanzapine versus risperidone in
schizophrenia. 151st Annual Meeting of American Psychiatric
Association. Toronto, ON, Canada. May 30-June 4,1998.

Kinon BJ, Zhao Z, Barber BL, Wirtz HS. Acute response to
olanzapine predicts the continued improvement in patients
with schizophrenia. Schizophrenia Research. 2003. [MEDLINE:
14687871; EMBASE 2003516387]

Kollack-Walker S, Lipkovich I, Ahmed S. Treatment-emergent
eps symptoms during treatment with olanzapine or risperidone.
156th Annual Meeting of the American Psychiatric Association;
2003 May 17-22; San Francisco, USA. 2003. [[NR562]]

Pickar D. Clinical profiles of the new antipsychotic agents.
Conquering Psychosis: From Molecules to Managed Care.
American Psychiatric Association; 1997 May 17; San Diego,
California. 1997.

Sutton VK, Street JS, Kennedy JS, Feldman PD, Breier A.
Superiority of olanzapine over risperidone in the
control of negative symptoms of schizophrenia and
related psychotic disorders in older patients. European
Neuropsychopharmacology (Abstracts of the 14th Congress of
the European College of Neuropsychopharmacology; 2001 Oct
13-17; Istanbul, Turkey). 2001, issue 3:276.

Tollefson GD, Andersen SW. Should we consider mood
disturbance in schizophrenia as an important determinant of
quality of life?. Journal of Clinical Psychiatry 1999;60 Suppl
5:23-9. [CSG NO. 4273]

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

42

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Tollefson GD, Andersen SW, Tran PV. The cause of depressive
symptoms in predicting relapse in schizophrenia: a double-
blind randomized comparison of olanzapine and risperidone.
Biological Psychiatry 1999;46(3):365-73.

Tollefson GD, Tran PV, Hamilton S, Kuntz A. Olanzapine versus
risperidone in the treatment of psychosis. Preliminary report.
Schizophrenia Research (Special Issue) - The VIth International
Congress on Schizophrenia Research, Colorado Springs, CO, USA
April 12-16, 1997;24:191.

Tollefson GD, Tran PV, Hamilton SH, Kuntz A. Olanzapine versus
risperidone in the treatment of psychosis. Preliminary report.
Schizophrenia Research 1997;24:191-2.

Tran P, Dellva M, Rampey V, Tollefson G, Beasley C. Long-term
continuation therapy with the novel antipsychotic olanzapine:A
review of the clinical experience. 9th Congress of the European
College of Neuropsychopharmacology, Amsterdam, The
Netherlands. 1996. [CSG NO. 3729]

Tran PV, Dellva MA, Tollefson GD, Beasley CMJr. Extrapyramidal
symptoms and tolerability of olanzapine versus haloperidol in
the acute treatment of schizophrenia: Correction. Journal of
Clinical Psychiatry 1997;58(6):275. [CSG NO. 4264]

Tran PV, Hamiliton SH, Kuntz AJ, Tollefson GD. Olanzapine
versus risperidone in the treatment of psychosis disorders:a
preliminary report. 1996 Annual meeting of the American
College of Neuropsychopharmacology, Puerto Rico. 1996. [CSG
NO. 3685]

Tran PV, Tollefson GD, Andersen SW, Kuntz AJ, Hamilton SH.
Olanzapine versus risperidone in the treatment of
schizophrenia and other psychotic disorders. 10th European
College of Neuropsychopharmacology Congress. Vienna,
Austria. Sep 13-17, 1997.

Tran PV, Tollefson GD, Andersen SW, Kuntz AJ, Hamilton SH.
Olanzapine versus risperidone in the treatment of
schizophrenia and other psychotic disorders. Schizophrenia
Research 1998;29(1-2):205.

Tran PV, Tollefson GD, Hamilton S. Olanzapine Versus
Risperidone in the Treatment of Schizophrenia and Other
Psychotic Disorders. 150th Annual Meeting of the American
Psychiatric Association, San Diego. 1997. [CSG NO. 2415]

Tran PV, Tollefson GD, Hamilton S, Kuntz A. Olanzapine vs.
risperidone in the treatment of psychosis. Sixth World Congress
of Biological Psychiatry. Nice, France. June 22-27, 1997.

Wirtz HS, Kinon BJ, Zhao Z, Barber BL. Acute response to
olanzapine but not to risperidone predicts the likelihood
of continued improvement over time in patients with
schizophrenia. Schizophrenia Research (Abstracts of the 11th
Biennial Winter Workshop on Schizophrenia). Elsevier Science
B.V, 2002, issue 3 Suppl.1:181.

Zhao Z, Kinon BJ, Barber BL, Wirtz HS. Acute response to
olanzapine predicts continued improvement in schizophrenia.
Schizophrenia Research 2003;60:308. [EMBASE: 2003241517]

Cochrane Database of Systematic Reviews

Wang 2002 {published data only}

Wang C, Feng Y, Wang L. A double-blind randomized
controlled study of olanzapine and clozapine on treatment of
schizophrenia. Shanghai Archives of Psychiatry 2002;14(3):143-5.
[MEDI0312]

Wang 2003 {published data only}

Wang Kangjian, Zhang Kai. A study of olanzapine and clozapine
in the treatment of schizophrenia. Shandong Archives of
Psychiatry 2003;16(03):141-3. [MEDI0310]

References to studies excluded from this review

Addington 1998 {published data only}

Addington DE, Addington JM. Costs of novel antipsychotics in
clinical practice. 151st Annual Meeting of American Psychiatric
Association. Toronto, ON, Canada. May 30-June 4, 1998.

Allison 1998 {published data only}

Allison DB, Mentor JL, Heo M, Weiden PJ, Chandler LP,
Cappelleri J. Weight gain associated with conventional and
newer antipsychotics: a meta-analysis. 151st Annual Meeting of
American Psychiatric Association. Toronto, ON, Canada. May 30-
June 4, 1998.

Allison DB, Mentor JL, Heo M, Weiden PJ, Chandler LP,
Cappelleri J. Weight gain associated with conventional and
newer antipsychotics: a meta-analysis. Proceedings of XXIst
Collegium Internationale Neuro-psychopharmacologicum.
Glasgow, Scotland, UK. July 12-16, 1998:american j of
psychiatry 1999 vol 156, p1686-96. [American J of Psychiatry
1999 vol 156, p1686-96]

Apicella 2001 {published data only}

Apicella A. National Alliance for Research on Schizophrenia ns
Depression. www.mhsource.com/narsad/bd/studyops.html
2001.

Apiquian 2003 {published data only}

Apiquian R, Fresan A, errera K, Ulloa RE, Loyzaga C,
De LaFuente-Sandoval C, Gutierrez D, Nicolini H. Minimum
effective doses of haloperidol for the treatment of first
psychotic episode: a comparative study with risperidone and
olanzapine. International Journal of Neuropsychopharmacology
2003;6(4):403-8. [EMBASE: 2004054013]

Aquila 2000 (HGEC) {published data only}

Aquila R, Weiden PJ, Kinon BJ, Milton DR, Zygmunt A,
Swindle RW, Stauffer VL. Effectiveness of olanzapine upon
psychiatric and vocational rehabilitation outcomes. 153rd
Annual Meeting of the American Psychiatric Association; 2000
May 13-18; Chicago, USA. 2000.

Arango 2001 {published data only}

Arango C, Summerfelt A, Buchanan RW. Olanzapine effects on
auditory sensory gating in schizophrenia. American Journal of
Psychiatry 2003;160(11):2066-8. [PMID 14594761]

Arango C, Summerfelt AT, Buchanan RW. Lack of P50 changes
in a randomized double blind study of olanzapine and

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

43

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

haloperidol. Schizophrenia Research 2001;49(1-2 Suppl):197.
[MEDLINE: 21040726]

Awad 2002b {published data only}

Awad AG, Vourganti L, Dugar A. Patient attitude after switch to
ziprasidone from other antipsychotics. European Psychiatry
(11th Association of European Psychiatrists Congress, 2002 4-8th
May, Stockholm, Sweden) 2002;17(Suppl 1):102s. [probably
Pfizzer study]

Baker 2003 {published data only}

Baker R, Kinon BJ, Liu H, Richey A, Hill AL, Bergstrom RF,
Schuh LM. Effectiveness of rapid initial dose escalation of
oral olanzapine for acute agitation. Schizophrenia Research
2003;60:272. [EMBASE 2003496187]

Baker RW, Kinon BJ, Maguire GA, Liu H, Hill AL. Effectiveness
of rapid initial dose escalation of up to forty milligrams per
day of oral olanzapine in acute agitation. Journal of Clinical
Psychopharmacology 2003;23(4):342-8. [PMID 12920409]

Beasley 1996c {published data only}

Beasley C, Tollefson G, Wood G, Tran P, Satterlee W, Beuzen J.
Safety overview of Olanzapine. Xth World Congress of
Psychiatry. Madrid, Spain. August 23-28, 1996.

Beasley 2003 (HGGI) {published data only}

Beasley CM, Hamilton SH, Dossenbach M. Relapse prevention
with olanzapine. Schizophrenia Research 2000;41(1):196-197.
[CSG NO. 4512]

Beasley CM, Sutton VK, Hamilton SH, Walker DJ, Dossenbach M,
Taylor CC, Alaka KJ, Bykowski D, Tollefson GD. A double-
blind, randomized, placebo-controlled trial of olanzapine
in the prevention of psychotic relapse. Journal of Clinical
Psychopharmacology 2003;23(6):582-94. [MEDLINE: 14624189]

Beasley Jr C, Hamilton S, Dossenbach M. Relapse prevention
with olanzapine. Journal of the European College of
Neuropsychopharmacology 2000;10(Suppl 3):S304.

Beuzen 1996 (HGCE) {published data only}

Beuzen JN. Olanzapine - cognitive and motor effects in healthy
elderly. Xth World Congress of Psychiatry. Madrid, Spain. August
23-28, 1996.

Taylor N, Beuzen JN, Wesnes K, Wood A. The effect of
olanzapine on cognition and psychomotor function in healthy
elderly volunteers. Schizophrenia Research 1996;18(2-3):VC2.

Birkett 1994 {published data only}

Birkett P. State of the Art - Winter Workshop on Schizophrenia,
Les Diablerets, Switzerland, January 1994. Journal of
Psychopharmacology 1995;9(2):157-60.

Breier 2003 {published data only}

Breier A, Young C, Purdon SE, Gold JM, Davis, KL, Keefe RSE.
A one year Double-blind Comparision of the Neurocognitive
Efficacy of Olanzapine, Risperidone and Haloperidol in Patients
with Schizophrenia. Schizophrenia Research March 29 - April
2003; Colorado Springs, CO. 2003.

Britto 2002 {published data only}

Britto D. Ziprasidone Quality of Life study in the treatment of
chronic schizophrenia. National Research Register 2002; Vol. 1.
[N0083099522]

Buchanan 2003 {published data only}

Buchanan RW, Ball MP, Weiner E, Kirkpatrick B, Gold J,
Carpenter WT. Olanzapine treatment of residual positive and
negative symptoms. Schizophrenia Research 2003;60:275.
[EMBASE: 2003241517]

Burgoyne 1996 {published data only}

Burgoyne K, Ananth J, Gadasally R, Smith M. Maintenance
treatment with olanzapine for schizophrenic patients.
Proceedings of XXIst Collegium Internationale Neuro-
psychopharmacologicum. Glasgow, Scotland, UK. July 12-16,
1998.

Burgoyne K, Ananth J, Smith M, Swartz JR, Gadasally R,
Arns P. Olanzapine versus haloperidol: the results of a double-
blind study on acute psychotic patients. XXth Collegium
Internationale Neuro-psychopharmacologicum. Melbourne,
Australia. June 23-27, 1996.

Castilla 2002 {published data only}

Castilla R. Early medication intervention in the treatment
of psychosis in children. International Journal of
Neuropsychopharmacology (Abstracts of the 23rd Congress of
the Collegium Internationale Neuro-Psychopharmacologicum;
2002 Jun 23-27; Montreal, Canada). 2002, issue Suppl 1:S51.

Clouth 1999 {published data only}

Clouth J. Pharmacoeconomic evaluation of the treatment of
schizophrenia in germany:a comparison of olanzapine and
haloperidol. APA Annual Meeting, May 15-20, 1999, Washington,
DC. 1999. [CSG NO. 4109]

Corya 2002 (HGGA) {published data only}

Corya S, Dubé S, Andersen SW, Sanger TM, Clemow D,
Tohen M, Tollefson GD. Olanzapine-fluoxetine combination
for psychotic major depression. International Journal of
Neuropsychopharmacology (Abstracts of the 23rd Congress of
the Collegium Internationale Neuro-Psychopharmacologicum;
2002 Jun 23-27; Montreal, Canada). 2002, issue Suppl 1:S144.
[lilly data]

Cutler 2002 {published data only}

Cutler NR, Simpson G, Weiden PJ, Romanoa SJ. Effects of
oral ziprasidone on weight and serum lipids in patients with
schizophrenia. Schizophrenia Research (Abstracts of the 11th
Biennial Winter Workshop on Schizophrenia). Elsevier Science
B.V, 2002, issue 3 Suppl.1:160.

Dalheim 1997 {published data only}

Dalheim LJ, Weiden PJ, Aquila R, Standard J, Emanuel M,
Zygmunt A. Olanzapine crossover in stable outpatients.
American Psychiatric Association, 150th Annual Meeting, San
Diego, CA, USA. 1997.

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

44

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Davis 1998 {published data only}

Davis JM, Janicak PG, Sharma RP, Manav R. Comparisons of the
effects of the newer atypical antipsychotics in the treatment
of schizophrenia: a meta-analysis. 151st Annual Meeting of
American Psychiatric Association. May 30-June 4, Toronto, ON,
Canada. 1998. [now published - independent data not lilly]

Davis JM, Sharma RP, Manav R. Comparisons of the effects
of the newer atypical antipsychotics in the treatment of
schizophrenia: a meta-analysis. 151st Annual Meeting of
American Psychiatric Association. May 30-June 4, Toronto, ON,
Canada. 1998.

Devanand 1998 {published data only}

Devanand DP. Classic neuroleptics in dementia. 151st Annual
Meeting of American Psychiatric Association. Toronto, ON,
Canada. May 30-June 4, 1998.

Devanand DP, Michaels K, Sackeim HA, Marder K, Mayeux RP.
Antipsychotics in the treatment of dementia complicated
by psychosis. 151st Annual Meeting of American Psychiatric
Association. Toronto, ON, Canada. May 30-June 4, 1998.

Docherty 2002 {published data only}

Docherty JP, Napolitano J, Mahmoud RA, Martinez RA,
Lasser RA, Pandina GJ, Gharabawi G. Anticholinergic effect
of atypical antipsychotics in elderly patients. 155th Annual
Meeting of the American Psychiatric Association; 2002 May
18-23; Philadelphia, PA, USA. 2002.

Tune L, Mulsant B, Gharabawi G. Anticholinergic effect
of atypical antipsychotics in elderly patients. European
Neuropsychopharmacology: The Journal of the European College
of Neuropsychopharmacology 2002;12(Supplement 3):S314.

Dolnak 2000 {published data only}

Dolnak DR, Hyman Rapaport M, Caligiuri M, Lohr J, Golshan S.
A prospective, randomized, double-blind study contrasting
motor dysfunction, negative symptoms and functioning
in schizophrenic patients treated with olanzapine and
risperidone.. 40th Annual Meeting of the New Clinical Drug
Evaluation Unit (NCDEU); 2000 May 30 - Jun 2; Boca Raton,
Florida, USA. 2000:133.

Dolnak DR, Minn K, Wieneke M, Watson, Espinoza S. Olanzapine
versus haloperidol in the treatment of schizophrenia. American
Psychiatric Association, 149th Annual Meeting. May 4-9, 1996.

Dolnak DR, Rapaport MH, Michael C, Shahrokh G. Motor
dysfunction in schizophrenia. 153rd Annual Meeting of the
American Psychiatric Association; 2000 May 13-18; Chicago,
USA. 2000.

Dolnak DR, Rapaport MH, Michael C, Shahrokh G. Motor
dysfunction in schizophrenia. 155th Annual Meeting of the
American Psychiatric Association; 2002 May 18-23; Philadelphia,
PA, USA. 2002.

Dolnak R, Rapaport MH. A prospective, randomized,
doubleblind study examining functioning in schizophrenic
patients treated with olanzapine and risperidone.
Schizophrenia Research (8th International Congress on

Cochrane Database of Systematic Reviews

Schizophrenia Research; 2001 Apr 28 - May 2; British Columbia,
Canada). 2001, issue 1-2 Suppl:225-6. [MEDLINE: 21040726]

Dossenbach 1997 {published data only}

Dossenbach M, Friedel P, Folnegovic V, Jackovljevic M,
Hutujac L, Uglesic B, Dodig G. Olanzapine vs. fluphenazine
- 6 weeks treatment of acute schizophrenia. 10th European
Colleague of Neuropsychopharmacology Congress 1997
September 13-17 Vienna. 1997.

Finzen 2002 {published data only}

Finzen A. Changing neuroleptics: From new to conventional
- And vice versa [Neuroleptikawechsel: von atypischen zu
konventionellen und zuruck - und - umgekehrt]. Psychiatrische
Praxis 2002;29(8):445-6.

Fleming 1999 {published data only}

Fleming K, Potkin SG, Alva G, Carreon D. Dissociation of
improvement in neurocognition and negative symptomatology
with olanzapine and clozapine conference abstract.
Schizophrenia Research (Abstracts of The 7th International
Congress on Schizophrenia Research; 1999 Apr 17-21; Santa Fe,
USA). 1999:279.

Gallinat 2001 {published data only}

Gallinat J, Riedel M, Juckel G, Sokullu S, Frodl T, Moukhtieva R,
Mavrogiorgou P, Nissle S, Muller N, Danker-Hopfe H,
Hegerl U. P300 and symptom improvement in schizophrenia.
Psychopharmacology 2001;158(1):55-65. [MEDLINE: 21542201]

Gothelf 2003 {published data only}

Gothelf D, Apter A, Reidman J, Brand-Gothelf A, Bloch Y,
Gal GKL, Tyano S, Weizman R, Ratzoni G. Olanzapine,
risperidone and haloperidol in the treatment of adolescent
patients with schizophrenia. Journal of Neural Transmission
2003;110(5):545-60. [MEDLINE: 22608218; PMID 12721815]

Hrdlicka 2001 {published data only}

Hrdlicka M, Rosillon D, Duchesne I. Czech results of the RODOS
study: Comparison of Risperidone and Olanzapine from the
point of view of efficacy, tolerability and treatment costs
[Ceske vysledky studie RODOS: Porovnani risperidonu a
olanzapinu z hlediska ucinnosti, snasenlivosti a nakladu lecby].
Ceska A Slovenska Psychiatrie 2001;97(7):343-9. [should be 3
publications Janssen data]

Irwin 2003 {published data only}

Irwin J, Moses SN, Edgar JC, Torres F, Thoma RJ, Hanlon FM,
Anderson L, Weisend MP, Miller GA, Tuason VB, Canive JM.
Olanzapine and risperidone in schizophrenia: A randomized
double-blind crossover study. Schizophrenia Research. 2003;
Vol. 60:286. [EMBASE: 2003241517]

Jarboe 2001 {published data only}

Jarboe KS, Lewine RR. Haloperidol versus olanzapine induced
weight gain and clinical relevance, a double-blind and open
label comparison. Schizophrenia Research (8th International
Congress on Schizophrenia Research; 2001 Apr 28 - May 2;
British Columbia, Canada). 2001, issue 1-2 Suppl:232. [MEDLINE:
21040726]

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

45

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Javitt 2001 {published data only}

Javitt DC, Silipo G, Cienfuegos A, Shelley AM, Bark N, Park M,
Lindenmayer JP, Suckow R, Zukin SR. Adjunctive high-dose
glycine in the treatment of schizophrenia. International Journal
of Neuropsychopharmacology 2001;4(4):385-91. [MEDLINE:
21666052]

Kinon BJ, Basson BR, Wang J, Malcolm SK, Stauffer VL.
Rapid reduction in hyperprolactinemia upon switching
treatment to olanzapine from conventional antipsychotic
drugs or risperidone. International Society of
Psychoneuroendocrinology (ISPNE). Orlando, FL, 1999. July 30-
August 3, 1999.

Jerrell 2002 {published data only}

Kinon 2003 {published data only}

Jerrell JM. Cost-effectiveness of risperidone, olanzapine, and
conventional antipsychotic medications. Schizophrenia Bulletin
2002;28(4):589-605. [EMBASE 2003196530]

Ahl J. Olanzapine reduces neuroleptic-induced
hyperprolactinemia in schizophrenia. Schizophrenia Research
2003;60:350. [EMBASE: 2003241517]

Kalali 2000 {published data only}

Kalali A, Lasser R, Campbell B, Cucchiaro J, El-Bizri H, Guven A,
Matkovits-Gupta T, Nann-Vernotica E, Narurkar M, Pirozzi C,
Gharabawi G. The management of cultural differences and the
importance of safety monitoring in global studies: the realize
clinical program. 39th Annual Meeting of the American College
of Neuropsychopharmacology; 2000; Dec 10-14; San Juan;
Puerto Rico. 2000.

Kinon (HGFW) {published data only}

Kinon BJ, Basson B, Wang J, Malcolm SK. Rapid reduction in
hyperprolactinemia upon switching treatment to olanzapine
from conventional antipsychotic drugs or risperidone.
Schizophrenia Research 2000;41(1):194-95. [CSG NO. 4510]

Kinon BJ, Basson B, Wang J, Malcolm SK, Stauffer VL. Rapid
reduction in hyperprolactinemia upon switching treatment
to olanzapine from conventional antipsychotic drugs or
risperidone. 40th Annual Meeting of the New Clinical Drug
Evaluation Unit (NCDEU); 2000 May 30 - Jun 2; Boca Raton,
Florida. 2000. [N0146103028]

Kinon BJ, Basson BR, Malcolm SK, Breier A. Strategies
for switching from conventional antipsychotic drugs and
risperidone to olanzapine. World Congress of Psychiatry (WPA).
Hamburg, Germany. August 8-11, 1999.

Kinon BJ, Basson BR, Malcolm SK, Tollefson GD. Strategies
for switching from conventional antipsychotic drugs and
risperidone to olanzapine. 2nd Annual Meeting of the College of
Psychiatric and Neurologic Pharmacists. Lake Tahoe, NV, USA.
March 25-28, 1999.

Kinon BJ, Basson BR, Malcolm SK, Tollefson GD. Strategies
for switching from conventional antipsychotic drugs
and risperidone to olanzapine. American College of
Neuropsychopharmacology (ACNP). Las Carabas, Puerto Rico.
December 14-18, 1998.

Kinon BJ, Basson BR, Malcolm SK, Tollefson GD. Strategies
for switching from conventional antipsychotic drugs and
risperidone to olanzapine. American Psychiatric Association
(APA). Washington, DC, USA. May 15-20, 1999.

Kinon BJ, Basson BR, Malcolm SK, Tollefson GD. Strategies
for switching from conventional antipsychotic drugs and
risperidone to olanzapine. Biennial Meeting, International
Congress on Schizophrenia Research (ICSR). Santa Fe, NM, USA.
April 17-21, 1999.

Kinon BJ, Liu H, Ahl J. Sexual dysfunction associated with
neuroleptic-induced hyperprolactinemia improves with
reduction in prolactin levels. 156th Annual Meeting of the
American Psychiatric Association; 2003 May 17-22; San
Francisco, USA. 2003. [[NR552]]

Kinon BJ, Liu H, Ahl J, Baker RW. Longitudinal effects of
olanzapine on fasting serum lipids: a randomized, prospective,
four- month study. 156th Annual Meeting of the American
Psychiatric Association; 2003 May 17-22; San Francisco, USA.
2003. [[NR553]]

Kinon BJ, Milton DR, Hill AL, Williamson DJ. Effective resolution
of acute presentation of behavioral agitation and positive
psychotic symptoms in schizophrenia with olanzapine.
Journal of Psychopharmacology. 2000; Vol. 14, issue 3:A60.
[N0146103028]

Knegtering 2000 {published data only}

Knegtering R, Boks M, Wiersma D, Blijd C, Bruggeman R,
Oer RBV. Sexual dysfunctions in patients on antipsychotics.
155th Annual Meeting of the American Psychiatric Association;
2002 May 18-23; Philadelphia, PA, USA. 2002.

Knegtering R, Boks M, Wiersma D, Blijd C, Bruggeman R,
van Oer RB. Sexual dysfunctions in patients on antipsychotics.
153rd Annual Meeting of the American Psychiatric Association;
2000 May 13-18; Chicago, USA. 2000.

Knegtering R, Castelein S, Bous H, Van Der Linde J,
Bruggeman R, Kluiter H, Van Den Bosch RJ. A Randomized
Open-Label Study of the Impact of Quetiapine Versus
Risperidone on Sexual Functioning. Journal of Clinical
Psychopharmacology 2004;24(1):56-61. [EMBASE: 2004050225]

Kolff 2000 {published data only}

Kolff M, Coenen A, van Dis H, Duigemans P. Differential effects
of antipsychotic drugs on clinical symptoms and cognitive
functions in the treatment of schizophrenia. Journal of the
European College of Neuropsychopharmacology. 2000, issue
Suppl 2:S59.

Kucerova 2002 {published data only}

Kucerova H. Olanzapine and improvement of tardive dyskinesia.
European Psychiatry 2002;17(7):421-4.

Lahti 1999a {published data only}

Lahti AC, Holcomb HH, Weiler MA, Parwani A, Michaelidis T,
Medoff DR, Tamminga CA. Changes rcbf after acute challenge
with haloperidol and olanzapine in patients with schizophrenia.

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

46

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Schizophrenia Research (Abstracts of The 7th International
Congress on Schizophrenia Research; 1999 Apr 17-21; Santa Fe,
USA). 1999:224. [MEDLINE: 20137242]

Lahti 1999b {published data only}

Lahti AC, Weiler MA, Parwani A, Holcomb HH, Michaelidis T,
Warfel D, Tamminga CA. Blockade of ketamine-induced
psychosis with olanzapine. Schizophrenia Research (Abstracts
of The 7th International Congress on Schizophrenia Research;
1999 Apr 17-21; Santa Fe, USA). 1999:310. [MEDLINE: 20137242]

Lilly (HGBM) 1999 {unpublished data only}

Eli Lilly. Open-label clinical trial on antipsychotic efficacy and
safety of olanzapine in schizophrenic patients with positive
or negative symptomatology. Data supplied to the Cochrane
Schizophrenia Group 1999.

Lilly (HGCL) 1999 {unpublished data only}

Eli Lilly. Efficacy and safety of olanzapine in the treatment of
schizophrenic, schizophreniform and schizoaffective patients
in Saudi Arabia. Data supplied to the Cochrane Schizophrenia
Group 1999.

Lilly (HGCV) 1999 {unpublished data only}

Eli Lilly. Olanzapine in schizophrenic patients intolerant of,
or resistant to, clozapine. Data supplied to the Cochrane
Schizophrenia Group 1999.

Lilly (HGDU) 1999 {unpublished data only}

Eli Lilly. Safety and efficacy of olanzapine in patients with
severe haloperidol side effects in Romania. Data supplied to the
Cochrane Schizophrenia Group 1999.

Lilly (HGDZ) 1999 {unpublished data only}

Eli Lilly. Efficacy and safety of olanzapine in the treatment
of schizophrenic and schizoaffective patients in Russia. Data
supplied to the Cochrane Schizophrenia Group 1999.

Lilly (HGEP) 1999 {unpublished data only}

Eli Lilly. Open-label olanzapine. Data supplied to the Cochrane
Schizophrenia Group 1999.

Lilly (HGFM) 1999 {unpublished data only}

Eli Lilly. Efficacy and safety of olanzapine in the treatment of
schizophrenic patients in China. Data supplied to the Cochrane
Schizophrenia Group. 1999.

Lindenmayer 1998 {published data only}

Lindenmayer JP. Beyond symptoms: optimizing real-world
outcomes. 151st Annual Meeting of American Psychiatric
Association. Toronto, ON, Canada. May 30-June 4, 1998.

Loza 2001 {published data only}

Loza B. Atypical antipsychotic treatment prognosis in
first-episode paranoid schizophrenia based on syllabic
and language-related dichotic listening scores. European
Neuropsychopharmacology: The Journal of the European
College of Neuropsychopharmacology. 2002, issue Supplement
3:S298.

Cochrane Database of Systematic Reviews

Loza B, Kucharska-Pietura K, Debowska G. Atypical versus
typical antipsychotic treatment prognosis in first-episode
paranoid schizophrenia based on wcst and dichotic
listening scores. European Neuropsychopharmacology
(Abstracts of the 14th Congress of the European College of
Neuropsychopharmacology; 2001 Oct 13-17; Istanbul, Turkey).
2001, issue 3:285.

Mahmoud 1999 {published data only}

Mahmoud RA, Engelhart LM, Janagap C, Awad G. Assessment
of symptoms affecting quality of life and patient satisfaction
with antipsychotic drugs:new insights for a trial of risperidone/
olanzapine. APA Annual Meeting, May 15-20, 1999, Washington,
DC. 1999. [CSG NO. 4121]

Mahmoud RA, Engelhart LM, Janagap C, Dogherty J. Symptoms
commonly attributed to prolactin:a new assessment tool and
findings from a trial of risperidone versus olanzapine. APA
Annual Meeting, May 15-20, 1999, Washington, DC. 1999. [CSG
NO. 4122]

Marder 1998 {published data only}

Marder SR. Newer antipsychotics: side-effect profiles. 151st
Annual Meeting of American Psychiatric Association. Toronto,
ON, Canada. May 30-June 4, 1998.

Mauri 2002 {published data only}

Mauri MC, Steinhilber CPC, Laini V, Pavone F, Barale F.
Olanzapine and quetiapine in the treatment of acute
schizophrenia: a descriptive analysis. International Journal of
Neuropsychopharmacology (Abstracts of the 23rd Congress of
the Collegium Internationale Neuro-Psychopharmacologicum;
2002 Jun 23-27; Montreal, Canada). 2002, issue Suppl 1:S119.

McElroy 1998 {published data only}

McElroy SL. Atypical antipsychotics in women with bipolar and
other psychiatric disorders. 151st Annual Meeting of American
Psychiatric Association. Toronto, ON, Canada. May 30-June 4,
1998.

McGurk 1998 {published data only}

McGurk SR. The effects of atypical antipsychotic drugs on
cognitive function in schizophrenia. 151st Annual Meeting of
American Psychiatric Association. Toronto, ON, Canada. May 30-
June 4, 1998.

McGurk SR, Meltzer HY. The affects of atypical antipsychotic
drugs on cognitive functioning in schizophrenia. Schizophrenia
Research 1998;29(1-2):160.

Meltzer 2003 {published data only}

Meltzer HY, Sumiyoshi T, Carpenter WT, Gold JM. Atypical
antipsychotic drugs improve cognition in schizophrenia.
Biological Psychiatry 2003;51(3):265-8.

Mintzer 1998 {published data only}

Mintzer JE. Efficacy and safety of atypical neuroleptics in
dementia. 151st Annual Meeting of American Psychiatric
Association. Toronto, ON, Canada. May 30-June 4, 1998.

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

47

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Mitchell 2003 {published data only}

Mitchell M, Earley W, Bari MA, Riesenberg RA, Marquez E,
Kurtz D, Falk D, Taylor CC, Cavazzoni P. A preliminary study
of the pharmacokinetics and tolerability of higher dose oral
olanzapine (20, 30, or 40mg/day) in stable patients with
serious mental disorders. Journal of the European College of
Neuropsychopharmacology 2003;13(4):S315. [P.2.081]

Mosolov 1998 {published data only}

Mosolov SN. Biological treatment of mental disorders in Russia.
151st Annual Meeting of American Psychiatric Association.
Toronto, ON, Canada. May 30-June 4, 1998.

Mulqueen 2000 {published data only}

Mulqueen AW, Wudarsky M, Nicolson RJ, Gochman P,
Hamburger S, Lenane M, Rapoport JHL. Weight gain in pediatric
patients on typical and atypical antipsychotics. 153rd Annual
Meeting of the American Psychiatric Association; 2000 May
13-18; Chicago, USA. 2000.

Mulqueen AW, Wudarsky M, Nicolson RJ, Gochman P,
Hamburger S, Lenane M, Rapoport JHL. Weight gain in pediatric
patients on typical and atypical antipsychotics. 155th Annual
Meeting of the American Psychiatric Association; 2002 May
18-23; Philadelphia, PA, USA. 2002.

Naber 1997 {published data only}

Naber D. Evidence of efficacy of neuroleptics in effective
versus negative symptoms. 10th European College of
Neuropsychopharmacology Congress. Vienna, Austria.
September 13-17, 1997.

Narendran 2003 {published data only}

Narendran R, Young CM, Pristach CA, Pato MT, Valenti AM,
Fass AR. Efficacy of clozapine in the treatment of atypical
antipsychotic refractory schizophrenia: A pilot study. Journal of
Clinical Psychopharmacology 2003;23(1):103-4.

Oliemeulen 2000 {published data only}

Oliemeulen EAP, Jogems-Kosterman BJM, van Hoof JJM.
Is olanzapine a subsitute for clozapine?. Schizophrenia
Research (Abstracts of The 7th International Congress on
Schizophrenia Research; 1999 Apr 17-21; Santa Fe, USA).
1999:146-7. [MEDLINE: 20137242]

Oliemeulen EAP, van Hoof JJM, Jogem-Kosterman BJM,
Hulsttijn W, Tuynman-Qua HG. Is olanzapine a substitute
for clozapine? The effects on psychomotor performance.
Schizophrenia Research 2000;41(1):187. [CSG NO. 4502]

Ortega-Solo (HGBS) {published data only}

Nicolini H, Cruz C, Camarena B, Ortega H. 5HT2A and DRD4
molecular genotypes in a clinical trial of olanzapine versus
risperidone in schizophrenic patients. European College
of Neuropsychopharmacology, congress, Vienna, Austria,
September 13-17 1997.

Ortega-Solo HA, Apiquian R, Ullca RE, Loyzaga C, Mendiazabal A,
Brunner E. Olanzapine versus risperidone a double blind
trial in Mexican patients. Regional meeting of the Collegium
Internationale Neuro-Psychopharmacologicum and the

Cochrane Database of Systematic Reviews

Collegio Mexicano de Neuropsicofarmacologia. Acapulco,
Mexico. August 21-23, 1997.

Parellada 1999 {published data only}

Parellada E, Lomena F, Catafau A, Font M, Gomez JC,
Salamero M, Bernardo M. Olanzapine versus haloperidol d2
occupancy:a single photon emission tomography study. APA
Annual Meeting, May 15-20, 1999, Washington, DC. 1999. [CSG
NO. 3999]

Perro 1999 {published data only}

Lambert M, Moritz S, Karow A, Krausz M, Naber D. Quality of
life in the treatment of schizophrenia- a randomised, open
label comparison trial of amisulpride, olanzapine, quetiapine,
risperidone and zotepine. Schizophrenia Research (Abstract of
the 11th Biannial Winter Workshop on Schizophrenia). 2002.

Perro C LMMSKMatAA. Depressive symptoms under atypical
neuroleptic treatment in schizophrenia. Acta Psychiatrica
Scandinavica (Abstracts of 13th International Symposium
for the Psychological Treatment of Schizophrenia and Other
Psychoses (ISPS); 2000 Jun 5-9; Stavanger, Norway). 2000, issue
Suppl.404:62-3.

Perro C, Lambert M, Moritz S, Krausz M, Naber D. A
comparison of clinical outcome of four atypical neuroleptics
in the treatment of schizophrenia. Pharmacopsychiatry
(Abstracts of 21st Symposium of the Arbeitsgemeinschaft
Neuropsychopharmakologie Und Pharmakopsychiatrie (AGNP);
1999 Oct 6-9; Nuremberg, Germany). 1999, issue 5:201.

Perro C, Naber D, Lambert M, Moritz S, Krause M. A prospective
clinical comparative-study of four atypical antipsychotic agents
in the treatment of schizophrenia. 11th World Congress of
Psychiatry; 1999 Aug 6-11; Hamburg, Germany. 1999:13.

Pivac 2002 {published data only}

Pivac N, Muck-Seler D, Jakovljevic M, Sagud M, Mihaljevic-
Peles A, Junaci S. The effects of olanzapine or fluphenazine
on peripheral biochemical markers in schizophrenic patients.
International Journal of Neuropsychopharmacology (Abstracts
of the 23rd Congress of the Collegium Internationale Neuro-
Psychopharmacologicum; 2002 Jun 23-27; Montreal, Canada).
2002, issue Suppl 1:S184.

Ratakonda 1998 {published data only}

Ratakonda S, Miller CE, Gorman JM, Sharif ZA. Efficacy
of a 12 week trial of olanzapine in treatment refractory
schizophrenia or schizoaffective disorder. Schizophrenia
Research 1998;29(1,2):150. [CSG NO. 4079]

Reus 1997 {published data only}

Kerwin R. Olanzapine. Lancet 1997;350:594.

*  Reus VI. Olanzapine: a novel atypical neuroleptic agent.
Lancet 1997;349:1264-5.

Sacchetti 2003 {published data only}

Sacchetti E, Valsecchi P, Regini C, Galluzzo A, Cacciani P,
Agrimi E, Mencacci C. Comparison of quetiapine, olanzapine
and risperidone in patients with schizophrenia: interim results
of a randomised, rater-blinded study. 16th European College of

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

48

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Neuropsychopharmacology (ECNP), 2003 Sep 20-24, Prague,
Czech Republic. 2003. [EMBASE: 2003409683]

Neuro-psychopharmacologicum. Glasgow, Scotland, UK. July
12-16, 1998.

Sacchetti E, Valsecchi P, Regini C, Galluzzo A, Cacciani P,
Agrimi E, Mencacci C. Comparison of quetiapine, olanzapine
and risperidone in patients with schizophrenia: interim results
of a randomised, rater-blinded study. Journal of the European
College of Neuropsychopharmacology 2003;13(4):S350. [P.2.162]

Sharma 2003 {published data only}

Sharma M. Efficacy and safety of Olanzapine versus Haloperidol
in Schizophrenic patients in India. http://www.kgmcindia.edu/
departments/psychiatry/psychiatry_ fac_ res.htm 2003.
[MEDLINE: 22417839]

Sacristan (HGGS) {published data only}

Sheitman 1997 {published data only}

Sacristan JA. Doses of olanzapine, risperidone, and
haloperidol in clinical practice: results of a prospective
pharmaco-epidemiological study (efeso). Schizophrenia
Research (Abstracts of the 10th Biennial Winter Workshop on
Schizophrenia; 2000 Feb 5-11; Davos, Switzerland). 2000, issue
1:188-9.

Sangar 1998 (HGEH) {published data only}

Sanger T M, Tohen M, Tollefson G D, McElroy S L, Greaney M
G, Toma V. Olanzapine VS Placebo in the Treatment of Acute
Mania. Schizophrenia Research (9th Biennial Winter Workshop
on Schizophrenia, 1998 Feb 7-13, Davos, Switzerland). 1998,
issue 1,2:152.

Sanger T, Tohen M, Tollefson GD, Jacobs T. Olanzapine versus
placebo in rapid-cycling bipolar disorder. Proceedings of XXIst
Collegium Internationale Neuro-psychopharmacologicum.
Glasgow, Scotland, UK. July 12-16, 1998.

Sanger TM, Tohen M, Vieta E, Dunner DL, Bowden CL,
Calabrese JR, Feldman PD, Jacobs TG, Breier A. Olanzapine in
the acute treatment of bipolar I disorder with a history of rapid
cycling. Journal of Affective Disorders 2003;73(1-2):155-61.

Toben M, Zarate C Jr, Sanger IM. A placebo-controlled trial
of olanzapine in psychotic or non-psychotic acute mania.
Schizophrenia Research 1998;29(1,2):204. [MEDLINE: 97055970]

Tohen M, Jacobs T, Gannon KS Sanger TM, Greaney M, Toma V,
Tollefson G. Olanzapine: acute and long term efficacy in bipolar
I patients. Schizophrenia Research 2000;41(1):192. [MEDLINE:
20170939]

Tohen M, Sanger T, McElroy S, Tollefson GD, Chengappa KN,
Roy MD, David G Tohen, Mauricio MD, DrPH, anger, Todd M. PhD,
McElroy, Susan L. MD, Tollefson, Gary D. MD, PhD, Chengappa,
K.N. Roy, MD, Daniel, David G. MD, Petty, Frederick MD, PhD,
Centorrino, Franca MD, Wang, Richard MD, PhD, Grundy, Starr
L. BScPharm, Greaney, Michael G. MS, Jacobs, Thomas G. MAS,
David, Stacy R. PhD, Toma, Verna BS Tohen, Mauricio MD,
DrPH, anger, Todd M. PhD, McElroy, Susan L. MD, Tollefson,
Gary D. MD, PhD, Chengappa, K.N. Roy, MD, Daniel, David G.
Olanzapine Versus Placebo in the Treatment of Acute Mania. The
American Journal of Psychiatry 1999;156(5):702-9.

Tohen M, Sanger T, Tollefson GD, McElroy SL, Greaney MG,
Toma V. Experience using olanzapine in the treatment of acute
bipolar mania. 151st Annual Meeting of American Psychiatric
Association. Toronto, ON, Canada. May 30-June 4, 1998.

Tohen M, Sanger T, Tollefson GD, McElroy SL, Greaney MG,
Toma V. Experience using olanzapine in the treatment of acute
bipolar mania. Proceedings of XXIst Collegium Internationale

Sheitman BB, Lindgren JC, Early J, Sved M. High dose
olanzapine for treatment-refractory schizophrenia. American
Journal of Psychiatry 1997;154(11):1626.

Sheitman 2000 {published data only}

Sheitman B. Olanzapine versus risperidone for people with
schizophrenia hospitalized after a relapse. Stanley Foundation
Research Awards - 2000 Research Award Recipients (http://
www.stanleyresearch.org/ accessed February 2001) 2000.

Sikich 2004 {published data only}

Sikich L, Hamer RM, Bashford RA, Sheitman BB, Lieberman JA.
A pilot study of risperidone, olanzapine, and haloperidol in
psychotic youth: a double-blind, randomized, 8-week trial.
Neuropsychopharmacology 2004;29(1):133-45. [EMBASE:
2004025276; 14583740 PMID]

Sikich L, Williamson K, Malekpour A, Bashford RA, Hooper S,
Sheitman B, Lieberman JA. Interim results of a randomized
controlled trial of haloperidol, risperidone, and olanzapine in
psychotic youth.. 38th Annual Meeting of the American College
of Neuropsychopharmacology; 1999 Dec 12-16; Acapulco,
Mexico. 1999.

Smelson 2003 {published data only}

Smelson DA, Ziedonis DM, Williams JA, Losonczy MF, Williams J,
Kaune M. A double-blind trial of olanzapine reduces cue-
elicited cocaine craving and relapses. 156th Annual Meeting
of the American Psychiatric Association; 2003 May 17-22; San
Francisco, USA. 2003. [[NR692]]

Smith 1998 {published data only}

Smith RC, Nigam S, Stern A, Infante M, Mehta R. Olanzapine
in Chronic Nonresponding Schizophrenia:Effects on
Psychopathology and Neurocognitive Function. 21st Congress
of Collegium Internationale Neuro-psychopharmacologicum,
Glasgow, Scotland, UK. 1998. [CSG NO. 3628]

Smith 2001 {published data only}

Smith RC, Lindenmayer J-P, Khandat A, Infante M, Singh A.
Olanzapine affects neurocognitive function in medication-
refractory schizophrenia. 155th Annual Meeting of the American
Psychiatric Association; 2002 May 18-23; Philadelphia, PA, USA.
2002.

Smith RC, Lindenmayer J-P, Khandat A, Infante M, Singh A.
Olanzapine affects neurocognitive function in medication-
refractory schizophrenia. Annual Meeting of the American
Psychiatric Association; 2001 May 5-10; LA, USA. Marathon
Multimedia, 2001. [MEDLINE: 21093232]

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

49

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Soutullo 1998 {published data only}

Soutullo CA, Sorter MT, Foster KD, McElroy SL, Keck PE.
Olanzapine in the treatment of adolescent acute mania:
preliminary report of seven cases. 151st Annual Meeting of
American Psychiatric Association. Toronto, ON, Canada. May 30-
June 4, 1998.

Stephenson 2000 {published data only}

Stephenson J. Delay in treating schizophrenia may narrow
therapeutic window of opportunity. Journal of the American
Medical Association 2000;283(16):2091-92.

Szafranski 1999 {published data only}

Szafranski T, Jarema M, Olajossy M, Chrzanowski W,
Araszkiewicz A, Landowski J, Rybakowski J, Bilikiewicz A,
Bomba J. Subjective experiences of schizophrenic
patients on atypical antipsychotic olanzapine and typical
antipsychotic perphenazine. Journal of the European College of
Neuropsychopharmacology. 1999:S273. [MEDLINE: 21040726]

Tamura 1996 (F1D-JE) {published data only}

Tamura RN, Tanaka Y, Satoh K, Takahashi M. Using the
proportional odds model to assess the relationship between
a multi-item and a global item efficacy scale in a psychiatric
clinical trial. Journal of Biopharmacological Statistics
1996;6:127-37.

Tang 2003 {published data only}

Tang T, Meltzer HY. Olanzapine causes greater increases
in serum lipids than risperidone. Schizophrenia Research
2003;60:367. [EMBASE: 2003241517]

Tohen 2000b (HGGW) {published data only}

Tohen M, Jacobs T, Toma V, Francis J, Zhang F, Gannon KS,
Sanger TM, Breier A. Is olanzapine a mood stabilizer?.
Schizophrenia Research 2000;41(1):193-4. [MEDLINE: 20170939]

Tohen M, Jacobs TG, Grundy SL, McElroy SL, Banov MC,
Janicak PG, Sanger T, Risser R, Zhang F, Toma V, Francis J,
Tollefson GD, Breier A. Efficacy of Olanzapine in Acute Bipolar
Mania: A Double-blind, Placebo-Controlled Study. Archives of
General Psychiatry 2000;57(9):841-9.

Tran 1998 (HGEJ) {published data only}

Tran PV, Tohen M, Mazzoti G, Silva C, Ospina J, Gattaz WF,
Larach V. Switching psychotic patients with symptomatic
extrapyramidal symptoms from haloperidol to olanzapine:
results of a multi-center, collaborative trial in Latin America.
151st Annual Meeting of American Psychiatric Association.
Toronto, ON, Canada. May 30-June 4, 1998.

Trandafir 1998 {published data only}

Trandafir AI, Berk M, Brook S. Olanzapine versus haloperidol
in cannabis induced psychosis: a randomised double-blind
trial. Proceedings of XXIst Collegium Internationale Neuro-
psychopharmacologicum. Glasgow, Scotland, UK. July 12-16,
1998.

Uzun 2002 {published data only}

Uzun S, Folnegovic-Smalc V, Mimica N, Ljubin T, Makaric G,
Ivezic S, Jelacic P, Vilibic M, Markan-Sosic V. Ziprasidone clinical

Cochrane Database of Systematic Reviews

trials conducted in Croatia. Schizophrenia Research (Abstracts
of the 11th Biennial Winter Workshop on Schizophrenia).
Elsevier Science B.V, 2002, issue 3 Suppl.1:182.

Volavka 2002 {published data only}

*  *Volavka J, Czobor P, Sheitman B, Lindenmayer JP, Citrome L,
McEvoy JP, Cooper TB, Chakos M, Lieberman JA. Clozapine,
olanzapine, risperidone, and haloperidol in the treatment
of patients with chronic schizophrenia and schizoaffective
disorder. American Journal of Psychiatry 2002;159:255-62.
[MEDLINE: 21680953]

Bilder RM, Goldman RS, Volavka J, Czobor P, Hoptman M,
Sheitman B, Lindenmayer J-P, Citrome L, McEvoy J, Kunz M,
Chakos M, Lieberman JA. Neurocognitive effects of clozapine,
olanzapine, risperidone, and haloperidol on treatment-resistant
patients with schizophrenia and schizoaffective disorder.
Schizophrenia Research (Abstracts of the 11th Biennial Winter
Workshop on Schizophrenia). Elsevier Science B.V, 2002, issue 3
Suppl.1:195.

Bilder RM, Goldman RS, Volavka J, Czobor P, Hoptman M,
Sheitman B, Lindenmayer JP, Citrome L, McEvoy J,
Kunz M, Chakos M, Cooper TB, Horowitz TL, Lieberman JA.
Neurocognitive effects of clozapine, olanzapine, risperidone,
and haloperidol in patients with chronic schizophrenia or
schizoaffective disorder. American Journal of Psychiatry
2002;159(6):1018-28. [MEDLINE: 22037449; Volavka study
(hostility study)]

Bilder RM, Goldman RS, Volavka J, Czobor P, Hoptman M,
Sheitman J-PLB, Citrome L, McEvoy J, Kunz M, Chakos M//
Lieberman JA. Neurocognitive effects of clozapine, olanzapine,
risperidone, and haloperidol on treatment-resistant patients
with schizophrenia and schizoaffective disorder. European
Neuropsychopharmacology (Abstracts of the 14th Congress of
the European College of Neuropsychopharmacology; 2001 Oct
13-17; Istanbul, Turkey). 2001, issue 3:256.

Citrome L, Volavka J, Czobor P, Sheitman B, Lindenmayer J-
P, McEvoy J, Cooper TB, Chakos M, Lieberman JA. Effects of
clozapine, olanzapine, risperidone, and haloperidol on hostility
among patients with schizophrenia. Psychiatric Services
2001;52(11):1510-4.

Citrome LL, Volavka J, Czobor P, Nolan K, Lieberman JA,
Lindenmayer J-P, Sheitman BB. Overt aggression and psychotic
symptoms in patients with schizophrenia treated with
clozapine, olanzapine, risperidone, or haloperidol. 156th
Annual Meeting of the American Psychiatric Association; 2003
May 17-22; San Francisco, USA. 2003. [[NR221]]

Citrome LL, Volavka J, Czobor P, Sheitman BB, Lindenmayer J-P,
McEvoy JP, Lieberman JA. Atypical antipsychotics and hostility
in schizophrenia: a double-blind study. 155th Annual Meeting
of the American Psychiatric Association; 2002 May 18-23;
Philadelphia, PA, USA. 2002.

Citrome LL, Volavka J, Czobor P, Sheitman BB, Lindenmayer J-P,
McEvoy JP, Lieberman JA. Atypical antipsychotics and hostility
in schizophrenia: a double-blind study. Annual Meeting of the
American Psychiatric Association; 2001 May 5-10; LA, USA.
Marathon Multimedia, 2001. [MEDLINE: 21093232]

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

50

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Lindenmayer J-P, Czobor P, Volavka J, Citrome LL, Sheitman BB,
McEvoy JP, Cooper TB. Changes in glucose and cholesterol in
schizophrenia treated with atypicals. 155th Annual Meeting
of the American Psychiatric Association; 2002 May 18-23;
Philadelphia, PA, USA. 2002. [full paper now published american
j of psychiatry 2003 vol 160, p290-296]

Lindenmayer JP, Czobor P, Volavka J, Lieberman JA,
Citrome LSB, McEvoy JP, Cooper TB, Chakos M. Effects of
atypical antipsychotics on the syndromal profile in treatment-
resistant schizophrenia. Journal of Clinical Psychiatry
2004;65(4):551-6. [MEDLINE: 15119920]

Lindenmayer JP, Smith RC, Singh A, Parker B, Chou E,
Kotsaftis A. Hyperglycemia in patients with schizophrenia
who are treated with olanzapine. Journal of Clinical
Psychopharmacology 2001;21(3):351-3. [MEDLINE: 21279818]

Lindenmayer JP, Volavka J, Lieberman JA, Citrome LL,
Sheitman B, McEnvoy, Jokseph P, Cooper T. Do typicals chake
the syndromal profile in treatment resistanr schizophrenia?.
155th Annual Meeting of the American Psychiatric Association,
May 18-23, Philadelphia, USA. 2002.

Mohr P, Volavka J, Lieberman JA, Czobor P, McEnvoy J,
Lindenmayer J-P, Citrome L, Sheitman B. Clozapine, olanzapine,
risperidone, and haloperidol in refractory schizophrenia..
European Psychiatry (Abstracts of 10th Congress of the
Association of European Psychiatrists (AEP); 2000 Oct 28 - Nov 1;
Prague, Czech Republic ). 2000, issue Suppl.2:284S.

Volavka J, Czobor P, Cooper TB, Sheitman B, Lindenmayer JP,
Citrome L, McEvoy JP, Lieberman JA. Prolactin levels in
schizophrenia and schizoaffective disorder patients treated
with clozapine, olanzapine, risperidone, or haloperidol. Journal
of Clinical Psychiatry 2004;65(1):57-61. [PMID 14744169]

Volavka J, Czobor P, Cooper TB, Sheitman B, Lindenmayer JP,
Citrome L, McEvoy JP, Lieberman JA. Prolactin levels in
schizophrenia and schizoaffective disorder patients treated
with clozapine, olanzapine, risperidone, or haloperidol. Journal
of Clinical Psychiatry 2004;65(1):57-61. [PMID 14744169]

Volavka J, Czobor P, Sheitman B, Lindenmayer J-P, Citrome L,
McEvoy J, Cooper TB, Chakos M Kline JALN. Clozapine,
olanzapine, risperidone, and haloperidol in refractory
schizophrenia. 39th Annual Meeting of the American College of
Neuropsychopharmacology; 2000; Dec 10-14; San Juan; Puerto
Rico. 2000.

Voruganti 2002 {published data only}

Voruganti L, Cortese L, Owyeumi L, Kotteda V, Cernovsky Z,
Zirul S, Awad A. Switching from conventional to novel
antipsychotic drugs: Results of a prospective naturalistic study.
Schizophrenia Research 2002;57(2-3):201-8.

Woods 2002 (HGGF) {published data only}

McGlashan TH, Miller TJ, Zipursky RB, Woods SW, Perkins DO,
Hawkins KA, Addington JM. Intervention in the schizophrenic
prodrome: the prevention through risk identification,
management, and education initiative. 156th Annual Meeting
of the American Psychiatric Association; 2003 May 17-22; San
Francisco, USA. 2003. [[SYMPOSIUM]No. 39]

Cochrane Database of Systematic Reviews

McGlashan TH, Zipursky RB, Perkins D, Addington J, Miller TJ,
Woods SW, Hawkins KA, Hoffman R, Lindborg S, Tohen M,
Breier A. The PRIME North America randomized double-blind
clinical trial of olanzapine versus placebo in patients at risk of
being prodromally symptomatic for psychosis. I. Study rationale
and design. Schizophrenia Research. 2003; Vol. 61, issue 1:7-18.
[MEDLINE: 22536522; PMID 12648731]

McGlashan TH, Zipursky RB, Perkins DO, Addington J,
Woods SW, Miller TJ, Lindborg S, Marquez E, Hawkins K,
Hoffman RE. Olanzapine versus placebo treatment of the
schizophrenia prodrome: One year results. Schizophrenia
Research. 2003; Vol. 60:295. [EMBASE: 2003241517]

McGlashan TH, Zipursky RB, Perkins DO, Addington JM,
Woods SW, Lindborg S, Breier AF. Olanzapine versus pbo for
the schizophrenic prodrome: one-year results. 156th Annual
Meeting of the American Psychiatric Association; 2003 May
17-22; San Francisco, USA. 2003. [[NR584]]

McGlashan TH, Zipursky RB, Perkins DO, Addington JM,
Woods SW, Lindborg S, Breier AF. Olanzapine versus pbo for
the schizophrenic prodrome: one-year results. 156th Annual
Meeting of the American Psychiatric Association; 2003 May
17-22; San Francisco, USA. 2003. [[NR584]]

Miller TJ, Zipursky RB, Perkins D, Addington J, Woods SW,
Hawkins KAHR, Preda A, Epstein I, Addington D, Lindborg S,
Marquez ETM, Breier A, McGlashan TH. The PRIME North
America randomized double-blind clinical trial of olanzapine
versus placebo in patients at risk of being prodromally
symptomatic for psychosis. II. Baseline characteristics of the
"prodromal" sample. Schizophrenia Research. 2003; Vol. 61,
issue 1:19-30. [MEDLINE: 22536523; PMID 12648732]

Woods S, Zipursky R, Perkins D, Addington J, Marquez E,
Breier A, McGlashan TH. Olanzapine versus placebo for
prodromal symptoms. 3rd International Conference on Early
Psychosis; 2002 Sep 26-28; Copenhagen, Denmark. 2002:43.

*  Woods SW, Breier A, Zipursky RB, Perkins DO, Addington J,
Miller TJ, Hawkins KA, Marquez E. Ransomized trial of
Olanzapine versus Placebo in the Symptomatic Acute
Treatment of the Schizophrenic Prodrome. Society of Biological
Psychiatry 2003;in press:in press.

Woods SW, Breier A, Zipursky RB, Perkins DO, Addington J,
Miller TJ, Hawkins KA, Marquez E, Lindborg SR, Tohen M,
McGlashan TH. Olanzapine versus placebo for prodromal
symptoms. Schizophrenia Research 2003;60:306-7. [EMBASE:
2003241517]

Woods SW, Breier A, Zipursky RB, Perkins DO, Addington J,
Miller TJ, Hawkins KA, Marquez E, Lindborg SR, Tohen M,
McGlashan TH. Randomized trial of olanzapine versus placebo
in the symptomatic acute treatment of the schizophrenic
prodrome.[erratum appears in Biol Psychiatry. 2003 Aug
15;54(4):497]. Biological Psychiatry 2003;54(4):453-64. [PMID
12915290]

Woods SW, Breier A, Zipursky RB, Perkins DO, Addington J,
Miller TJ, Hawkins KA, Marquez E, Lindborg SR, Tohen M,
McGlashan TH. Randomized trial of olanzapine versus placebo
in the symptomatic acute treatment of the schizophrenic

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

51

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

prodrome.[erratum appears in Biol Psychiatry. 2003 Aug
15;54(4):497]. Biological Psychiatry 2003;54(4):453-64. [PMID
12915290]

Psychotherapie und Nervenheilkunde: "Psychiatrie im Jahr 2000
- die europaische Perspektive", 2000 September 20-23, Aachen,
Germany) 2000;71(Suppl.1):S135-S136.

Woods SW, McGlashan TH. Sample size planning for prodromal
intervention trials. Schizophrenia Research (Abstracts of the
11th Biennial Winter Workshop on Schizophrenia). Elsevier
Science B.V, 2002, issue 3 Suppl.1:40.

Woodward 2001 {published data only}

Woodward ND, Purdon SE, David SR, Stip E. Procedural learning
over six months double blind treatment with haloperidol,
risperidone or olanzapine. Schizophrenia Research (8th
International Congress on Schizophrenia Research; 2001 Apr 28
- May 2; British Columbia, Canada). 2001, issue 1-2 Suppl:125.
[MEDLINE: 21040726]

Wright 2003 (HGAB) {published data only}

King KG, Wright P, Meehan K, Birkett M, David SR, Taylor CC.
Transition from intramuscular to oral olanzapine. XIIth World
Congress of Psychiatry; 2002 Aug 24-29; Yokohama, Japan.
2002. [now published lwad author wright part of (HGAB) clinical
therapeutics 2003, vol 25, p420-28]

*  Padraig Wright, Karena Meehan, Martin Birkett, Stacy
R. Lindborg, Cindy C. Taylor, Philip Morris, Alan Breier. A
comparison of the efficacy and safety of olanzapine versus
haloperidol during transition from intramuscular to oral
therapy. Clinical Therapeutics 2003;25(5):1420-28.

Wright P, Lindborg SR, Birkett M, Meehan K, Jones B, Alaka K,
Ferchland I, Pickard A, Taylor CC, Roth J, Battaglia J, Bitter I,
Chouinard G, Morris P, Breier A. Intramuscular olanzapine and
intramuscular haloperidol in acute schizophrenia: antipsychotic
efficacy and extrapyramidal safety during the first 24 hours
of treatment. The Canadian Journal of Psychiatry (submitted)
2003;48:11. [EMBASE: 2003409683]

Wright P, Lindborg SR, Birkett M, Meehan K, Jones B, Alaka KF-
HI Pickard A, Taylor CC, Roth J, Battaglia J, Bitter I, Chouinard G,
Morris PL, Breier A. Intramuscular olanzapine and intramuscular
haloperidol in acute schizophrenia: antipsychotic efficacy and
extrapyramidal safety during the first 24 hours of treatment.
Canadian Journal of Psychiatry - Revue Canadienne de
Psychiatrie 2003;48(11):716-21. [PMID 14733451]

Wright P, Meehan K, Birkett M, Lindborg SR, Taylor CC,
Morris PBA. A comparison of the efficacy and safety of
olanzapine versus haloperidol during transition from
intramuscular to oral therapy. Clinical Therapeutics
2003;25(5):1420-8. [MEDLINE: 22749560; PMID 12867218]

Wudarsky 1999 {published data only}

Wudarsky M, Nicolson R, Hamburger SD, Spechler L,
Gochman P, Bedwell J, Lenane MC, Rapoport JL.
Elevated prolactin in pediatric patients on typical and
atypical antipsychotics. Journal of Child and Adolescent
Psychopharmacology 1999;9(4):239-45. [MEDLINE: 20094149]

Yagdiran 2000 {published data only}

Yagdiran O, Krausz M. Depressive symptoms under atypical
neuroleptic treatment in schizophrenia.. Der Nervenarzt
(Congress of the Deutsche Gesselschaft fur Psychiatrie,

Zhang 1999 {published and unpublished data}

*  Zhang F, Tran PV, Taylor C, Hwu GH, Chen YS, Chang WH,
Cheng J, Wang A, Chang S, Sze S, Chen RYK, Dunn E, Lieh
Mak F. Efficacy and safety study comparing olanzapine
versus haloperidol in the treatment of Chinese patients with
schizophrenia in Taiwan and Hong Kong. World Psychiatric
Association. Hamburg, Germany. 1999.

Ziherl (HGCZ) 1999 {unpublished data only}

Ziherl S, Novak G, Kores-Plesnicar B, Kosorok M, Juch H,
Dossenbach M. Efficacy and safety of olanzapine in
the treatment of schizophrenic, schizophreniform and
schizoaffective patients in Slovenia. ECNP. London, England,
UK. 1999.

References to ongoing studies

Centorrino 2001 {published data only}

Centorrino F. A double-blind, multi-center controlled study
comparing the safety and efficacy of ziprasidone and
olanzapine in patients with schizophrenia or schizoaffective
disorder needing inpatient care. Clinical Research
Net Psychiatry Clinical Trials (Massachusetts) (http://
crnet.mgh.harvard.edu/home/home.asp accessed Feb 2001)
2001.

Hirsch 2000 {published data only}

Hirsch S. Ziprasidone in the treatment of chronic schizophrenia
(maintenance) versus olanzapine - efficacy and side effects.
National Research Register 2000.

Krakowski 2001 {published data only}

Krakowski MI. Clozapine and olanzapine in violent
schizophrenics. CRISP database (https://www-
commons.cit.nih.gov/crisp/index.html accessed 19th February
2001) 2001.

Ramamurthy 2000a {published data only}

Palazidou E. A multicentre, double-blind, randomised
comparative study of aripiprazole and olanzapine in the
treatment of patients with acute schizophrenia. National
Research Register 2002; Vol. 1. [N0146099645]

Ramamurthy 2000. A multi-centre, double blind, randomised
comparative study of aripiprazole and olanzapine in the
treatment of patients with acute schizophrenia. National
Research Register 2000.

Reveley 2000 {published data only}

Reveley M. Effectiveness trials of antipsychotic drugs. National
Research Register 2000.

Reynolds 2003 {published data only}

Reynolds RF, Romano SJ, Stemhagen A, Dieck G. Ziprasidone
observational study of cardiac outcomes (zodiac) large simple
trial: rationale and design. Schizophrenia Research. 2003; Vol.
60:365. [EMBASE: 2003241517]

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

52

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Singh 2000b {published data only}

Carpenter 1994

Singh V. A six month international controlled trial of the
therapeutic activity of amisulpride 200 to 800mg/day verses
olanzapine 5 to 20mg/day in patiients with schizophrenic
disorders. National Research Register 2000.

Turner 2002 {published data only}

Turner T. Quality of life - Pfizer trial. National Research Register
2002; Vol. 1. [N0146103028]

Additional references

Alderson 2004

Alderson P, Green S, Higgins JPT. Cochrane Reviewers'
Handbook 4.2.2 [updated December 2003]. Cochrane Database
of Systematic Reviews. Chichester, UK: John Wiley & Sons, Ltd,
2004, issue Issue 1.

Altman 1996

Altman DG, Bland JM. Detecing skewness from summary
information. BMJ 1996;313:1200. [OLZ020600]

AMDP-5 1981

Arbeltsgemelnschaft fur methodik und dokumentation in
der psychiatrie (AMDP) [Association for Methodology and
Documentation in Psychiatry]. Das AMDP-System: Manual zur
dokumentation psychiatricher befunde. Berlin: Auflage, 1981.

Andreasen 1983

Andreasen NC. Negative symptoms in schizophrenia. Archives of
General Psychiatry 1982;39:784-8.

Anonymous 1997

Anonymous. Olanzapine, sertindole and schizophrenia. Drugs
and Therapeutics Bulletin 1997;35:11.

APA 1994

American Psychiatric Association. Diagnostic and Statistical
Manual of Mental Disorders (DSM-IV). 4th Edition. Washington
DC: American Psychiatric Association, 1994.

Barnes 1989

Barnes TR. A rating scale for drug-induced akathisia. British
Journal of Psychiatry 1989;154:672-6.

Bland 1997

Bland JM. Statistics notes. Trials randomised in clusters. BMJ
1997;315:600.

Breier 1994

Breier A, Buchanan RW, Kirkpatrick B, Davis OR, Irish D,
Summerfeldt A, et al. Effect of clozapine on positive and
negative symptoms in outpatients with schizophrenia. American
Journal of Psychiatry 1994;151(1):20-6.

Carpenter 1984

Heinrichs DW, Hanlon ET, Carpenter WT Jr. The quality of
life scale: an instrument for rating the schizophrenic deficit
syndrome. Schizophrenia Bulletin 1984;10:388-96.

Carpenter WT Jr, Buchanan RW. Schizophrenia. New England
Journal of Medicine 1994;330:681-90.

Chalmers 1983

Chalmers TC, Celano P, Sacks HS, Smith H Jr. Bias in treatment
assignment in controlled clinical trials. New England Journal of
Medicine 1983;309:1358-61.

Chouinard 1980

Chouinard G, Ross-Chouinard A, Annable L. Extrapyramidal
symptom rating scale. Canadian Journal of Neurological Science
1980;7:233.

COSTART 1990

US Food, Drug Administration. COSTART coding sysmbols for
thesaurus of adverse reaction terms. 2nd Edition. Rockville MD:
Food and Drug Administration, 1990.

de Haan 2002

de Haan L, Weisfelt M, Dingemans P.M.A.J, et al. Psychometric
properties of the Subjective Well-Being Under Neuroleptics
scale and the Subjective Deficit Syndrome Scale.
Psychopharmacology 2002;162:24-28.

de Haan 2002a

de Haan L, Weisfelt M, Dingemans PMAJ, Linszen DH, Wouters L.
Psychometric properties of the Subjective Well-Being Under
Neuroleptics Scale (SWN) and the Subjective Deficit Syndrome
Scale (SDSS). Psychopharmacology (Berl) 2002;162:24-8.

Divine 1992

Divine GW, Brown JT, Frazier LM. The unit of analysis error in
studies about physicians' patient care behavior. Journal of
General Internal Medicine 1992;7(6):623-9.

Donner 2002

Donner A, Klar N. Issues in the meta-analysis of cluster
randomized trials. Statistics in Medicine 2002;21:2971-80.

Egger 1997

Egger M, Davey-Smith G, Schneider M, Minder CSO. Bias
in meta-analysis detected by a simple, graphical test. BMJ
1997;13:629-34.

Fabre 1995

Fabre LF, Arvanitis L, Pultz J, Jones VM, Malick JB, Slotnick VB.
ICI 204,636, a novel, atypical antipsychotic - early indication
of safety and efficacy in patients with chronic and subchronic
schizophrenia. Clinical Therapeutics 1995;17:366-78.

Fleischhacker 1989

Fleischhacker WW, Bergmann KJ, Perovich R, Pestreich LK,
Borenstein M, Lieberman JA, Kane JM. The Hillside Akathisia
Scale: a new rating instrument for neuroleptic-induced
akathisia.. Psychopharmacology Bulletin 1989;25(2):222-6.
[MEDLINE: 2574895]

Folstein 1975

Folstein NF, Folstein SE, McHugh PR. Mini-Mental State: a
practical method for grading the cognitive state of patients

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

53

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

for the clinician Folstein NF, Folstein SE, McHugh PR. Mini-
Mental State: a practical method for grading the cognitive state
of patients for the clinician. Journal of Psychiatric Research
1975;12:189-98.. Journal of Psychiatric Research 1975;12:189-98.

Gulliford 1999

Gulliford MC. Components of variance and intraclass
correlations for the design of community-based surveys and
intervention studies: data from the Health Survey for England
1994. American Journal of Epidemiology 1999;149:876-83
876-83.

Guy 1976

Guy W. Early clinical drug evaluation (ECDEU) assessment
manual for psychopharmacology. Washington, DC: National
Institute of Mental Health, 1976:217-22. [Publication No.76-338.]

Hamilton 1960

Hamilton M. A rating scale of depression. Journal of Neurology,
Neurosurgery and Psychiatry 1960;23:56-62.

Kane 1988

Kane J, Honigfeld G, Singer J, Meltzer H, et al. Clozapine
for the treatment-resistant schizophrenic: a double-blind
comparison with chlorpromazine. Archives of General Psychiatry
1988;45:789-96.

Kay 1986

Kay SR, Opler LA, Fiszbein A. Positive and negative syndrome
scale (PANSS) manual. North Tonawanda (NY): Multi-Health
Systems, 1986.

Lehman 1983

Lehman A. The well being of chronic mental patients:
assessing their quality of life. Archives of General Psychiatry
1983;40:369-73.

Lieberman 1998

Liebermann JA, Mailman RB, Duncan G, Sikich L, Chakos M,
Nichols DE, Kraus JE. Serotonergic basis of antipsychotic effects
in schizophrenia. Biological Psychiatry 1998;44(11):1099-117.

Hamilton 1969

Lingjaerde 1987

Hamilton A. Diagnosis and Rating of Anxiety. British Journal of
Psychiatry 1969;S3:76-9.

Hamilton 1998

Hamilton, S H, Revicki, D A, Genduso, L A, Beasley. CM Jr.
Olanzapine versus placebo and haloperidol: quality of life
and efficacy results of the North American double-blind trial.
Neuropsychopharmacology 1998;18:41-9.

Higgins 2003

Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring
inconsistency in meta-analyses. BMJ 2003;327:557-60.

Hoadley 2004

Hoadley JF. The continued need for independent research on
prescription drugs. Health Affairs Jan/Feb 2004;23(1):244.

Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. The UKU
side effect rating scale. A new comprehensive rating scale for
psychotropic drugs and a cross-sectional study of side effects
in neuroleptic-treated patients. Acta Psychiatrica Scandinavica
Supplementum 1987;76(334):100.

Marshall 2000

Marshall M, Lockwood A, Bradley C, Adams C, Joy C, Fenton M.
Unpublished rating scales: a major source of bias in randomised
controlled trials of treatments for schizophrenia. British Journal
of Psychiatry 2000;176:249-52.

McEwan 1993

McEwan GW. New antipsychotic medications: do research
results relate to clinical practice?. Canadian Journal of
Psychiatry 1993;38(Suppl):75-9.

Hogan 1983

Moher 2001

Hogan TP, Awad AG, Eastwood R. A Self-report Predictive
of Drug Compliance in Schizophrenia: Reliability and
Discriminative Ability Psychological Medicine. Psychological
Medicine 1983;13:177-83.

Hunter 2003

Hunter R, Joy C, Kennedy E, Gilbody S, Song F. Risperidone
versus typical antipsychotic medication for schizophrenia.
Cochrane Database of Systematic Reviews 2003, Issue 2. [DOI:
10.1002/14651858.CD000440]

ICD-10

World Health Organization. The ICD-10 Classification of Mental
and Behavioural Disorders. Geneva: World Health Organization,
1992.

Inada 1996

Inada M. Evaluation and Diagnosis of Drug-Enduced
Extrapyramidal Symptoms: Commentary on the DIEPSS and
guide to its usage. Tokyo: Seiwa Shoten, 1996.

Moher D, Schulz KF, Altman D. The CONSORT statement: revised
recommendations for improving the quality of reports of
parallel-group randomized trials. JAMA 2001;285:1987-91.

Montgomery 1979

Montgomery SA, Asberg M. A new depression scale designed
to be sensitive to change. Montgomery SA, Asberg M. A new
depression scale designed to be sensitive to change. British
Journal of Psychiatry 1979;134:382-9. Montgomery 1979
Montgomery SA, Asberg M. A new depression scale designed
to be sensitive to change. British Journal of Psychiatry
1979;134:382-9.. British Journal of Psychiatry 1979;134:382-9.

Offerhaus 2004

Offerhaus L. The pharmaceutical industry in scandal: Mercury
or Aesculapius? [De geneesmiddelenindustrie in opspraak:
Mercurius of Aesculapius?]. Nederlands Tijdschrift voor
Geneeskunde 2004;148(51):2554-6.

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

54

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Overall 1962

Srisurapanont 2004

Overall JE, Gorham DR. The Brief Psychiatric Rating Scale.
Psychological Reports 1962;10:799-812.

Parrott 1980

Srisurapanont M, Maneeton B, Maneeton N. Quetiapine for
schizophrenia. Cochrane Database of Systematic Reviews 2004,
Issue 2. [DOI: 10.1002/14651858.CD000967.pub2]

Parrott AC, Hindmarch I Parrott A.C, Hindmarch I. The Leeds
Sleep Evaluation Questionnaire in psychopharmacological
investigations - a review. Psychopharmacology 1980;71:173-79.

Tamminga 1998

Tamminga CA. Serotonin and schizophrenia. Biological
Psychiatry 1998;44:1079-80.

Pocock 1975

Thornley 2003

Pocock SJ, Simon R. Sequential treatment assignment with
balancing for prognostic factors in the controlled clinical trial.
Biometrics 1975;31(1):103-15.

Schulz 1995

Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence
of bias: dimensions of methodological quality associated
with estimates of treatment effects in controlled trials. JAMA
1995;273:408-12.

Seeman 1987

Thornley B, Rathbone J, Adams CE, Awad G.
Chlorpromazine versus placebo for schizophrenia. Cochrane
Database of Systematic Reviews 2003, Issue 2. [DOI:
10.1002/14651858.CD000284.pub2]

Tollefson 1997

Tollefson GD, Beasley CM Jr, Tran PV, et al. Olanzapine
versus haloperidol in the treatment of schizophrenia and
schizoaffective and schizophreniform disorder: results of an
international collaborative trial. American Journal of Psychiatry
1997;154:457-65.

Seeman P. Dopamine receptors and the dopamine hypothesis of
schizophrenia. Synapse 1987;1:133-52.

Ukoumunne 1999

Sellers 2003

Sellers LJ. Fourth annual 50. Special Report. Pharmaceutical
Executive. http://www.pharmexec.com/pharmexec/article/
articleDetail.jsp?id=55215 May 2003:45-52.

Ukoumunne OC, Gulliford MC, Chinn S, Sterne JAC, Burney PGJ.
Methods for evaluating area-wide and organistation-based
intervention in health and health care: a systematic review.
Health Technology Assessment 1999;3(5):1-75.

Wahlbeck 1999

Simpson 1970

Simpson GM, Angus JWS. A rating scale for extrpyramidal
side-effects. Acta Psychiatrica Scandinavica Supplementum
1970;212:11-9.

Wahlbeck K, Cheine M, Essali MA, Rezk E. Clozapine
versus 'typical' neuroleptic medication for schizophrenia.
Cochrane Database of Systematic Reviews 1999, Issue 4. [DOI:
10.1002/14651858.CD000059]

* Indicates the major publication for the study

C H A R A C T E R I S T I C S   O F   S T U D I E S

Characteristics of included studies [ordered by study ID]

Altamura 1999 (HGBQ) 

Methods

Participants

Allocation: randomised, computer-generated, blocks for each investigator 1:1, concealed from investi-
gators. 
Blindness: double, medication kits issued. 
Duration: 14 weeks (preceded by screening phase, unspecified). 
Design: multicentre, 1 week wash out period.

Diagnosis: schizophrenia, paranoid (DSM-IV). 
History: informed consent obtained. 
N=28.* 
Age: not reported. 
Sex: not clearly reported. 
Setting: not reported. 
Inclusion criteria: partial or non-responders to treatment according to preset criteria.

Interventions

1. Olanzapine: dose range 5-20 mg, mean 12.4 mg/day. N=13. 
2. Haloperidol: dose range 5-20 mg, mean 12.3 mg/day. N=15.

Outcomes

Leaving the study early.

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

55

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Altamura 1999 (HGBQ)  (Continued)

Cochrane Database of Systematic Reviews

Unable to use - 
Global state: CGI (no data). 
Mental state: BPRS, SANS (no usable data). 
Adverse events: AIMS, BAS, SAS (no usable data), weight gain (unpublished data with unclear denomi-
nator).

*Data supplied by company suggests 48 people were randomised and presents detailed results. Profes-
sor Altamura, however, in a personal communication suggests that these are projected figures and not
true ratings.

Authors' judgement

Support for judgement

Notes

Risk of bias

Bias

Allocation concealment
(selection bias)

Low risk

A - Adequate

Avasthi 2001 

Methods

Participants

Interventions

Outcomes

Notes

Risk of bias

Bias

Allocation: randomised. 
Blindness: open label. 
Duration: 12 weeks. 
Design: parallel groups, with washout period.

Diagnosis: schizophrenia (DSM-IV). 
History: informed consent obtained. 
N=27. 
Age: between 18-65 years. 
Sex: male and female. 
Setting: hospital & community. 
Inclusion criteria: =/> 3 on the CGI severity scale. 
Excluded: hepatitis, jaundice, current agranulocytosis.

1. Olanzapine: dose range 5-20 mg/day. N=17. 
2. Haloperidol: dose range 5-20 mg/day. N=10.

Leaving the study early. 
Global state: CGI. 
Mental state: BPRS, PANSS-P, PANSS-N, MADRS, SANS. 
Adverse events: BAS, SAS, treatment emergent side-effects. 
Quality of Life: QoL. 
Weight gain.

Unable to use - 
Mental state: HAM-S (no usable data). 
Adverse events: UKU (no data).

Authors' judgement

Support for judgement

Allocation concealment
(selection bias)

Unclear risk

B - Unclear

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

56

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Barak 2002 

Methods

Participants

Interventions

Outcomes

Notes

Risk of bias

Bias

Allocation: randomised - no further details. 
Blindness: open label. 
Duration: 3 months. 
Design: parallel group.

Diagnosis: schizophrenia (DSM IV). Elderly. 
History: mean length of illness 35.3 years, informed consent obtained. 
N=20. 
Age: range 68-83, mean 72.7 years. 
Sex: 10 M, 10 F. 
Setting: hospitalised. 
Inclusion criteria: PANSS total score of >50.

1. Olanzapine: dose 13.1 mg/day. N=10. 
2. Haloperidol: dose 7.2 mg/day. N=10.

Leaving study early. 
Global state: CGI. 
Mental state: PANSS. 
Weight change. 
Additional medication.

Authors' judgement

Support for judgement

Allocation concealment
(selection bias)

Unclear risk

B - Unclear

Beasley 1996a (HGAD) 

Methods

Participants

Allocation: randomised, computer generated, block by investigator, concealed from investigator. 
Blindness: double, medication kits issued. 
Duration: 6 weeks (preceded by placebo lead-in of 4-7 days; 46 week extension for responders). 
Investigators: trained on BPRS & SANS. 
Design: dosage study.

Diagnosis: schizophrenia (DSM-III-R). 
History: acute exacerbation, informed consent obtained. 
N=335. 
Age: mode ˜ 30's, range 18-65. 
Sex: ˜ 90% M. 
Setting: hospital & community. 
Inclusion criteria: BPRS >23, CGI >3, off neuroleptics prior to study, lead-in period responders (BPRS to-
tal decreased by >24% / <24) excluded. 
Excluded: substance misuse within 3 months, serious suicidal risk, unstable medical illness, parkin-
sons disease, myasthenia gravis, hepatitis, jaundice, history of seizures, leukopenia.

Interventions

1. Olanzapine low: dose 2.5-7.5 mg/day. N=65. 
2. Olanzapine medium: dose 7.5-12.5 mg/day. N=64. 
3. Olanzapine high: dose 12.5-17.5mg/day*. N=69. 
4. Haloperidol: dose 10-20 mg/day. N=69. 

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

57

 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Beasley 1996a (HGAD)  (Continued)

5. Placebo: N=68.

Cochrane Database of Systematic Reviews

Up to 10mg/day lorazepam (day 1-21) & benztropine 6mg/day as required.

Outcomes

Leaving study early. 
Global effect: CGI-S. 
Mental state: BPRS-anchored version**, needing additional benzodiazepines, SANS. 
Adverse events: AIMS, BAS, SAS, requiring benztropine, COSTART list, weight change.

Unable to use - 
Hospital status: (no data). 
Laboratory tests and physiological measures: (no data).

Notes

*Chosen as comparator with other trials as mean dose = 13.2mg/day.

**A priori efficacy >39 decrease from baseline or to <19 BPRS total.

Risk of bias

Bias

Authors' judgement

Support for judgement

Allocation concealment
(selection bias)

Low risk

A - Adequate

Beasley 1996b (HGAP) 

Methods

Participants

Interventions

Outcomes

Allocation: randomised, computer-generated, block by investigative site, concealed from investigator. 
Blindness: double, medication kits issued. 
Duration: 6 weeks (preceded by placebo lead-in of 4-7 days). 
Investigators: trained in PANSS. 
Design: multicentre, 12 sites in USA.

Diagnosis: schizophrenia (DSM-III-R). 
History: informed consent obtained. 
N=152. 
Age: mean 38 years. 
Sex: ˜ 70% M. 
Setting: initially all in hospital.* 
Inclusion criteria: BPRS >23, CGI >3, not involved in previous olanzapine trial, off neuroleptics prior to
entering study, lead-in period responders (BPRS total decreased by >24% / <24) excluded. 
Excluded: serious unstable medical conditions, parkinsons disease, myasthenia gravis, hepatitis, jaun-
dice, history of seizures, leukopenia.

1. Olanzapine: dose 1 mg/day. N=52. 
2. Olanzapine: dose 10mg/day. N=50. 
3. Placebo: N=50.

Up to 10mg/day lorazepam (day 1-21) & benztropine 6mg/day allowed as required.

Leaving study early. 
Global state: CGI-S. 
Mental State: BPRS**, needing additional benzodiazepines, PANSS. 
Adverse events: AIMS, BAS, requiring benztropine, SAS, COSTART list, weight change.

Unable to use - 
Hospital status: (no data). 
Global state: PGI (no data). 
Laboratory tests & physiological measures: (no data).

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

58

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Beasley 1996b (HGAP)  (Continued)

Cochrane Database of Systematic Reviews

Notes

* Eligible for discharge if BPRS total decreased by >24% from baseline or was <24.

** BPRS (scored 0-6) extracted from PANSS - no reference given for validity of procedure.

** A priori efficacy >39 decrease from baseline or to <19 BPRS total.

Risk of bias

Bias

Authors' judgement

Support for judgement

Allocation concealment
(selection bias)

Low risk

A - Adequate

Beasley 1997 (E003) 

Methods

Participants

Interventions

Outcomes

Allocation: randomised, computer-generated - blocks of 5, concealed from investigators. 
Blindness: double, medication kits issued. 
Duration: 6 weeks (preceded by placebo lead-in of 4-7 days: 46 week extension for responders). 
Design: multicentre, 50 sites, Europe, South Africa, Israel and Australia.

Diagnosis: schizophrenia (DSM-III-R). 
History: informed consent obtained. 
N=431. 
Age:18-65. 
Sex: 275 M, 156 F. 
Setting: initially all in hospital.* 
Inclusion criteria: BPRS >23, CGI >3, off neuroleptics prior to entering study, lead-in period responders
(BPRS total decreased by >24% / <24) excluded. 
Excluded: substance misuse within last 3 months, suicide risk, parkinsons disease, myasthenia gravis,
hepatitis, jaundice, history of seizures, leukopenia.

1. Olanzapine (OLZ-1): dose 1mg/day. N=88. 
2. Olanzapine (OLZ-L): dose 2.5-7.5mg/day. N=87. 
3. Olanzapine (OLZ-M): dose 7.5-12.5mg/day. N=86. 
4. Olanzapine (OLZ-H): dose 12.5-17.5mg/day**. N=89. 
5. Haloperidol (HAL): dose 10-20mg/day. N=81.

Up to 10mg/day benzodiazipine (day 1-21) & biperiden up to 6mg/day as required.

Leaving study early. 
Global state: CGI-S. 
Mental State: BPRS***, needing additional benzodiazepines, PANSS. 
Death.**** 
Adverse events: AIMS, BAS, requiring benztropine, SAS, COSTART list, weight change.

Unable to use - 
Hospital status: (no data). 
Global state: PGI (no data). 
Laboratory tests & physiological measures: (no data).

Notes

* Eligible for discharge if BPRS total decreased by >24% from baseline or was <24.

** Chosen as the comparitor with other trials as mean dose = 13.2mg/day.

*** BPRS (scored 0-6) extracted from PANSS - no reference given for validity of procedure.

*** A priori efficacy >39 decrease from baseline or to <19 total.

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

59

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Beasley 1997 (E003)  (Continued)

****Deaths reported during the study or within 30 days of discontinuation.

Risk of bias

Bias

Authors' judgement

Support for judgement

Allocation concealment
(selection bias)

Low risk

A - Adequate

Bernardo 2001 (HGDD) 

Methods

Allocation: randomised - no further details. 
Blindness: double. 
Duration: 4 weeks. 
Design: parallel group.

Participants

Interventions

Outcomes

Notes

Risk of bias

Bias

Diagnosis: schizophrenia (DSM IV). 
History: all experiencing acute psychosis, (n=11, first episode, neuroleptic naive), (n=16 neuroleptic
free after minimum washout of 7 days), informed consent obtained. 
N=27. 
Age: range 19-44 years, mean 28. 
Sex: M 17, F 10. 
Setting: inpatients. 
Inclusion criteria: not reported.

1. Olanzapine: dose 10 mg/day. N=14. 
2. Haloperidol: dose 10 mg/day. N=13.

Leaving the study early. 
Global improvement: CGI. 
Mental state: BPRS, PANSS, PANSS-P, PANSS-N. 
Adverse events: SAS, BAS.

Authors' judgement

Support for judgement

Allocation concealment
(selection bias)

Unclear risk

B - Unclear

Beuzen 1998 (HGCF) 

Methods

Participants

Allocation: randomised, block design, computer-generated, concealed from investigators. 
Blindness: double. 
Duration: 18 weeks (preceeded by washout period). 
Design: multicentre, 14 sites, Europe and Africa.

Diagnosis: schizophrenia (DSM IV). 
History: informed consent obtained. 
N=180. 
Age: range 18-70 years. 
Sex: male and female. 

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

60

 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Beuzen 1998 (HGCF)  (Continued)

Cochrane Database of Systematic Reviews

Setting: inpatients and outpatients. 
Inclusion criteria: treatment resistant, >3 on at least 2 items of PANSS positive sub-scale. 
Excluded: previously treated with olanzapine or were olanzapine or clozapine non-responders.

Interventions

1. Olanzapine: dose range 15-25 mg/day. N=90. 
2. Clozapine: dose range 200-600 mg/day. N=90.

Benzodiazipines, biperiden, benztropine & chloral hydrate as required.

Outcomes

Leaving study early. 
Global improvement: CGI. 
Mental state: BPRS, Kane criteria, PANSS, COSTART list, weight change.

Unable to use - 
Global improvement: use of additional medication (no data). 
Laboratory tests & physiological measures (no data).

Notes

Risk of bias

Bias

Authors' judgement

Support for judgement

Allocation concealment
(selection bias)

Low risk

A - Adequate

Bitter 2004 (HGCK) 

Methods

Participants

Allocation: randomised - no further details. 
Blindness: double. 
Duration: 18 weeks. 
Design: multicentre, Hungary and South Africa.

Diagnosis: treatment resistant or treatment intolerant schizophrenia (DSM IV). 
History: informed consent obtained. 
N=150. 
Age: 18-65 years. 
Sex: 88 M, 59 F. 
Setting: hospitalised. 
Inclusion criteria: minimum score of at at least 42 of the BPRS, extracted from the PANSS scale; failure
to respond to standard antipsychotic treatment (at least one treatment trial of 4-6 weeks duration at
400-600mg-equivalents of chlorpromazine, because of either insufficient effectiveness or intolerable
side effects). 
Excluded: failure on clozapine due to adverse event or lack of efficacy. Substance related disorder, se-
rious suicide risk, pregnancy, breast feeding, seizures, leukopenia, leucocytes <3.5 GI/L, neutrophils <
2.0 GI/L, jaundice, or active hepatitis B.

Interventions

Outcomes

1. Olanzapine: dose range 5-25 mg/day. N=76. 
2. Clozapine: dose range 100-500 mg/day. N=74.

No important clinical response. 
Leaving the study early. 
Adverse events.

Unable to use - 
Mental state: PANSS (no usable data). 
Global state: CGI (no usable data). 

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

61

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Bitter 2004 (HGCK)  (Continued)

Addtional medication (data unclear).

Notes

Risk of bias

Bias

Authors' judgement

Support for judgement

Allocation concealment
(selection bias)

Unclear risk

B - Unclear

Casey 2003 

Methods

Participants

Allocation: randomised - no further details. 
Blindness: double; raters proficiency had to meet predefined criteria. 
Duration: 28 days. 
Informed consent obtained. 
Design: multicentre, parallel group with 4 week washout phase.

Diagnosis: schizophrenia (DSM IV). 
N=125*. 
Age: 18-65. 
Sex: 91 M, 29 F. 
Setting: hospitalised with leave allowed for max. 7 days. 
Inclusion criteria:PANSS score =/>60 and have had a positive response to treatment with antipsy-
chotics within the previous 2 years. 
Excluded: current diagnosis of schizoaffective disorder, drug induced psychosis, manic episode, de-
pressive episode, violent, homicidal ideation; pregnancy, lactating females, clinically significant abnor-
mal laboratory data, unstable medical condition or an underlying condition that would confound the
interpretation of study results.

Interventions

1. Olanzapine: dose 15 mg/day. N=65. 
2. Risperidone: dose 6 mg/day. N=60.

Outcomes

Adverse events.

Unable to use - 
Adverse events: SAS, BAS, AIMS (no usable data). 
Global state: CGI (no usable data). 
Mental state: PANSS (no usable data).

*total randomised was 249 with 4 arms, only 2 arms usable.

Authors' judgement

Support for judgement

Notes

Risk of bias

Bias

Allocation concealment
(selection bias)

Unclear risk

B - Unclear

Chan 2003 

Methods

Allocation: randomised - no further details. 
Blindness: single 'rater blind' 

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

62

 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Chan 2003  (Continued)

Participants

Interventions

Outcomes

Notes

Risk of bias

Bias

Duration: 8 weeks. 
Design: parallel group.

Diagnosis: schizophrenia (DSM IV). 
History: informed consent obtained. 
N=60. 
Age: 18-65. 
Sex: 30 M, 30 F. 
Setting: hopitalised. 
Inclusion criteria: not reported.

1. Olanzapine: dose range 2.5-20 mg/day. N=30. 
2. Risperidone: dose range 0.5-6 mg/day. N=30.

Leaving the study early. 
Needing addtional benzodiazapines. 
Weight change.

Unable to use - 
Global state: CGI (no usable data). 
Mental state: BPRS (no usable data). 
Adverse effects: EPRS (no usable data). 
Needing addtional antipsychotics (unclear data).

Authors' judgement

Support for judgement

Allocation concealment
(selection bias)

Unclear risk

B - Unclear

Chang 2003 

Methods

Participants

Interventions

Outcomes

Notes

Allocation: randomised - no further details. 
Blindness: not reported. 
Duration: 8 weeks. 
Design: parallel group.

Diagnosis: schizophrenia. 
History: length of illness 4-5 years. 
N=62. 
Age: 18-53. 
Sex: male and female. 
Setting: hospital and community. 
Inclusion criteria: not reported.

1. Olanzapine: 5-20 mg/day. N=32. 
2. Chlorpromazine: 25-600 mg/day. N=30.

Leaving the study early. 
Mental state: BPRS.

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

63

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Chang 2003  (Continued)

Risk of bias

Bias

Authors' judgement

Support for judgement

Allocation concealment
(selection bias)

Unclear risk

B - Unclear

Chaudhry 2003 

Methods

Participants

Interventions

Outcomes

Notes

Risk of bias

Bias

Allocation: randomised - no further details. 
Blindness: double. 
Duration: 24 weeks. 
Design: multicentre Phillipines, Malaysia, Pakistan, Thailand, Singapore.

Diagnosis: schizophrenia (DSM IV). 
History: informed consent obtained. 
N=276. 
Age: mean 32.3 years. 
Sex: male and female. 
Setting: outpatients. 
Inclusion criteria: BPRS score > 18 at baseline.

1. Olanzapine: dose range 5-20 mg/day. N=144. 
2. Haloperidol: dose range 5-20 mg/day. N=132.

Adverse events. 
Additional medication: anticholinergics. 
Weight gain.

Authors' judgement

Support for judgement

Allocation concealment
(selection bias)

Unclear risk

B - Unclear

Chen 2003 

Methods

Participants

Allocation: randomised - no further details. 
Blindness: double. 
Duration: 8 weeks. 
Design: parallel group.

Diagnosis: schizophrenia. 
History: not reported. 
N=64. 
Age: mean 63.3 years. 
Sex: male and female. 
Setting: hospitalised. 
Inclusion criteria: not reported.

Interventions

1. Olanzapine: dose range 5-25 mg/day. N=30. 

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

64

 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Chen 2003  (Continued)

2. Clozapine: dose range 25-500 mg/day. N=34.

Outcomes

Notes

Risk of bias

Bias

Leaving the study early. 
Mental state: PANSS.

Authors' judgement

Support for judgement

Allocation concealment
(selection bias)

Unclear risk

B - Unclear

Conley 1998 

Methods

Participants

Allocation: randomised - no further details. 
Blindness: double - no further details. 
Duration: 8 weeks (preceded by 6 weeks of haloperidol and 1-2 weeks washout). 
Investigators: trained on BPRS & SANS. 
Design: multicentre, 3 sites USA.

Diagnosis: schizophrenia (DSM-III-R). 
History: treatment resistant, informed consent obtained. 
N=84. 
Age: mean 42.7 years. 
Sex: 62 M, 22 F. 
Setting: hospital. 
Inclusion criteria: minimum BPRS of 45, CGI-S score >3, treatment resistant, non-responders during
haloperidol phase, not responded to 2 previous antipsychotics.

Interventions

1. Olanzapine: dose 25 mg/day. N=42. 
2. Chlorpromazine: dose 1200 mg/day & benztropine 4mg/day. N=42.

Benzodiazipine during washout & first 3 weeks of trial as required.

Outcomes

Leaving study early. 
Global state: CGI. 
Mental state: BPRS*, SANS. 
Adverse events: BAS, SAS.

Unable to use - 
Global state: use of benzodiazipines (no data). 
Adverse events: COSTART list, weight change (no data). 
Hospital status: (no data). 
Laboratory tests & physiological measures: (no data).

Notes

* A priori efficacy >19 decrease from baseline or to <34 total score.

Treatment resistance 
1. >2 periods of treatment in last 5 years with antipsychotics (from >2 different classes, excluding
haloperidol, dose >/= 1g/day chlorpromazine for 6 weeks) without significant relief; 
2. No period of good functioning in last 5 years; and 
3. BPRS total >/=45, CGI >/=4, >2 BPRS psychosis items >/=4.

Risk of bias

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

65

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Conley 1998  (Continued)

Bias

Authors' judgement

Support for judgement

Allocation concealment
(selection bias)

Low risk

A - Adequate

Conley 2001 

Methods

Participants

Allocation: randomised, stratified by site , BMI, Investigator, baseline PANSS total and ESRS scores. 
Blindness: double - capsules identical in appearance, taste and smell. Investigators were provided with
a sealed envelope for each subject. Placebo capsules were used to supplement certain doses of risperi-
done in order to match the number of olanzapine capsules. 
Duration: 8 weeks (preceeded by 1 week washout). 
Design: multicentre, 41 sites, 2 of which were excluded (n=30) because of data quality concerns.

Diagnosis: schizophrenia or schizoaffective disorder (DSM-IV). 
History: 48% in RISP group and 51% in OLZ group had previously taken atypical antipsychotics. 16%
and 14% respectively had taken depot antipsychotic medication. 
N=377. 
Age: 18-64. 
Sex: 274 M, 103 F. 
Setting: hospital (within 4 weeks of admission) or outpatient. 
Inclusion criteria: PANSS between 60 and 120, not treatment resistant, or refractory to RIS or OLZ, no
previous CLOZ.

Interventions

1. Olanzapine: mean modal dose 12.43 mg/day, range 5-20 mg. N=189. 
2. Risperidone: mean modal dose 4.78 mg/day, range 2-6 mg. N=188.

Outcomes

Notes

Risk of bias

Bias

Additional use of anticholinergics and lorazepam allowed.

Leaving study early. 
Mental state: PANSS, use of addtional lorazepam. 
Adverse events: ESRS, use of anticholinergic drugs, weight change.

Unable to use - 
Laboratory tests & physiological measures: (no usable data).

Data from two sites not included because of concerns over data quality, (n=30). 
All individual participants files audited post study.

Authors' judgement

Support for judgement

Allocation concealment
(selection bias)

Unclear risk

B - Unclear

Corrigan 2004 

Methods

Allocation: randomised - no further details. 
Blindness: double, identical capsules. 
Duration: 6 weeks. 
Design: multicentre. 
Informed consent obtained.

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

66

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Corrigan 2004  (Continued)

Participants

Diagnosis: schizophrenia (DSM IV). 
N=467. 
Age: 18-65. 
Sex: male and female. 
Setting: hospitalised. 
Inclusion criteria: PANSS score >/=60. 
Excluded: clinically significant disease, clinically significant abnormalities on physical examination,
electrocardiogram, lab tests, history of failure to respond to antipsychotic drugs, drug and alcohol
abuse.

Interventions

1.Olanzapine: dose 15 mg/day. N=93. 
2. Sonepiprazole: dose 1.5 mg/day. N=96. 
3. Sonepiprazole: dose 10 mg/day. N=99. 
4. Sonepiprazole: dose 60 mg/day. N=91. 
5. Placebo: OD. N=87.

Additional medication allowed included. chloral hydrate, anticholinergics, benzotropine mesylate,
benzhexol hydrochloride, oral diphenhydramine, lorazepam, zolpidemor flunitrazepam.

Outcomes

Leaving the study early.

Unable to use - 
Mental state: PANSS, BPRS, Calgary Depression Scale (no SD). 
Global state: CGI (no usable data). 
Adverse events: SAS, BAS, (no usable data).

Notes

Risk of bias

Bias

Authors' judgement

Support for judgement

Allocation concealment
(selection bias)

Unclear risk

B - Unclear

de Haan 2002 

Methods

Participants

Allocation: randomised - no further details. 
Blindness: not reported. 
Duration: 6 weeks. 
Design: parallel groups.

Diagnosis: schizophrenia (DSM IV) or related disorders. 
History: recent onset, informed consent obtained. 
N=36*. 
Age: mean 22.4 years. 
Sex: 92 M, 21 F. 
Setting: hospitalised. 
Inclusion criteria: not reported. 
Excluded: neurological or endocrine diseases and mental retardation.

Interventions

1. Olanzapine: mean dose 14.2 mg/frequency not reported. N=19. 
2. Risperidone: mean dose 4.2 mg/frequency not reported. N=17.

Outcomes

Behaviour: Yale Brown Obsessive Compulsive Scale.

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

67

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

de Haan 2002  (Continued)

Notes

Risk of bias

Bias

*113 randomised, but only 36 were not receiving olanzapine or risperidone before the study, or were
switched from olanzapine to risperidone or vise versa.

Authors' judgement

Support for judgement

Allocation concealment
(selection bias)

Unclear risk

B - Unclear

de Hann 2003 

Methods

Participants

Allocation: randomised, block design. 
Blindness: double. 
Duration: 6 weeks. 
Design: parallel group.

Diagnosis: schizophrenia (DSM IV). 
History: recent onset schizophrenia, informed consent obtained. 
N=24. 
Age: 17-28 years. 
Sex: male and female. 
Setting: hopitalised and community. 
Inclusion criteria: not reported. 
Excluded: neurological or endocrine disease, mental retardation, use of adjunctive medication such as
mood stabilizers or antidepressants, history of clozapine treatment, or history of unresponsiveness to
haloperidol or olanzapine and intramuscular antipsychotic treatment within a year.

Interventions

1. Olanzapine: dose 7.5 mg/day. N=12. 
2. Haloperidol: dose 2.5 mg/day. N=12.

Additional medication, benzodiazepine oxazepine oxazepam.

Outcomes

Notes

Risk of bias

Bias

Leaving the study early. 
Mental state: PANSS, MADRS. 
Subjective Wellbeing Under Neuroleptic Scale.

Unable to use - 
Glaobal state: CGI (no usable data). 
Adverse events: SAS, BAS (no usable data).

Authors' judgement

Support for judgement

Allocation concealment
(selection bias)

Unclear risk

B - Unclear

Esel 2001 

Methods

Allocation: randomised - no further details. 
Blindness: not reported. 

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

68

 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Esel 2001  (Continued)

Participants

Interventions

Outcomes

Notes

Risk of bias

Bias

Duration: 6 weeks. 
Design: parallel group.

Diagnosis: schizophrenia (DSM IV). 
History: not reported. 
N=29. 
Age: range 17-28, mean 29.3 years. 
Sex: male. 
Setting: hospital. 
Inclusion criteria: not reported.

1. Olanzapine: dose 10 mg/day. N=15. 
2. Haloperidol: dose 10 mg/day. N=14.

Leaving the study early. 
Mental state: BPRS 
Global state: CGI. 
Adverse events: ESRS.

Author contacted who stated the study was randomised.

Authors' judgement

Support for judgement

Allocation concealment
(selection bias)

Unclear risk

B - Unclear

He 2003 

Methods

Participants

Allocation: randomised - no further details. 
Blindness: open label. 
Duration: 8 weeks. 
Design: parallel groups.

Diagnosis: schizophrenia (CCMD-2-R). 
History: mean length of illness, olanzapine 1.5 years; chlorpromazine 2.2 years. 
N=80. 
Age: 18-60. 
Sex: male and female. 
Setting: hospitalised. 
Inclusion criteria: not reported.

Interventions

1. Olanzapine: dose 5-30 mg/day. N=40. 
2. Chlorpromazine: dose 100-600 mg/day. N=40.

Outcomes

Leaving the study early.

Unable to use - 
Mental state: PANSS (data unclear). 
Adverse events: TESS (data unclear).

Notes

Risk of bias

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

69

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

He 2003  (Continued)

Bias

Authors' judgement

Support for judgement

Allocation concealment
(selection bias)

Unclear risk

B - Unclear

HGBJ (Finland) 

Methods

Participants

Allocation: randomised, computer-generated, blocks for each investigator 1:1, concealed from investi-
gators. 
Blindness: double, medication kits issued. 
Duration: 26 weeks (preceded by screening phase, unspecified). 
Design: multicentre, Finland.

Diagnosis: schizophrenia (DSM-IV). 
History: acute symptoms. 
N=46. 
Age: range 18-70 years, mean 37.6. 
Sex: M 28, F 18. 
Setting: not reported 
Inclusion criteria: severity of illness at least moderately ill (CGI 4).

Interventions

1. Olanzapine: dose range 5-20 mg/day. N=23. 
2. Perphenazine: dose range 8-32 mg/day. N=23.

Outcomes

Notes

Risk of bias

Bias

Leaving study early. 
Adverse events: COSTART list, weight change.

Authors' judgement

Support for judgement

Allocation concealment
(selection bias)

Low risk

A - Adequate

HGBL 1997 

Methods

Participants

Allocation: randomised, computer-generated, blocks, 1:1 for each investigator, concealed from investi-
gators. 
Blindness: double, medication kits issued. 
Duration: 4 weeks (preceded by placebo lead-in of 4-7 days. 
Design: parallel groups.

Diagnosis: schizophrenia (DSM-IV). 
History: not reported. 
N=30. 
Age: not reported. 
Sex: not reported. 
Setting: inpatients. 
Inclusion criteria: not reported.

Interventions

1. Olanzapine: dose range 5-20 mg/day. N=15. 

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

70

 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

HGBL 1997  (Continued)

2. Flupentixol: dose range 5-20 mg/day. N=15.

Outcomes

Leaving study early. 
Adverse events: COSTART list, weight change.

Unable to use - 
Adverse events: extrapyramidal (no data).

Notes

Risk of bias

Bias

Authors' judgement

Support for judgement

Allocation concealment
(selection bias)

Low risk

A - Adequate

HGCJ (Hong Kong) 

Methods

Participants

Interventions

Outcomes

Notes

Risk of bias

Bias

Allocation: randomised, computer-generated, blocks, 1:1 for each investigator, concealed from investi-
gators. 
Blindness: double, medication kits issued. 
Duration: 14 weeks. 
Design: parallel groups.

Diagnosis: schizophrenia, schiziphreniform disorder, schizoaffective disorder (DSM-IV). 
History: not reported. 
N=31. 
Age: not reported. 
Sex: not reported. 
Setting: inpatients and outpatients. 
Inclusion criteria: screening used, no further details.

1. Olanzapine: dose range 5-20 mg/day. N=17. 
2. Haloperidol: dose range 5-20 mg/day. N=14.

Leaving study early. 
Global state: CGI-S. 
Mental state: BPRS, MADRS, PANSS. 
Adverse events: COSTART list, weight change.

Unable to use - 
Adverse events: extrapyramidal (no data).

Authors' judgement

Support for judgement

Allocation concealment
(selection bias)

Low risk

A - Adequate

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

71

 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

HGCQ (Turkey) 2000 

Methods

Participants

Allocation: randomised, blocks, computer-generated, 2:1 for each investigator, concealed from investi-
gators. 
Blindness: double, medication kits issued. 
Duration: 6 weeks. 
Design: 2 centres, Turkey.

Diagnosis: schizophrenia (DSM-IV). 
History: informed consent obtained. 
N=30. 
Age: range 18-47 years, mean 32.8. 
Sex: M 17, F 13. 
Setting: inpatients and outpatients. 
Inclusion criteria: CGI severity at least 4. 
Excluded: pregnancy, seriously unstable illness, including hepatic, renal, gastroenterologic, respirato-
ry, cardiovascular, endocrinologic, neurologic or hematologic disease; glaucoma, uncontrolled thyroid
disease, myasthenia gravis, urinary retention, seizures, leucopenia.

Interventions

Outcomes

Notes

Risk of bias

Bias

1. Olanzapine: dose range 5-20 mg/day. N=20. 
2. Chlorpromazine: dose range 200-800 mg/day. N=10.

Leaving the study early. 
Mental state: BPRS, PANSS. 
Global state: CGI. 
Adverse events: ESRS, COSTART list, weight change. 
Quality of Life: VPS, LSEQ.

Unable to use - 
Adverse events: UKU, weight change (no data).

Authors' judgement

Support for judgement

Allocation concealment
(selection bias)

Low risk

A - Adequate

HGCU (Taiwan) 1998 

Methods

Participants

Allocation: randomised, blocks, computer-generated, 1:1 for each investigator, concealed from investi-
gators. 
Blindness: double, medication kits issued. 
Duration: 14 weeks. 
Design: multicentre, 4 sites.

Diagnosis: schizophrenia, schiziphreniform disorder, schizoaffective disorder (DSM-IV). 
History: not reported. 
N=54. 
Age: not reported. 
Sex: not reported. 
Setting: inpatients and outpatients. 
Inclusion criteria: not reported.

Interventions

1. Olanzapine: dose range 5-20 mg/day. N=26. 
2. Haloperidol: dose range 5-20 mg/day. N=28.

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

72

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

HGCU (Taiwan) 1998  (Continued)

Outcomes

Leaving study early. 
Global state: CGI-S. 
Mental state: BPRS, MADRS, PANSS. 
Adverse events: COSTART list, weight change.

Unable to use - 
Adverse events: extrapyramidal (no data).

Notes

Risk of bias

Bias

Authors' judgement

Support for judgement

Allocation concealment
(selection bias)

Low risk

A - Adequate

HGDV (Morocco) 1999 

Methods

Participants

Allocation: randomised, computer-generated, blocks for each investigator, 2:1, olanzapine to chlorpro-
mazine. 
Blindness: open-label, medication kits issued. 
Duration: 6 weeks (preceded by washout phase; extension for responders). 
Design: single centre Morocco.

Diagnosis: schizophrenia (DSM-IV). 
History: previously hospitalised (mean ˜ 1.5 times), informed consent obtained. 
N=40. 
Age: 18-47. 
Sex: 6 male, 33 female. 
Setting: inpatients and outpatients. 
Inclusion criteria: initial CGI severity score of 4. 
Excluded: pregnancy, seriously unstable illness, including hepatic, renal, gastroenterologic, respirato-
ry, cardiovascular, endocrinologic, neurologic or hematologic disease; glaucoma, uncontrolled thyroid
disease, myasthenia gravis, urinary retention, seizures, leucopenia.

Interventions

Outcomes

Notes

Risk of bias

Bias

1. Olanzapine: dose range 5-20 mg/day. N=27. 
2. Chlorpromazine: dose range 200-800 mg/day. N=13.

Leaving study early. 
Mental state: BPRS, PANSS, MADRS, HAM-S. 
Global state: CGI. 
Adverse events: EPRS, COSTART list, weight gain.

Authors' judgement

Support for judgement

Allocation concealment
(selection bias)

Low risk

A - Adequate

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

73

 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

HGFH (Korea) 1998 

Methods

Participants

Allocation: randomised, computer-generated, blocks for each investigator, 1:1. 
Blindness: open label. 
Duration: 6 weeks (preceded by washout phase, unspecified; extension for responders). 
Design: single centre, Korea.

Diagnosis: schizophrenia, schizophreniform and schizoaffective disorder (DSM-IV). 
History: not reported. 
N=104. 
Age: not reported. 
Sex: not reported. 
Setting: inpatients & outpatients. 
Inclusion criteria: not reported.

Interventions

1. Olanzapine: dose range 5-20 mg/day. N=53. 
2. Haloperidol: dose range 1.5-20 mg/day. N=51.

Outcomes

Notes

Risk of bias

Bias

Leaving study early. 
Adverse events: COSTART list, weight gain.

Authors' judgement

Support for judgement

Allocation concealment
(selection bias)

Low risk

A - Adequate

Ishigooka 2001 

Methods

Participants

Interventions

Outcomes

Allocation: randomised - no further details. 
Blindness: double. 
Duration: 8 weeks. 
Design: multicentre, 67 investigative institutions in Japan.

Diagnosis: schizophrenia (ICD 10). 
History: informed consent obtained. 
N=182. 
Age: 18-65 years. 
Sex: male and female. 
Setting: inpatients and outpatients. 
Inclusion criteria: not reported. 
Excluded: previous olanzapine treatment or haloperidol within previous 2 weeks, serious illness,
seizures, pregnancy, leukopenia, granulocytopenia, Parkinson's disease.

1. Olanzapine: dose range 5-15 mg/day. N=93. 
2. Haloperidol: dose range 4-12 mg/day. N=89.

Leaving the study early. 
Mental state: BPRS, PANSS, PANSS-N, PANSS-P. 
Adverse events: ADR, DIEPSS, treatment emergent side-effects. 
Death.

Unable to use - 
Global state: FGIR (scale not validated). 
Physiological measurements: (no SD).

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

74

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Ishigooka 2001  (Continued)

Notes

Risk of bias

Bias

Contacted author for further information on 20/04/04

Authors' judgement

Support for judgement

Allocation concealment
(selection bias)

Unclear risk

B - Unclear

Jakovljevic1999 HGCH 

Methods

Participants

Interventions

Outcomes

Notes

Risk of bias

Bias

Allocation: randomised, blocks 1:1, computer-generated, concealed from investigators. 
Blindness: double, medication kit issued. 
Duration: 6 weeks followed by extension for 22 weeks (preceded by washout period of 2-9 days). 
Design: multicentre 3 sites, Croatia.

Diagnosis: schizophrenia, no further details. 
History: informed consent obtained. 
N=60. 
Age: between 18 and 65 years. 
Sex: male and female. 
Setting: hospitalised. 
Inclusion criteria: minimum PANSS score of at least 42 and at least 4 on the CGI severity scale. 
Excluded: serious unstable illness, history of intolerance to olanzapine, substance dependence within
last 30 days, risk of suicide, pregnancy, breast feeding.

1. Olanzapine: dose range 5-20 mg/day. N=30. 
2. Fluphenazine: dose range 6-21 mg/day. N=30.

Leaving study early. 
Global state: CGI-S. 
Mental state: BPRS, PANSS. 
Adverse events: treatment emergent side-effects: COSTART list, weight change. 
Quality of life: DAI, LSEQ.

Unable to use - 
Adverse events: extrapyramidal (no data).

Authors' judgement

Support for judgement

Allocation concealment
(selection bias)

Low risk

A - Adequate

Jeste 2003 

Methods

Allocation: randomised, using a minimization technique to ensure no imbalances occurred in either
group based on scores from the ESRS, PANSS and MMSE scales. 
Blindness: double. 
Duration: 8 weeks, 1 week washout. 
Design: mulitcentre, 32 sites, USA, Poland, Israel, Norway, Netherlands and Austria. 

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

75

 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Jeste 2003  (Continued)

Participants

Informed consent obtained,

Diagnosis: schizophrenia or schizoaffective disorder (DSM-IV). 
History: mean duration of illness 36 years. 
N=175. 
Age: over 60 years (mean over 71 years). 
Sex: M 62, F 113. 
Setting: inpatients and outpatients. 
Inclusion criteria: PANSS baseline score between 50-120. 
Excluded: DSM-IV diagnosis of substance abuse in previous 3 months, major depressive episode as de-
fined by DSM-IV criteria within 6 months before screening, MMSE score of less than 18, CNS disorders,
QTc >500msec, unresponsive to risperidone or olanzapine in the past, any acute unstable, significant,
or untreated medical illnesses and renal, hepatic, or gastrointestinal disease that could potentially in-
terfere with the absorption, excretion or metabolism of trial medications.

Interventions

1. Olanzapine: dose lowest dose not stated, range ˜5-20 mg/day. N= 88. 
2. Risperidone: dose range 1-3 mg/day.N= 87.

Flexible doses used to acheive maximum efficacy with minimum adverse events.

Additional medication, Lorazepam max 4 mg/day.

Outcomes

Notes

Risk of bias

Bias

Death. 
Leaving the study early. 
Global state: CGI. 
Mental state: PANSS. 
Adverse effects: ESRS. 
Other adverse events. 
Use of antiparkinsonian medication.

Unable to use - 
Mental state: HAM-D (no usable data). 
Adverse events: weight change: (no usable data).

Concomitant medications disallowed during the study period included antidepressants, anticonvul-
sants, mood stabilizers other antipsychotics, sedatives, anxiolytics, and other psychoactive drugs (ex-
cept lorazepam during washout period, for agitation).

Authors' judgement

Support for judgement

Allocation concealment
(selection bias)

Unclear risk

B - Unclear

Jones 1998 (P022) 

Methods

Participants

Allocation: random, computer-generated, blocks by investigator, concealed from investigator. 
Blindness: double. 
Duration: 54 weeks (preceded by 1 month stabilization phase followed by 1 week washout, screening
period). 
Design: multicentre, Canada.

Diagnosis: schizophrenia. 
History: 'early phase', first 5 years of illness. 
N=65. 
Age: mean 28.9 years. 
Sex: male and female. 

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

76

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Jones 1998 (P022)  (Continued)

Cochrane Database of Systematic Reviews

Setting: outpatients. 
Inclusion criteria: not reported. 
Excluded: if PANSS>90.

1. Olanzapine: dose range 5-20 mg/day. N=21. 
2. Risperidone: dose range 4-10 mg/day. N=21. 
3. Haloperidol: dose range 5-20 mg/day. N=23.

Leaving the study early. 
Mental state: PANSS. 
Adverse events: treatment emergent side-effects, ESRS, COSTART list, weight change.

Unable to use - 
Cost: (no data). 
Cognitive function: GCIS, neuropsychological test battery (no usable data).

Authors' judgement

Support for judgement

Interventions

Outcomes

Notes

Risk of bias

Bias

Allocation concealment
(selection bias)

Low risk

A - Adequate

Kelly 2003 

Methods

Participants

Allocation: randomised- no further details. 
Blindness: double. 
Duration: 8 weeks. 
Design: crossover.

Diagnosis: treatment resistant schizophrenia (DSM IV). 
History: infomed consent obtained. 
N=13. 
Age: mean 37 years. 
Sex: not reported. 
Setting: hospital. 
Inclusion criteria: treament resistant schizophrenia as evidenced by persistent positive psychotic
symptoms: item score >/=4 (moderate) on at least two of four positive symptom items on BPRS, the
current presence of at least moderately severe illness as rated by the total BPRS score (score>/=45 on
the 18-item scale) and a score >/=4 (moderate) on the CGI, two failed historical trials of antipsychotics
of at least 6-weeks duration at doses of at least 600mg/day chlorpromazine equivalents and no stable
period of good social and/or occupational functioning within the last 5 years. 
Excluded: previously failed clozapine treatment.

Interventions

1. Olanzapine: dose range 50 mg/day. N=8. 
2. Clozapine: dose range 450 mg/day. N=5.

Additional medication: lorazepam and benztropine mesylate.

Outcomes

Leaving the study early.

Unable to use - 
Global state: CGI (no usable data prior to crossover). 
Mental state: BPRS (no usable data prior to crossover).

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

77

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Kelly 2003  (Continued)

Notes

Risk of bias

Bias

Authors' judgement

Support for judgement

Allocation concealment
(selection bias)

Unclear risk

B - Unclear

Kern 2001 

Methods

Participants

Interventions

Outcomes

Notes

Risk of bias

Bias

Allocation: randomised - no further details. 
Blindness: open-label. 
Duration: 26 weeks. 
Design: multicentre, parallel group.

Diagnosis: schizophrenia or schizoaffective disorder. 
History: chronic stable, not hospitalised for > 2 months prior to randomisation, previously on stable
dose of antipsychotic for > 2 months. 
N=255. 
Age: mean ˜40, range 18-65 years. 
Sex: M 164, F 92. 
Setting: outpatient. 
Inclusion criteria: not reported.

1. Olanzapine: dose range 15 mg/day, after 10 mg/day 1-7. N=127. 
2. Aripiprazole: dose range 30 mg/day. N=128.

Adverse effects: spontaneously reported adverse effects occurring in >10%, clinically significant weight
gain.

Unable to use - 
Adverse effects: weight change (no SD). 
Cognitive functioning: California Verbal Learning test, Benton visual retention test, Winsconsin card
sorting test, Trail making A and B, Continuous perfomance test, Verbal Fluency, Letter-number se-
quencing from the WAIS III, Grooved pegboard test (no usable data/no SDs).

Authors' judgement

Support for judgement

Allocation concealment
(selection bias)

Unclear risk

B - Unclear

Lecrubier 1999 

Methods

Allocation: randomised, computer-generated, blocks for each investigator, 2:2:2:1, concealed from in-
vestigator. 
Blindness: double, medication kits issued. 
Duration: 6 months. 
Design: 4 treatment groups.

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

78

 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Lecrubier 1999  (Continued)

Participants

Diagnosis: "schizophrenic patients with primarily negative symptoms" - no further details. 
History: primarily negative symptoms. 
N=244. 
Age: not reported. 
Sex: not reported. 
Setting: not reported. 
Inclusion criteria: minimum SANS summary score of 10 (excluding attention subscore) & no score > 4
on hallucination & delusion items of PANSS (normalized, scored 0-6).

Interventions

Outcomes

Notes

Risk of bias

Bias

1. Olanzapine: dose 5 mg/day. N=70. 
2. Olanzapine: dose 20 mg/day. N=70. 
3. Amisulpride: dose 150 mg/day. N=70. 
4. Placebo: N=34.

Leaving study early. 
Mental state: SANS. 
Adverse events: COSTART list, weight change. 
Quality of life: QLS.

Unable to use - 
Mental state: PANSS (no usable data). 
Adverse events: extrapyramidal (no data).

Authors' judgement

Support for judgement

Allocation concealment
(selection bias)

Low risk

A - Adequate

Lieberman 2003 (HGDH 

Methods

Participants

Allocation: randomised - no further details. 
Blindness: double. 
Duration. 12 weeks (acute phase). 
Design: multicentre, 14 sites, North America and Europe.

Diagnosis: schizophrenia (DSM IV). 
History: first episode schizophrenia, informed consent obtained. 
N=263. 
Age: 16-40. 
Sex: M 215, F 48. 
Setting: not clear. 
Inclusion criteria: scored =/> 4 on at least two positive and negative syndrome scale and CGI =/> 4. 
Excluded: 1 month of substance abuse; previoulsy revceived antipsychotics for more than 16 cumula-
tive weeks, had been treated with clozapine at anytime, or had an depot neuroleptic within three dos-
ing intervals before study entry; pregnancy/nursing; serious unstable illness.

Interventions

1. Olanzapine: dose range 5-20 mg/day. N=132. 
2. Haloperidol: dose range 2-20 mg/day. N=131.

Additional medication, chloral hydrate, lorazepam, diazepam; benztropine, biperiden, propranolol,
procyclidine.

Outcomes

Leaving the study early. 

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

79

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Lieberman 2003 (HGDH  (Continued)

Cochrane Database of Systematic Reviews

Global state: CGI. 
Mental state: PANSS, MADRS. 
Adverse events: requiring anticholinergics, benzodiazepines, propranolol, treatment emergent parkin-
sonism, akathisia, weight gain.

Notes

Risk of bias

Bias

Authors' judgement

Support for judgement

Allocation concealment
(selection bias)

Unclear risk

B - Unclear

Lima 2003 (HGHS) 

Methods

Participants

Interventions

Outcomes

Notes

Risk of bias

Bias

Allocation: randomised - no further details. 
Blindness: open label. 
Duration: 9 months. 
Design: multicentre, Brazil.

Diagnosis: schizophrenia (DSM IV), or related disorders. 
History: participants experiencing an acute psychiatric admission or recently discharded, informed
consent obtained. 
N=197* 
Age: mean 33.8. 
Sex: M 154, F 43. 
Setting: not reported. 
Inclusion criteria: not reported.

1. Olanzapine: dose as clinically indicated, no further details. N=104. 
2. Conventional antipsychotics (mainly haloperidol or chlorpromazine, no further details. N=93.

Leaving the study early. 
Global state: CGI. 
Mental state: PANSS. 
Adverse events.

Unable to use - 
Additional medication (data unclear).

*Abstract reports 190 participants.

Authors' judgement

Support for judgement

Allocation concealment
(selection bias)

Unclear risk

B - Unclear

Littrell 1999 

Methods

Allocation: randomised - no further details. 
Blindness: open label. 

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

80

 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Littrell 1999  (Continued)

Participants

Interventions

Outcomes

Notes

Risk of bias

Bias

Duration: 1 year. 
Design: parallel groups.

Diagnosis: schizophrenia. 
History: chronic illness. 
N=24. 
Age: not reported. 
Sex: not reported. 
Setting: outpatients. 
Inclusion criteria: not reported.

1. Olanzapine: dose 19.2 mg/day. N=12. 
2. Risperidone: dose 5.2 mg/day. N=12.

Leaving the study early. 
Mental state: PANSS, PANSS-N, PANSS-P.

Unable to use - 
Adverse events: SAS (no usable data).

Authors' judgement

Support for judgement

Allocation concealment
(selection bias)

Unclear risk

B - Unclear

Loza 1999 (HGDT) 

Methods

Participants

Allocation: randomised, computer-generated, blocks for each investigator, 2:1, olanzapine to chlorpro-
mazine, concealed from investigators. 
Blindness: double, medication kits issued. 
Duration: 6 weeks (preceded by washout phase of 2-9 days; extension for responders). 
Design: multicentre: 2 sites, Egypt.

Diagnosis: schizophrenia (DSM-IV). 
History: informed consent obtained. 
N=41. 
Age: range 17-47 years, mean 32.3. 
Sex: M 33, F 8. 
Setting: inpatients & outpatients. 
Inclusion criteria: initial score of at least 4 on the CGI severity scale. 
Excluded: pregnancy, seriously unstable illness, including hepatic, renal, gastroenterologic, respirato-
ry, cardiovascular, endocrinologic, neurologic or hematologic disease; glaucoma, uncontrolled thyroid
disease, myasthenia gravis, urinary retention, seizures, leucopenia.

Interventions

Outcomes

1. Olanzapine: dose range 5-20 mg/day. N=27. 
2. Chlorpromazine: dose range 200-800 mg/day. N=14.

Leaving study early. 
Mental state: BPRS, PANSS. 
Global state: CGI-S. 
Quality of Life Scale: QoL. 
Adverse events: ESRS, COSTART list, weight change.

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

81

 
 
 
 
 
Cochrane Database of Systematic Reviews

Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Loza 1999 (HGDT)  (Continued)

Unable to use - 
Adverse events: UKU (no data). 
Hospital status: (no data). 
Laboratory tests & physiological measures: (no data).

Authors' judgement

Support for judgement

Notes

Risk of bias

Bias

Allocation concealment
(selection bias)

Low risk

A - Adequate

Malyarov 1999 

Methods

Participants

Allocation: randomised - no further details. 
Blindness: not reported. 
Duration: 6 months. 
Design: three treatment groups.

Diagnosis: schizophrenia (ICD 10). 
History: acute psychotic state. 
N=43. 
Age: mean 24.5 years. 
Sex: M 28, F 15. 
Setting: inpatients. 
Inclusion criteria: not reported.

Interventions

1. Olanzapine: dose range 5-15 mg/day. N=15. 
2. Haloperidol: dose range 5-20 mg/day. N=18. 
3. Risperidone: dose range 3-6 mg/day. N=10.

Outcomes

Leaving the study early.

Unable to use - 
Mental state: PANSS (no SD). 
Global state: GAF (no SD).

Notes

Risk of bias

Bias

Authors' judgement

Support for judgement

Allocation concealment
(selection bias)

Unclear risk

B - Unclear

Martin 2002 

Methods

Allocation: randomised - no further details. 
Blindness: double. 
Duration: 2 months. 

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

82

 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Martin 2002  (Continued)

Participants

Design: multicentre, 76 sites, Belgium, Switzerland, Denmark, France, Great Britain, Czech Republic,
Tunisia, Hungary, Morocco and Portugal.

Diagnosis: schizophrenia (DSM-IV). 
History: informed consent obtained. 
N=377. 
Age: mean 37.8 years. 
Sex: M/F (˜2:1) ratio. 
Setting: inpatients and outpatients. 
Inclusion criteria: 18-65 years with BPRS score minimum of 36 (extracted from PANSS) and a positive
PANSS rating higher than the negative PANSS rating. 
Excluded: patients whose BPRS score improved by more than 40% between the screening and baseline
visit; pregnant and lactating women and inadequate use of contraception in fertile women.

Interventions

Outcomes

Notes

Risk of bias

Bias

1. Olanzapine: mean dose 12 mg/day. N=188. 
2. Amisulpride: mean dose 489 mg/day. N=189.

Leaving the study early. 
Global state: CGI. 
Mental state: BPRS , PANSS, MADRS. 
Adverse events: SAS.

Unable to use - 
Weight change: (no SD). 
Mental state: PANSS change score - endpoint data takes precendence over change.

BPRS Data calculated from graphic figure 1.

Authors' judgement

Support for judgement

Allocation concealment
(selection bias)

Unclear risk

B - Unclear

McQuade 2003 

Methods

Participants

Allocation: randomised - no further details. 
Blindness: double. 
Duration: 26 weeks. 
Design: parallel, multi-centre.

Diagnosis: schizophrenia. 
History: acute relapse, mean age at first episode ˜25 years, mean time since current acute episode be-
gan ˜21 days. 
N=317. 
Age: mean ˜38 years. 
Sex: M 229, F 88. 
Setting: not reported. 
Inclusion criteria: not reported.

Interventions

1. Olanzapine: dose range 10-20 mg/day. N=161. 
2. Aripiprazole: dose range 15-30 mg/day. N=156.

Outcomes

Leaving the study early.

Unable to use - 

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

83

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

McQuade 2003  (Continued)

Cochrane Database of Systematic Reviews

Global state: CGI (no usable data). 
Mental state: PANSS (no SDs). 
Adverse effects: mean change in weight (no SDs), clinically significant weight gain, serum prolactin,
EPS, plasma lipids outside normal limits (no usable data).

Notes

Risk of bias

Bias

Greater than 60% discontinuation rate.

Authors' judgement

Support for judgement

Allocation concealment
(selection bias)

Unclear risk

B - Unclear

Meltzer (InterSept) 

Methods

Participants

Interventions

Outcomes

Notes

Risk of bias

Bias

Allocation: randomised, block allocated 1:1 ratio. 
Blindness: open label with raters blinded. 
Duration: 2 years. 
Informed consent obtained. 
Design: suicide prevention, parallel groups, multicentre, 67 sites, 11 countries USA, Canada, France,
Italy, the United Kingdom, the Czech Republic, Hungary, Croatia, South Africa, Argentina and Chile.

Diagnosis: schizophrenia and schizoaffective disorder (DSM IV). 
N=980*. 
Age: range 18-66 years, mean 37. 
Sex: M 602, F 378. 
Setting: hospital and community. 
Inclusion criteria: attempted suicide or were hospitalised to prevent sucide within the three years be-
fore their baseline evaluation or demonstrated moderate to severe suicidal ideation with a depressive
or delusinal component within 1 week before their baseline evaluation were considered at high risk of
suicidality.

1. Olanzapine: dose 16.4 mg/day. N=477. 
2. Clozapine: dose 274 mg/day. N=479.

Death. 
Leaving the study early. 
Adverse events. 
Rescue interventions including hospitalisation, increased level of surveillance and addition of an anti-
depressant.

Unable to use - 
Global state: CGI-SS (no usable data). 
Mental state: PANSS, Calgary Depression Scale (no usable data).

*24 never treated for administrative reasons, unknown from which arm.

Authors' judgement

Support for judgement

Allocation concealment
(selection bias)

Unclear risk

B - Unclear

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

84

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Naber 2001 (HGBF) 

Methods

Participants

Allocation: randomised 1:1 block allocation. 
Blindness: double. 
Duration: 26 weeks. 
Design: multicentre, parallel group.

Diagnosis: schizophrenia (DSM IV). 
History: all participants had either failed to respond to at least one antipsychotic other than clozap-
ine and olanzapine or had experienced intolerable side effects during these prior antipsychotic treat-
ments. 
N=114. 
Age: range 18-59, mean 34. 
Sex: M 69, F 45. 
Setting: not reported. 
Inclusion criteria: minimum BPRS score of 24. 
Excluded: prior olanzapine treatment at any time or prior clozapine treatment within the last 3
months.

Interventions

1. Olanzapine: dose range 5-25 mg/day. N=57. 
2. Clozapine: dose range 100-400 mg/day. N=57.

Outcomes

Leaving the study early.

Unable to use - (>50% drop out). 
Global state: CGI. 
Mental state: PANSS, BPRS. 
Quality of life: MLDL, SWN. 
Adverse events: SAS, side effects.

Notes

Risk of bias

Bias

Authors' judgement

Support for judgement

Allocation concealment
(selection bias)

Unclear risk

B - Unclear

Namjoshi 2002 

Methods

Participants

Allocation: randomised - no further details. 
Blindness: not described. 
Duration: 1 year. 
Design: three treatment groups; 
six participants were randomised, though not reported on in the study reports; we have made an as-
sumption that two were missing from each group and added them back in.

Diagnosis: schizophrenia. 
History: not reported. 
N=364. 
Age: mean 39.4 years. 
Sex: male and female. 
Setting: outpatients. 
Inclusion criteria: not reported.

Interventions

1. Olanzapine: dose range 5-20 mg/day. N=142. 
2. Risperidone: dose range 2-10 mg/day. N=136. 

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

85

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Namjoshi 2002  (Continued)

3. Haloperidol: dose range 2-9 mg/day. N=86.

Outcomes

Hospital admission.

Unable to use - 
Mental state: PANSS (no usable data). 
Cost effectiveness: (no usable data).

Notes

Risk of bias

Bias

Authors' judgement

Support for judgement

Allocation concealment
(selection bias)

Unclear risk

B - Unclear

Ritchie 2003 

Methods

Participants

Interventions

Outcomes

Notes

Risk of bias

Bias

Allocation: randomised, blocks of six by study site. 
Blindness: allocation concealed from local investigators, open label; investigators trained in use of
scales using videos. 
Duration: first arm approx. four weeks (unclear). 
Design: multicentre, 8 sites Australia, crossover. 
Informed consent obtained.

Diagnosis: schizophrenia. 
N=66. 
Age: mean 69.6 years. 
Sex: M 19, 47 F. 
Setting: not reported. 
Inclusion criteria: people >60 years who were taking conventional antipsychotics. 
Excluded: idiopathic parkinson's disease, epilepsy or previous treatment failure with olanzapine or
risperidone.

1. Olanzapine: dose ˜9.9 mg/day. N=34. 
2. Risperidone: dose ˜1.7 mg/day. N=32.

Leaving the study early. 
Global state: CGI. 
Mental state: PANSS. 
Adverse events. 
Additional medication(data unclear).

Authors' judgement

Support for judgement

Allocation concealment
(selection bias)

Unclear risk

B - Unclear

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

86

 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Rosenheck 2003(HGFI) 

Methods

Participants

Allocation: randomised, random sequence numbers. 
Blindness: double, medication kits issued. 
Duration: 12 months. 
Design: parallel group.

Diagnosis: schizophrenia (DSM IV). 
History: informed consent obtained. 
N=309. 
Age: mean age 46.5 years. 
Sex: M 153, F 144. 
Setting: hospital and community. 
Inclusion criteria: BPRS score >36. 
Excluded: previous participation in olanzapine research.

Interventions

1. Olanzapine: dose range 5-20 mg/day. N=159. 
2. Haloperidol: dose range 5-20 mg/day. N=150.

Outcomes

Leaving the study early.

Unable to use - (>50% lost to follow in both arms). 
Global state: CGI. 
Mental state: PANSS. 
Quality of Life. 
Adverse events: SAS, AIMS, BAS, check lists. 
Assessment of Health Care Costs.

Notes

Risk of bias

Bias

Authors' judgement

Support for judgement

Allocation concealment
(selection bias)

Low risk

A - Adequate

Simpson 2004 

Methods

Participants

Allocation: randomised - no further details. 
Blindness: double. 
Duration: 6 weeks. 
Design: multicentre. 
Informed consent obtained.

Diagnosis: schizophrenia (DSM IV). 
N=269. 
Age: 18-55. 
Sex: M 176, F 93. 
Setting: inpatients. 
Inclusion criteria: persistant psychotic symptoms for a week before hospital admission; CGI score =/
>4 and score =/>4 on PANSS positive scale; normal laboratory test results and normal ECG and negative
urine drug test at entry.

Interventions

1. Olanzapine: dose range 5-15 mg/day. N=133. 
2. Ziprasidone: dose range 40-80 mg/bid. N=136.

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

87

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Simpson 2004  (Continued)

Outcomes

Additional medication, lorazepam permitted for control of agiitation or insomnia and benzotropine for
extrapyramidal symptoms.

Leaving the study early. 
Global state: CGI. 
Mental state: BPRS. 
Additional medication (benzodiazepines, anticholinergics). 
Adverse events.

Unable to use - 
Mental state: PANSS, Calgary Depression Scale (no usable data). 
Adverse events: ESRS, BAS, AIMS (no usable data). 
Weight changes (no usable data).

Notes

Risk of bias

Bias

Authors' judgement

Support for judgement

Allocation concealment
(selection bias)

Unclear risk

B - Unclear

Svestka 2003 

Methods

Participants

Interventions

Outcomes

Notes

Risk of bias

Bias

Allocation: randomised - no further details. 
Blindness: double. 
Duration: 6 weeks. 
Design: parallel group.

Diagnosis: schizophrenia (ICD 10). 
History: first episode. 
N=42. 
Age: not reported. 
Sex: female. 
Setting: not reported. 
Inclusion criteria: not reported.

1. Olanzapine: dose range 10-20 mg/day. N=21. 
2. Risperidone: dose range 4-6 mg/day. N=21.

Mental state: PANSS. 
Adverse events: EPS, rhinitis, use of antiparkinsonics, hyperprolactinaemia.

Unable to use - 
Global state: CGI (no usable data). 
Adverse events: EPS (no usable 
data).

Authors' judgement

Support for judgement

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

88

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Svestka 2003  (Continued)

Allocation concealment
(selection bias)

Thomas 1998 (HGBU) 

Methods

Participants

Interventions

Outcomes

Notes

Risk of bias

Bias

Unclear risk

B - Unclear

Allocation: randomised, computer-generated, blocks for each investigator, 1:1, concealed from investi-
gator. 
Blindness: double, medication kits issued. 
Duration: 30 weeks. 
Design: multicentre, Australia (6 sites), New Zealand (2 sites).

Diagnosis: schizophrenia, schizophreniform and schizoaffective disorder (DSM-IV). 
History: informed consent obtained. 
N=65. 
Age: 18 years or over. 
Sex: M 38, F 27. 
Setting: patients could begin the study as either in or out patients. 
Inclusion criteria: scores greater than 36 (on items scored 1 to 7) on the BPRS; excluded pregnant fe-
males and patients who did not respond to >400 mg/day of clozapine taken for a minimum of 6 weeks. 
Excluded: pregnacy, failure to show a response to clozapine at a dose of >400mg/day for at least 6
weeks.

1. Olanzapine: dose range 10-20 mg/day. N=32. 
2. Risperidone: dose 4-8 mg/day. N=33.

Leaving study early. 
Global state: CGI-S. 
Mental state: BPRS, PANSS. 
Adverse events: COSTART list, weight change. 
Quality of life: QLS.

Unable to use - 
Quality of life: SF-36 (no total score).

Authors' judgement

Support for judgement

Allocation concealment
(selection bias)

Low risk

A - Adequate

Tollefson 1997 Conti 

Methods

Participants

Interventions

Outcomes

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

89

 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Tollefson 1997 Conti  (Continued)

Notes

Risk of bias

Bias

Authors' judgement

Support for judgement

Allocation concealment
(selection bias)

Low risk

A - Adequate

Tollefson 1997(HGAJ) 

Methods

Participants

Allocation: randomised, computer-generated, blocks,ratio 2:1, concealed from investigators. 
Blindness: double. 
Duration: 6 weeks (preceded by a screening phase of 2-9 days, maintenance phase of 46/52 for respon-
ders), and a 3 year, double blind extension phase. 
Design: multicentre, 174 sites in 17 countries.

Diagnosis: schizophrenia, schizophreniform or schizoaffective disorder (DSM-III-R). 
History: informed consent obtained. 
N=1996. 
Age: mean ˜ 39 years. 
Sex: male and female. 
Setting: not reported. 
Inclusion criteria: >18 BPRS and/or intolerant of current antipsychotics.

Interventions

1. Olanzapine: dose range 5-20 mg/day. N=1336. 
2. Haloperidol: dose range 5-20 mg/day. N=660.

Benztropine & benzodiazepine as required.

Outcomes

Leaving study early. 
Global state: (CGI). 
Mental state: (BPRS*, needing additional benzodiazepines, MADRS, PANSS). 
Death.** 
Adverse effects: (AMDP, Barnes Akathisia Scale, requiring benztropine, SAS). 
Other adverse events: (COSTART list, weight change).

Unable to use - 
Hospital status: (no data). 
Laboratory tests & physiological measures: (no data). 
Weight loss: (undefined subgroup reported from 3 year extension phase).

Notes

* BPRS (scored 0-6) extracted from PANSS - no reference given for validity of procedure.

* A priori efficacy response was 40% improvement in BPRS score and three weeks in study.

**Deaths reported during the study or within 30 days of discontinuation.

Risk of bias

Bias

Authors' judgement

Support for judgement

Allocation concealment
(selection bias)

Low risk

A - Adequate

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

90

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Tollefson 1999(HGDY) 

Methods

Participants

Allocation: randomly assigned - no further details. 
Blindness: double. 
Duration: 3-5 days (preceeded by 2-12 days clozapine discontinuation). 
Design: multicentre, 11 sites in USA.

Diagnosis: schizophrenia (DSM-IV). 
History: informed consent obtained. 
N=106. 
Age: mean 38.8 years. 
Sex: M 75, F 31. 
Setting: inpatients and outpatients. 
Inclusion criteria: received clozapine maximum dose 900mg/day for minimum of 4 weeks prior to
study entrance. 
Excluded: substance use or substance dependence, risk of suicide, unstable medical condition or pre-
viously treated with olanzapine.

Interventions

Outcomes

Notes

Risk of bias

Bias

1. Olanzapine: dose range 10 mg/day. N=53. 
2. Placebo. N=53.

Leaving the study early. 
Relapse. 
Global state: (CGI). 
Mental state: (PANSS, MADRS, MMSE).

Authors' judgement

Support for judgement

Allocation concealment
(selection bias)

Unclear risk

B - Unclear

Tran 1997 (HGBG) 

Methods

Participants

Allocation: randomised, computer-generated, blocks, concealed from investigators. 
Blindness: double, medication kits issued. 
Duration: 28 weeks (preceeded by 2-9 day washout). 
Investigators: trained on PANSS. 
Design: multicentre, 9 countries.

Diagnosis: schizophrenia, schizophreniform disorder or schizoaffective disorder (DSM-IV). 
History: informed consent obtained. 
N=339. 
Age: range 16-65 years. 
Sex: M 220, F 119. 
Setting: inpatients or outpatients. 
Inclusion criteria: not reported. 
Excluded: "treatment resistant".

Interventions

1. Olanzapine: dose range 10-20 mg/day, mean modal dose 17.2, +/- 3.6 mg/day. N=172. 
2. Risperidone: dose 4-12 mg/day, mean modal dose 7.2 +/-2.7 mg/day. N=167.

Benzodiazepines, chloral hydrate, benztropine mesylate, biperiden as required.

Outcomes

Leaving study early. 

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

91

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Tran 1997 (HGBG)  (Continued)

Cochrane Database of Systematic Reviews

Global state: (CGI). 
Mental state: (BPRS*, PANSS, SANS). 
Adverse effects: (AIMS, Barnes Akathisia Scale, requiring benztropine or biperiden, SAS). 
Other adverse effects: (AMDP, COSTART list, neutrophil counts, prolactin, weight change). 
Hospital status. 
Quality of life: (QOL).

Unable to use - 
Laboratory tests & physiological measures: (no data). 
Economic burden: (no SD).

* BPRS (scored 0-6) extracted from PANSS - no reference given for validity of procedure. 
PANSS response rates reported >/= 20%,>/= 30%,>/= 40%>/= 50%.

Authors' judgement

Support for judgement

Notes

Risk of bias

Bias

Allocation concealment
(selection bias)

Low risk

A - Adequate

Wang 2002 

Methods

Participants

Interventions

Outcomes

Notes

Risk of bias

Bias

Allocation: randomised - no further details. 
Blindness: double. 
Duration: 8 weeks. 
Design: parallel groups.

Diagnosis: schizophrenia. 
History: not reported. 
N=63. 
Age: 18-55. 
Sex: male and female. 
Setting:hospital and community. 
Inclusion criteria: not reported.

1. Olanzapine: dose 5-20 mg/day. N=30. 
2. Clozapine: dose: 25-400 mg/day. N=33.

Leaving the study early. 
Mental state: BPRS.

Adverse events.

Authors' judgement

Support for judgement

Allocation concealment
(selection bias)

Unclear risk

B - Unclear

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

92

 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Wang 2003 

Methods

Participants

Interventions

Outcomes

Notes

Risk of bias

Bias

Allocation: randomised - no further details. 
Blindness: double. 
Duration: 6 weeks. 
Design: parallel groups.

Diagnosis: schizophrenia (CLMD-3). 
History: not reported. 
N=122. 
Age: 18-60. 
Sex: male and female. 
Setting: hospitalised. 
Inclusion criteria: not reported.

1.Olanzapine: dose 5-20 mg/day. N=61. 
2. Clozapine: dose 50-450 mg/day. N=61.

Leaving the study early. 
Mental state: PANSS. 
Adverse events.

Authors' judgement

Support for judgement

Allocation concealment
(selection bias)

Unclear risk

B - Unclear

Diagnostic tool
DSM III-R and DSM-IV - Diagnostic Statistical Manual version 3 Revised and version 4.
ICD 10 - The International Statistical Classification of Diseases and Related Health Problems.
BMI - Body Mass Index.
Rating Scales:
Cognitive function -
GCIS - General Cognitive Index Score.
Behaviour -
YBOCS - Yale Brown Obsessive Compulsive Scale
Global rating scales:
CGI - Clinical Global Impressions.
CGI-S - Clinical Global Impression-Severity.
CGI-I - Clinical Global Impression-Improvement.
PGI - Patient Global Impression.
Mental state:
BPRS - Brief Psychiatric Rating Scale.
HAM-S -Hamilton Anxiety Scale.
MADRS - Montgomery-Asberg Depression Rating Scale.
MMSE - Wiing Mini Mental State Examination.
PANSS - Positive and Negative Syndrome Scale.
SANS - Scale for the Assessment of Negative Symptoms.
Side effects:
ADR - Adverse Drug Reaction.
AIMS - Abnormal Involuntary Movement Scale.
AMDP-5 - Association for Methodology and Documentation in Psychiatry adverse event questionnaire.
BAS - Barnes Akathisia Scale.
BMI - Body mass index.
COSTART - Coding Symbols and Thesaurs for Adverse Reaction Terms.
DIEPSS - Drug-Induced Extrapyramidal Symptoms Scale.

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

93

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

ESRS - Extrapyramidal Syndrome Rating Scale.
HAS - Hillside Akathisia Scale.
SAS - Simpson-Angus Index - for neurological side effects.
UKU - Udvalg for kliniske ndersogelser Side Effect Rating Scale -side effect rating scale.
Quality of Life:
QoL - Quality of Life Scale.
Van Putten Scale.
Drug Attitude Inventory.
Leeds Sleep Evaluation Questionaire.
MLDL- Munich Life Dimension List
SWN -Subjective Well-being List

Characteristics of excluded studies [ordered by study ID]

Study

Reason for exclusion

Addington 1998

Allocation: not randomised.

Allison 1998

Allocation: not randomised, meta-analysis.

Apicella 2001

Allocation: not described.

Apiquian 2003

Allocation: not randomised.

Aquila 2000 (HGEC)

Allocation: randomised. 
Participants: people with schizophrenia. 
Interventions: olanzapine versus 'comparator antipsychotic' versus risperidone. 
Outcomes: no usable data.

Arango 2001

Awad 2002b

Baker 2003

Allocation: randomised. 
Participants: people with schizophrenia. 
Intervention: olanzapine versus haloperidol. 
Outcomes: no usable data.

Allocation: randomised. 
Participants: people with schizophrenia. 
Intervention: participants switiched to ziprasidone.

Allocation: randomised. 
Participants: people with schizophrenia. 
Intervention: olanzapine dosage study.

Beasley 1996c

Allocation: not randomised, meta-analysis.

Beasley 2003 (HGGI)

Allocation: randomised. 
Participants: people with schizophrenia. 
Intervention: olanzapine versus clozapine. 
Outcomes: no usable data.

Beuzen 1996 (HGCE)

Allocation: randomised. 
Participants: healthy elderly volunteers.

Birkett 1994

Breier 2003

Allocation: not randomised.

Allocation: randomised. 
Participants: people with schizophrenia. 
Interventions: olanzapine versus risperidone versus haloperidol. 
Outcomes: no usable data.

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

94

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study

Britto 2002

Buchanan 2003

Reason for exclusion

Allocation: randomised. 
Participants: people with schizophrenia. 
Intervention: olanzapine versus ziprasadone. 
Outcomes: no usable data.

Allocation: unclear. 
Participants: people with schizophrenia. 
Intervention: olanzapine versus haloperidol. 
Outcomes: no usable data.

Burgoyne 1996

Allocation: not described.

Castilla 2002

Allocation: randomised. 
Participants: children with psychosis.

Clouth 1999

Allocation: not randomised, economic drug analysis.

Corya 2002 (HGGA)

Allocation: randomised. 
Participants: major depression with psychosis.

Cutler 2002

Allocation: randomised. 
Participants: people with schizophrenia. 
Intervention: olanzapine versus ziprasidone. 
Outcomes: no usable data.

Dalheim 1997

Allocation: randomised crossover study.

Davis 1998

Allocation: not randomised, meta-analysis.

Devanand 1998

Docherty 2002

Dolnak 2000

Allocation: randomised. 
Participants: people with dementia.

Allocation: randomised. 
Participants: people with schizophrenia. 
Intervention: olanzapine versus risperidone. 
Outcomes: no usable data.

Allocation: randomised. 
Participants: people with schizophrenia. 
Intervention: olanzapine versus haloperidol. 
Outcomes: no usable data.

Dossenbach 1997

Allocation: not randomised.

Finzen 2002

Allocation: not randomised.

Fleming 1999

Gallinat 2001

Allocation: unclear. 
Participants: people with schizophrenia. 
Interventions: olanzapine versus placebo. 
Outcomes: no usable data.

Allocation: double blind. 
Participants: people with schizophrenia and healthy volunteers. 
Interventions: olanzapine or clozapine (schizophrenia group) versus healthy volunteers. 
Outcomes: data for treatment group (olanzapine or clozapine) not differentiated.

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

95

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study

Reason for exclusion

Gothelf 2003

Allocation: not randomised.

Hrdlicka 2001

Allocation: not randomised, retrospective analysis of patients records.

Irwin 2003

Jarboe 2001

Javitt 2001

Jerrell 2002

Allocation: randomised. 
Participants: people with schizophrenia. 
Interventions: olanzapine versus risperidone. 
Outcomes: no usable data.

Allocation: not randomised.

Allocation: randomised. 
Participants: people with schizophrenia. 
Intervention: current antipsychotic medication and glycine versus current antipsychotic medica-
tion and placebo.

Allocation: randomised. 
Participants: people with schizophrenia. 
Interventions: olanzapine versus risperisone versus haloperidol. 
Outcomes: no usable data.

Kalali 2000

Allocation: not randomised.

Kinon (HGFW)

Kinon 2003

Knegtering 2000

Kolff 2000

Allocation: randomised. 
Participants: people with schizophrenia. 
Interventions: olanzapine switching study.

Allocation: randomised. 
Participants: people with schizophrenia. 
Interventions: current therapy or risperidone vesus olanzapine.

Allocation: randomised. 
Participants: people with schizophrenia. 
Interventions: olanzapine versus risperidone. 
Outcomes: no usable data.

Allocation: randomised. 
Participants: people with schizophrenia. 
Interventions: olanzapine versus risperidone. 
Outcomes: no usable data.

Kucerova 2002

Allocation: not randomised, case reports.

Lahti 1999a

Lahti 1999b

Allocation: not randomised.

Allocation: not randomised.

Lilly (HGBM) 1999

Allocation: not randomised, open-label, single-arm study of olanzapine.

Lilly (HGCL) 1999

Allocation: not randomised, open-label, single-arm study of olanzapine.

Lilly (HGCV) 1999

Allocation: not randomised, open-label, single-arm study of olanzapine.

Lilly (HGDU) 1999

Allocation: not randomised, open-label, single-arm study of olanzapine.

Lilly (HGDZ) 1999

Allocation: not randomised, open-label, single-arm study of olanzapine.

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

96

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study

Reason for exclusion

Lilly (HGEP) 1999

Allocation: not randomised, open-label, single-arm study of olanzapine.

Lilly (HGFM) 1999

Allocation: not randomised, open-label, single-arm study of olanzapine.

Lindenmayer 1998

Allocation: not randomised, review.

Loza 2001

Mahmoud 1999

Marder 1998

Mauri 2002

Allocation: randomised. 
Participants: people with schizophrenia. 
Interventions: several typical antipsychotics versus several atypical antipsychotics. 
Outcomes: no usable data, full publication pending in Psychiatricia, ISSN 1643/0956.

Allocation: randomised. 
Participants: not described.

Allocation: not randomised, case series.

Allocation: randomised. 
Participants: people with schizophrenia. 
Interventions: olanzapine versus quetiapine. 
Outcomes: no usable data.

McElroy 1998

Allocation: not randomised, review.

McGurk 1998

Meltzer 2003

Mintzer 1998

Mitchell 2003

Allocation: not described.

Allocation: not randomised.

Allocation: not randomised, review.

Allocation: randomised. 
Participants: people with schizophrenia. 
Interventions: olanzapine dosage study, no comparator drug.

Mosolov 1998

Allocation: not randomised, review.

Mulqueen 2000

Allocation: not described.

Naber 1997

Allocation: not randomised.

Narendran 2003

Allocation: not randomised.

Oliemeulen 2000

Ortega-Solo (HGBS)

Parellada 1999

Allocation: randomised. 
Participants: people with schizophrenia. 
Interventions: olanzapine versus clozapine. 
Outcomes: no usable data.

Allocation: randomised. 
Participants: people with schizophrenia. 
Interventions: olanzapine versus risperidone. 
Outcomes: no usable data.

Allocation: randomised. 
Participants: people with schizophrenia. 
Interventions: olanzapine versus haloperidol. 
Outcomes: no usable data.

Perro 1999

Allocation: randomised. 

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

97

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study

Reason for exclusion

Participants: people with schizophrenia. 
Interventions: olanzapine versus risperidone versus zotepin versus sertindole. 
Outcomes: no usable data.

Pivac 2002

Allocation: not randomised.

Ratakonda 1998

Allocation: not randomised.

Reus 1997

Allocation: not randomised, review.

Sacchetti 2003

Allocation: randomised. 
Participants: people with schizophrenia. 
Interventions: olanzapine versus risperidone versus quetiapine. 
Outcomes: no data available.

Sacristan (HGGS)

Allocation: not randomised.

Sangar 1998 (HGEH)

Allocation: unclear. 
Participants: those with rapid-cycling bipolar disorder.

Sharma 2003

Allocation: unclear. 
Participants: people with schizophrenia. 
Interventions: olanzapine versus haloperidol. 
Outcomes: no data available.

Sheitman 1997

Allocation: not randomised, case series.

Sheitman 2000

Sikich 2004

Smelson 2003

Smith 1998

Smith 2001

Allocation: randomised. 
Participants: people with schizophrenia. 
Interventions: olanzapine versus risperidone. 
Outcomes: no usable data.

Allocation: randomised. 
Participants: people with schizophrenia (8-19 years).

Allocation: randomised. 
Participants: people with schizophrenia and cocaine addiction. 
Interventions: olanzapine versus haloperidol. 
Outcomes: no usable data.

Allocation: not randomised.

Allocation: randomised. 
Participants: people with schizophrenia. 
Interventions: olanzapine versus haloperidol. 
Outcomes: no usable data.

Soutullo 1998

Allocation: not randomised, case series.

Stephenson 2000

Allocation: not randomised, review article.

Szafranski 1999

Allocation: randomised. 
Participants: people with schizophrenia. 
Interventions: olanzapine versus perphenazine. 
Outcomes: no usable data.

Tamura 1996 (F1D-JE)

Allocation: not randomised, testing a questionnaire.

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

98

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study

Tang 2003

Reason for exclusion

Allocation: randomised. 
Participants: people with schizophrenia. 
Intervention: olanzapine versus risperidone. 
Outcomes: no usable data.

Tohen 2000b (HGGW)

Allocation: randomised. 
Participants: not described.

Tran 1998 (HGEJ)

Allocation: not randomised, case series.

Trandafir 1998

Uzun 2002

Volavka 2002

Allocation: randomised. 
Participants: people with drug-induced psychosis.

Allocation: randomised. 
Participants: people with schizophrenia. 
Interventions: olanzapine versus ziprasidone. 
Outcomes: no usable data.

Allocation: randomised. 
Participants: people with schizophrenia. 
Interventions: olanzapine versus clozapine versus haloperidol versus risperidone. 
Outcomes: olanzapine arm added during study without equal randomisation.

Voruganti 2002

Allocation: naturalistic cohort study.

Woods 2002 (HGGF)

Allocation: randomised. 
Participants: people with suspected prodromal schizophrenia.

Woodward 2001

Allocation: not randomised.

Wright 2003 (HGAB)

Wudarsky 1999

Yagdiran 2000

Allocation: randomised. 
Participants: people with schizophrenia. 
Interventions: IM olanzapine, followed by oral olanzapine versus IM haloperidol followed by oral
haloperidol.

Allocation: double blind and open. 
Participants: childhood onset schizophrenia.

Allocation: randomised. 
Participants: people with schizophrenia. 
Interventions: olanzapine versus risperidone versus amisulpride, clozapine. 
Outcomes: no usable data.

Zhang 1999

Allocation: not randomised, open-label, single-arm study of olanzapine.

Ziherl (HGCZ) 1999

Allocation: not randomised, open-label, single-arm study of olanzapine.

Characteristics of ongoing studies [ordered by study ID]

Centorrino 2001 

Trial name or title

A double-blind, multi-center controlled study comparing the safety and efficacy of ziprasidone
and olanzapine in patients with schizophrenia or schizoaffective disorder needing inpatient care

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

99

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Centorrino 2001  (Continued)

Methods

Participants

People with schizophrenia.

Interventions

Olanzapine versus ziprasidone.

Outcomes

Starting date

Contact information

Notes

Hirsch 2000 

Trial name or title

Methods

Participants

Interventions

Outcomes

Starting date

Contact information

Notes

Krakowski 2001 

Trial name or title

Methods

Participants

Interventions

Outcomes

Not known.

Not known.

Ziprasidone in the treatment of chronic schizophrenia (maintenance) versus olanzap-
ine - efficacy and side effects

People with schizophrenia.

Olanzapine versus ziprasidone.

Not known.

Not known.

Clozapine and olanzapine in violent schizophrenics.

People with schizophrenia.

Olanzapine vs. Haloperidol vs. Clozapine.

Behaviour 
Mental State 
Cognitive function 
Clinical Global Impression

Starting date

Not known.

Contact information

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

100

 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Krakowski 2001  (Continued)

Notes

Cochrane Database of Systematic Reviews

Ramamurthy 2000a 

Trial name or title

Methods

Participants

Interventions

Outcomes

Starting date

Contact information

Notes

Reveley 2000 

Trial name or title

Methods

Participants

Interventions

Outcomes

Starting date

Contact information

Notes

Reynolds 2003 

Trial name or title

Methods

Participants

Interventions

A multi-centre, double blind, randomised comparative study of aripiprazole and olanzap-
ine in the treatment of patients with acute schizophrenia.

People with schizophrenia.

Aripiprazole vs. olanzapine.

Not known.

Not known.

Effectiveness trials of antipsychotic drugs.

People with schizophrenia.

Olanzapine versus risperidone.

Not known.

Not known.

Ziprasidone observational study of cardiac outcomes (zodiac) large simple trial: ratio-
nale and design.

People with schizophrenia.

Olanzapine versus ziprasidone.

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

101

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Not known.

Not known.

A six month international controlled trial of the therapeutic activity of amisulpride 200 to
800mg/day verses olanzapine 5 to 20mg/day in patiients with schizophrenic disorders.

People with schizophrenia.

Olanzapine versus amisulpride.

Mental state.

Not known.

Quality of life - Pfizer trial

People with schizophrenia.

Olanzapine versus ziprasidone.

Not known.

Not known.

Reynolds 2003  (Continued)

Outcomes

Starting date

Contact information

Notes

Singh 2000b 

Trial name or title

Methods

Participants

Interventions

Outcomes

Starting date

Contact information

Notes

Turner 2002 

Trial name or title

Methods

Participants

Interventions

Outcomes

Starting date

Contact information

Notes

D A T A   A N D   A N A L Y S E S

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

102

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Comparison 1.   OLANZAPINE vs PLACEBO

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

2

2

1

2

1

1

2

2

1

1

1

1

1 Global effect: 1. No important clinical
response - by 6 weeks*

1.1 any dose of olanzapine

1.2 15mg olanzapine

1.3 10mg olanzapine

1.4 5mg olanzapine

1.5 1mg olanzapine

2 Global effect: 2. CGI endpoint score -
by 6 weeks (high score=poor)*

3 Global effect: 3. Needing additional
benzodiazepines - by six weeks*

4 Mental state: 1. BPRS total - by 6 weeks
(endpoint, high score=poor)*

5 Mental state: 2. BPRS total - by 6 weeks
(endpoint, high score=poor, skewed da-
ta)*

6 Mental state: 3. PANSS total - by 6
weeks (endpoint, high score=poor)*

7 Mental state: 4. Negative symptoms
- by 6 months (SANS, endpoint, high
score=poor)*

8 Mental state: 5. Negative symptoms
- by 6 weeks (PANSS, endpoint, high
score=poor)*

9 Mental state: 6. Negative symptoms -
by 6 weeks (skewed data)*

9.1 as measured by BPRS (endpoint,
high=poor)

9.2 as measured by SANS (endpoint,
high=poor)

10 Mental state: 7. Positive symptoms -
by 6 weeks (endpoint, high score=poor,
skewed data)*

418

137

232

133

102

230

418

98

98

94

98

Risk Ratio (M-H, Random,
95% CI)

Subtotals only

Risk Ratio (M-H, Random,
95% CI)

0.88 [0.80, 0.98]

Risk Ratio (M-H, Random,
95% CI)

0.74 [0.56, 0.97]

Risk Ratio (M-H, Random,
95% CI)

0.82 [0.71, 0.95]

Risk Ratio (M-H, Random,
95% CI)

0.94 [0.74, 1.18]

Risk Ratio (M-H, Random,
95% CI)

0.98 [0.87, 1.11]

Mean Difference (IV, Ran-
dom, 95% CI)

-0.53 [-0.89, -0.17]

Risk Ratio (M-H, Random,
95% CI)

0.96 [0.86, 1.08]

Mean Difference (IV, Ran-
dom, 95% CI)

-6.86 [-12.34,
-1.38]

Other data

No numeric data

Mean Difference (IV, Ran-
dom, 95% CI)

-12.43 [-22.54,
-2.32]

Mean Difference (IV, Ran-
dom, 95% CI)

-0.5 [-2.87, 1.87]

Mean Difference (IV, Ran-
dom, 95% CI)

-1.39 [-4.42, 1.64]

Other data

No numeric data

Other data

No numeric data

Other data

No numeric data

Other data

No numeric data

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

103

 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

10.1 BPRS

10.2 PANSS

Other data

Other data

11 Mental state: 8. Positive symptoms
- by 6 weeks (PANSS endpoint, high
score=poor)*

1

98

Mean Difference (IV, Ran-
dom, 95% CI)

No numeric data

No numeric data

-4.0 [-7.10, -0.90]

12 Leaving the study early: 1. Any reason

4

12.1 by 6 weeks

12.2 by 6 months

12.3 not eligible, or eligibile and unwill-
ing to continue on study medication be-
yond 6 weeks

12.4 by 52 weeks

13 Leaving the study early: 2. Due to lack
of efficacy

13.1 by 6 weeks

13.2 by 6 months

13.3 by 52 weeks

14 Adverse events: 1. Anticholinergic ef-
fects - specific symptoms by 6 weeks *

14.1 dry mouth

14.2 dizziness

15 Adverse events: 2a. Extrapyramidal -
needing anticholinergic medication by 6
weeks*

16 Adverse events: 2b. Extrapyramidal -
specific symptoms by 6 weeks*

16.1 akathisia

3

1

1

1

4

3

1

1

1

1

1

2

1

1

598

175

266

266

598

175

58

266

266

418

266

Risk Ratio (M-H, Random,
95% CI)

Subtotals only

Risk Ratio (M-H, Random,
95% CI)

0.86 [0.75, 0.98]

Risk Ratio (M-H, Random,
95% CI)

1.34 [0.87, 2.07]

Risk Ratio (M-H, Random,
95% CI)

0.96 [0.83, 1.10]

Risk Ratio (M-H, Random,
95% CI)

0.94 [0.89, 1.00]

Risk Ratio (M-H, Random,
95% CI)

Subtotals only

Risk Ratio (M-H, Random,
95% CI)

0.61 [0.43, 0.89]

Risk Ratio (M-H, Random,
95% CI)

0.65 [0.25, 1.70]

Risk Ratio (M-H, Random,
95% CI)

0.41 [0.20, 0.87]

Risk Ratio (M-H, Random,
95% CI)

Subtotals only

Risk Ratio (M-H, Random,
95% CI)

1.60 [0.47, 5.41]

Risk Ratio (M-H, Random,
95% CI)

3.95 [0.96, 16.31]

Risk Ratio (M-H, Random,
95% CI)

0.90 [0.29, 2.79]

Risk Ratio (M-H, Random,
95% CI)

Subtotals only

Risk Ratio (M-H, Random,
95% CI)

4.12 [0.55, 31.11]

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

104

 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

16.2 tremor

1

266

17 Adverse events: 2c. Extrapyramidal -
specific symptoms - by 6 weeks (various
scales, skewed data)*

17.1 akathisia - (Barnes Akathisia Scale,
low score=good)

17.2 dyskinesia (AIMS, endpoint,
high=poor)

17.3 parkinsonism (Simpson-Angus
Scale, endpoint, low score=good)

18 Adverse events: 3. Gastrointesti-
nal - sickness - nausea/vomiting - by 6
weeks*

19 Adverse events: 4. Other problems -
by 6 weeks*

19.1 agitation

19.2 hostility

19.3 withdrawl

20 Adverse events: 5. Sleep problems -
by 6 weeks*

21 Adverse events: 6. Weight*

21.1 by 6-8 weeks

21.2 by 3 -12 months

22 Quality of Life: 1. QLS total - by six
months (endpoint, high score=good)*

1

2

2

2

1

2

3

2

1

1

266

418

418

266

418

227

104

80

Risk Ratio (M-H, Random,
95% CI)

2.40 [0.30, 19.19]

Other data

No numeric data

Other data

No numeric data

Other data

No numeric data

Other data

No numeric data

Risk Ratio (M-H, Random,
95% CI)

0.40 [0.14, 1.15]

Risk Ratio (M-H, Random,
95% CI)

Subtotals only

Risk Ratio (M-H, Random,
95% CI)

1.20 [0.70, 2.07]

Risk Ratio (M-H, Random,
95% CI)

0.97 [0.57, 1.63]

Risk Ratio (M-H, Random,
95% CI)

0.86 [0.44, 1.69]

Risk Ratio (M-H, Random,
95% CI)

0.93 [0.59, 1.45]

Mean Difference (IV, Ran-
dom, 95% CI)

Subtotals only

Mean Difference (IV, Ran-
dom, 95% CI)

3.58 [-1.18, 8.34]

Mean Difference (IV, Ran-
dom, 95% CI)

-0.52 [-6.14, 5.10]

Mean Difference (IV, Ran-
dom, 95% CI)

8.20 [-2.47, 18.87]

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

105

 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

1.1.1 any dose of olanzapine

Beasley 1996a (HGAD)

Beasley 1996b (HGAP)

Subtotal (95% CI)

Analysis 1.1.   Comparison 1 OLANZAPINE vs PLACEBO, Outcome
1 Global effect: 1. No important clinical response - by 6 weeks*.

Treatment

n/N

Control

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

116/198

85/102

300

48/68

46/50

118

27.62%

72.38%

100%

0.83[0.68,1.01]

0.91[0.8,1.02]

0.88[0.8,0.98]

Total events: 201 (Treatment), 94 (Control)

Heterogeneity: Tau2=0; Chi2=0.75, df=1(P=0.39); I2=0%

Test for overall effect: Z=2.38(P=0.02)

1.1.2 15mg olanzapine

Beasley 1996a (HGAD)

Subtotal (95% CI)

36/69

69

48/68

68

Total events: 36 (Treatment), 48 (Control)

Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%

Test for overall effect: Z=2.17(P=0.03)

1.1.3 10mg olanzapine

Beasley 1996a (HGAD)

Beasley 1996b (HGAP)

Subtotal (95% CI)

37/64

38/50

114

48/68

46/50

118

Total events: 75 (Treatment), 94 (Control)

Heterogeneity: Tau2=0; Chi2=0, df=1(P=0.95); I2=0%

Test for overall effect: Z=2.61(P=0.01)

100%

100%

0.74[0.56,0.97]

0.74[0.56,0.97]

31.48%

68.52%

100%

0.82[0.63,1.06]

0.83[0.69,0.98]

0.82[0.71,0.95]

1.1.4 5mg olanzapine

Beasley 1996a (HGAD)

Subtotal (95% CI)

Total events: 43 (Treatment), 48 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=0.55(P=0.58)

1.1.5 1mg olanzapine

Beasley 1996b (HGAP)

Subtotal (95% CI)

Total events: 47 (Treatment), 46 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=0.29(P=0.77)

43/65

65

48/68

68

100%

100%

0.94[0.74,1.18]

0.94[0.74,1.18]

47/52

52

46/50

50

100%

100%

0.98[0.87,1.11]

0.98[0.87,1.11]

*>50% loss of data

0.5

0.7

1

1.5

2

PRONE TO BIAS

Analysis 1.2.   Comparison 1 OLANZAPINE vs PLACEBO, Outcome 2
Global effect: 2. CGI endpoint score - by 6 weeks (high score=poor)*.

Study or subgroup

Treatment

Control

Beasley 1996a (HGAD)

Beasley 1996b (HGAP)

Total ***

N

Mean(SD)

N

Mean(SD)

66

49

115

4.1 (1.4)

4.3 (1.3)

66

49

115

4.6 (1.5)

4.9 (1.3)

Mean Difference

Random, 95% CI

Weight

Mean Difference

52.69%

47.31%

Random, 95% CI

-0.49[-0.98,0]

-0.57[-1.09,-0.05]

100%

-0.53[-0.89,-0.17]

Favours treatment

-1

-0.5

0

0.5

1

Favours control

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

106

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Treatment

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

Heterogeneity: Tau2=0; Chi2=0.05, df=1(P=0.83); I2=0%

Test for overall effect: Z=2.89(P=0)

Favours treatment

-1

-0.5

0

0.5

1

Favours control

Study or subgroup

Beasley 1996a (HGAD)

Beasley 1996b (HGAP)

Total (95% CI)

Analysis 1.3.   Comparison 1 OLANZAPINE vs PLACEBO, Outcome 3
Global effect: 3. Needing additional benzodiazepines - by six weeks*.

Treatment

n/N

Control

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

140/198

84/102

300

52/68

41/50

118

49.52%

50.48%

0.92[0.79,1.08]

1[0.86,1.18]

100%

0.96[0.86,1.08]

Total events: 224 (Treatment), 93 (Control)

Heterogeneity: Tau2=0; Chi2=0.53, df=1(P=0.46); I2=0%

Test for overall effect: Z=0.64(P=0.52)

*>50% loss of data

0.5

0.7

1

1.5

2

PRONE TO BIAS

Analysis 1.4.   Comparison 1 OLANZAPINE vs PLACEBO, Outcome 4
Mental state: 1. BPRS total - by 6 weeks (endpoint, high score=poor)*.

Study or subgroup

Treatment

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Beasley 1996b (HGAP)

49

29.7 (13.1)

49

36.6 (14.5)

Weight

Mean Difference

Random, 95% CI

100%

-6.86[-12.34,-1.38]

Total ***

49

49

100%

-6.86[-12.34,-1.38]

Heterogeneity: Not applicable

Test for overall effect: Z=2.45(P=0.01)

>50% loss of people

-100

-50

0

50

100

Last observ'n used

Analysis 1.5.   Comparison 1 OLANZAPINE vs PLACEBO, Outcome 5 Mental
state: 2. BPRS total - by 6 weeks (endpoint, high score=poor, skewed data)*.

Study

Intervention

Mean

SD

N

Mental state: 2. BPRS total - by 6 weeks (endpoint, high score=poor, skewed data)*

Beasley 1996a (HGAD)

Beasley 1996a (HGAD)

Olanzapine

Placebo

27.43

36.00

17.28

20.50

65

62

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

107

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.6.   Comparison 1 OLANZAPINE vs PLACEBO, Outcome 6
Mental state: 3. PANSS total - by 6 weeks (endpoint, high score=poor)*.

Study or subgroup

Treatment

Control

Mean(SD)

N

Mean(SD)

86 (24.1)

49

98.4 (26.9)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

100%

-12.43[-22.54,-2.32]

Beasley 1996b (HGAP)

Total ***

Heterogeneity: Not applicable

Test for overall effect: Z=2.41(P=0.02)

N

49

49

49

100%

-12.43[-22.54,-2.32]

>50% loss of people

-100

-50

0

50

100

Last observ'n used

Analysis 1.7.   Comparison 1 OLANZAPINE vs PLACEBO, Outcome 7 Mental state:
4. Negative symptoms - by 6 months (SANS, endpoint, high score=poor)*.

Study or subgroup

Treatment

Control

Lecrubier 1999

Total ***

Heterogeneity: Not applicable

Test for overall effect: Z=0.41(P=0.68)

Mean(SD)

12.1 (5.2)

N

64

64

Mean(SD)

12.6 (5.6)

N

30

30

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

100%

-0.5[-2.87,1.87]

100%

-0.5[-2.87,1.87]

favours intervention

-10

-5

0

5

10

favours control

Analysis 1.8.   Comparison 1 OLANZAPINE vs PLACEBO, Outcome 8 Mental
state: 5. Negative symptoms - by 6 weeks (PANSS, endpoint, high score=poor)*.

Study or subgroup

Treatment

Control

Beasley 1996b (HGAP)

Total ***

Heterogeneity: Not applicable

Test for overall effect: Z=0.9(P=0.37)

Mean(SD)

23.6 (7)

N

49

49

Mean(SD)

25 (8.3)

N

49

49

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

100%

-1.39[-4.42,1.64]

100%

-1.39[-4.42,1.64]

>50% loss of people

-10

-5

0

5

10

Last observ'n used

Analysis 1.9.   Comparison 1 OLANZAPINE vs PLACEBO, Outcome 9
Mental state: 6. Negative symptoms - by 6 weeks (skewed data)*.

Study

Intervention

Mean

SD

N

Mental state: 6. Negative symptoms - by 6 weeks (skewed data)*

Beasley 1996a (HGAD)

Beasley 1996a (HGAD)

Beasley 1996b (HGAP)

Beasley 1996b (HGAP)

Beasley 1996a (HGAD)

Beasley 1996a (HGAD)

Olanzapine

Placebo

Olanzapine

Placebo

Olanzapine

Placebo

as measured by BPRS (endpoint, high=poor)

4.42

6.55

5.71

6.37

3.56

4.98

3.06

3.88

as measured by SANS (endpoint, high=poor)

9.32

12.40

5.39

6.95

65

65

49

49

65

65

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

108

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.10.   Comparison 1 OLANZAPINE vs PLACEBO, Outcome 10 Mental state:
7. Positive symptoms - by 6 weeks (endpoint, high score=poor, skewed data)*.

Mental state: 7. Positive symptoms - by 6 weeks (endpoint, high score=poor, skewed data)*

Study

Intervention

Beasley 1996a (HGAD)

Beasley 1996a (HGAD)

Beasley 1996b (HGAP)

Beasley 1996b (HGAP)

Tollefson 1999(HGDY)

Tollefson 1999(HGDY)

Olanzapine

Placebo

Olanzapine

Placebo

Olanzapine

Placebo

Mean

BPRS

PANSS

9.12

11.29

9.96

12.29

-0.06

0.88

6.21

6.90

5.17

4.96

3.38

5.52

SD

N

65

63

49

49

53

53

Analysis 1.11.   Comparison 1 OLANZAPINE vs PLACEBO, Outcome 11 Mental
state: 8. Positive symptoms - by 6 weeks (PANSS endpoint, high score=poor)*.

Study or subgroup

Treatment

Control

Beasley 1996b (HGAP)

Total ***

Heterogeneity: Not applicable

Test for overall effect: Z=2.53(P=0.01)

Mean(SD)

20.5 (7.6)

N

49

49

N

49

49

Mean(SD)

24.5 (8)

Mean Difference

Random, 95% CI

Weight

Mean Difference

100%

100%

Random, 95% CI

-4[-7.1,-0.9]

-4[-7.1,-0.9]

Favours treatment

-10

-5

0

5

10

Favours control

Analysis 1.12.   Comparison 1 OLANZAPINE vs PLACEBO, Outcome 12 Leaving the study early: 1. Any reason.

Study or subgroup

1.12.1 by 6 weeks

Beasley 1996a (HGAD)

Beasley 1996b (HGAP)

Corrigan 2004

Subtotal (95% CI)

Treatment

n/N

Control

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

111/198

71/102

24/93

393

46/68

40/50

23/87

205

42.39%

50.2%

7.41%

100%

0.83[0.67,1.02]

0.87[0.72,1.05]

0.98[0.6,1.6]

0.86[0.75,0.98]

Total events: 206 (Treatment), 109 (Control)

Heterogeneity: Tau2=0; Chi2=0.41, df=2(P=0.81); I2=0%

Test for overall effect: Z=2.22(P=0.03)

1.12.2 by 6 months

Lecrubier 1999

Subtotal (95% CI)

Total events: 75 (Treatment), 14 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=1.32(P=0.19)

75/140

140

14/35

35

100%

100%

1.34[0.87,2.07]

1.34[0.87,2.07]

1.12.3 not eligible, or eligibile and unwilling to continue on study med-
ication beyond 6 weeks

Beasley 1996a (HGAD)

153/198

55/68

0.2

0.5

1

2

5

100%

0.96[0.83,1.1]

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

109

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Treatment

n/N

Control

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Subtotal (95% CI)

198

68

100%

0.96[0.83,1.1]

Total events: 153 (Treatment), 55 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=0.65(P=0.52)

1.12.4 by 52 weeks

Beasley 1996a (HGAD)

Subtotal (95% CI)

181/198

198

66/68

68

Total events: 181 (Treatment), 66 (Control)

Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%

Test for overall effect: Z=1.98(P=0.05)

100%

100%

0.94[0.89,1]

0.94[0.89,1]

0.2

0.5

1

2

5

Analysis 1.13.   Comparison 1 OLANZAPINE vs PLACEBO,
Outcome 13 Leaving the study early: 2. Due to lack of efficacy.

Treatment

n/N

Control

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

32/68

30/50

16/87

205

5/35

35

7/13

13

44.94%

44.81%

10.26%

100%

0.69[0.5,0.95]

0.69[0.5,0.95]

0.23[0.08,0.67]

0.61[0.43,0.89]

100%

100%

0.65[0.25,1.7]

0.65[0.25,1.7]

100%

100%

0.41[0.2,0.87]

0.41[0.2,0.87]

Study or subgroup

1.13.1 by 6 weeks

Beasley 1996a (HGAD)

Beasley 1996b (HGAP)

Corrigan 2004

Subtotal (95% CI)

64/198

42/102

4/93

393

Total events: 110 (Treatment), 78 (Control)

Heterogeneity: Tau2=0.05; Chi2=4.11, df=2(P=0.13); I2=51.36%

Test for overall effect: Z=2.6(P=0.01)

1.13.2 by 6 months

Lecrubier 1999

Subtotal (95% CI)

Total events: 13 (Treatment), 5 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=0.88(P=0.38)

1.13.3 by 52 weeks

Beasley 1996a (HGAD)

Subtotal (95% CI)

13/140

140

10/45

45

Total events: 10 (Treatment), 7 (Control)

Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%

Test for overall effect: Z=2.33(P=0.02)

Favours treatment

0.1

0.2

0.5

1

2

5

10

Favours control

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

110

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.14.   Comparison 1 OLANZAPINE vs PLACEBO, Outcome 14
Adverse events: 1. Anticholinergic effects - specific symptoms by 6 weeks *.

Treatment

n/N

Control

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Study or subgroup

1.14.1 dry mouth

Beasley 1996a (HGAD)

Subtotal (95% CI)

Total events: 14 (Treatment), 3 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=0.76(P=0.45)

1.14.2 dizziness

Beasley 1996a (HGAD)

Subtotal (95% CI)

Total events: 23 (Treatment), 2 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=1.9(P=0.06)

14/198

198

23/198

198

3/68

68

2/68

68

100%

100%

1.6[0.47,5.41]

1.6[0.47,5.41]

100%

100%

3.95[0.96,16.31]

3.95[0.96,16.31]

Favours treatment

0.01

0.1

1

10

100

Favours control

Analysis 1.15.   Comparison 1 OLANZAPINE vs PLACEBO, Outcome 15 Adverse
events: 2a. Extrapyramidal - needing anticholinergic medication by 6 weeks*.

Treatment

n/N

Control

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

36/198

8/102

300

8/68

8/50

118

53.29%

46.71%

1.55[0.76,3.16]

0.49[0.2,1.23]

100%

0.9[0.29,2.79]

Study or subgroup

Beasley 1996a (HGAD)

Beasley 1996b (HGAP)

Total (95% CI)

Total events: 44 (Treatment), 16 (Control)

Heterogeneity: Tau2=0.49; Chi2=3.75, df=1(P=0.05); I2=73.36%

Test for overall effect: Z=0.18(P=0.86)

Favours Treatment

0.1

0.2

0.5

1

2

5

10

Favours Control

Study or subgroup

1.16.1 akathisia

Beasley 1996a (HGAD)

Subtotal (95% CI)

Total events: 12 (Treatment), 1 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=1.37(P=0.17)

1.16.2 tremor

Beasley 1996a (HGAD)

Subtotal (95% CI)

Analysis 1.16.   Comparison 1 OLANZAPINE vs PLACEBO, Outcome 16
Adverse events: 2b. Extrapyramidal - specific symptoms by 6 weeks*.

Treatment

n/N

Control

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

12/198

198

7/198

198

1/68

68

1/68

68

100%

100%

4.12[0.55,31.11]

4.12[0.55,31.11]

100%

100%

2.4[0.3,19.19]

2.4[0.3,19.19]

Favours treatment

0.01

0.1

1

10

100

Favours control

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

111

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Treatment

n/N

Control

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Total events: 7 (Treatment), 1 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=0.83(P=0.41)

Favours treatment

0.01

0.1

1

10

100

Favours control

Analysis 1.17.   Comparison 1 OLANZAPINE vs PLACEBO, Outcome 17 Adverse events:
2c. Extrapyramidal - specific symptoms - by 6 weeks (various scales, skewed data)*.

Adverse events: 2c. Extrapyramidal - specific symptoms - by 6 weeks (various scales, skewed data)*

Study

Intervention

Mean

SD

N

Beasley 1996a (HGAD)

Beasley 1996a (HGAD)

Beasley 1996a (HGAD)

Beasley 1996a (HGAD)

Beasley 1996a (HGAD)

Beasley 1996a (HGAD)

Olanzapine

Placebo

Olanzapine

Placebo

Olanzapine

Placebo

akathisia - (Barnes Akathisia Scale, low score=good)

0.42

0.47

0.66

0.87

dyskinesia (AIMS, endpoint, high=poor)

2.09

2.56

3.53

4.25

parkinsonism (Simpson-Angus Scale, endpoint, low score=good)

1.35

1.16

2.44

2.74

65

64

65

64

63

64

Analysis 1.18.   Comparison 1 OLANZAPINE vs PLACEBO, Outcome 18 Adverse
events: 3. Gastrointestinal - sickness - nausea/vomiting - by 6 weeks*.

Study or subgroup

Beasley 1996a (HGAD)

Total (95% CI)

Total events: 7 (Treatment), 6 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=1.7(P=0.09)

Treatment

n/N

Control

n/N

7/198

198

6/68

68

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

100%

0.4[0.14,1.15]

100%

0.4[0.14,1.15]

Favours treatment

0.01

0.1

1

10

100

Favours control

Study or subgroup

1.19.1 agitation

Beasley 1996a (HGAD)

Beasley 1996b (HGAP)

Subtotal (95% CI)

Analysis 1.19.   Comparison 1 OLANZAPINE vs PLACEBO,
Outcome 19 Adverse events: 4. Other problems - by 6 weeks*.

Treatment

n/N

Control

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

48/198

16/102

300

16/68

4/50

118

75.93%

24.07%

100%

1.03[0.63,1.69]

1.96[0.69,5.56]

1.2[0.7,2.07]

Total events: 64 (Treatment), 20 (Control)

Heterogeneity: Tau2=0.04; Chi2=1.22, df=1(P=0.27); I2=18.04%

Test for overall effect: Z=0.66(P=0.51)

Favours treatment

0.1

0.2

0.5

1

2

5

10

Favours Control

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

112

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Treatment

n/N

Control

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

1.19.2 hostility

Beasley 1996a (HGAD)

Beasley 1996b (HGAP)

Subtotal (95% CI)

28/198

14/102

300

10/68

7/50

118

Total events: 42 (Treatment), 17 (Control)

Heterogeneity: Tau2=0; Chi2=0, df=1(P=0.97); I2=0%

Test for overall effect: Z=0.12(P=0.91)

1.19.3 withdrawl

Beasley 1996a (HGAD)

Subtotal (95% CI)

25/198

198

10/68

68

Total events: 25 (Treatment), 10 (Control)

Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%

Test for overall effect: Z=0.44(P=0.66)

61.4%

38.6%

100%

0.96[0.49,1.87]

0.98[0.42,2.28]

0.97[0.57,1.63]

100%

100%

0.86[0.44,1.69]

0.86[0.44,1.69]

Favours treatment

0.1

0.2

0.5

1

2

5

10

Favours Control

Study or subgroup

Beasley 1996a (HGAD)

Beasley 1996b (HGAP)

Total (95% CI)

Analysis 1.20.   Comparison 1 OLANZAPINE vs PLACEBO,
Outcome 20 Adverse events: 5. Sleep problems - by 6 weeks*.

Treatment

n/N

Control

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

42/198

12/102

300

15/68

7/50

118

73.52%

26.48%

0.96[0.57,1.62]

0.84[0.35,2]

100%

0.93[0.59,1.45]

Total events: 54 (Treatment), 22 (Control)

Heterogeneity: Tau2=0; Chi2=0.07, df=1(P=0.79); I2=0%

Test for overall effect: Z=0.33(P=0.74)

Favours treatment

0.1

0.2

0.5

1

2

5

10

Favours control

Analysis 1.21.   Comparison 1 OLANZAPINE vs PLACEBO, Outcome 21 Adverse events: 6. Weight*.

Study or subgroup

Treatment

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

1.21.1 by 6-8 weeks

Beasley 1996a (HGAD)

Beasley 1996b (HGAP)

Subtotal ***

83.4 (20.8)

82.7 (17)

64

50

114

65

48

113

79.8 (15.2)

79 (19.7)

Heterogeneity: Tau2=0; Chi2=0, df=1(P=0.98); I2=0%

Test for overall effect: Z=1.47(P=0.14)

57.34%

42.66%

100%

3.53[-2.76,9.82]

3.65[-3.64,10.94]

3.58[-1.18,8.34]

1.21.2 by 3 -12 months

Lecrubier 1999

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=0.18(P=0.86)

72.9 (13.6)

70

70

73.4 (13.8)

34

34

100%

100%

-0.52[-6.14,5.1]

-0.52[-6.14,5.1]

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

113

Used LOCF

-10

-5

0

5

10

Prone to bias

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.22.   Comparison 1 OLANZAPINE vs PLACEBO, Outcome 22
Quality of Life: 1. QLS total - by six months (endpoint, high score=good)*.

Study or subgroup

Treatment

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Lecrubier 1999

53

53.3 (25.4)

27

45.1 (21.7)

Weight

Mean Difference

Random, 95% CI

100%

8.2[-2.47,18.87]

Total ***

53

27

100%

8.2[-2.47,18.87]

Heterogeneity: Not applicable

Test for overall effect: Z=1.51(P=0.13)

USED LOCF

-100

-50

0

50

100

Prone to bias

Comparison 2.   OLANZAPINE vs PLACEBO (3 to 5 days)

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

1 Global effect: 1. CGI severity of ill-
ness (very short term 3-5 days, change,
high=poor)

2 Global effect: 2. Relapse (very short
term 3-5 days)

3 Mental state: 1. PANSS total (very
short term 3 to 5 days, change, high
score=poor)

4 Mental state: 2. Negative symptoms
(very short term 3 to 5 days, PANSS, end-
point, high score=poor)

5 Mental state: 3. Positive symptoms (very
short term 3 to 5 days, PANSS 3-5 days)

6 Mental state: 4. Depression (very short
term 3 to 5 days, MADRS, change, high
score=poor)

7 Mental state: 5. Mental state (very short
term 3 to 5 days, MMSE, high score=poor)

8 Leaving the study early. Any reason - by
5 days

9 Adverse events: 1. Anticholinergic ef-
fects - headache (very short term 3 to 5
days,)*

10 Adverse events: 2. Gastrointestinal
(very short term 3 to 5 days,)*

1

1

1

1

1

1

1

1

1

1

106

106

106

106

106

106

106

106

106

Mean Difference (IV, Ran-
dom, 95% CI)

-0.23 [-0.52, 0.06]

Risk Ratio (M-H, Fixed,
95% CI)

0.13 [0.02, 0.96]

Mean Difference (IV, Ran-
dom, 95% CI)

-5.23 [-9.98,
-0.48]

Mean Difference (IV, Ran-
dom, 95% CI)

0.01 [-1.55, 1.57]

Mean Difference (IV, Ran-
dom, 95% CI)

-0.94 [-2.68, 0.80]

Mean Difference (IV, Ran-
dom, 95% CI)

-4.52 [-6.99,
-2.05]

Mean Difference (IV, Ran-
dom, 95% CI)

0.30 [-1.05, 1.65]

Risk Ratio (M-H, Random,
95% CI)

0.38 [0.11, 1.34]

Risk Ratio (M-H, Random,
95% CI)

3.0 [0.32, 27.93]

Risk Ratio (M-H, Random,
95% CI)

Subtotals only

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

114

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

10.1 diarrhoea

10.2 nausea

10.3 vomiting

10.4 nausea and vomiting

1

1

1

1

106

106

106

106

Risk Ratio (M-H, Random,
95% CI)

0.75 [0.18, 3.19]

Risk Ratio (M-H, Random,
95% CI)

0.33 [0.01, 8.00]

Risk Ratio (M-H, Random,
95% CI)

0.33 [0.04, 3.10]

Risk Ratio (M-H, Random,
95% CI)

3.0 [0.12, 72.02]

Analysis 2.1.   Comparison 2 OLANZAPINE vs PLACEBO (3 to 5 days), Outcome 1
Global effect: 1. CGI severity of illness (very short term 3-5 days, change, high=poor).

Study or subgroup

Treatment

Control

Tollefson 1999(HGDY)

Total ***

Heterogeneity: Not applicable

Test for overall effect: Z=1.55(P=0.12)

Mean(SD)

-0 (0.7)

N

53

53

Mean(SD)

0.2 (0.9)

N

53

53

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

100%

-0.23[-0.52,0.06]

100%

-0.23[-0.52,0.06]

Favours treatment

-10

-5

0

5

10

Favours control

Analysis 2.2.   Comparison 2 OLANZAPINE vs PLACEBO (3 to 5 days),
Outcome 2 Global effect: 2. Relapse (very short term 3-5 days).

Study or subgroup

Tollefson 1999(HGDY)

Total (95% CI)

Total events: 1 (Treatment), 8 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=1.99(P=0.05)

Treatment

n/N

Control

n/N

Risk Ratio

M-H, Fixed, 95% CI

1/53

53

8/53

53

Weight

Risk Ratio

M-H, Fixed, 95% CI

100%

0.13[0.02,0.96]

100%

0.13[0.02,0.96]

Favours treatment

0.01

0.1

1

10

100

Favours control

Analysis 2.3.   Comparison 2 OLANZAPINE vs PLACEBO (3 to 5 days), Outcome 3
Mental state: 1. PANSS total (very short term 3 to 5 days, change, high score=poor).

Study or subgroup

Treatment

Control

Tollefson 1999(HGDY)

N

53

Mean(SD)

-1.2 (8)

N

53

Mean(SD)

4 (15.7)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

100%

-5.23[-9.98,-0.48]

Favours treatment

-10

-5

0

5

10

Favours control

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

115

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Study or subgroup

Treatment

Control

Total ***

Heterogeneity: Not applicable

Test for overall effect: Z=2.16(P=0.03)

Mean(SD)

N

53

N

53

Mean(SD)

Cochrane Database of Systematic Reviews

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

100%

-5.23[-9.98,-0.48]

Favours treatment

-10

-5

0

5

10

Favours control

Analysis 2.4.   Comparison 2 OLANZAPINE vs PLACEBO (3 to 5 days), Outcome 4 Mental state:
2. Negative symptoms (very short term 3 to 5 days, PANSS, endpoint, high score=poor).

Study or subgroup

Treatment

Control

Tollefson 1999(HGDY)

Total ***

Mean(SD)

0.7 (2.9)

N

53

53

Mean(SD)

0.7 (5)

N

53

53

Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%

Test for overall effect: Z=0.01(P=0.99)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

100%

0.01[-1.55,1.57]

100%

0.01[-1.55,1.57]

Favours treatment

-10

-5

0

5

10

Favours control

Analysis 2.5.   Comparison 2 OLANZAPINE vs PLACEBO (3 to 5 days), Outcome 5
Mental state: 3. Positive symptoms (very short term 3 to 5 days, PANSS 3-5 days).

Study or subgroup

Treatment

Control

Tollefson 1999(HGDY)

Total ***

Mean(SD)

-0.1 (3.4)

N

53

53

N

53

53

Mean(SD)

0.9 (5.5)

Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%

Test for overall effect: Z=1.06(P=0.29)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

100%

-0.94[-2.68,0.8]

100%

-0.94[-2.68,0.8]

Favours treatment

-10

-5

0

5

10

Favours control

Analysis 2.6.   Comparison 2 OLANZAPINE vs PLACEBO (3 to 5 days), Outcome 6 Mental
state: 4. Depression (very short term 3 to 5 days, MADRS, change, high score=poor).

Study or subgroup

Treatment

Control

Tollefson 1999(HGDY)

Total ***

Heterogeneity: Not applicable

Test for overall effect: Z=3.58(P=0)

Mean(SD)

-1.6 (6.1)

N

53

53

N

53

53

Mean(SD)

2.9 (6.9)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

100%

-4.52[-6.99,-2.05]

100%

-4.52[-6.99,-2.05]

Favours treatment

-10

-5

0

5

10

Favours control

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

116

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 2.7.   Comparison 2 OLANZAPINE vs PLACEBO (3 to 5 days), Outcome 7
Mental state: 5. Mental state (very short term 3 to 5 days, MMSE, high score=poor).

Study or subgroup

Treatment

Control

Tollefson 1999(HGDY)

Total ***

Heterogeneity: Not applicable

Test for overall effect: Z=0.44(P=0.66)

Mean(SD)

-0.6 (3.5)

N

53

53

N

53

53

Mean(SD)

-0.9 (3.6)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

100%

0.3[-1.05,1.65]

100%

0.3[-1.05,1.65]

Favours treatment

-10

-5

0

5

10

Favours control

Analysis 2.8.   Comparison 2 OLANZAPINE vs PLACEBO (3 to 5
days), Outcome 8 Leaving the study early. Any reason - by 5 days.

Study or subgroup

Tollefson 1999(HGDY)

Total (95% CI)

Total events: 3 (Treatment), 8 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=1.51(P=0.13)

Treatment

n/N

Control

n/N

3/53

53

8/53

53

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

100%

0.38[0.11,1.34]

100%

0.38[0.11,1.34]

Favours treatment

0.1

0.2

0.5

1

2

5

10

Favours control

Analysis 2.9.   Comparison 2 OLANZAPINE vs PLACEBO (3 to 5 days), Outcome 9
Adverse events: 1. Anticholinergic effects - headache (very short term 3 to 5 days,)*.

Study or subgroup

Tollefson 1999(HGDY)

Total (95% CI)

Total events: 3 (Treatment), 1 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=0.97(P=0.33)

Treatment

n/N

Control

n/N

3/53

53

1/53

53

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

3[0.32,27.93]

3[0.32,27.93]

100%

100%

Favours treatment

0.1

0.2

0.5

1

2

5

10

Favours control

Analysis 2.10.   Comparison 2 OLANZAPINE vs PLACEBO (3 to 5 days), Outcome
10 Adverse events: 2. Gastrointestinal (very short term 3 to 5 days,)*.

Study or subgroup

2.10.1 diarrhoea

Tollefson 1999(HGDY)

Subtotal (95% CI)

Total events: 3 (Treatment), 4 (Control)

Treatment

n/N

Control

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

3/53

53

4/53

53

100%

100%

0.75[0.18,3.19]

0.75[0.18,3.19]

Favours treatment

0.01

0.1

1

10

100

Favours control

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

117

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Treatment

n/N

Control

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Heterogeneity: Not applicable

Test for overall effect: Z=0.39(P=0.7)

2.10.2 nausea

Tollefson 1999(HGDY)

Subtotal (95% CI)

Total events: 0 (Treatment), 1 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=0.68(P=0.5)

2.10.3 vomiting

Tollefson 1999(HGDY)

Subtotal (95% CI)

Total events: 1 (Treatment), 3 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=0.97(P=0.33)

2.10.4 nausea and vomiting

Tollefson 1999(HGDY)

Subtotal (95% CI)

Total events: 1 (Treatment), 0 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=0.68(P=0.5)

0/53

53

1/53

53

1/53

53

1/53

53

3/53

53

0/53

53

100%

100%

0.33[0.01,8]

0.33[0.01,8]

100%

100%

0.33[0.04,3.1]

0.33[0.04,3.1]

100%

100%

3[0.12,72.02]

3[0.12,72.02]

Favours treatment

0.01

0.1

1

10

100

Favours control

Comparison 3.   OLANZAPINE vs TYPICAL ANTIPSYCHOTICS

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

1 Death: deaths during study or with-
in 30 days of study discontinuation

1.1 all causes

1.2 other causes

1.3 suicide and accidental injury

1.4 unknown

2 Global effect: 1. No important clini-
cal response - by 6-8 weeks

2.1 any dose of olanzapine

3

2

2

3

1

4

4

2427

2427

2609

1996

2778

Risk Ratio (M-H, Random,
95% CI)

Subtotals only

Risk Ratio (M-H, Random,
95% CI)

1.84 [0.48, 7.11]

Risk Ratio (M-H, Random,
95% CI)

1.48 [0.15, 14.22]

Risk Ratio (M-H, Random,
95% CI)

1.28 [0.17, 9.70]

Risk Ratio (M-H, Random,
95% CI)

0.16 [0.01, 4.04]

Risk Ratio (M-H, Random,
95% CI)

Subtotals only

Risk Ratio (M-H, Random,
95% CI)

0.90 [0.76, 1.06]

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

118

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

2.2 15mg olanzapine

2.3 10 mg olanzapine

2.4 5mg olanzapine

2.5 1mg olanzapine

3 Global effect: 2. No important clini-
cal response - by 12 weeks

4 Global effect: 3. No important clini-
cal response by 9 months

4.1 >/= 40% reduction in PANSS end-
point score

4.2 >/=2 CGI

5 Global effect: 4. Relapse/hospitali-
sation by 52 weeks*

2

2

2

1

1

1

1

1

2

6 Global effect: 5. CGI total (endpoint,
high=poor)

14

6.1 by 6 weeks

6.2 by 3-12 months

7 Global effect: 6. CGI severity of ill-
ness (endpoint, high=poor, skewed
data)

8 Mental state: 1. Needing additional
benzodiazepines - by 12 weeks

9 Mental state: 2. BPRS total by 3
months (endpoint, high score=poor)

10 Mental state: 3. BPRS total (end-
point, high score=poor, skewed data)

11 Mental state: 4. PANSS total (end-
point, high score=poor)

11.1 by 8 weeks

9

5

3

6

15

8

308

300

302

169

263

197

197

495

2503

411

2526

397

Risk Ratio (M-H, Random,
95% CI)

0.87 [0.70, 1.08]

Risk Ratio (M-H, Random,
95% CI)

0.97 [0.79, 1.19]

Risk Ratio (M-H, Random,
95% CI)

1.08 [0.89, 1.31]

Risk Ratio (M-H, Random,
95% CI)

1.13 [0.87, 1.48]

Risk Ratio (M-H, Random,
95% CI)

0.82 [0.64, 1.06]

Risk Ratio (M-H, Random,
95% CI)

Subtotals only

Risk Ratio (M-H, Random,
95% CI)

0.85 [0.69, 1.05]

Risk Ratio (M-H, Random,
95% CI)

0.82 [0.67, 1.00]

Risk Ratio (M-H, Random,
95% CI)

0.68 [0.19, 2.38]

Mean Difference (IV, Ran-
dom, 95% CI)

Subtotals only

Mean Difference (IV, Ran-
dom, 95% CI)

-0.31 [-0.57, -0.06]

Mean Difference (IV, Ran-
dom, 95% CI)

-0.46 [-0.83, -0.09]

Other data

No numeric data

Risk Ratio (M-H, Random,
95% CI)

0.91 [0.85, 0.96]

Mean Difference (IV, Ran-
dom, 95% CI)

0.00 [-3.38, 3.38]

Other data

No numeric data

Mean Difference (IV, Ran-
dom, 95% CI)

Subtotals only

2427

Mean Difference (IV, Ran-
dom, 95% CI)

-6.04 [-11.11, -0.96]

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

119

 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

6

1

10

4

5

1

2

8

4

3

1

11.2 by 3-12 months

11.3 over 12 months

12 Mental state: 5. Negative symp-
toms (PANSS, endpoint, high
score=poor)

12.1 by 3 months

12.2 by 3-12 months

12.3 over 12 months

13 Mental state: 6. Negative symp-
toms (various scales, endpoint, high
score=poor, skewed data)

13.1 as measured by BPRS

13.2 as measured by PANSS-N

13.3 as measured by SANS

14 Mental state: 7. Positive symp-
toms - 8 weeks (BPRS, endpoint, high
score=poor)

15 Mental state: 8. Positive symptoms
(PANSS, endpoint, high score=poor)

15.1 by 3 months

15.2 by 3 - 12 months

15.3 over 12 months

16 Mental state: 9. Positive symp-
toms (various scales, endpoint, high
score=poor, skewed data)

16.1 as measured by BPRS - by 6
weeks

16.2 as measured by PANSS-P - by 6
to 12 weeks

563

44

2297

408

44

110

2297

334

44

Mean Difference (IV, Ran-
dom, 95% CI)

-8.48 [-13.84, -3.12]

Mean Difference (IV, Ran-
dom, 95% CI)

-7.32 [-18.63, 3.99]

Mean Difference (IV, Ran-
dom, 95% CI)

Subtotals only

Mean Difference (IV, Ran-
dom, 95% CI)

-1.20 [-2.37, -0.02]

Mean Difference (IV, Ran-
dom, 95% CI)

-2.11 [-3.34, -0.88]

Mean Difference (IV, Ran-
dom, 95% CI)

-4.75 [-8.10, -1.40]

Other data

No numeric data

Other data

Other data

Other data

Mean Difference (IV, Ran-
dom, 95% CI)

No numeric data

No numeric data

No numeric data

-0.97 [-2.21, 0.28]

Mean Difference (IV, Ran-
dom, 95% CI)

Subtotals only

Mean Difference (IV, Ran-
dom, 95% CI)

-1.03 [-1.63, -0.43]

Mean Difference (IV, Ran-
dom, 95% CI)

-2.20 [-5.42, 1.02]

Mean Difference (IV, Ran-
dom, 95% CI)

-0.26 [-3.42, 2.90]

Other data

No numeric data

Other data

No numeric data

Other data

No numeric data

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

120

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

17 Mental state: 10. Depression
(MADRS, endpoint, high score=poor,
skewed data)

17.1 by 3 months

17.2 by 3 to 12 months

18 Mental state: 11. Anxiety - by
14 weeks (HAMA, endpoint, high
score=poor, skewed data)

19 Mental state: 12. Subjective Well-
Being Under Neuroleptic Scale - by 6
weeks (high score=

20 Leaving the study early: 1a. Any
reason

20.1 by 4-8 weeks

20.2 not eligible, or eligibile and un-
willing to continue on study medica-
tion beyond 6 weeks

20.3 by 3 - 12 months

20.4 over 12 months

21 Leaving the study early: 1b. Any
reason (Peto Odds ratio)

21.1 by 4-8 weeks

22 Leaving the study early: 2. Due to
lack of efficacy

22.1 by 4-8 weeks

22.2 by 3 - 12 months

22.3 over 12 months

23 Adverse events: 1. Anticholinergic
effects - specific symptoms - by 6 to
12 weeks*

1

26

14

3

12

4

14

14

15

8

6

4

6

Other data

No numeric data

Other data

Other data

Other data

No numeric data

No numeric data

No numeric data

Mean Difference (IV, Ran-
dom, 95% CI)

-10.58 [-38.34,
17.18]

Risk Ratio (M-H, Random,
95% CI)

Subtotals only

Risk Ratio (M-H, Random,
95% CI)

0.81 [0.65, 1.02]

Risk Ratio (M-H, Random,
95% CI)

0.90 [0.75, 1.08]

Risk Ratio (M-H, Random,
95% CI)

0.76 [0.61, 0.94]

Risk Ratio (M-H, Random,
95% CI)

0.93 [0.86, 1.02]

Peto Odds Ratio (Peto,
Fixed, 95% CI)

Peto Odds Ratio (Peto,
Fixed, 95% CI)

0.54 [0.46, 0.63]

0.54 [0.46, 0.63]

Risk Ratio (M-H, Random,
95% CI)

Subtotals only

Risk Ratio (M-H, Random,
95% CI)

0.86 [0.59, 1.25]

Risk Ratio (M-H, Random,
95% CI)

0.57 [0.34, 0.96]

Risk Ratio (M-H, Random,
95% CI)

0.79 [0.57, 1.10]

Risk Ratio (M-H, Random,
95% CI)

Subtotals only

20

3344

2694

1112

2738

3344

3344

2981

482

1012

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

121

 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

23.1 blurred vision

23.2 cardiovascular - dizziness

23.3 cardiovascular - palpitations

23.4 cardiovascular - orthostatic
changes

23.5 constipation

23.6 salivation - dry mouth

23.7 salivation - hypersalivation

23.8 urination difficulties

24 Adverse events: 2a. Extrapyrami-
dal - ESRS - by 6 weeks (endpoint,
high score=poor)

25 Adverse events: 2b. Extrapyrami-
dal - needing additional anticholiner-
gic medication*

25.1 by 6 to 12 weeks

25.2 by 3 to 12 months

26 Adverse events: 2c. Extrapyramidal
- specific symptoms*

26.1 abnormal gait - by 12 weeks

26.2 akathisia - by 6 to 12 weeks

26.3 any extrapyramidal event - by 6
to 8 weeks

26.4 bradykinesia - by 8 weeks

26.5 choreoathetosis - by 9 months

3

2

2

1

1

4

4

2

4

5

4

1

9

1

7

3

1

1

2107

351

2080

84

27

2374

2636

2023

139

2957

276

182

3193

2511

182

197

Risk Ratio (M-H, Random,
95% CI)

0.60 [0.31, 1.18]

Risk Ratio (M-H, Random,
95% CI)

1.20 [0.61, 2.37]

Risk Ratio (M-H, Random,
95% CI)

0.43 [0.11, 1.66]

Risk Ratio (M-H, Random,
95% CI)

0.13 [0.05, 0.35]

Risk Ratio (M-H, Random,
95% CI)

1.18 [0.37, 3.70]

Risk Ratio (M-H, Random,
95% CI)

0.94 [0.51, 1.74]

Risk Ratio (M-H, Random,
95% CI)

0.37 [0.20, 0.71]

Risk Ratio (M-H, Random,
95% CI)

0.50 [0.23, 1.05]

Mean Difference (IV, Ran-
dom, 95% CI)

-3.62 [-8.11, 0.87]

Risk Ratio (M-H, Random,
95% CI)

Subtotals only

Risk Ratio (M-H, Random,
95% CI)

0.28 [0.21, 0.38]

Risk Ratio (M-H, Random,
95% CI)

0.55 [0.35, 0.86]

Risk Ratio (M-H, Random,
95% CI)

Subtotals only

Risk Ratio (M-H, Random,
95% CI)

0.11 [0.03, 0.47]

Risk Ratio (M-H, Random,
95% CI)

0.28 [0.21, 0.38]

Risk Ratio (M-H, Random,
95% CI)

0.41 [0.28, 0.60]

Risk Ratio (M-H, Random,
95% CI)

0.11 [0.03, 0.47]

Risk Ratio (M-H, Random,
95% CI)

0.18 [0.01, 3.68]

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

122

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

2511

2721

197

2694

2023

2286

27

197

907

26.6 dyskinetic movements - by 6 to 8
weeks

26.7 dystonia, acute - by 6 to 8 weeks

26.8 dystonia, acute - by 9 months

26.9 hypertonia - by 6 weeks

26.10 hypokinesia - by 6 to 8 weeks

26.11 parkinsonism - by 4 to 12 weeks

26.12 rigidity - by 12 weeks

26.13 tardive dyskinesia - by 9
months

26.14 tremor - by 6 to 12 weeks

3

4

1

3

2

3

1

1

4

27 Adverse events: 2d. Extrapyra-
midal - specific symptoms (various
scales, endpoint, skewed data)*

27.1 akathisia - by 4 to 12 weeks
(Barnes Akathisia Scale)

27.2 dyskinesia - by 6 weeks (AIMS)

27.3 parkinsonism (ESRS) - over 12
months

27.4 parkinsonism - by 4 to 12 weeks
(Simpson-Angus Scale)

28 Adverse events: 2e. Extrapyrami-
dal - Van Putten - by 6 weeks (end-
point, skewed data)

29 Adverse events: 2f. Extrapyramidal
- DIEPSS scale - by 8 weeks (endpoint,
skewed data)

29.1 DIEPSS total score

29.2 akathisia

29.3 dyskinesia

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Risk Ratio (M-H, Random,
95% CI)

0.20 [0.03, 1.36]

Risk Ratio (M-H, Random,
95% CI)

0.11 [0.03, 0.41]

Risk Ratio (M-H, Random,
95% CI)

0.60 [0.17, 2.05]

Risk Ratio (M-H, Random,
95% CI)

0.25 [0.11, 0.55]

Risk Ratio (M-H, Random,
95% CI)

0.43 [0.33, 0.55]

Risk Ratio (M-H, Random,
95% CI)

0.39 [0.31, 0.50]

Risk Ratio (M-H, Random,
95% CI)

0.15 [0.04, 0.56]

Risk Ratio (M-H, Random,
95% CI)

0.15 [0.03, 0.65]

Risk Ratio (M-H, Random,
95% CI)

0.23 [0.10, 0.50]

Other data

No numeric data

Other data

No numeric data

Other data

Other data

No numeric data

No numeric data

Other data

No numeric data

Other data

No numeric data

Other data

No numeric data

Other data

Other data

Other data

No numeric data

No numeric data

No numeric data

123

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

29.4 dystonia

29.5 overall severity

29.6 parkinsonism

30 Adverse events: 3. Requiring pro-
pranolol - by 12 weeks

31 Adverse events: 4. Adverse drug re-
action, requiring dose reduction or
additional medication - by 8 weeks

32 Adverse events: 5. Gastrointestinal
- specific symptoms*

32.1 anorexia - by 12 weeks

32.2 appetite increase - by 6 weeks

32.3 sickness - nausea - by 6 to 12
weeks

32.4 sickness - vomiting - by 6 weeks

33 Adverse events: 6. Other prob-
lems*

33.1 agitation - by 6 weeks

33.2 anxiety - by 12 weeks

33.3 asthenia - by 12 weeks

33.4 excitement - by 12 weeks

33.5 hostility - by 6 weeks

33.6 incapacitation - by 9 months

33.7 malaise - by 12 weeks

33.8 rash - by 6 weeks

1

1

4

1

1

4

1

5

1

1

1

1

1

1

1

1

Other data

Other data

Other data

Risk Ratio (M-H, Random,
95% CI)

No numeric data

No numeric data

No numeric data

0.12 [0.04, 0.40]

Risk Ratio (M-H, Random,
95% CI)

0.91 [0.74, 1.12]

Risk Ratio (M-H, Random,
95% CI)

Subtotals only

Risk Ratio (M-H, Random,
95% CI)

0.26 [0.09, 0.74]

Risk Ratio (M-H, Random,
95% CI)

1.65 [1.35, 2.01]

Risk Ratio (M-H, Random,
95% CI)

0.71 [0.38, 1.32]

Risk Ratio (M-H, Random,
95% CI)

0.59 [0.45, 0.78]

Risk Ratio (M-H, Random,
95% CI)

Subtotals only

Risk Ratio (M-H, Random,
95% CI)

0.80 [0.52, 1.23]

Risk Ratio (M-H, Random,
95% CI)

0.74 [0.42, 1.30]

Risk Ratio (M-H, Random,
95% CI)

0.78 [0.38, 1.60]

Risk Ratio (M-H, Random,
95% CI)

0.96 [0.51, 1.80]

Risk Ratio (M-H, Random,
95% CI)

1.63 [0.70, 3.76]

Risk Ratio (M-H, Random,
95% CI)

0.26 [0.10, 0.68]

Risk Ratio (M-H, Random,
95% CI)

0.96 [0.42, 2.19]

Risk Ratio (M-H, Random,
95% CI)

0.5 [0.03, 7.19]

263

182

182

1996

2529

1996

267

182

27

182

267

197

182

30

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

124

 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

33.9 withdrawal - by 12 weeks

34 Adverse events: 7. Sleep prob-
lems*

34.1 difficulty in getting to sleep by 6
to 12 weeks

34.2 drowsiness - by 6 to 12 weeks

35 Adverse events: 8. Sleep problems
by 6 weeks (LSEQ)

35.1 Awaking from sleep

35.2 Getting to sleep score

35.3 Quality of sleep

1

7

5

6

1

1

1

1

36 Adverse events: 9. Sleep problems,
Behaviour following waking - by 6
weeks (skewed data)

37 Adverse events: 10. Weight aver-
age increase*

13

37.1 weight increase by 3 months

37.2 weight increase by 3-12 months

37.3 weight increase over 12 months

38 Adverse events: 11. Weight: aver-
age increase - by 12 weeks (change
data)*

39 Adverse events: 12. Weight: gain

39.1 by 6 to 12 weeks

39.2 by 24 weeks

40 Adverse events: 13. Weight de-
crease - by 12 weeks

8

4

1

2

5

4

1

1

267

2960

2636

90

30

30

30

2455

186

47

283

552

276

182

Risk Ratio (M-H, Random,
95% CI)

0.58 [0.33, 1.04]

Risk Ratio (M-H, Random,
95% CI)

Subtotals only

Risk Ratio (M-H, Random,
95% CI)

0.88 [0.55, 1.40]

Risk Ratio (M-H, Random,
95% CI)

0.82 [0.73, 0.93]

Mean Difference (IV, Ran-
dom, 95% CI)

7.12 [-3.21, 17.45]

Mean Difference (IV, Ran-
dom, 95% CI)

5.30 [-11.31, 21.91]

Mean Difference (IV, Ran-
dom, 95% CI)

0.60 [-18.68, 19.88]

Mean Difference (IV, Ran-
dom, 95% CI)

15.0 [-3.07, 33.07]

Other data

No numeric data

Mean Difference (IV, Ran-
dom, 95% CI)

Subtotals only

Mean Difference (IV, Ran-
dom, 95% CI)

0.81 [-0.56, 2.18]

Mean Difference (IV, Ran-
dom, 95% CI)

4.62 [0.60, 8.64]

Mean Difference (IV, Ran-
dom, 95% CI)

0.96 [-10.53, 12.45]

Mean Difference (IV, Ran-
dom, 95% CI)

3.53 [1.28, 5.79]

Risk Ratio (M-H, Random,
95% CI)

Subtotals only

Risk Ratio (M-H, Random,
95% CI)

1.64 [0.71, 3.77]

Risk Ratio (M-H, Random,
95% CI)

1.38 [1.01, 1.88]

Risk Ratio (M-H, Random,
95% CI)

0.14 [0.02, 1.09]

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

125

 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

41 Adverse events: 14. Plasma pro-
lactin levels, endpoint 6 weeks

1

42 Quality of life: endpoint - by 6 to 12
weeks (high score=good, skewed da-
ta)

43 Drug compliance: DAI-30, mean
change - by 22 weeks (skewed data)

No. of partici-
pants

29

Statistical method

Effect size

Mean Difference (IV, Ran-
dom, 95% CI)

-15.01 [-17.94,
-12.08]

Other data

No numeric data

Other data

No numeric data

Analysis 3.1.   Comparison 3 OLANZAPINE vs TYPICAL ANTIPSYCHOTICS, Outcome
1 Death: deaths during study or within 30 days of study discontinuation.

Study or subgroup

Olanzapine

Haloperidol

Risk Ratio

Weight

Risk Ratio

n/N

n/N

M-H, Random, 95% CI

M-H, Random, 95% CI

3.1.1 all causes

Beasley 1997 (E003)

Tollefson 1997(HGAJ)

Subtotal (95% CI)

3/350

12/1336

1686

Total events: 15 (Olanzapine), 3 (Haloperidol)

Heterogeneity: Tau2=0.13; Chi2=1.14, df=1(P=0.29); I2=11.93%

Test for overall effect: Z=0.88(P=0.38)

3.1.2 other causes

Beasley 1997 (E003)

Tollefson 1997(HGAJ)

Subtotal (95% CI)

Total events: 3 (Olanzapine), 1 (Haloperidol)

Heterogeneity: Not applicable

Test for overall effect: Z=0.34(P=0.73)

3.1.3 suicide and accidental injury

Beasley 1997 (E003)

Ishigooka 2001

Tollefson 1997(HGAJ)

Subtotal (95% CI)

0/350

3/1336

1686

3/350

0/93

9/1336

1779

Total events: 12 (Olanzapine), 2 (Haloperidol)

Heterogeneity: Tau2=1.28; Chi2=3.31, df=2(P=0.19); I2=39.6%

Test for overall effect: Z=0.24(P=0.81)

1/81

2/660

741

0/81

1/660

741

1/81

1/89

0/660

830

32.91%

67.09%

100%

0.69[0.07,6.59]

2.96[0.67,13.21]

1.84[0.48,7.11]

100%

100%

Not estimable

1.48[0.15,14.22]

1.48[0.15,14.22]

41.16%

27.24%

31.6%

100%

0.69[0.07,6.59]

0.32[0.01,7.73]

9.39[0.55,161.14]

1.28[0.17,9.7]

3.1.4 unknown

Tollefson 1997(HGAJ)

Subtotal (95% CI)

Total events: 0 (Olanzapine), 1 (Haloperidol)

Heterogeneity: Not applicable

Test for overall effect: Z=1.1(P=0.27)

0/1336

1336

1/660

660

100%

100%

0.16[0.01,4.04]

0.16[0.01,4.04]

Favours treatment

0.001

0.1

1

10

1000

Favours control

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

126

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 3.2.   Comparison 3 OLANZAPINE vs TYPICAL ANTIPSYCHOTICS,
Outcome 2 Global effect: 1. No important clinical response - by 6-8 weeks.

Treatment

n/N

Control

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Study or subgroup

3.2.1 any dose of olanzapine

Beasley 1996a (HGAD)

Beasley 1997 (E003)

Conley 1998

Tollefson 1997(HGAJ)

Subtotal (95% CI)

116/198

183/350

39/42

718/1336

1926

40/69

43/81

42/42

471/660

852

Total events: 1056 (Treatment), 596 (Control)

Heterogeneity: Tau2=0.02; Chi2=19.44, df=3(P=0); I2=84.56%

Test for overall effect: Z=1.31(P=0.19)

3.2.2 15mg olanzapine

Beasley 1996a (HGAD)

Beasley 1997 (E003)

Subtotal (95% CI)

36/69

40/89

158

Total events: 76 (Treatment), 83 (Control)

Heterogeneity: Tau2=0; Chi2=0.08, df=1(P=0.78); I2=0%

Test for overall effect: Z=1.23(P=0.22)

3.2.3 10 mg olanzapine

Beasley 1996a (HGAD)

Beasley 1997 (E003)

Subtotal (95% CI)

37/64

43/86

150

Total events: 80 (Treatment), 83 (Control)

Heterogeneity: Tau2=0; Chi2=0.07, df=1(P=0.79); I2=0%

Test for overall effect: Z=0.29(P=0.77)

3.2.4 5mg olanzapine

Beasley 1996a (HGAD)

Beasley 1997 (E003)

Subtotal (95% CI)

43/65

47/87

152

Total events: 90 (Treatment), 83 (Control)

Heterogeneity: Tau2=0; Chi2=0.34, df=1(P=0.56); I2=0%

Test for overall effect: Z=0.79(P=0.43)

40/69

43/81

150

40/69

43/81

150

40/69

43/81

150

19.71%

20.02%

29.43%

30.84%

100%

1.01[0.8,1.28]

0.98[0.78,1.24]

0.93[0.85,1.02]

0.75[0.7,0.81]

0.9[0.76,1.06]

50.91%

49.09%

100%

0.9[0.67,1.22]

0.85[0.62,1.15]

0.87[0.7,1.08]

50.71%

49.29%

100%

1[0.75,1.33]

0.94[0.7,1.26]

0.97[0.79,1.19]

52.96%

47.04%

100%

1.14[0.87,1.49]

1.02[0.77,1.35]

1.08[0.89,1.31]

3.2.5 1mg olanzapine

Beasley 1997 (E003)

Subtotal (95% CI)

Total events: 53 (Treatment), 43 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=0.93(P=0.35)

53/88

88

43/81

81

100%

100%

1.13[0.87,1.48]

1.13[0.87,1.48]

0.2

0.5

1

2

5

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

127

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 3.3.   Comparison 3 OLANZAPINE vs TYPICAL ANTIPSYCHOTICS,
Outcome 3 Global effect: 2. No important clinical response - by 12 weeks.

Study or subgroup

Treatment

n/N

Control

n/N

Lieberman 2003 (HGDH

59/132

71/131

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

100%

0.82[0.64,1.06]

Total (95% CI)

132

131

100%

0.82[0.64,1.06]

Total events: 59 (Treatment), 71 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=1.53(P=0.13)

Favours treatment

0.1

0.2

0.5

1

2

5

10

Favours control

Analysis 3.4.   Comparison 3 OLANZAPINE vs TYPICAL ANTIPSYCHOTICS,
Outcome 4 Global effect: 3. No important clinical response by 9 months.

Study or subgroup

Treatment

n/N

Control

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

3.4.1 >/= 40% reduction in PANSS endpoint score

Lima 2003 (HGHS)

Subtotal (95% CI)

62/104

104

65/93

93

100%

100%

0.85[0.69,1.05]

0.85[0.69,1.05]

Total events: 62 (Treatment), 65 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=1.51(P=0.13)

3.4.2 >/=2 CGI

Lima 2003 (HGHS)

Subtotal (95% CI)

Total events: 62 (Treatment), 68 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=2(P=0.05)

62/104

104

68/93

93

100%

100%

0.82[0.67,1]

0.82[0.67,1]

Favours treatment

0.1

0.2

0.5

1

2

5

10

Favours control

Analysis 3.5.   Comparison 3 OLANZAPINE vs TYPICAL ANTIPSYCHOTICS,
Outcome 5 Global effect: 4. Relapse/hospitalisation by 52 weeks*.

Treatment

n/N

Control

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

181/198

21/142

340

67/69

27/86

155

51.96%

48.04%

0.94[0.89,1]

0.47[0.28,0.78]

100%

0.68[0.19,2.38]

Study or subgroup

Beasley 1996a (HGAD)

Namjoshi 2002

Total (95% CI)

Total events: 202 (Treatment), 94 (Control)

Heterogeneity: Tau2=0.8; Chi2=24.82, df=1(P<0.0001); I2=95.97%

Test for overall effect: Z=0.61(P=0.54)

*>50% loss people

0.5

0.7

1

1.5

2

PRONE TO BIAS

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

128

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 3.6.   Comparison 3 OLANZAPINE vs TYPICAL ANTIPSYCHOTICS,
Outcome 6 Global effect: 5. CGI total (endpoint, high=poor).

Study or subgroup

Treatment

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

3.6.1 by 6 weeks

Beasley 1996a (HGAD)

Beasley 1997 (E003)

Bernardo 2001 (HGDD)

Conley 1998

Esel 2001

HGCQ (Turkey) 2000

HGDV (Morocco) 1999

Loza 1999 (HGDT)

Tollefson 1997(HGAJ)

Subtotal ***

66

85

14

42

15

20

27

27

1318

1614

4.1 (1.4)

4 (1.5)

3.2 (1.5)

5.3 (1)

3.3 (0.5)

4 (1.4)

2.9 (0.6)

4 (1.3)

3.7 (1.2)

Heterogeneity: Tau2=0.08; Chi2=24.16, df=8(P=0); I2=66.89%

Test for overall effect: Z=2.42(P=0.02)

3.6.2 by 3-12 months

Barak 2002

HGCJ (Hong Kong)

HGCU (Taiwan) 1998

Jakovljevic1999 HGCH

Lieberman 2003 (HGDH

Subtotal ***

3.8 (0.9)

3.3 (1.1)

3.9 (1.3)

3.2 (1.3)

3 (1.1)

10

16

24

27

127

204

Heterogeneity: Tau2=0.08; Chi2=7.41, df=4(P=0.12); I2=46.03%

Test for overall effect: Z=2.46(P=0.01)

3.9 (1.2)

4.2 (1.3)

2.8 (1.1)

5.4 (0.8)

3.5 (0.7)

4.6 (1.1)

4.3 (0.9)

4.6 (1)

4.1 (1.1)

4.4 (0.5)

4.5 (1.3)

4 (1.2)

3.9 (1.8)

3.2 (1)

68

79

13

39

14

10

12

14

640

889

10

14

28

28

127

207

12.74%

12.72%

4.97%

13.62%

12.96%

5.55%

10.23%

7.72%

19.5%

100%

19.1%

12.67%

17.35%

13.68%

37.2%

100%

0.15[-0.28,0.58]

-0.25[-0.68,0.18]

0.4[-0.59,1.39]

-0.1[-0.49,0.29]

-0.13[-0.55,0.29]

-0.6[-1.52,0.32]

-1.4[-1.96,-0.84]

-0.6[-1.32,0.12]

-0.34[-0.45,-0.23]

-0.31[-0.57,-0.06]

-0.6[-1.24,0.04]

-1.25[-2.12,-0.38]

-0.16[-0.85,0.53]

-0.7[-1.53,0.13]

-0.17[-0.43,0.09]

-0.46[-0.83,-0.09]

-1

-0.5

0

0.5

1

Last observ'n used

Analysis 3.7.   Comparison 3 OLANZAPINE vs TYPICAL ANTIPSYCHOTICS, Outcome
7 Global effect: 6. CGI severity of illness (endpoint, high=poor, skewed data).

Study

Intervention

Mean

SD

N

Global effect: 6. CGI severity of illness (endpoint, high=poor, skewed data)

Avasthi 2001

Avasthi 2001

Olanzapine

Haloperidol

3.19

2.86

0.98

1.57

16

7

Analysis 3.8.   Comparison 3 OLANZAPINE vs TYPICAL ANTIPSYCHOTICS,
Outcome 8 Mental state: 1. Needing additional benzodiazepines - by 12 weeks.

Study or subgroup

Beasley 1996a (HGAD)

Lieberman 2003 (HGDH

Tollefson 1997(HGAJ)

Treatment

n/N

Control

n/N

140/198

83/132

808/1336

53/69

97/131

437/660

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

14.23%

12.87%

72.9%

0.92[0.79,1.08]

0.85[0.72,1]

0.91[0.85,0.98]

Total (95% CI)

1666

860

100%

0.91[0.85,0.96]

Total events: 1031 (Treatment), 587 (Control)

Heterogeneity: Tau2=0; Chi2=0.68, df=2(P=0.71); I2=0%

*>50% loss people

0.5

0.7

1

1.5

2

PRONE TO BIAS

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

129

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Treatment

n/N

Control

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Test for overall effect: Z=3.26(P=0)

*>50% loss people

0.5

0.7

1

1.5

2

PRONE TO BIAS

Analysis 3.9.   Comparison 3 OLANZAPINE vs TYPICAL ANTIPSYCHOTICS,
Outcome 9 Mental state: 2. BPRS total by 3 months (endpoint, high score=poor).

Study or subgroup

Treatment

Control

Bernardo 2001 (HGDD)

Chang 2003

Conley 1998

Esel 2001

Ishigooka 2001

Loza 1999 (HGDT)

N

Mean(SD)

N

Mean(SD)

14

31

42

15

81

27

36.6 (12.5)

33 (7)

54.1 (14.1)

24.2 (4.5)

40.4 (13.7)

35.4 (16)

13

27

39

14

80

14

34.4 (11.9)

27 (9)

56.9 (11.7)

24.5 (4.5)

40.4 (13.1)

44 (11.2)

Total ***

210

187

Heterogeneity: Tau2=10.04; Chi2=12.83, df=5(P=0.03); I2=61.03%

Test for overall effect: Z=0(P=1)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

9.27%

20.35%

16.27%

23.15%

20.52%

10.44%

2.2[-7,11.4]

6[1.81,10.19]

-2.8[-8.43,2.83]

-0.3[-3.59,2.99]

0[-4.14,4.14]

-8.6[-17.02,-0.18]

100%

0[-3.38,3.38]

-10

-5

0

5

10

Last observ'n used

Analysis 3.10.   Comparison 3 OLANZAPINE vs TYPICAL ANTIPSYCHOTICS,
Outcome 10 Mental state: 3. BPRS total (endpoint, high score=poor, skewed data).

Study

Intervention

Mean

SD

N

Mental state: 3. BPRS total (endpoint, high score=poor, skewed data)

Avasthi 2001

Avasthi 2001

Beasley 1996a (HGAD)

Beasley 1996a (HGAD)

Beasley 1997 (E003)

Beasley 1997 (E003)

HGCJ (Hong Kong)

HGCJ (Hong Kong)

HGCQ (Turkey) 2000

HGCQ (Turkey) 2000

HGCU (Taiwan) 1998

HGCU (Taiwan) 1998

HGDV (Morocco) 1999

Olanzapine

Haloperidol

Olanzapine

Haloperidol

Olanzapine

Haloperidol

Olanzapine

Haloperidol

Olanzapine

Chlorpromazine

Olanzapine

Haloperidol

Olanzapine

HGDV (Morocco) 1999

Chlorpromazine

Jakovljevic1999 HGCH

Olanzapine

Jakovljevic1999 HGCH

Fluphenazine group

Tollefson 1997(HGAJ)

Tollefson 1997(HGAJ)

Olanzapine

Haloperidol

9.50

12.57

27.43

28.99

25.95

28.78

12.75

26.86

20.2

24.7

15.83

20.32

6.7

20.7

17.9

25.6

22.16

26.16

7.06

13.39

17.28

15.86

16.20

15.41

8.81

13.71

17.9

18.4

11.33

12.21

6.4.

12.9

14.1

19.2

13.36

13.34

16

7

65

68

85

79

16

14

20

10

24

28

27

12

27

27

1312

636

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

130

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 3.11.   Comparison 3 OLANZAPINE vs TYPICAL ANTIPSYCHOTICS,
Outcome 11 Mental state: 4. PANSS total (endpoint, high score=poor).

Study or subgroup

treatment

control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

3.11.1 by 8 weeks

Beasley 1997 (E003)

Bernardo 2001 (HGDD)

de Hann 2003

HGCQ (Turkey) 2000

HGDV (Morocco) 1999

Ishigooka 2001

Loza 1999 (HGDT)

Tollefson 1997(HGAJ)

Subtotal ***

78.9 (28.6)

68 (23.3)

58.9 (21.9)

67.5 (30.5)

44.6 (12.8)

77.5 (24.6)

97.1 (29.9)

72.4 (23.5)

85

14

9

20

27

80

27

1312

1574

Heterogeneity: Tau2=21.8; Chi2=14.53, df=7(P=0.04); I2=51.84%

Test for overall effect: Z=2.33(P=0.02)

3.11.2 by 3-12 months

Barak 2002

HGCJ (Hong Kong)

HGCU (Taiwan) 1998

Jakovljevic1999 HGCH

Lieberman 2003 (HGDH

Lima 2003 (HGHS)

Subtotal ***

65.1 (19.3)

57.3 (17.3)

61.9 (19.3)

57 (23.6)

55.9 (16.5)

65.9 (21.7)

10

16

24

27

126

84

287

Heterogeneity: Tau2=18.28; Chi2=9.1, df=5(P=0.11); I2=45.03%

Test for overall effect: Z=3.1(P=0)

85.2 (25.6)

62.7 (20.7)

60.5 (21)

72.7 (30.9)

69.1 (22.5)

75.7 (22.7)

110.9 (17.8)

78.7 (22.9)

74.3 (9.6)

78.4 (23.7)

70.1 (23.7)

77.4 (33.4)

59.4 (16.6)

71.1 (25.8)

79

13

11

10

12

78

14

636

853

10

14

28

27

125

72

276

16.89%

-6.29[-14.59,2.01]

7.17%

5.83%

4.1%

9.58%

18.67%

8.65%

29.11%

100%

11.55%

9.7%

13.89%

9.32%

32.99%

22.56%

100%

5.3[-11.3,21.9]

-1.56[-20.49,17.37]

-5.2[-28.56,18.16]

-24.5[-38.12,-10.88]

1.77[-5.6,9.14]

-13.8[-28.43,0.83]

-6.32[-8.51,-4.13]

-6.04[-11.11,-0.96]

-9.2[-22.56,4.16]

-21.18[-36.2,-6.16]

-8.19[-19.88,3.5]

-20.4[-35.83,-4.97]

-3.5[-7.6,0.6]

-5.2[-12.75,2.35]

-8.48[-13.84,-3.12]

3.11.3 over 12 months

Jones 1998 (P022)

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=1.27(P=0.2)

58.1 (19.7)

21

21

65.4 (18.5)

23

23

100%

100%

-7.32[-18.63,3.99]

-7.32[-18.63,3.99]

-10

-5

0

5

10

Last observ'n used

Analysis 3.12.   Comparison 3 OLANZAPINE vs TYPICAL ANTIPSYCHOTICS, Outcome
12 Mental state: 5. Negative symptoms (PANSS, endpoint, high score=poor).

Study or subgroup

Treatment

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

3.12.1 by 3 months

Beasley 1997 (E003)

Bernardo 2001 (HGDD)

Ishigooka 2001

Tollefson 1997(HGAJ)

Subtotal ***

85

14

80

1312

1491

21.2 (8.3)

17.8 (5.5)

23.4 (8.4)

19.6 (6.9)

79

13

78

636

806

23.1 (6.1)

18 (5.6)

22.5 (7.5)

21.3 (6.9)

Heterogeneity: Tau2=0.52; Chi2=4.52, df=3(P=0.21); I2=33.58%

Test for overall effect: Z=2(P=0.05)

19.85%

7.01%

16.75%

56.39%

100%

-1.84[-4.05,0.37]

-0.2[-4.39,3.99]

0.92[-1.57,3.41]

-1.72[-2.37,-1.07]

-1.2[-2.37,-0.02]

3.12.2 by 3-12 months

Barak 2002

10

15.2 (3)

10

20.5 (6.9)

6.95%

-5.3[-9.96,-0.64]

-10

-5

0

5

10

Last observ'n used

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

131

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Treatment

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

HGCJ (Hong Kong)

HGCU (Taiwan) 1998

Jakovljevic1999 HGCH

Lieberman 2003 (HGDH

Subtotal ***

14.8 (6.6)

14.7 (6.8)

17 (6.3)

16.1 (6)

16

24

27

126

203

Heterogeneity: Tau2=0; Chi2=3.07, df=4(P=0.55); I2=0%

Test for overall effect: Z=3.36(P=0)

3.12.3 over 12 months

Jones 1998 (P022)

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=2.78(P=0.01)

15.9 (5.1)

21

21

18.5 (7.9)

17.7 (8.3)

19.5 (8.8)

17.6 (6)

20.7 (6.2)

14

28

27

126

205

23

23

5.51%

9%

9.07%

69.46%

100%

-3.75[-8.99,1.49]

-3[-7.1,1.1]

-2.5[-6.58,1.58]

-1.49[-2.97,-0.01]

-2.11[-3.34,-0.88]

100%

100%

-4.75[-8.1,-1.4]

-4.75[-8.1,-1.4]

-10

-5

0

5

10

Last observ'n used

Analysis 3.13.   Comparison 3 OLANZAPINE vs TYPICAL ANTIPSYCHOTICS, Outcome 13 Mental
state: 6. Negative symptoms (various scales, endpoint, high score=poor, skewed data).

Study

Intervention

Mean

SD

N

Mental state: 6. Negative symptoms (various scales, endpoint, high score=poor, skewed data)

as measured by BPRS

Beasley 1996a (HGAD)

Beasley 1996a (HGAD)

Beasley 1997 (E003)

Beasley 1997 (E003)

Esel 2001

Esel 2001

Jakovljevic1999 HGCH

Olanzapine

Haloperidol

Olanzapine

Haloperidol

Olanzapine

Haloperidol

Olanzapine

Jakovljevic1999 HGCH

Fluphenazine

Tollefson 1997(HGAJ)

Tollefson 1997(HGAJ)

Avasthi 2001

Avasthi 2001

Avasthi 2001

Avasthi 2001

Beasley 1996a (HGAD)

Beasley 1996a (HGAD)

Conley 1998

Conley 1998

Olanzapine

Haloperidol

Olanzapine

Haloperidol

Olanzapine

Haloperidol

Olanzapine

Haloperidol

Olanzapine

Chlorpromazine

4.42

4.87

5.26

6.23

6.46

8.2

3.8

5.1

4.62

5.55

as measured by PANSS-N

15.62

16.86

as measured by SANS

21.87

27.43

9.32

11.22

13.1

14.0

3.56

3.44

3.27

2.97

1.59

5.6

2.7

4.2

3.0

3.22

7.93

8.71

19.47

19.48

5.39

4.80

8.2

9.5

65

68

85

79

15

14

27

27

1312

636

16

7

16

7

65

68

42

39

Analysis 3.14.   Comparison 3 OLANZAPINE vs TYPICAL ANTIPSYCHOTICS, Outcome
14 Mental state: 7. Positive symptoms - 8 weeks (BPRS, endpoint, high score=poor).

Study or subgroup

Treatment

Control

Conley 1998

N

42

Mean(SD)

18.1 (4.2)

N

39

Mean(SD)

19.4 (3.1)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

60.6%

-1.3[-2.9,0.3]

Favours treatment

-10

-5

0

5

10

Favours control

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

132

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Study or subgroup

Treatment

Control

Esel 2001

Total ***

Mean(SD)

7.9 (2.6)

N

15

57

Mean(SD)

8.4 (2.8)

N

14

53

Heterogeneity: Tau2=0; Chi2=0.43, df=1(P=0.51); I2=0%

Test for overall effect: Z=1.52(P=0.13)

Cochrane Database of Systematic Reviews

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

39.4%

-0.45[-2.43,1.53]

100%

-0.97[-2.21,0.28]

Favours treatment

-10

-5

0

5

10

Favours control

Analysis 3.15.   Comparison 3 OLANZAPINE vs TYPICAL ANTIPSYCHOTICS, Outcome
15 Mental state: 8. Positive symptoms (PANSS, endpoint, high score=poor).

Study or subgroup

Treatment

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

3.15.1 by 3 months

Beasley 1997 (E003)

Bernardo 2001 (HGDD)

Ishigooka 2001

Tollefson 1997(HGAJ)

Subtotal ***

18.1 (7.8)

18.8 (7.6)

14.9 (6.4)

16.5 (7.1)

85

14

80

1312

1491

Heterogeneity: Tau2=0; Chi2=2.73, df=3(P=0.44); I2=0%

Test for overall effect: Z=3.34(P=0)

3.15.2 by 3 - 12 months

HGCJ (Hong Kong)

HGCU (Taiwan) 1998

Lieberman 2003 (HGDH

Subtotal ***

14.6 (5.8)

16.6 (7.4)

12.1 (4.1)

16

24

126

166

Heterogeneity: Tau2=5.24; Chi2=5.68, df=2(P=0.06); I2=64.77%

Test for overall effect: Z=1.34(P=0.18)

3.15.3 over 12 months

Jones 1998 (P022)

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=0.16(P=0.87)

12.5 (5.6)

21

21

79

13

78

636

806

14

28

126

168

23

23

18.8 (8)

16.4 (7.1)

15 (6.5)

17.8 (6.9)

20.1 (7.4)

19.5 (8.2)

12.3 (4.5)

12.8 (5.1)

6.24%

1.19%

9.04%

83.53%

100%

23.98%

27.23%

48.79%

100%

-0.69[-3.11,1.73]

2.4[-3.14,7.94]

-0.06[-2.07,1.95]

-1.21[-1.87,-0.55]

-1.03[-1.63,-0.43]

-5.51[-10.32,-0.7]

-2.88[-7.12,1.36]

-0.19[-1.26,0.88]

-2.2[-5.42,1.02]

100%

100%

-0.26[-3.42,2.9]

-0.26[-3.42,2.9]

-10

-5

0

5

10

Last observ'n used

Analysis 3.16.   Comparison 3 OLANZAPINE vs TYPICAL ANTIPSYCHOTICS, Outcome 16 Mental
state: 9. Positive symptoms (various scales, endpoint, high score=poor, skewed data).

Study

Interventions

Mean

SD

N

Mental state: 9. Positive symptoms (various scales, endpoint, high score=poor, skewed data)

as measured by BPRS - by 6 weeks

Beasley 1996a (HGAD)

Beasley 1996a (HGAD)

Beasley 1997 (E003)

Beasley 1997 (E003)

Jakovljevic1999 HGCH

Jakovljevic1999 HGCH

Tollefson 1997(HGAJ)

Olanzapine

Haloperidol

Olanzapine

Haloperidol

Olanzapine

Fluphenazine

Olanzapine

9.12

8.59

7.87

7.91

5.6

8.8

6.83

6.21

5.32

4.89

4.74

5.8

7.1

4.66

65

68

85

79

27

28

1312

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

133

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study

Interventions

Mean

SD

N

Mental state: 9. Positive symptoms (various scales, endpoint, high score=poor, skewed data)

Tollefson 1997(HGAJ)

Haloperidol

7.61

4.54

as measured by PANSS-P - by 6 to 12 weeks

Avasthi 2001

Avasthi 2001

Barak 2002

Barak 2002

He 2003

He 2003

Jakovljevic1999 HGCH

Jakovljevic1999 HGCH

Olanzapine

Haloperidol

Olanzapine

Haloperidol

Olanzapine

Chlorpromazine

Olanzapine

Fluphenazine

11.44

10.86

15.4

17.3

10.2

11.7

15.0

19.6

4.11

8.49

7.8

6.10

4.9

6.2

9.4

10.9

636

16

7

10

10

40

40

27

28

Analysis 3.17.   Comparison 3 OLANZAPINE vs TYPICAL ANTIPSYCHOTICS, Outcome
17 Mental state: 10. Depression (MADRS, endpoint, high score=poor, skewed data).

Mental state: 10. Depression (MADRS, endpoint, high score=poor, skewed data)

Study

Intervention

Mean

by 3 months

SD

N

Avasthi 2001

Avasthi 2001

de Hann 2003

de Hann 2003

HGDV (Morocco) 1999

Olanzapine

Haloperidol

Olanzapine

Haloperidol

Olanzapine

HGDV (Morocco) 1999

Chlorpromazine

Lieberman 2003 (HGDH

Lieberman 2003 (HGDH

Tollefson 1997(HGAJ)

Tollefson 1997(HGAJ)

HGCJ (Hong Kong)

HGCJ (Hong Kong)

HGCU (Taiwan) 1998

HGCU (Taiwan) 1998

Olanzapine

Haloperidol

Olanzapine

Haloperidol

Olanzapine

Haloperidol

Olanzapine

Haloperidol

3.00

5.00

10.56

7.91

3.3

6.9

6.95

8.38

10.65

13.64

4.06

12.29

3.67

4.79

by 3 to 12 months

2.42

4.58

9.81

5.39

2.0

4.8

7.01

8.21

8.3

9.82

4.39

10.56

5.43

5.14

16

7

11

9

27

12

125

126

1053

428

16

14

24

28

Analysis 3.18.   Comparison 3 OLANZAPINE vs TYPICAL ANTIPSYCHOTICS, Outcome 18
Mental state: 11. Anxiety - by 14 weeks (HAMA, endpoint, high score=poor, skewed data).

Study

Intervention

Mean

SD

N

Mental state: 11. Anxiety - by 14 weeks (HAMA, endpoint, high score=poor, skewed data)

HGDV (Morocco) 1999

Olanzapine

HGDV (Morocco) 1999

Chlorpromazine

3.3

7.6

1.8

5.8

27

12

Analysis 3.19.   Comparison 3 OLANZAPINE vs TYPICAL ANTIPSYCHOTICS, Outcome 19
Mental state: 12. Subjective Well-Being Under Neuroleptic Scale - by 6 weeks (high score=.

Study or subgroup

Treatment

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

de Hann 2003

9

158.8 (30.2)

11

169.4 (33.1)

Weight

Mean Difference

Random, 95% CI

100%

-10.58[-38.34,17.18]

Favours treatment

-10

-5

0

5

10

Favours control

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

134

 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Study or subgroup

Treatment

Control

Total ***

Heterogeneity: Not applicable

Test for overall effect: Z=0.75(P=0.46)

N

Mean(SD)

9

Mean(SD)

N

11

Cochrane Database of Systematic Reviews

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

100%

-10.58[-38.34,17.18]

Favours treatment

-10

-5

0

5

10

Favours control

Analysis 3.20.   Comparison 3 OLANZAPINE vs TYPICAL
ANTIPSYCHOTICS, Outcome 20 Leaving the study early: 1a. Any reason.

Treatment

n/N

Control

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Study or subgroup

3.20.1 by 4-8 weeks

Beasley 1996a (HGAD)

Beasley 1997 (E003)

Bernardo 2001 (HGDD)

Chang 2003

Conley 1998

de Hann 2003

Esel 2001

HGBL 1997

HGCQ (Turkey) 2000

HGDV (Morocco) 1999

HGFH (Korea) 1998

Ishigooka 2001

Loza 1999 (HGDT)

Tollefson 1997(HGAJ)

Subtotal (95% CI)

111/198

146/350

0/14

1/32

12/42

3/12

0/15

6/15

5/20

0/27

13/53

18/93

3/27

39/69

38/81

0/13

3/30

13/42

1/12

0/14

3/13

1/10

2/12

16/51

30/89

1/14

448/1336

2234

351/660

1110

Total events: 766 (Treatment), 498 (Control)

Heterogeneity: Tau2=0.05; Chi2=24.94, df=11(P=0.01); I2=55.9%

Test for overall effect: Z=1.76(P=0.08)

3.20.2 not eligible, or eligibile and unwilling to continue on study med-
ication beyond 6 weeks

Beasley 1996a (HGAD)

Beasley 1997 (E003)

Tollefson 1997(HGAJ)

Subtotal (95% CI)

153/198

302/350

802/1336

1884

59/69

67/81

504/660

810

Total events: 1257 (Treatment), 630 (Control)

Heterogeneity: Tau2=0.02; Chi2=22.11, df=2(P<0.0001); I2=90.95%

Test for overall effect: Z=1.11(P=0.27)

3.20.3 by 3 - 12 months

Altamura 1999 (HGBQ)

Avasthi 2001

Barak 2002

HGBJ (Finland)

HGCJ (Hong Kong)

HGCU (Taiwan) 1998

Jakovljevic1999 HGCH

Jones 1998 (P022)

0/13

1/17

0/10

11/23

5/17

10/26

9/30

10/21

7/15

3/10

0/10

12/23

10/14

14/28

13/30

14/23

Favours Treatment

0.2

0.5

1

2

5

Favours control

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

19.87%

19.08%

1.04%

8.24%

1.12%

3.35%

1.24%

0.59%

8.86%

11.36%

1.07%

24.17%

100%

31.7%

32.78%

35.52%

100%

0.6%

1.01%

9.96%

5.96%

9.21%

7.8%

10.56%

0.99[0.78,1.26]

0.89[0.68,1.16]

Not estimable

0.31[0.03,2.84]

0.92[0.48,1.78]

3[0.36,24.92]

Not estimable

1.73[0.54,5.59]

2.5[0.34,18.63]

0.09[0,1.8]

0.78[0.42,1.46]

0.57[0.35,0.95]

1.56[0.18,13.61]

0.63[0.57,0.7]

0.81[0.65,1.02]

0.9[0.8,1.02]

1.04[0.94,1.16]

0.79[0.74,0.84]

0.9[0.75,1.08]

0.08[0,1.22]

0.2[0.02,1.64]

Not estimable

0.92[0.51,1.64]

0.41[0.18,0.92]

0.77[0.42,1.42]

0.69[0.35,1.37]

0.78[0.45,1.36]

135

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Treatment

n/N

Control

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Study or subgroup

Lieberman 2003 (HGDH

Lima 2003 (HGHS)

Malyarov 1999

Rosenheck 2003(HGFI)

Subtotal (95% CI)

42/132

12/104

0/15

91/159

567

Total events: 191 (Treatment), 236 (Control)

Heterogeneity: Tau2=0.04; Chi2=14.87, df=10(P=0.14); I2=32.75%

Test for overall effect: Z=2.49(P=0.01)

3.20.4 over 12 months

Beasley 1996a (HGAD)

Beasley 1997 (E003)

Jones 1998 (P022)

Tollefson 1997(HGAJ)

Subtotal (95% CI)

181/198

334/350

9/21

1053/1336

1905

Total events: 1577 (Treatment), 748 (Control)

Heterogeneity: Tau2=0.01; Chi2=19.32, df=3(P=0); I2=84.47%

Test for overall effect: Z=1.54(P=0.12)

60/131

14/93

3/18

86/150

545

67/69

77/81

14/23

590/660

833

20.11%

7.2%

0.55%

27.03%

100%

31.47%

32.13%

2.02%

34.38%

100%

0.69[0.51,0.95]

0.77[0.37,1.57]

0.17[0.01,3.05]

1[0.82,1.21]

0.76[0.61,0.94]

0.94[0.89,1]

1[0.95,1.06]

0.7[0.39,1.27]

0.88[0.85,0.92]

0.93[0.86,1.02]

Favours Treatment

0.2

0.5

1

2

5

Favours control

Analysis 3.21.   Comparison 3 OLANZAPINE vs TYPICAL ANTIPSYCHOTICS,
Outcome 21 Leaving the study early: 1b. Any reason (Peto Odds ratio).

Treatment

n/N

Control

n/N

Peto Odds Ratio

Peto, Fixed, 95% CI

Weight

Peto Odds Ratio

Peto, Fixed, 95% CI

111/198

146/350

0/14

1/32

12/42

3/12

0/15

6/15

5/20

0/27

13/53

18/93

3/27

39/69

38/81

0/13

3/30

13/42

1/12

0/14

3/13

1/10

2/12

16/51

30/89

1/14

448/1336

2234

351/660

1110

7.94%

10.13%

0.6%

2.79%

0.55%

0.99%

0.69%

0.26%

3.31%

5.58%

0.52%

66.64%

100%

0.98[0.57,1.7]

0.81[0.5,1.32]

Not estimable

0.33[0.04,2.44]

0.89[0.35,2.26]

3.16[0.39,25.84]

Not estimable

2.11[0.44,10.07]

2.48[0.38,15.99]

0.04[0,0.74]

0.71[0.3,1.68]

0.48[0.25,0.93]

1.55[0.18,13.31]

0.44[0.36,0.53]

0.54[0.46,0.63]

Study or subgroup

3.21.1 by 4-8 weeks

Beasley 1996a (HGAD)

Beasley 1997 (E003)

Bernardo 2001 (HGDD)

Chang 2003

Conley 1998

de Hann 2003

Esel 2001

HGBL 1997

HGCQ (Turkey) 2000

HGDV (Morocco) 1999

HGFH (Korea) 1998

Ishigooka 2001

Loza 1999 (HGDT)

Tollefson 1997(HGAJ)

Subtotal (95% CI)

Total events: 766 (Treatment), 498 (Control)

Heterogeneity: Tau2=0; Chi2=25.58, df=11(P=0.01); I2=57%

Test for overall effect: Z=7.78(P<0.0001)

Total (95% CI)

2234

1110

100%

0.54[0.46,0.63]

Total events: 766 (Treatment), 498 (Control)

Heterogeneity: Tau2=0; Chi2=25.58, df=11(P=0.01); I2=57%

Test for overall effect: Z=7.78(P<0.0001)

Favours treatment

0.2

0.5

1

2

5

Favours control

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

136

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 3.22.   Comparison 3 OLANZAPINE vs TYPICAL ANTIPSYCHOTICS,
Outcome 22 Leaving the study early: 2. Due to lack of efficacy.

Treatment

n/N

Control

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Study or subgroup

3.22.1 by 4-8 weeks

Beasley 1996a (HGAD)

Beasley 1997 (E003)

Conley 1998

HGBL 1997

HGCQ (Turkey) 2000

HGFH (Korea) 1998

Loza 1999 (HGDT)

Tollefson 1997(HGAJ)

Subtotal (95% CI)

64/198

40/350

5/42

3/15

3/20

0/53

3/27

277/1336

2041

Total events: 395 (Treatment), 252 (Control)

Heterogeneity: Tau2=0.09; Chi2=13.09, df=7(P=0.07); I2=46.52%

Test for overall effect: Z=0.81(P=0.42)

3.22.2 by 3 - 12 months

Altamura 1999 (HGBQ)

HGBJ (Finland)

HGCJ (Hong Kong)

HGCU (Taiwan) 1998

Jakovljevic1999 HGCH

Lieberman 2003 (HGDH

Subtotal (95% CI)

0/13

5/23

1/17

2/26

4/30

8/132

241

Total events: 20 (Treatment), 37 (Control)

Heterogeneity: Tau2=0; Chi2=4.01, df=5(P=0.55); I2=0%

Test for overall effect: Z=2.11(P=0.03)

3.22.3 over 12 months

Beasley 1996a (HGAD)

Beasley 1997 (E003)

Jones 1998 (P022)

Tollefson 1997(HGAJ)

Subtotal (95% CI)

10/45

6/48

1/21

88/648

762

Total events: 105 (Treatment), 41 (Control)

Heterogeneity: Tau2=0; Chi2=0.53, df=3(P=0.91); I2=0%

Test for overall effect: Z=1.38(P=0.17)

19/69

16/81

2/42

1/13

0/10

1/51

1/14

212/660

940

3/15

3/23

3/14

5/28

7/30

16/131

241

2/10

3/14

1/23

35/203

250

26.23%

22.46%

4.95%

2.87%

1.64%

1.35%

2.8%

37.7%

100%

3.32%

16%

5.94%

11.41%

21.89%

41.45%

100%

5.99%

7.02%

1.5%

85.5%

100%

1.17[0.76,1.81]

0.58[0.34,0.98]

2.5[0.51,12.17]

2.6[0.31,22.05]

3.67[0.21,64.8]

0.32[0.01,7.7]

1.56[0.18,13.61]

0.65[0.55,0.75]

0.86[0.59,1.25]

0.16[0.01,2.89]

1.67[0.45,6.17]

0.27[0.03,2.36]

0.43[0.09,2.03]

0.57[0.19,1.75]

0.5[0.22,1.12]

0.57[0.34,0.96]

1.11[0.29,4.31]

0.58[0.17,2.04]

1.1[0.07,16.43]

0.79[0.55,1.13]

0.79[0.57,1.1]

Favours Treatment

0.1

0.2

0.5

1

2

5

10

Favours Control

Study or subgroup

3.23.1 blurred vision

Avasthi 2001

Conley 1998

Analysis 3.23.   Comparison 3 OLANZAPINE vs TYPICAL ANTIPSYCHOTICS, Outcome
23 Adverse events: 1. Anticholinergic effects - specific symptoms - by 6 to 12 weeks*.

Treatment

n/N

Control

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

1/17

4/42

5/10

5/42

9.9%

21.13%

0.12[0.02,0.87]

0.8[0.23,2.77]

*>50% loss people

0.1

0.2

0.5

1

2

5

10

PRONE TO BIAS

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

137

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Study or subgroup

Tollefson 1997(HGAJ)

Subtotal (95% CI)

Treatment

n/N

Control

n/N

169/1336

1395

120/660

712

Total events: 174 (Treatment), 130 (Control)

Heterogeneity: Tau2=0.16; Chi2=3.07, df=2(P=0.22); I2=34.88%

Test for overall effect: Z=1.48(P=0.14)

3.23.2 cardiovascular - dizziness

Beasley 1996a (HGAD)

Conley 1998

Subtotal (95% CI)

23/198

6/42

240

5/69

7/42

111

Total events: 29 (Treatment), 12 (Control)

Heterogeneity: Tau2=0; Chi2=0.82, df=1(P=0.37); I2=0%

Test for overall effect: Z=0.53(P=0.6)

3.23.3 cardiovascular - palpitations

Conley 1998

Tollefson 1997(HGAJ)

Subtotal (95% CI)

1/42

116/1336

1378

7/42

87/660

702

Total events: 117 (Treatment), 94 (Control)

Heterogeneity: Tau2=0.63; Chi2=2.12, df=1(P=0.15); I2=52.91%

Test for overall effect: Z=1.22(P=0.22)

3.23.4 cardiovascular - orthostatic changes

Conley 1998

Subtotal (95% CI)

Total events: 4 (Treatment), 30 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=4.15(P<0.0001)

3.23.5 constipation

Avasthi 2001

Subtotal (95% CI)

Total events: 6 (Treatment), 3 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=0.28(P=0.78)

4/42

42

6/17

17

3.23.6 salivation - dry mouth

Avasthi 2001

Beasley 1996a (HGAD)

Conley 1998

Tollefson 1997(HGAJ)

Subtotal (95% CI)

5/17

14/198

16/42

320/1336

1593

Total events: 355 (Treatment), 164 (Control)

Heterogeneity: Tau2=0.26; Chi2=14.6, df=3(P=0); I2=79.45%

Test for overall effect: Z=0.19(P=0.85)

3.23.7 salivation - hypersalivation

Avasthi 2001

Beasley 1997 (E003)

Ishigooka 2001

Tollefson 1997(HGAJ)

Subtotal (95% CI)

4/17

2/350

4/93

143/1336

1796

30/42

42

3/10

10

3/10

3/69

31/42

127/660

781

3/10

5/81

15/89

148/660

840

Cochrane Database of Systematic Reviews

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

68.97%

100%

0.7[0.56,0.86]

0.6[0.31,1.18]

53.91%

46.09%

100%

1.6[0.63,4.05]

0.86[0.31,2.34]

1.2[0.61,2.37]

27.21%

72.79%

100%

0.14[0.02,1.11]

0.66[0.51,0.86]

0.43[0.11,1.66]

100%

100%

0.13[0.05,0.35]

0.13[0.05,0.35]

100%

100%

1.18[0.37,3.7]

1.18[0.37,3.7]

15.59%

15.33%

32.23%

36.85%

100%

16.91%

11.94%

21.34%

49.81%

100%

0.98[0.3,3.25]

1.63[0.48,5.49]

0.52[0.34,0.79]

1.24[1.04,1.49]

0.94[0.51,1.74]

0.78[0.22,2.81]

0.09[0.02,0.47]

0.26[0.09,0.74]

0.48[0.39,0.59]

0.37[0.2,0.71]

138

*>50% loss people

0.1

0.2

0.5

1

2

5

10

PRONE TO BIAS

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Treatment

n/N

Control

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Total events: 153 (Treatment), 171 (Control)

Heterogeneity: Tau2=0.2; Chi2=5.74, df=3(P=0.12); I2=47.77%

Test for overall effect: Z=3.03(P=0)

3.23.8 urination difficulties

Avasthi 2001

Tollefson 1997(HGAJ)

Subtotal (95% CI)

2/17

77/1336

1353

5/10

63/660

670

Total events: 79 (Treatment), 68 (Control)

Heterogeneity: Tau2=0.16; Chi2=1.56, df=1(P=0.21); I2=36.07%

Test for overall effect: Z=1.83(P=0.07)

21.03%

78.97%

100%

0.24[0.06,0.99]

0.6[0.44,0.83]

0.5[0.23,1.05]

*>50% loss people

0.1

0.2

0.5

1

2

5

10

PRONE TO BIAS

Analysis 3.24.   Comparison 3 OLANZAPINE vs TYPICAL ANTIPSYCHOTICS, Outcome 24
Adverse events: 2a. Extrapyramidal - ESRS - by 6 weeks (endpoint, high score=poor).

Study or subgroup

Treatment

Control

Esel 2001

HGCQ (Turkey) 2000

HGDV (Morocco) 1999

Loza 1999 (HGDT)

Total ***

N

Mean(SD)

N

Mean(SD)

11.7 (1.3)

12.6 (1.2)

12.3 (0.5)

12 (0)

15

20

27

27

89

20.2 (3.2)

14.2 (2.9)

13.2 (1.3)

12 (0)

14

10

12

14

50

Heterogeneity: Tau2=15.1; Chi2=57.52, df=2(P<0.0001); I2=96.52%

Test for overall effect: Z=1.58(P=0.11)

Mean Difference

Random, 95% CI

Weight

Mean Difference

32.87%

32.74%

34.38%

Random, 95% CI

-8.47[-10.28,-6.66]

-1.6[-3.47,0.27]

-0.9[-1.66,-0.14]

Not estimable

100%

-3.62[-8.11,0.87]

Favours treatment

-4

-2

0

2

4

Favours control

Analysis 3.25.   Comparison 3 OLANZAPINE vs TYPICAL ANTIPSYCHOTICS, Outcome 25
Adverse events: 2b. Extrapyramidal - needing additional anticholinergic medication*.

Treatment

n/N

Control

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Study or subgroup

3.25.1 by 6 to 12 weeks

Beasley 1996a (HGAD)

Beasley 1997 (E003)

Lieberman 2003 (HGDH

Tollefson 1997(HGAJ)

Subtotal (95% CI)

36/198

29/350

23/132

228/1336

2016

47/69

39/81

68/131

315/660

941

Total events: 316 (Treatment), 469 (Control)

Heterogeneity: Tau2=0.07; Chi2=12.08, df=3(P=0.01); I2=75.16%

Test for overall effect: Z=8.06(P<0.0001)

3.25.2 by 3 to 12 months

Chaudhry 2003

Subtotal (95% CI)

Total events: 24 (Treatment), 40 (Control)

24/144

144

40/132

132

24.6%

21.34%

21.7%

32.36%

100%

0.27[0.19,0.37]

0.17[0.11,0.26]

0.34[0.22,0.5]

0.36[0.31,0.41]

0.28[0.21,0.38]

100%

100%

0.55[0.35,0.86]

0.55[0.35,0.86]

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

139

0.1

0.2

0.5

1

2

5

10

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Treatment

n/N

Control

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Heterogeneity: Not applicable

Test for overall effect: Z=2.62(P=0.01)

0.1

0.2

0.5

1

2

5

10

Analysis 3.26.   Comparison 3 OLANZAPINE vs TYPICAL ANTIPSYCHOTICS,
Outcome 26 Adverse events: 2c. Extrapyramidal - specific symptoms*.

Study or subgroup

Treatment

n/N

Control

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

2/93

93

17/89

89

100%

100%

0.11[0.03,0.47]

0.11[0.03,0.47]

3.26.1 abnormal gait - by 12 weeks

Ishigooka 2001

Subtotal (95% CI)

Total events: 2 (Treatment), 17 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=2.98(P=0)

3.26.2 akathisia - by 6 to 12 weeks

Avasthi 2001

Beasley 1996a (HGAD)

Beasley 1997 (E003)

Bernardo 2001 (HGDD)

Ishigooka 2001

Lieberman 2003 (HGDH

Tollefson 1997(HGAJ)

Subtotal (95% CI)

2/17

12/198

4/350

1/14

10/93

16/132

104/1336

2140

Total events: 149 (Treatment), 278 (Control)

Heterogeneity: Tau2=0.04; Chi2=8.56, df=6(P=0.2); I2=29.92%

Test for overall effect: Z=8.34(P<0.0001)

3.26.3 any extrapyramidal event - by 6 to 8 weeks

Beasley 1997 (E003)

Conley 1998

Tollefson 1997(HGAJ)

Subtotal (95% CI)

10/350

12/42

256/1336

1728

Total events: 278 (Treatment), 330 (Control)

Heterogeneity: Tau2=0.06; Chi2=3.86, df=2(P=0.14); I2=48.24%

Test for overall effect: Z=4.69(P<0.0001)

5/10

11/69

12/81

4/13

30/89

67/131

149/660

1053

11/81

21/42

298/660

783

3.93%

11.58%

6.35%

2.01%

14.81%

21.67%

39.65%

100%

15.51%

25.77%

58.72%

100%

0.24[0.06,0.99]

0.38[0.18,0.82]

0.08[0.03,0.23]

0.23[0.03,1.82]

0.32[0.17,0.61]

0.24[0.15,0.39]

0.34[0.27,0.44]

0.28[0.21,0.38]

0.21[0.09,0.48]

0.57[0.32,1.01]

0.42[0.37,0.49]

0.41[0.28,0.6]

3.26.4 bradykinesia - by 8 weeks

Ishigooka 2001

Subtotal (95% CI)

Total events: 2 (Treatment), 17 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=2.98(P=0)

2/93

93

17/89

89

100%

100%

0.11[0.03,0.47]

0.11[0.03,0.47]

3.26.5 choreoathetosis - by 9 months

Lima 2003 (HGHS)

Subtotal (95% CI)

0/104

104

2/93

93

Total events: 0 (Treatment), 2 (Control)

100%

100%

0.18[0.01,3.68]

0.18[0.01,3.68]

*>50% loss people

0.01

0.1

1

10

100

PRONE TO BIAS

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

140

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Treatment

n/N

Control

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Heterogeneity: Not applicable

Test for overall effect: Z=1.12(P=0.26)

3.26.6 dyskinetic movements - by 6 to 8 weeks

Beasley 1997 (E003)

Conley 1998

Tollefson 1997(HGAJ)

Subtotal (95% CI)

2/350

1/42

26/1336

1728

Total events: 29 (Treatment), 35 (Control)

Heterogeneity: Tau2=2.26; Chi2=11.37, df=2(P=0); I2=82.41%

Test for overall effect: Z=1.64(P=0.1)

3.26.7 dystonia, acute - by 6 to 8 weeks

Avasthi 2001

Beasley 1996a (HGAD)

Beasley 1997 (E003)

Tollefson 1997(HGAJ)

Subtotal (95% CI)

1/17

0/198

0/350

19/1336

1901

Total events: 20 (Treatment), 52 (Control)

Heterogeneity: Tau2=0.89; Chi2=6.01, df=3(P=0.11); I2=50.08%

Test for overall effect: Z=3.27(P=0)

5/81

15/42

15/660

783

4/10

9/69

4/81

35/660

820

31.81%

28.57%

39.63%

100%

23%

15.32%

14.72%

46.97%

100%

0.09[0.02,0.47]

0.07[0.01,0.48]

0.86[0.46,1.61]

0.2[0.03,1.36]

0.15[0.02,1.14]

0.02[0,0.31]

0.03[0,0.48]

0.27[0.15,0.47]

0.11[0.03,0.41]

4/104

104

6/93

93

100%

100%

0.6[0.17,2.05]

0.6[0.17,2.05]

3.26.8 dystonia, acute - by 9 months

Lima 2003 (HGHS)

Subtotal (95% CI)

Total events: 4 (Treatment), 6 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=0.82(P=0.41)

3.26.9 hypertonia - by 6 weeks

Beasley 1996a (HGAD)

Beasley 1997 (E003)

Tollefson 1997(HGAJ)

Subtotal (95% CI)

11/198

3/350

140/1336

1884

17/69

8/81

158/660

810

Total events: 154 (Treatment), 183 (Control)

Heterogeneity: Tau2=0.36; Chi2=8.52, df=2(P=0.01); I2=76.53%

Test for overall effect: Z=3.4(P=0)

3.26.10 hypokinesia - by 6 to 8 weeks

Avasthi 2001

Tollefson 1997(HGAJ)

Subtotal (95% CI)

2/17

97/1336

1353

5/10

110/660

670

Total events: 99 (Treatment), 115 (Control)

Heterogeneity: Tau2=0; Chi2=0.68, df=1(P=0.41); I2=0%

Test for overall effect: Z=6.59(P<0.0001)

3.26.11 parkinsonism - by 4 to 12 weeks

Bernardo 2001 (HGDD)

Lieberman 2003 (HGDH

Tollefson 1997(HGAJ)

Subtotal (95% CI)

1/14

34/132

128/1336

1482

6/13

72/131

177/660

804

Total events: 163 (Treatment), 255 (Control)

34.11%

20.78%

45.11%

100%

0.23[0.11,0.46]

0.09[0.02,0.32]

0.44[0.36,0.54]

0.25[0.11,0.55]

3.07%

96.93%

100%

0.24[0.06,0.99]

0.44[0.34,0.56]

0.43[0.33,0.55]

1.48%

36.69%

61.83%

100%

0.15[0.02,1.12]

0.47[0.34,0.65]

0.36[0.29,0.44]

0.39[0.31,0.5]

*>50% loss people

0.01

0.1

1

10

100

PRONE TO BIAS

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

141

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Treatment

n/N

Control

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Heterogeneity: Tau2=0.01; Chi2=2.71, df=2(P=0.26); I2=26.09%

Test for overall effect: Z=7.63(P<0.0001)

3.26.12 rigidity - by 12 weeks

Avasthi 2001

Subtotal (95% CI)

Total events: 2 (Treatment), 8 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=2.81(P=0)

2/17

17

8/10

10

100%

100%

0.15[0.04,0.56]

0.15[0.04,0.56]

3.26.13 tardive dyskinesia - by 9 months

Lima 2003 (HGHS)

Subtotal (95% CI)

2/104

104

12/93

93

100%

100%

0.15[0.03,0.65]

0.15[0.03,0.65]

Total events: 2 (Treatment), 12 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=2.54(P=0.01)

3.26.14 tremor - by 6 to 12 weeks

Avasthi 2001

Beasley 1996a (HGAD)

Beasley 1997 (E003)

Ishigooka 2001

Subtotal (95% CI)

6/17

7/198

2/350

6/93

658

7/10

10/69

9/81

27/89

249

Total events: 21 (Treatment), 53 (Control)

Heterogeneity: Tau2=0.39; Chi2=8.08, df=3(P=0.04); I2=62.86%

Test for overall effect: Z=3.71(P=0)

29.62%

26.12%

16.26%

28.01%

100%

0.5[0.24,1.08]

0.24[0.1,0.62]

0.05[0.01,0.23]

0.21[0.09,0.49]

0.23[0.1,0.5]

*>50% loss people

0.01

0.1

1

10

100

PRONE TO BIAS

Analysis 3.27.   Comparison 3 OLANZAPINE vs TYPICAL ANTIPSYCHOTICS, Outcome 27 Adverse
events: 2d. Extrapyramidal - specific symptoms (various scales, endpoint, skewed data)*.

Adverse events: 2d. Extrapyramidal - specific symptoms (various scales, endpoint, skewed data)*

Study

Intervention

Mean

SD

N

akathisia - by 4 to 12 weeks (Barnes Akathisia Scale)

Avasthi 2001

Avasthi 2001

Beasley 1996a (HGAD)

Beasley 1996a (HGAD)

Beasley 1997 (E003)

Beasley 1997 (E003)

Bernardo 2001 (HGDD)

Bernardo 2001 (HGDD)

Conley 1998

Conley 1998

Beasley 1996a (HGAD)

Beasley 1996a (HGAD)

Beasley 1997 (E003)

Beasley 1997 (E003)

Olanzapine

Haloperidol

Olanzapine

Haloperidol

Olanzapine

Haloperidol

Olanzapine

Haloperidol

Olanzapine

Chlorpromazine

Olanzapine

Haloperidol

Olanzapine

Haloperidol

0.0

0.29

0.42

0.87

0.38

0.91

0.4

0.8

0.60

0.60

dyskinesia - by 6 weeks (AIMS)

2.09

2.49

1.38

1.90

0.0

0.49

0.66

1.12

0.79

1.24

1.1

1.0

1.40

1.70

3.53

3.93

2.80

3.64

Jones 1998 (P022)

Olanzapine

1.19

1.86

parkinsonism (ESRS) - over 12 months

16

7

65

68

85

79

14

13

42

39

65

68

85

78

21

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

142

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Adverse events: 2d. Extrapyramidal - specific symptoms (various scales, endpoint, skewed data)*

Study

Intervention

Mean

SD

N

Jones 1998 (P022)

Haloperidol

2.57

2.61

parkinsonism - by 4 to 12 weeks (Simpson-Angus Scale)

Avasthi 2001

Avasthi 2001

Beasley 1996a (HGAD)

Beasley 1996a (HGAD)

Beasley 1997 (E003)

Beasley 1997 (E003)

Bernardo 2001 (HGDD)

Bernardo 2001 (HGDD)

Conley 1998

Conley 1998

Olanzapine

Haloperidol

Haloperidol

Olanzapine

Olanzapine

Haloperidol

Olanzapine

Haloperidol

Olanzapine

Chlorpromazine

0.75

0.86

3.34

1.35

1.8

5.59

0.2

4.5

1.50

2.10

1.39

1.86

4.39

2.44

3.10

7.93

1.7

3.4

2.40

2.30

23

16

7

67

63

85

79

14

13

41

39

N

N

Analysis 3.28.   Comparison 3 OLANZAPINE vs TYPICAL ANTIPSYCHOTICS, Outcome 28
Adverse events: 2e. Extrapyramidal - Van Putten - by 6 weeks (endpoint, skewed data).

Study

Intervention

mean

SD

Adverse events: 2e. Extrapyramidal - Van Putten - by 6 weeks (endpoint, skewed data)

HGCQ (Turkey) 2000

HGCQ (Turkey) 2000

Olanzapine

Chlorpromazine

6.7

9.6

7.2

7.2

20

10

Analysis 3.29.   Comparison 3 OLANZAPINE vs TYPICAL ANTIPSYCHOTICS, Outcome 29
Adverse events: 2f. Extrapyramidal - DIEPSS scale - by 8 weeks (endpoint, skewed data).

Study

Intervention

Mean

SD

Adverse events: 2f. Extrapyramidal - DIEPSS scale - by 8 weeks (endpoint, skewed data)

Ishigooka 2001

Ishigooka 2001

Ishigooka 2001

Ishigooka 2001

Ishigooka 2001

Ishigooka 2001

Ishigooka 2001

Ishigooka 2001

Ishigooka 2001

Ishigooka 2001

Ishigooka 2001

Ishigooka 2001

Olanzapine

Haloperidol

Olanzapine

Haloperidol

Olanzapine

Haloperidol

Olanzapine

Haloperidol

Olanzapine

Haloperidol

Olanzapine

Haloperidol

DIEPSS total score

akathisia

dyskinesia

dystonia

overall severity

parkinsonism

2.0

3.30

0.20

0.50

0.10

0.20

0.10

0.10

0.70

1.00

1.70

2.60

3.0

3.90

0.50

0.90

0.40

0.50

0.30

0.40

0.70

0.90

2.50

3.30

81

80

81

80

81

80

81

80

81

80

81

80

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

143

 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 3.30.   Comparison 3 OLANZAPINE vs TYPICAL ANTIPSYCHOTICS,
Outcome 30 Adverse events: 3. Requiring propranolol - by 12 weeks.

Study or subgroup

Treatment

n/N

Control

n/N

Lieberman 2003 (HGDH

3/132

24/131

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

100%

0.12[0.04,0.4]

Total (95% CI)

132

131

100%

0.12[0.04,0.4]

Total events: 3 (Treatment), 24 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=3.48(P=0)

Favours treatment

0.1

0.2

0.5

1

2

5

10

Favours control

Analysis 3.31.   Comparison 3 OLANZAPINE vs TYPICAL ANTIPSYCHOTICS, Outcome 31 Adverse
events: 4. Adverse drug reaction, requiring dose reduction or additional medication - by 8 weeks.

Study or subgroup

Treatment

n/N

Control

n/N

Ishigooka 2001

58/93

61/89

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

100%

0.91[0.74,1.12]

Total (95% CI)

93

89

100%

0.91[0.74,1.12]

Total events: 58 (Treatment), 61 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=0.87(P=0.38)

Favours treatment

0.2

0.5

1

2

5

Favours control

Analysis 3.32.   Comparison 3 OLANZAPINE vs TYPICAL ANTIPSYCHOTICS,
Outcome 32 Adverse events: 5. Gastrointestinal - specific symptoms*.

Study or subgroup

Treatment

n/N

Control

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

3.32.1 anorexia - by 12 weeks

Ishigooka 2001

Subtotal (95% CI)

Total events: 4 (Treatment), 15 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=2.52(P=0.01)

4/93

93

15/89

89

100%

100%

0.26[0.09,0.74]

0.26[0.09,0.74]

3.32.2 appetite increase - by 6 weeks

Tollefson 1997(HGAJ)

Subtotal (95% CI)

343/1336

1336

103/660

660

Total events: 343 (Treatment), 103 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=4.89(P<0.0001)

3.32.3 sickness - nausea - by 6 to 12 weeks

100%

100%

1.65[1.35,2.01]

1.65[1.35,2.01]

Beasley 1996a (HGAD)

Conley 1998

Ishigooka 2001

7/198

5/42

2/93

1/69

5/42

10/89

7.92%

19.81%

13.76%

2.44[0.31,19.47]

1[0.31,3.2]

0.19[0.04,0.85]

*>50% loss people

0.1

0.2

0.5

1

2

5

10

PRONE TO BIAS

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

144

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Study or subgroup

Tollefson 1997(HGAJ)

Subtotal (95% CI)

Treatment

n/N

Control

n/N

162/1336

1669

111/660

860

Total events: 176 (Treatment), 127 (Control)

Heterogeneity: Tau2=0.16; Chi2=4.68, df=3(P=0.2); I2=35.83%

Test for overall effect: Z=1.09(P=0.27)

3.32.4 sickness - vomiting - by 6 weeks

Tollefson 1997(HGAJ)

Subtotal (95% CI)

97/1336

1336

81/660

660

Total events: 97 (Treatment), 81 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=3.68(P=0)

Cochrane Database of Systematic Reviews

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

58.51%

100%

0.72[0.58,0.9]

0.71[0.38,1.32]

100%

100%

0.59[0.45,0.78]

0.59[0.45,0.78]

*>50% loss people

0.1

0.2

0.5

1

2

5

10

PRONE TO BIAS

Study or subgroup

3.33.1 agitation - by 6 weeks

Beasley 1996a (HGAD)

Subtotal (95% CI)

Analysis 3.33.   Comparison 3 OLANZAPINE vs TYPICAL
ANTIPSYCHOTICS, Outcome 33 Adverse events: 6. Other problems*.

Treatment

n/N

Control

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

48/198

198

21/69

69

100%

100%

0.8[0.52,1.23]

0.8[0.52,1.23]

Total events: 48 (Treatment), 21 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=1.03(P=0.3)

3.33.2 anxiety - by 12 weeks

Ishigooka 2001

Subtotal (95% CI)

Total events: 17 (Treatment), 22 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=1.05(P=0.29)

3.33.3 asthenia - by 12 weeks

Avasthi 2001

Subtotal (95% CI)

Total events: 8 (Treatment), 6 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=0.67(P=0.51)

3.33.4 excitement - by 12 weeks

Ishigooka 2001

Subtotal (95% CI)

Total events: 16 (Treatment), 16 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=0.14(P=0.89)

3.33.5 hostility - by 6 weeks

17/93

93

22/89

89

100%

100%

0.74[0.42,1.3]

0.74[0.42,1.3]

8/17

17

6/10

10

100%

100%

0.78[0.38,1.6]

0.78[0.38,1.6]

16/93

93

16/89

89

100%

100%

0.96[0.51,1.8]

0.96[0.51,1.8]

Beasley 1996a (HGAD)

28/198

6/69

100%

1.63[0.7,3.76]

*>50% loss people

0.01

0.1

1

10

100

PRONE TO BIAS

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

145

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Treatment

n/N

Control

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Subtotal (95% CI)

198

69

100%

1.63[0.7,3.76]

Total events: 28 (Treatment), 6 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=1.14(P=0.26)

3.33.6 incapacitation - by 9 months

Lima 2003 (HGHS)

Subtotal (95% CI)

Total events: 5 (Treatment), 17 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=2.74(P=0.01)

5/104

104

17/93

93

100%

100%

0.26[0.1,0.68]

0.26[0.1,0.68]

3.33.7 malaise - by 12 weeks

Ishigooka 2001

Subtotal (95% CI)

10/93

93

10/89

89

Total events: 10 (Treatment), 10 (Control)

Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%

Test for overall effect: Z=0.1(P=0.92)

100%

100%

0.96[0.42,2.19]

0.96[0.42,2.19]

3.33.8 rash - by 6 weeks

HGCQ (Turkey) 2000

Subtotal (95% CI)

Total events: 1 (Treatment), 1 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=0.51(P=0.61)

3.33.9 withdrawal - by 12 weeks

Beasley 1996a (HGAD)

Subtotal (95% CI)

Total events: 25 (Treatment), 15 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=1.84(P=0.07)

1/20

20

1/10

10

100%

100%

0.5[0.03,7.19]

0.5[0.03,7.19]

25/198

198

15/69

69

100%

100%

0.58[0.33,1.04]

0.58[0.33,1.04]

*>50% loss people

0.01

0.1

1

10

100

PRONE TO BIAS

Analysis 3.34.   Comparison 3 OLANZAPINE vs TYPICAL
ANTIPSYCHOTICS, Outcome 34 Adverse events: 7. Sleep problems*.

Study or subgroup

Treatment

n/N

Control

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

3.34.1 difficulty in getting to sleep by 6 to 12 weeks

Beasley 1996a (HGAD)

Beasley 1997 (E003)

Conley 1998

Ishigooka 2001

Tollefson 1997(HGAJ)

Subtotal (95% CI)

42/198

25/350

6/42

19/93

329/1336

2019

14/69

2/81

2/42

42/89

207/660

941

Total events: 421 (Treatment), 267 (Control)

Heterogeneity: Tau2=0.16; Chi2=13.77, df=4(P=0.01); I2=70.95%

Test for overall effect: Z=0.54(P=0.59)

23.97%

8.19%

7.2%

26.37%

34.26%

100%

1.05[0.61,1.79]

2.89[0.7,11.97]

3[0.64,14.02]

0.43[0.27,0.68]

0.79[0.68,0.91]

0.88[0.55,1.4]

*>50%loss to f/up

0.1

0.2

0.5

1

2

5

10

Prone to bias

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

146

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Treatment

n/N

Control

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

3.34.2 drowsiness - by 6 to 12 weeks

Avasthi 2001

Beasley 1996a (HGAD)

Conley 1998

He 2003

Ishigooka 2001

Tollefson 1997(HGAJ)

Subtotal (95% CI)

9/17

59/198

15/42

2/40

9/93

369/1336

1726

5/10

23/69

22/42

6/40

6/89

223/660

910

Total events: 463 (Treatment), 285 (Control)

Heterogeneity: Tau2=0; Chi2=3.68, df=5(P=0.6); I2=0%

Test for overall effect: Z=3.1(P=0)

2.58%

9.6%

6.08%

0.64%

1.53%

79.57%

100%

1.06[0.49,2.28]

0.89[0.6,1.33]

0.68[0.41,1.12]

0.33[0.07,1.55]

1.44[0.53,3.87]

0.82[0.71,0.94]

0.82[0.73,0.93]

*>50%loss to f/up

0.1

0.2

0.5

1

2

5

10

Prone to bias

Analysis 3.35.   Comparison 3 OLANZAPINE vs TYPICAL ANTIPSYCHOTICS,
Outcome 35 Adverse events: 8. Sleep problems by 6 weeks (LSEQ).

Study or subgroup

Treatment

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

53.7 (20.6)

61.9 (25.4)

67 (24.8)

3.35.1 Awaking from sleep

HGCQ (Turkey) 2000

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=0.63(P=0.53)

3.35.2 Getting to sleep score

HGCQ (Turkey) 2000

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=0.06(P=0.95)

3.35.3 Quality of sleep

HGCQ (Turkey) 2000

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=1.63(P=0.1)

Total ***

20

20

20

20

20

20

60

Heterogeneity: Tau2=0; Chi2=1.22, df=2(P=0.54); I2=0%

Test for overall effect: Z=1.35(P=0.18)

Test for subgroup differences: Chi2=1.22, df=1 (P=0.54), I2=0%

48.4 (22.5)

61.3 (25.4)

52 (23.3)

10

10

10

10

10

10

30

38.65%

38.65%

5.3[-11.31,21.91]

5.3[-11.31,21.91]

28.69%

28.69%

0.6[-18.68,19.88]

0.6[-18.68,19.88]

32.65%

32.65%

15[-3.07,33.07]

15[-3.07,33.07]

100%

7.12[-3.21,17.45]

Favours treatment

-100

-50

0

50

100

Favours control

Analysis 3.36.   Comparison 3 OLANZAPINE vs TYPICAL ANTIPSYCHOTICS, Outcome 36
Adverse events: 9. Sleep problems, Behaviour following waking - by 6 weeks (skewed data).

Study

Intervention

mean

SD

N

HGCQ (Turkey) 2000

Olanzapine

55.9

18.8

20

Adverse events: 9. Sleep problems, Behaviour following waking - by 6 weeks (skewed data)

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

147

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study

Intervention

mean

SD

N

HGCQ (Turkey) 2000

Chlorpromazine

55.1

28.3

10

Adverse events: 9. Sleep problems, Behaviour following waking - by 6 weeks (skewed data)

Analysis 3.37.   Comparison 3 OLANZAPINE vs TYPICAL ANTIPSYCHOTICS,
Outcome 37 Adverse events: 10. Weight average increase*.

Study or subgroup

Treatment

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

3.37.1 weight increase by 3 months

Beasley 1996a (HGAD)

Beasley 1997 (E003)

HGBL 1997

HGCQ (Turkey) 2000

HGDV (Morocco) 1999

HGFH (Korea) 1998

Loza 1999 (HGDT)

Tollefson 1997(HGAJ)

Subtotal ***

83.4 (20.8)

73.9 (15.1)

74.6 (13.1)

75.2 (11.4)

74.5 (10.7)

59.9 (10.8)

73.2 (13.5)

78.3 (17)

64

85

14

20

27

51

27

1303

1591

Heterogeneity: Tau2=0; Chi2=6.86, df=7(P=0.44); I2=0%

Test for overall effect: Z=1.16(P=0.25)

3.37.2 weight increase by 3-12 months

HGBJ (Finland)

HGCJ (Hong Kong)

HGCU (Taiwan) 1998

Jakovljevic1999 HGCH

Subtotal ***

79.3 (12.3)

64.7 (13.7)

70.9 (11.9)

78.2 (14)

23

16

24

30

93

Heterogeneity: Tau2=0; Chi2=1.74, df=3(P=0.63); I2=0%

Test for overall effect: Z=2.25(P=0.02)

3.37.3 weight increase over 12 months

Jones 1998 (P022)

Subtotal ***

84.8 (17.7)

22

22

Heterogeneity: Not applicable

Test for overall effect: Z=0.16(P=0.87)

83.9 (16.6)

73.4 (16)

74.5 (17.2)

72.1 (13.2)

66.6 (7.6)

60.1 (10.9)

69.2 (14.9)

78 (17.9)

78.6 (20.8)

59.4 (11.1)

63.1 (13.2)

75.7 (15.4)

83.8 (22.5)

67

77

12

10

12

39

14

633

864

23

14

27

29

93

25

25

4.52%

8.17%

1.33%

2.05%

5.39%

9.17%

2.18%

67.19%

100%

16.5%

20.58%

34.28%

28.65%

100%

-0.56[-7.01,5.89]

0.5[-4.3,5.3]

0.07[-11.82,11.96]

3.06[-6.52,12.64]

7.9[1.99,13.81]

-0.19[-4.72,4.34]

3.98[-5.32,13.28]

0.35[-1.32,2.02]

0.81[-0.56,2.18]

0.72[-9.18,10.62]

5.35[-3.51,14.21]

7.8[0.93,14.67]

2.53[-4.98,10.04]

4.62[0.6,8.64]

100%

100%

0.96[-10.53,12.45]

0.96[-10.53,12.45]

Used LOCF

-10

-5

0

5

10

Analysis 3.38.   Comparison 3 OLANZAPINE vs TYPICAL ANTIPSYCHOTICS, Outcome
38 Adverse events: 11. Weight: average increase - by 12 weeks (change data)*.

Study or subgroup

Treatment

Control

Barak 2002

Lieberman 2003 (HGDH

Total ***

Mean(SD)

4.5 (0.6)

7.3 (6.1)

N

10

132

142

Mean(SD)

2.1 (1.8)

2.6 (4.5)

N

10

131

141

Heterogeneity: Tau2=2.25; Chi2=6.64, df=1(P=0.01); I2=84.94%

Test for overall effect: Z=3.07(P=0)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

50.72%

49.28%

2.4[1.22,3.58]

4.7[3.41,5.99]

100%

3.53[1.28,5.79]

Favours treatment

-10

-5

0

5

10

Favours control

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

148

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

3.39.1 by 6 to 12 weeks

Avasthi 2001

He 2003

Ishigooka 2001

Lieberman 2003 (HGDH

Subtotal (95% CI)

Analysis 3.39.   Comparison 3 OLANZAPINE vs TYPICAL
ANTIPSYCHOTICS, Outcome 39 Adverse events: 12. Weight: gain.

Treatment

n/N

Control

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

14/17

3/40

10/93

81/132

282

5/10

10/40

2/89

30/131

270

29.25%

20.33%

16.68%

33.74%

100%

1.65[0.85,3.18]

0.3[0.09,1.01]

4.78[1.08,21.23]

2.68[1.9,3.77]

1.64[0.71,3.77]

Total events: 108 (Treatment), 47 (Control)

Heterogeneity: Tau2=0.5; Chi2=13.45, df=3(P=0); I2=77.7%

Test for overall effect: Z=1.16(P=0.24)

3.39.2 by 24 weeks

Chaudhry 2003

Subtotal (95% CI)

Total events: 63 (Treatment), 42 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=2.01(P=0.04)

63/144

144

42/132

132

100%

100%

1.38[1.01,1.88]

1.38[1.01,1.88]

Favours treatment

0.1

0.2

0.5

1

2

5

10

Favours control

Analysis 3.40.   Comparison 3 OLANZAPINE vs TYPICAL ANTIPSYCHOTICS,
Outcome 40 Adverse events: 13. Weight decrease - by 12 weeks.

Study or subgroup

Ishigooka 2001

Total (95% CI)

Treatment

n/N

Control

n/N

1/93

93

7/89

89

Total events: 1 (Treatment), 7 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=1.88(P=0.06)

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

100%

0.14[0.02,1.09]

100%

0.14[0.02,1.09]

Favours treatment

0.01

0.1

1

10

100

Favours control

Analysis 3.41.   Comparison 3 OLANZAPINE vs TYPICAL ANTIPSYCHOTICS,
Outcome 41 Adverse events: 14. Plasma prolactin levels, endpoint 6 weeks.

Study or subgroup

Treatment

Control

Esel 2001

Total ***

Mean(SD)

15.3 (1.7)

N

15

15

Mean(SD)

30.3 (5.3)

N

14

14

Heterogeneity: Not applicable

Test for overall effect: Z=10.05(P<0.0001)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

100%

-15.01[-17.94,-12.08]

100%

-15.01[-17.94,-12.08]

Favours treatment

-10

-5

0

5

10

Favours control

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

149

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 3.42.   Comparison 3 OLANZAPINE vs TYPICAL ANTIPSYCHOTICS, Outcome
42 Quality of life: endpoint - by 6 to 12 weeks (high score=good, skewed data).

Study

Intervention

mean

SD

Quality of life: endpoint - by 6 to 12 weeks (high score=good, skewed data)

Avasthi 2001

Avasthi 2001

Loza 1999 (HGDT)

Loza 1999 (HGDT)

Olanzapine

Haloperidol

Olanzapine

Chlorpromazine

51.19

49.14

56.6

47.7

23.38

33.88

31.3

26.6

16

7

27

14

Analysis 3.43.   Comparison 3 OLANZAPINE vs TYPICAL ANTIPSYCHOTICS,
Outcome 43 Drug compliance: DAI-30, mean change - by 22 weeks (skewed data).

Study

Intervention

mean change

SD

Drug compliance: DAI-30, mean change - by 22 weeks (skewed data)

Jakovljevic1999 HGCH

Jakovljevic1999 HGCH

Olanzapine

Fluphenazine

1.0

-0.2

1.9

2.6

26

26

N

N

Comparison 4.   OLANZAPINE vs TYPICAL ANTIPSYCHOTICS FOR PEOPLE WITH TREATMENT RESISTANT ILLNESS

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

1 Global effect: 1. No important clinical
response - by 8 weeks

2 Global effect: 2. CGI total - by 8 weeks
(endpoint, high score=poor)

3 Mental state: 1. BPRS total - by 8 weeks
(endpoint score, high score=poor)

4 Mental state: 2. Negative symptoms - 8
weeks (SANS, endpoint, high score=poor,
skewed data)

5 Mental state: 3. Positive symptoms by 8
weeks (BPRS, endpoint, high score=poor)

6 Leaving the study early: 1. Any reason

6.1 by 8 weeks

6.2 by 3-12 months

7 Leaving the study early: 2. Due to lack of
efficacy

7.1 by 8 weeks

1

1

1

1

2

1

1

2

1

84

81

81

81

84

28

84

Risk Ratio (M-H, Random,
95% CI)

0.93 [0.85, 1.02]

Mean Difference (IV, Ran-
dom, 95% CI)

-0.10 [-0.49, 0.29]

Mean Difference (IV, Ran-
dom, 95% CI)

-2.80 [-8.43, 2.83]

Other data

No numeric data

Mean Difference (IV, Ran-
dom, 95% CI)

-1.30 [-2.90, 0.30]

Risk Ratio (M-H, Random,
95% CI)

Subtotals only

Risk Ratio (M-H, Random,
95% CI)

0.92 [0.48, 1.78]

Risk Ratio (M-H, Random,
95% CI)

0.08 [0.00, 1.22]

Risk Ratio (M-H, Random,
95% CI)

Subtotals only

Risk Ratio (M-H, Random,
95% CI)

2.5 [0.51, 12.17]

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

150

 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

7.2 by 3-12 months

8 Adverse events: 1. Anticholinergic ef-
fects - specific symptoms - by 8 weeks

8.1 blurred vision

8.2 cardiovascular - dizziness

8.3 cardiovascular - orthostatic changes

8.4 cardiovascular - palpitations

8.5 salivation - dry mouth

9 Adverse effects: 2a. Extrapyramidal -
specific symptoms - by 8 weeks

9.1 any extrapyramidal event

9.2 dyskinetic movements

10 Adverse effects: 2b. Extrapyramidal -
specific symptoms - by 8 weeks (various
scales, endpoint, high=poor, ske

10.1 akathisia (Barnes Scale)

10.2 parkinsonism (Simpson-Angus Scale)

11 Adverse effects: 3. Gastrointestinal -
nausea / vomiting - by 8 weeks

12 Adverse events: 4. Sleep problems - by
8 weeks

12.1 difficulty getting to sleep

12.2 drowsiness

1

1

1

1

1

1

1

1

1

1

1

1

1

1

28

84

84

84

84

84

84

84

84

84

84

Risk Ratio (M-H, Random,
95% CI)

0.16 [0.01, 2.89]

Risk Ratio (M-H, Random,
95% CI)

Subtotals only

Risk Ratio (M-H, Random,
95% CI)

0.8 [0.23, 2.77]

Risk Ratio (M-H, Random,
95% CI)

0.86 [0.31, 2.34]

Risk Ratio (M-H, Random,
95% CI)

0.13 [0.05, 0.35]

Risk Ratio (M-H, Random,
95% CI)

0.14 [0.02, 1.11]

Risk Ratio (M-H, Random,
95% CI)

0.52 [0.34, 0.79]

Risk Ratio (M-H, Random,
95% CI)

Subtotals only

Risk Ratio (M-H, Random,
95% CI)

0.57 [0.32, 1.01]

Risk Ratio (M-H, Random,
95% CI)

0.07 [0.01, 0.48]

Other data

No numeric data

Other data

Other data

Risk Ratio (M-H, Random,
95% CI)

No numeric data

No numeric data

0.63 [0.22, 1.75]

Risk Ratio (M-H, Random,
95% CI)

Subtotals only

Risk Ratio (M-H, Random,
95% CI)

3.0 [0.64, 14.02]

Risk Ratio (M-H, Random,
95% CI)

0.68 [0.41, 1.12]

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

151

 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 4.1.   Comparison 4 OLANZAPINE vs TYPICAL ANTIPSYCHOTICS FOR PEOPLE WITH TREATMENT
RESISTANT ILLNESS, Outcome 1 Global effect: 1. No important clinical response - by 8 weeks.

Study or subgroup

Treatment

n/N

Control

n/N

Conley 1998

39/42

42/42

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

100%

0.93[0.85,1.02]

Total (95% CI)

42

42

100%

0.93[0.85,1.02]

Total events: 39 (Treatment), 42 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=1.52(P=0.13)

Favours treatment

0.5

0.7

1

1.5

2

Faovours control

Analysis 4.2.   Comparison 4 OLANZAPINE vs TYPICAL ANTIPSYCHOTICS FOR PEOPLE WITH TREATMENT
RESISTANT ILLNESS, Outcome 2 Global effect: 2. CGI total - by 8 weeks (endpoint, high score=poor).

Study or subgroup

Treatment

Control

Conley 1998

Total ***

Heterogeneity: Not applicable

Test for overall effect: Z=0.5(P=0.62)

Mean(SD)

5.3 (1)

N

42

42

N

39

39

Mean(SD)

5.4 (0.8)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

100%

-0.1[-0.49,0.29]

100%

-0.1[-0.49,0.29]

Favours treatment

-1

-0.5

0

0.5

1

Favours control

Analysis 4.3.   Comparison 4 OLANZAPINE vs TYPICAL ANTIPSYCHOTICS FOR PEOPLE WITH TREATMENT
RESISTANT ILLNESS, Outcome 3 Mental state: 1. BPRS total - by 8 weeks (endpoint score, high score=poor).

Study or subgroup

Treatment

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Conley 1998

42

54.1 (14.1)

39

56.9 (11.7)

Weight

Mean Difference

Random, 95% CI

100%

-2.8[-8.43,2.83]

Total ***

42

39

100%

-2.8[-8.43,2.83]

Heterogeneity: Not applicable

Test for overall effect: Z=0.98(P=0.33)

-10

-5

0

5

10

Analysis 4.4.   Comparison 4 OLANZAPINE vs TYPICAL ANTIPSYCHOTICS FOR PEOPLE WITH TREATMENT RESISTANT
ILLNESS, Outcome 4 Mental state: 2. Negative symptoms - 8 weeks (SANS, endpoint, high score=poor, skewed data).

Study

Intervention

Mean

SD

N

Mental state: 2. Negative symptoms - 8 weeks (SANS, endpoint, high score=poor, skewed data)

Conley 1998

Conley 1998

Olanzapine

Chlorpromazine

13.1

14.0

8.2

9.5

42

39

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

152

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 4.5.   Comparison 4 OLANZAPINE vs TYPICAL ANTIPSYCHOTICS FOR PEOPLE WITH TREATMENT RESISTANT
ILLNESS, Outcome 5 Mental state: 3. Positive symptoms by 8 weeks (BPRS, endpoint, high score=poor).

Study or subgroup

Treatment

Control

Conley 1998

Total ***

Heterogeneity: Not applicable

Test for overall effect: Z=1.59(P=0.11)

Mean(SD)

18.1 (4.2)

N

42

42

Mean(SD)

19.4 (3.1)

N

39

39

Mean Difference

Random, 95% CI

Weight

Mean Difference

100%

100%

Random, 95% CI

-1.3[-2.9,0.3]

-1.3[-2.9,0.3]

-10

-5

0

5

10

Analysis 4.6.   Comparison 4 OLANZAPINE vs TYPICAL ANTIPSYCHOTICS FOR PEOPLE WITH
TREATMENT RESISTANT ILLNESS, Outcome 6 Leaving the study early: 1. Any reason.

Study or subgroup

4.6.1 by 8 weeks

Conley 1998

Subtotal (95% CI)

Treatment

n/N

Control

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

12/42

42

13/42

42

100%

100%

0.92[0.48,1.78]

0.92[0.48,1.78]

Total events: 12 (Treatment), 13 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=0.24(P=0.81)

4.6.2 by 3-12 months

Altamura 1999 (HGBQ)

Subtotal (95% CI)

Total events: 0 (Treatment), 7 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=1.82(P=0.07)

0/13

13

7/15

15

100%

100%

0.08[0,1.22]

0.08[0,1.22]

Favours treatment

0.1

0.2

0.5

1

2

5

10

Faovours control

Analysis 4.7.   Comparison 4 OLANZAPINE vs TYPICAL ANTIPSYCHOTICS FOR PEOPLE WITH
TREATMENT RESISTANT ILLNESS, Outcome 7 Leaving the study early: 2. Due to lack of efficacy.

Study or subgroup

4.7.1 by 8 weeks

Conley 1998

Subtotal (95% CI)

Total events: 5 (Treatment), 2 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=1.13(P=0.26)

4.7.2 by 3-12 months

Altamura 1999 (HGBQ)

Subtotal (95% CI)

Total events: 0 (Treatment), 3 (Control)

Heterogeneity: Not applicable

Treatment

n/N

Control

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

5/42

42

0/13

13

2/42

42

3/15

15

100%

100%

2.5[0.51,12.17]

2.5[0.51,12.17]

100%

100%

0.16[0.01,2.89]

0.16[0.01,2.89]

Favours treatment

0.001

0.1

1

10

1000

Faovours control

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

153

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Treatment

n/N

Control

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Test for overall effect: Z=1.24(P=0.22)

Favours treatment

0.001

0.1

1

10

1000

Faovours control

Analysis 4.8.   Comparison 4 OLANZAPINE vs TYPICAL ANTIPSYCHOTICS FOR PEOPLE WITH TREATMENT
RESISTANT ILLNESS, Outcome 8 Adverse events: 1. Anticholinergic effects - specific symptoms - by 8 weeks.

Treatment

n/N

Control

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Study or subgroup

4.8.1 blurred vision

Conley 1998

Subtotal (95% CI)

Total events: 4 (Treatment), 5 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=0.35(P=0.73)

4.8.2 cardiovascular - dizziness

Conley 1998

Subtotal (95% CI)

Total events: 6 (Treatment), 7 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=0.3(P=0.76)

4.8.3 cardiovascular - orthostatic changes

Conley 1998

Subtotal (95% CI)

Total events: 4 (Treatment), 30 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=4.15(P<0.0001)

4.8.4 cardiovascular - palpitations

Conley 1998

Subtotal (95% CI)

Total events: 1 (Treatment), 7 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=1.86(P=0.06)

4.8.5 salivation - dry mouth

Conley 1998

Subtotal (95% CI)

Total events: 16 (Treatment), 31 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=3.05(P=0)

4/42

42

6/42

42

4/42

42

1/42

42

5/42

42

7/42

42

30/42

42

7/42

42

100%

100%

0.8[0.23,2.77]

0.8[0.23,2.77]

100%

100%

0.86[0.31,2.34]

0.86[0.31,2.34]

100%

100%

0.13[0.05,0.35]

0.13[0.05,0.35]

100%

100%

0.14[0.02,1.11]

0.14[0.02,1.11]

16/42

42

31/42

42

100%

100%

0.52[0.34,0.79]

0.52[0.34,0.79]

Favours treatment

0.01

0.1

1

10

100

Faovours control

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

154

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 4.9.   Comparison 4 OLANZAPINE vs TYPICAL ANTIPSYCHOTICS FOR PEOPLE WITH TREATMENT
RESISTANT ILLNESS, Outcome 9 Adverse effects: 2a. Extrapyramidal - specific symptoms - by 8 weeks.

Study or subgroup

Treatment

n/N

Control

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

4.9.1 any extrapyramidal event

Conley 1998

Subtotal (95% CI)

Total events: 12 (Treatment), 21 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=1.94(P=0.05)

4.9.2 dyskinetic movements

Conley 1998

Subtotal (95% CI)

Total events: 1 (Treatment), 15 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=2.68(P=0.01)

12/42

42

21/42

42

100%

100%

0.57[0.32,1.01]

0.57[0.32,1.01]

1/42

42

15/42

42

100%

100%

0.07[0.01,0.48]

0.07[0.01,0.48]

Favours treatment

0.01

0.1

1

10

100

Faovours control

Analysis 4.10.   Comparison 4 OLANZAPINE vs TYPICAL ANTIPSYCHOTICS FOR
PEOPLE WITH TREATMENT RESISTANT ILLNESS, Outcome 10 Adverse effects: 2b.
Extrapyramidal - specific symptoms - by 8 weeks (various scales, endpoint, high=poor, ske.

Adverse effects: 2b. Extrapyramidal - specific symptoms - by 8 weeks (various scales, endpoint, high=poor, ske

Study

Intervention

Mean

SD

N

Conley 1998

Conley 1998

Conley 1998

Conley 1998

Olanzapine

Chlorpromazine

Olanzapine

Chlorpromazine

akathisia (Barnes Scale)

0.60

0.60

1.40

1.70

parkinsonism (Simpson-Angus Scale)

1.50

2.10

2.40

2.30

42

39

41

39

Analysis 4.11.   Comparison 4 OLANZAPINE vs TYPICAL ANTIPSYCHOTICS FOR PEOPLE WITH TREATMENT
RESISTANT ILLNESS, Outcome 11 Adverse effects: 3. Gastrointestinal - nausea / vomiting - by 8 weeks.

Study or subgroup

Conley 1998

Total (95% CI)

Treatment

n/N

Control

n/N

5/42

42

8/42

42

Total events: 5 (Treatment), 8 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=0.89(P=0.37)

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

100%

0.63[0.22,1.75]

100%

0.63[0.22,1.75]

Favours treatment

0.1

0.2

0.5

1

2

5

10

Faovours control

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

155

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 4.12.   Comparison 4 OLANZAPINE vs TYPICAL ANTIPSYCHOTICS FOR PEOPLE WITH
TREATMENT RESISTANT ILLNESS, Outcome 12 Adverse events: 4. Sleep problems - by 8 weeks.

Study or subgroup

Treatment

n/N

Control

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

4.12.1 difficulty getting to sleep

Conley 1998

Subtotal (95% CI)

Total events: 6 (Treatment), 2 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=1.4(P=0.16)

4.12.2 drowsiness

Conley 1998

Subtotal (95% CI)

Total events: 15 (Treatment), 22 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=1.51(P=0.13)

6/42

42

2/42

42

100%

100%

3[0.64,14.02]

3[0.64,14.02]

15/42

42

22/42

42

100%

100%

0.68[0.41,1.12]

0.68[0.41,1.12]

Favours treatment

0.1

0.2

0.5

1

2

5

10

Faovours control

Comparison 5.   OLANZAPINE vs ATYPICAL ANTIPSYCHOTICS

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

1 Death

1.1 any cause

1.2 suicide

2 Global effect: 1. No clinically im-
portant response

2.1 as measured by CGI by 8 weeks

2.2 as measured by CGI by 3 to 12
months

2.3 as measured by Kane criteria by
3 to 12 months

3 Global effect: 2. Relapse/hospitali-
sation by 52 weeks

4 Global effect: 3. CGI total by 3 -12
months (endpoint, high score=poor)

5 Mental state: 1a. Needing addtion-
al benzodiazepines

5

5

1

7

5

2

2

1

3

5

1778

980

1258

330

330

278

570

Risk Ratio (M-H, Random,
95% CI)

Subtotals only

Risk Ratio (M-H, Random,
95% CI)

0.70 [0.31, 1.60]

Risk Ratio (M-H, Random,
95% CI)

1.67 [0.40, 6.94]

Risk Ratio (M-H, Random,
95% CI)

Subtotals only

Risk Ratio (M-H, Random,
95% CI)

0.93 [0.85, 1.03]

Risk Ratio (M-H, Random,
95% CI)

0.89 [0.73, 1.08]

Risk Ratio (M-H, Random,
95% CI)

0.97 [0.80, 1.17]

Risk Ratio (M-H, Random,
95% CI)

0.49 [0.31, 0.79]

Mean Difference (IV, Random,
95% CI)

-0.00 [-0.20, 0.19]

Risk Ratio (M-H, Random,
95% CI)

Subtotals only

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

156

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

5.1 by 6 to 12 weeks

5.2 by 18 weeks

5.3 by 2 years

6 Mental state: 1b. Needing antide-
pressants by 2 years

6.1 Any antidepressant

6.2 as a rescue intervention to pre-
vent suicide

7 Mental state: 2. No important clini-
cal response (decrease in PANSS to-
tal score)

7.1 short term - by 6 to 8 weeks (20
to 25% decrease in PANSS total
score)

7.2 short term - by 6 weeks (50% de-
crease in PANSS total score)

7.3 medium term - by 18-28 weeks
(40% decrease in PANSS total score)

8 Mental state: 3. No important clini-
cal response (decrease in BPRS total
score)

8.1 >20% improvement - 6 to 8
weeks

8.2 >40% improvement - by 8 weeks

9 Mental state: 4. BPRS total at 8
weeks (endpoint, high score=worse)

10 Mental state: 5. BPRS total at 3-12
months (endpoint, high score=poor,
skewed data)

11 Mental state: 6. PANSS total (end-
point, high score=poor)

11.1 by 3-12 months

3

1

1

1

1

1

8

4

1

3

2

2

1

1

6

5

706

180

980

980

980

738

42

669

332

269

61

715

Risk Ratio (M-H, Random,
95% CI)

0.90 [0.68, 1.19]

Risk Ratio (M-H, Random,
95% CI)

1.09 [0.88, 1.36]

Risk Ratio (M-H, Random,
95% CI)

1.11 [1.01, 1.22]

Risk Ratio (M-H, Random,
95% CI)

Subtotals only

Risk Ratio (M-H, Random,
95% CI)

1.12 [0.99, 1.27]

Risk Ratio (M-H, Random,
95% CI)

2.20 [1.21, 4.00]

Risk Ratio (M-H, Random,
95% CI)

Subtotals only

Risk Ratio (M-H, Random,
95% CI)

1.00 [0.87, 1.15]

Risk Ratio (M-H, Random,
95% CI)

0.83 [0.30, 2.31]

Risk Ratio (M-H, Random,
95% CI)

0.88 [0.80, 0.97]

Risk Ratio (M-H, Random,
95% CI)

Subtotals only

Risk Ratio (M-H, Random,
95% CI)

1.08 [0.86, 1.35]

Risk Ratio (M-H, Random,
95% CI)

1.26 [0.80, 1.99]

Mean Difference (IV, Random,
95% CI)

-1.60 [-2.96, -0.24]

Other data

No numeric data

Mean Difference (IV, Random,
95% CI)

Subtotals only

Mean Difference (IV, Random,
95% CI)

3.01 [-5.74, 11.76]

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

157

 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

1

6

1

4

1

1

4

1

2

1

11.2 over 12 months

12 Mental state: 7. Negative symp-
toms (PANSS, endpoint, high
score=poor)

12.1 by 8 weeks

12.2 by 3-12 months

12.3 over 12 months

13 Mental state: 8. Negative symp-
toms (various scales, endpoint, high
score=poor, skewed data)

13.1 as measured by BPRS - by 18
weeks

13.2 as measured by SANS - by 28
weeks

13.3 PANSS - by 6 to 8 weeks

14 Mental state: 9. Negative symp-
toms change data at 6 months
(SANS, high score=poor)

15 Mental state: 10. Positive symp-
toms (PANSS, endpoint, high
score=poor)

15.1 by 8 weeks

15.2 3-12 months

15.3 over 12 months

16 Mental state: 11. Positive symp-
toms (various scales, endpoint, high
score=poor, skewed data)

16.1 as measured by BPRS - by 18
weeks

16.2 as measured by PANSS - by 6 to
8 weeks

42

278

593

42

131

278

86

42

Mean Difference (IV, Random,
95% CI)

1.86 [-9.08, 12.80]

Mean Difference (IV, Random,
95% CI)

Subtotals only

Mean Difference (IV, Random,
95% CI)

0.20 [-1.11, 1.51]

Mean Difference (IV, Random,
95% CI)

1.52 [-2.08, 5.13]

Mean Difference (IV, Random,
95% CI)

-0.20 [-3.76, 3.36]

Other data

No numeric data

Other data

No numeric data

Other data

No numeric data

Other data

No numeric data

Mean Difference (IV, Random,
95% CI)

0.0 [-1.78, 1.78]

Mean Difference (IV, Random,
95% CI)

Subtotals only

Mean Difference (IV, Random,
95% CI)

0.30 [-1.09, 1.69]

Mean Difference (IV, Random,
95% CI)

3.47 [-3.87, 10.81]

Mean Difference (IV, Random,
95% CI)

0.62 [-2.43, 3.67]

Other data

No numeric data

Other data

No numeric data

Other data

No numeric data

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

158

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

16.3 as measured by PANSS at 28
weeks

17 Mental state: 12. Depression - by
8 weeks (Hamilton or MADRS rating
scale, high score=poor, skewed da-
ta)

18 Mental state: 13. Depression - by
18 weeks (MADRS, high score=poor,
skewed data)

19 Leaving the study early: 1. Any
reason

19.1 by 8 weeks

19.2 by 3-12 months

19.3 over 12 months

20 Leaving the study early: 2. Due to
lack of efficacy

20.1 by 8 weeks

20.2 by 3-12 months

20.3 over 12 months

21 Adverse events: 1. Anticholinergic
effects - specific symptoms

21.1 constipation by 6 to 8 weeks

21.2 constipation - by 18 weeks

21.3 constipation - by 2 years

21.4 dizziness by 6 to 8 weeks

21.5 dizziness - by 18 weeks

23

12

11

2

11

6

4

1

9

2

1

1

3

2

Other data

No numeric data

Other data

No numeric data

Other data

No numeric data

Risk Ratio (M-H, Random,
95% CI)

Subtotals only

Risk Ratio (M-H, Random,
95% CI)

0.87 [0.74, 1.03]

Risk Ratio (M-H, Random,
95% CI)

0.91 [0.82, 1.00]

Risk Ratio (M-H, Random,
95% CI)

0.98 [0.84, 1.14]

Risk Ratio (M-H, Random,
95% CI)

Subtotals only

Risk Ratio (M-H, Random,
95% CI)

0.93 [0.51, 1.69]

Risk Ratio (M-H, Random,
95% CI)

0.85 [0.52, 1.37]

Risk Ratio (M-H, Random,
95% CI)

0.25 [0.03, 2.05]

Risk Ratio (M-H, Random,
95% CI)

Subtotals only

Risk Ratio (M-H, Random,
95% CI)

0.47 [0.25, 0.89]

Risk Ratio (M-H, Random,
95% CI)

0.35 [0.15, 0.85]

Risk Ratio (M-H, Random,
95% CI)

0.45 [0.34, 0.60]

Risk Ratio (M-H, Random,
95% CI)

0.52 [0.20, 1.35]

Risk Ratio (M-H, Random,
95% CI)

0.39 [0.14, 1.11]

2304

1847

1004

1643

556

42

247

180

980

624

330

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

159

 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

21.6 diizziness - by 2 years

21.7 dry mouth by 6 to 8 weeks

21.8 dry mouth by 18 weeks

21.9 dry mouth - by 2 years

21.10 did not report improvement in
libido - by 4 weeks

21.11 rhinitis - by 6 to 8 weeks

21.12 rhinitis - by 18 weeks

21.13 salivation - by 6 weeks

21.14 salivation by 18 weeks

21.15 salivation by 2 years

21.16 urinary incontinence - by 2
years

21.17 vision abnormalities - by 8
weeks

21.18 vision abnormalities by 2
years

22 Adverse events: 2a. Extrapyrami-
dal - needing anticholinergic med-
ication

22.1 by 8 weeks

22.2 by 3 to 12 months

23 Adverse events: 2b. Extrapyrami-
dal - any

23.1 any extrapyramidal event by 8
weeks

1

3

1

1

1

3

1

1

2

1

1

1

1

7

5

2

5

4

980

562

180

980

66

544

180

122

330

980

980

377

980

923

519

657

Risk Ratio (M-H, Random,
95% CI)

0.51 [0.40, 0.66]

Risk Ratio (M-H, Random,
95% CI)

1.35 [0.76, 2.41]

Risk Ratio (M-H, Random,
95% CI)

1.79 [0.99, 3.21]

Risk Ratio (M-H, Random,
95% CI)

1.51 [1.02, 2.25]

Risk Ratio (M-H, Random,
95% CI)

0.78 [0.61, 0.99]

Risk Ratio (M-H, Random,
95% CI)

0.39 [0.09, 1.61]

Risk Ratio (M-H, Random,
95% CI)

1.67 [0.41, 6.77]

Risk Ratio (M-H, Random,
95% CI)

0.02 [0.00, 0.36]

Risk Ratio (M-H, Random,
95% CI)

0.32 [0.15, 0.67]

Risk Ratio (M-H, Random,
95% CI)

0.17 [0.13, 0.23]

Risk Ratio (M-H, Random,
95% CI)

0.45 [0.27, 0.77]

Risk Ratio (M-H, Random,
95% CI)

1.57 [0.79, 3.15]

Risk Ratio (M-H, Random,
95% CI)

3.0 [0.12, 73.46]

Risk Ratio (M-H, Random,
95% CI)

Subtotals only

Risk Ratio (M-H, Random,
95% CI)

0.64 [0.46, 0.91]

Risk Ratio (M-H, Random,
95% CI)

0.56 [0.40, 0.79]

Risk Ratio (M-H, Random,
95% CI)

Subtotals only

Risk Ratio (M-H, Random,
95% CI)

0.76 [0.54, 1.08]

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

160

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Outcome or subgroup title

No. of studies

23.2 any extrapyramidal event by
3-12 months

24 Adverse events: 2c. Extrapyrami-
dal - parkinsonism ESRS (endpoint,
high score=poor, skewed data)

24.1 by 8 weeks

24.2 by 1 year

25 Adverse events: 2d. Extrapyrami-
dal - specific symptoms

25.1 akathisia - by 3 to 12 months

25.2 akathisia - by 2 years

25.3 dyskinetic movements - by 8
weeks

25.4 dyskinetic movements - by 3 to
12 months

25.5 new parkinsonism - by 3 to 12
months

25.6 restlessness - by 6 weeks

25.7 tardive dyskinesia

25.8 tremor - by 6 to 8 weeks

26 Adverse events: 3. Treatment
emergent adverse events -by 4 to 8
weeks

27 Adverse events: 4. Other:

27.1 agitation - by 8 weeks

27.2 agitation - by 18 to 26 weeks

27.3 anxiety - by 6 to 8 weeks

1

7

4

1

1

2

2

1

1

2

3

9

2

2

2

Cochrane Database of Systematic Reviews

No. of partici-
pants

339

Statistical method

Effect size

Risk Ratio (M-H, Random,
95% CI)

0.60 [0.41, 0.88]

Other data

No numeric data

Other data

Other data

Risk Ratio (M-H, Random,
95% CI)

No numeric data

No numeric data

Subtotals only

Risk Ratio (M-H, Random,
95% CI)

0.98 [0.64, 1.49]

Risk Ratio (M-H, Random,
95% CI)

1.63 [1.07, 2.48]

Risk Ratio (M-H, Random,
95% CI)

0.70 [0.42, 1.15]

Risk Ratio (M-H, Random,
95% CI)

0.99 [0.40, 2.46]

Risk Ratio (M-H, Random,
95% CI)

0.61 [0.40, 0.94]

Risk Ratio (M-H, Random,
95% CI)

1.0 [0.15, 6.87]

Risk Ratio (M-H, Random,
95% CI)

1.5 [0.44, 5.14]

Risk Ratio (M-H, Random,
95% CI)

0.54 [0.15, 1.91]

Risk Ratio (M-H, Random,
95% CI)

0.90 [0.82, 0.98]

Risk Ratio (M-H, Random,
95% CI)

Subtotals only

Risk Ratio (M-H, Random,
95% CI)

0.96 [0.48, 1.93]

Risk Ratio (M-H, Random,
95% CI)

1.10 [0.25, 4.97]

Risk Ratio (M-H, Random,
95% CI)

0.80 [0.30, 2.14]

924

980

175

519

519

122

180

297

569

552

435

502

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

161

 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

27.4 anxiety - by 18 to 26 weeks

27.5 asthenia - by 4 weeks

27.6 asthenia - by 18 weeks

27.7 asthenia - by 2 years

27.8 decrease in white blood cells -
4 weeks

27.9 decrease in white blood cells -
by 18 to 26 weeks

27.10 decrease in white blood cells -
by 2 years

27.11 diabetes mellitus - by 2 years

27.12 dyspepsia - by 4 weeks

27.13 dyspepsia - by 2 years

27.14 fever - by 18 weeks

27.15 flu syndrome - by 18 weeks

27.16 headache - 4 to 8 weeks

27.17 headache - 18 to 26 weeks

27.18 hyperprolactinaemia - by 6
weeks

27.19 increased transaminase - by 6
weeks

27.20 nausea - by 4 weeks

27.21 nausea - by 18 to 26 weeks

2

1

2

1

1

2

1

1

1

1

1

2

3

2

1

1

1

2

435

125

330

980

122

330

980

980

125

980

180

330

677

405

42

122

125

435

Risk Ratio (M-H, Random,
95% CI)

0.46 [0.11, 1.94]

Risk Ratio (M-H, Random,
95% CI)

0.69 [0.16, 2.97]

Risk Ratio (M-H, Random,
95% CI)

0.66 [0.32, 1.37]

Risk Ratio (M-H, Random,
95% CI)

0.51 [0.32, 0.82]

Risk Ratio (M-H, Random,
95% CI)

0.0 [0.0, 0.0]

Risk Ratio (M-H, Random,
95% CI)

0.20 [0.03, 1.13]

Risk Ratio (M-H, Random,
95% CI)

0.44 [0.25, 0.76]

Risk Ratio (M-H, Random,
95% CI)

1.26 [0.77, 2.05]

Risk Ratio (M-H, Random,
95% CI)

0.92 [0.43, 1.97]

Risk Ratio (M-H, Random,
95% CI)

0.69 [0.50, 0.95]

Risk Ratio (M-H, Random,
95% CI)

0.2 [0.02, 1.68]

Risk Ratio (M-H, Random,
95% CI)

0.84 [0.39, 1.82]

Risk Ratio (M-H, Random,
95% CI)

0.72 [0.54, 0.96]

Risk Ratio (M-H, Random,
95% CI)

0.90 [0.57, 1.44]

Risk Ratio (M-H, Random,
95% CI)

0.24 [0.10, 0.58]

Risk Ratio (M-H, Random,
95% CI)

0.2 [0.02, 1.66]

Risk Ratio (M-H, Random,
95% CI)

0.51 [0.18, 1.44]

Risk Ratio (M-H, Random,
95% CI)

0.27 [0.09, 0.75]

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

162

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

27.22 nausea - by 2 years

27.23 pain - by 4 weeks

27.24 postural hypotension - by 18
weeks

27.25 SGPT increased - by 4 weeks

27.26 sweating - by 18 weeks

27.27 tachycardia - by 6 weeks

27.28 tooth disorder

27.29 vomiting - by 4 weeks

27.30 vomiting - by 18 weeks

27.31 vomiting - by 2 years

28 Adverse events: 8. Simpson and
Angus Scale - by 2 months (end-
point, high score=poor, skewed da-
ta)

29 Adverse events: 9. Yale Brown
Obsessive Compulsive Scale - by 6
weeks (endpoint, high score=poor,
skewed da

30 Adverse events: 10. Sleep prob-
lems

30.1 insomnia by 6 to 8 weeks

30.2 insomnia by 18 to 26 weeks

30.3 insomnia - by 2 years

30.4 somnolence by 6 to 8 weeks

1

1

1

1

1

1

1

1

1

1

8

2

1

1

4

980

125

150

125

180

122

180

125

180

980

499

255

980

687

Risk Ratio (M-H, Random,
95% CI)

0.67 [0.49, 0.90]

Risk Ratio (M-H, Random,
95% CI)

0.59 [0.24, 1.42]

Risk Ratio (M-H, Random,
95% CI)

0.85 [0.33, 2.23]

Risk Ratio (M-H, Random,
95% CI)

10.17 [0.57, 180.04]

Risk Ratio (M-H, Random,
95% CI)

0.40 [0.08, 2.01]

Risk Ratio (M-H, Random,
95% CI)

0.06 [0.01, 0.40]

Risk Ratio (M-H, Random,
95% CI)

0.11 [0.01, 2.03]

Risk Ratio (M-H, Random,
95% CI)

0.35 [0.10, 1.24]

Risk Ratio (M-H, Random,
95% CI)

0.8 [0.22, 2.88]

Risk Ratio (M-H, Random,
95% CI)

0.61 [0.45, 0.83]

Other data

No numeric data

Other data

No numeric data

Risk Ratio (M-H, Random,
95% CI)

Subtotals only

Risk Ratio (M-H, Random,
95% CI)

1.43 [0.20, 10.09]

Risk Ratio (M-H, Random,
95% CI)

0.34 [0.20, 0.60]

Risk Ratio (M-H, Random,
95% CI)

1.57 [1.28, 1.93]

Risk Ratio (M-H, Random,
95% CI)

0.74 [0.45, 1.20]

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

163

 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

30.5 somnolence by 18 to 26 weeks

30.6 somnolence - by 2 years

31 Adverse events: 6. Weight gain

31.1 4 to 8 weeks

31.2 3 to 12 months

31.3 over 12 months

32 Adverse events: 7. Weight gain

32.1 by 3-12 months

32.2 over 12 months

33 Adverse events: 8. Weight - by 8
weeks (change data)

34 Quality of life: 1. QOL total -
by 3 to 12 months(endpoint, high
score=good)

35 Quality of life: 2. QLS total by
3 to 12 months (endpoint, high
score=good)

36 Service outcome:1. Discharged
from hospital - by 8 weeks

37 Service outcome: 2. Hospitalisa-
tion for imminent risk of suicide - by
2 years

38 Service outcome: 3. Increase in
level of surveillance - by two years

3

1

7

3

3

1

4

3

1

3

1

2

1

1

1

585

980

250

585

980

535

44

463

240

172

214

980

980

Risk Ratio (M-H, Random,
95% CI)

0.86 [0.33, 2.28]

Risk Ratio (M-H, Random,
95% CI)

0.57 [0.48, 0.67]

Risk Ratio (M-H, Random,
95% CI)

Subtotals only

Risk Ratio (M-H, Random,
95% CI)

0.92 [0.42, 2.02]

Risk Ratio (M-H, Random,
95% CI)

1.76 [0.68, 4.59]

Risk Ratio (M-H, Random,
95% CI)

1.73 [1.49, 2.00]

Mean Difference (IV, Random,
95% CI)

Subtotals only

Mean Difference (IV, Random,
95% CI)

2.18 [-0.63, 4.98]

Mean Difference (IV, Random,
95% CI)

10.09 [-0.68, 20.86]

Mean Difference (IV, Random,
95% CI)

1.42 [0.62, 2.23]

Mean Difference (IV, Random,
95% CI)

2.42 [-3.93, 8.77]

Mean Difference (IV, Random,
95% CI)

-1.39 [-9.80, 7.01]

Risk Ratio (M-H, Random,
95% CI)

0.97 [0.88, 1.07]

Risk Ratio (M-H, Random,
95% CI)

1.28 [1.02, 1.61]

Risk Ratio (M-H, Random,
95% CI)

1.39 [0.95, 2.04]

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

164

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 5.1.   Comparison 5 OLANZAPINE vs ATYPICAL ANTIPSYCHOTICS, Outcome 1 Death.

Study or subgroup

5.1.1 any cause

Beuzen 1998 (HGCF)

Conley 2001

Jeste 2003

Meltzer (InterSept)

Ritchie 2003

Subtotal (95% CI)

Treatment

n/N

Control

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

0/90

0/189

1/88

8/490

0/34

891

0/90

0/188

0/87

12/490

1/32

887

Not estimable

Not estimable

2.97[0.12,71.83]

0.67[0.27,1.62]

0.31[0.01,7.45]

0.7[0.31,1.6]

6.68%

86.54%

6.78%

100%

Total events: 9 (Treatment), 13 (Control)

Heterogeneity: Tau2=0; Chi2=1.05, df=2(P=0.59); I2=0%

Test for overall effect: Z=0.85(P=0.4)

5.1.2 suicide

Meltzer (InterSept)

Subtotal (95% CI)

Total events: 5 (Treatment), 3 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=0.7(P=0.48)

5/490

490

3/490

490

100%

100%

1.67[0.4,6.94]

1.67[0.4,6.94]

Favours Treatment

0.1

0.2

0.5

1

2

5

10

Favours Control

Analysis 5.2.   Comparison 5 OLANZAPINE vs ATYPICAL ANTIPSYCHOTICS,
Outcome 2 Global effect: 1. No clinically important response.

Study or subgroup

Treatment

n/N

Control

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

5.2.1 as measured by CGI by 8 weeks

Chan 2003

Conley 2001

Jeste 2003

Martin 2002

Simpson 2004

Subtotal (95% CI)

13/30

120/189

56/88

78/188

58/133

628

Total events: 325 (Treatment), 349 (Control)

Heterogeneity: Tau2=0; Chi2=3.24, df=4(P=0.52); I2=0%

Test for overall effect: Z=1.34(P=0.18)

5.2.2 as measured by CGI by 3 to 12 months

Beuzen 1998 (HGCF)

Bitter 2004 (HGCK)

Subtotal (95% CI)

45/90

41/76

166

Total events: 86 (Treatment), 96 (Control)

Heterogeneity: Tau2=0; Chi2=0.75, df=1(P=0.39); I2=0%

Test for overall effect: Z=1.22(P=0.22)

5.2.3 as measured by Kane criteria by 3 to 12 months

Beuzen 1998 (HGCF)

Bitter 2004 (HGCK)

Subtotal (95% CI)

Total events: 88 (Treatment), 89 (Control)

56/90

32/76

166

20/30

124/188

59/87

77/189

69/136

630

55/90

41/74

164

60/90

29/74

164

4.17%

43.39%

21.02%

16.53%

14.89%

100%

0.65[0.4,1.05]

0.96[0.83,1.12]

0.94[0.76,1.16]

1.02[0.8,1.3]

0.86[0.67,1.11]

0.93[0.85,1.03]

54.87%

45.13%

100%

0.82[0.63,1.07]

0.97[0.73,1.3]

0.89[0.73,1.08]

76.05%

23.95%

100%

0.93[0.75,1.16]

1.07[0.73,1.58]

0.97[0.8,1.17]

Favours Treatment

0.2

0.5

1

2

5

Favours Control

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

165

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Treatment

n/N

Control

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Heterogeneity: Tau2=0; Chi2=0.41, df=1(P=0.52); I2=0%

Test for overall effect: Z=0.36(P=0.72)

Favours Treatment

0.2

0.5

1

2

5

Favours Control

Analysis 5.3.   Comparison 5 OLANZAPINE vs ATYPICAL ANTIPSYCHOTICS,
Outcome 3 Global effect: 2. Relapse/hospitalisation by 52 weeks.

Study or subgroup

Treatment

n/N

Control

n/N

Namjoshi 2002

21/142

41/136

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

100%

0.49[0.31,0.79]

Total (95% CI)

142

136

100%

0.49[0.31,0.79]

Total events: 21 (Treatment), 41 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=2.97(P=0)

Favours treatment

0.1

0.2

0.5

1

2

5

10

Favours control

Analysis 5.4.   Comparison 5 OLANZAPINE vs ATYPICAL ANTIPSYCHOTICS,
Outcome 4 Global effect: 3. CGI total by 3 -12 months (endpoint, high score=poor).

Study or subgroup

Treatment

Control

Beuzen 1998 (HGCF)

Thomas 1998 (HGBU)

Tran 1997 (HGBG)

Total ***

Mean(SD)

4.4 (1.3)

3.6 (0.9)

3.6 (1.4)

N

89

32

166

287

Mean(SD)

4.5 (1.3)

3.3 (1)

3.6 (1.1)

N

87

30

166

283

Heterogeneity: Tau2=0; Chi2=1.9, df=2(P=0.39); I2=0%

Test for overall effect: Z=0.01(P=0.99)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

27.47%

17.04%

55.49%

-0.09[-0.46,0.28]

0.3[-0.17,0.77]

-0.05[-0.31,0.21]

100%

-0[-0.2,0.19]

-1

-0.5

0

0.5

1

Analysis 5.5.   Comparison 5 OLANZAPINE vs ATYPICAL ANTIPSYCHOTICS,
Outcome 5 Mental state: 1a. Needing addtional benzodiazepines.

Treatment

n/N

Control

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

3/30

98/189

100/133

352

13/30

93/188

113/136

354

5.38%

43.84%

50.77%

100%

0.23[0.07,0.73]

1.05[0.86,1.28]

0.9[0.8,1.02]

0.9[0.68,1.19]

Study or subgroup

5.5.1 by 6 to 12 weeks

Chan 2003

Conley 2001

Simpson 2004

Subtotal (95% CI)

Total events: 201 (Treatment), 219 (Control)

Heterogeneity: Tau2=0.04; Chi2=7.24, df=2(P=0.03); I2=72.36%

Test for overall effect: Z=0.76(P=0.45)

Favours treatment

0.1

0.2

0.5

1

2

5

10

Favours control

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

166

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

5.5.2 by 18 weeks

Beuzen 1998 (HGCF)

Subtotal (95% CI)

Treatment

n/N

Control

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

60/90

90

55/90

90

100%

100%

1.09[0.88,1.36]

1.09[0.88,1.36]

Total events: 60 (Treatment), 55 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=0.77(P=0.44)

5.5.3 by 2 years

Meltzer (InterSept)

Subtotal (95% CI)

Total events: 331 (Treatment), 297 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=2.26(P=0.02)

331/490

490

297/490

490

100%

100%

1.11[1.01,1.22]

1.11[1.01,1.22]

Favours treatment

0.1

0.2

0.5

1

2

5

10

Favours control

Analysis 5.6.   Comparison 5 OLANZAPINE vs ATYPICAL ANTIPSYCHOTICS,
Outcome 6 Mental state: 1b. Needing antidepressants by 2 years.

Treatment

n/N

Control

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

263/490

490

235/490

490

100%

100%

1.12[0.99,1.27]

1.12[0.99,1.27]

Study or subgroup

5.6.1 Any antidepressant

Meltzer (InterSept)

Subtotal (95% CI)

Total events: 263 (Treatment), 235 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=1.79(P=0.07)

5.6.2 as a rescue intervention to prevent suicide

Meltzer (InterSept)

Subtotal (95% CI)

33/490

490

15/490

490

Total events: 33 (Treatment), 15 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=2.59(P=0.01)

100%

100%

2.2[1.21,4]

2.2[1.21,4]

Favours treatment

0.1

0.2

0.5

1

2

5

10

Favours control

Analysis 5.7.   Comparison 5 OLANZAPINE vs ATYPICAL ANTIPSYCHOTICS, Outcome
7 Mental state: 2. No important clinical response (decrease in PANSS total score).

Study or subgroup

Treatment

n/N

Control

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

5.7.1 short term - by 6 to 8 weeks (20 to 25% decrease in PANSS total
score)

Chen 2003

Conley 2001

Jeste 2003

Wang 2003

2/30

121/189

36/88

4/61

3/34

119/188

37/87

3/61

0.65%

82.75%

15.69%

0.91%

0.76[0.14,4.22]

1.01[0.87,1.18]

0.96[0.68,1.37]

1.33[0.31,5.71]

Favours Treatment

0.5

0.7

1

1.5

2

Favours Control

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

167

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Treatment

n/N

Control

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Subtotal (95% CI)

368

370

100%

1[0.87,1.15]

Total events: 163 (Treatment), 162 (Control)

Heterogeneity: Tau2=0; Chi2=0.32, df=3(P=0.96); I2=0%

Test for overall effect: Z=0.06(P=0.95)

5.7.2 short term - by 6 weeks (50% decrease in PANSS total score)

Svestka 2003

Subtotal (95% CI)

Total events: 5 (Treatment), 6 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=0.35(P=0.73)

5/21

21

6/21

21

100%

100%

0.83[0.3,2.31]

0.83[0.3,2.31]

5.7.3 medium term - by 18-28 weeks (40% decrease in PANSS total
score)

Beuzen 1998 (HGCF)

Bitter 2004 (HGCK)

Tran 1997 (HGBG)

Subtotal (95% CI)

66/90

41/76

111/172

338

76/90

41/74

123/167

331

Total events: 218 (Treatment), 240 (Control)

Heterogeneity: Tau2=0; Chi2=0.51, df=2(P=0.77); I2=0%

Test for overall effect: Z=2.47(P=0.01)

41.39%

11.4%

47.21%

100%

0.87[0.75,1.01]

0.97[0.73,1.3]

0.88[0.76,1.01]

0.88[0.8,0.97]

Favours Treatment

0.5

0.7

1

1.5

2

Favours Control

Analysis 5.8.   Comparison 5 OLANZAPINE vs ATYPICAL ANTIPSYCHOTICS, Outcome
8 Mental state: 3. No important clinical response (decrease in BPRS total score).

Study or subgroup

Treatment

n/N

Control

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

5.8.1 >20% improvement - 6 to 8 weeks

Simpson 2004

Wang 2002

Subtotal (95% CI)

71/133

8/30

163

66/136

10/33

169

Total events: 79 (Treatment), 76 (Control)

Heterogeneity: Tau2=0; Chi2=0.29, df=1(P=0.59); I2=0%

Test for overall effect: Z=0.67(P=0.5)

5.8.2 >40% improvement - by 8 weeks

Simpson 2004

Subtotal (95% CI)

32/133

133

26/136

136

Total events: 32 (Treatment), 26 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=0.98(P=0.33)

91.83%

8.17%

100%

1.1[0.87,1.39]

0.88[0.4,1.93]

1.08[0.86,1.35]

100%

100%

1.26[0.8,1.99]

1.26[0.8,1.99]

Favours treatment

0.1

0.2

0.5

1

2

5

10

Favours control

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

168

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 5.9.   Comparison 5 OLANZAPINE vs ATYPICAL ANTIPSYCHOTICS,
Outcome 9 Mental state: 4. BPRS total at 8 weeks (endpoint, high score=worse).

Study or subgroup

Treatment

Control

Wang 2002

Total ***

Heterogeneity: Not applicable

Test for overall effect: Z=2.3(P=0.02)

Mean(SD)

21.7 (2.9)

N

30

30

Mean(SD)

23.3 (2.5)

N

31

31

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

100%

-1.6[-2.96,-0.24]

100%

-1.6[-2.96,-0.24]

Favours treatment

-10

-5

0

5

10

Favours control

Analysis 5.10.   Comparison 5 OLANZAPINE vs ATYPICAL ANTIPSYCHOTICS, Outcome 10
Mental state: 5. BPRS total at 3-12 months (endpoint, high score=poor, skewed data).

Study

Intervention

Mean

SD

N

Mental state: 5. BPRS total at 3-12 months (endpoint, high score=poor, skewed data)

Beuzen 1998 (HGCF)

Beuzen 1998 (HGCF)

Thomas 1998 (HGBU)

Thomas 1998 (HGBU)

Tran 1997 (HGBG)

Tran 1997 (HGBG)

Olanzapine

Clozapine

Olanzapine

Risperidone

Olanzapine

Risperidone

27.16

27.05

15.5

19.4

19.66

21.05

17.10

14.93

14.2

8.2

14.86

12.73

89

87

32

30

166

165

Analysis 5.11.   Comparison 5 OLANZAPINE vs ATYPICAL ANTIPSYCHOTICS,
Outcome 11 Mental state: 6. PANSS total (endpoint, high score=poor).

Study or subgroup

Treatment

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

5.11.1 by 3-12 months

Beuzen 1998 (HGCF)

Littrell 1999

Thomas 1998 (HGBU)

Tran 1997 (HGBG)

Wang 2003

Subtotal ***

82.6 (29.1)

78.6 (32.5)

60.6 (22.5)

62.3 (25)

24.2 (5)

89

12

32

166

61

360

82.6 (25.7)

38.4 (8.1)

64.4 (16.3)

70.8 (22.6)

19.9 (7.1)

87

12

30

165

61

355

Heterogeneity: Tau2=78.68; Chi2=37.44, df=4(P<0.0001); I2=89.32%

Test for overall effect: Z=0.67(P=0.5)

20.83%

11.59%

19.3%

23.32%

24.96%

100%

0.03[-8.07,8.13]

40.2[21.25,59.15]

-3.8[-13.54,5.94]

-8.53[-13.67,-3.39]

4.28[2.1,6.46]

3.01[-5.74,11.76]

5.11.2 over 12 months

Jones 1998 (P022)

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=0.33(P=0.74)

58.8 (19.7)

21

21

21

21

57 (16.3)

100%

100%

1.86[-9.08,12.8]

1.86[-9.08,12.8]

Favours Treatment

-10

-5

0

5

10

Favours Control

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

169

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 5.12.   Comparison 5 OLANZAPINE vs ATYPICAL ANTIPSYCHOTICS, Outcome
12 Mental state: 7. Negative symptoms (PANSS, endpoint, high score=poor).

Study or subgroup

Treatment

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

5.12.1 by 8 weeks

Conley 2001

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=0.3(P=0.76)

5.12.2 by 3-12 months

Beuzen 1998 (HGCF)

Littrell 1999

Thomas 1998 (HGBU)

Tran 1997 (HGBG)

Subtotal ***

144

144

89

12

32

166

299

17.9 (5.4)

22 (7.6)

23.6 (9.3)

16.5 (7.3)

18.7 (6.8)

134

134

87

12

30

165

294

17.7 (5.7)

22.8 (7.2)

10.2 (4.7)

17.8 (6.6)

19.5 (6.4)

Heterogeneity: Tau2=10.73; Chi2=21.7, df=3(P<0.0001); I2=86.17%

Test for overall effect: Z=0.83(P=0.41)

100%

100%

0.2[-1.11,1.51]

0.2[-1.11,1.51]

28.29%

17.13%

24.47%

30.1%

100%

-0.75[-2.94,1.44]

13.4[7.5,19.3]

-1.3[-4.76,2.16]

-0.8[-2.22,0.62]

1.52[-2.08,5.13]

5.12.3 over 12 months

Jones 1998 (P022)

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=0.11(P=0.91)

15.9 (5.1)

21

21

16.1 (6.6)

21

21

100%

100%

-0.2[-3.76,3.36]

-0.2[-3.76,3.36]

Favours Treatment

-10

-5

0

5

10

Favours Control

Analysis 5.13.   Comparison 5 OLANZAPINE vs ATYPICAL ANTIPSYCHOTICS, Outcome 13 Mental
state: 8. Negative symptoms (various scales, endpoint, high score=poor, skewed data).

Study

Intervention

Mean

SD

N

Mental state: 8. Negative symptoms (various scales, endpoint, high score=poor, skewed data)

Beuzen 1998 (HGCF)

Beuzen 1998 (HGCF)

Tran 1997 (HGBG)

Tran 1997 (HGBG)

Martin 2002

Martin 2002

Wang 2003

Wang 2003

Olanzapine

Clozapine

Olanzapine

Risperidone

Olanzapine

Amisulpride

Olanzapine

Clozapine

as measured by BPRS - by 18 weeks

5.15

5.28

as measured by SANS - by 28 weeks

7.94

8.70

PANSS - by 6 to 8 weeks

-2.2

-2.0

9.37

10.01

3.22

2.57

5.19

4.69

5.8

5.7

5.70

7.73

89

87

157

151

186

186

31

31

Analysis 5.14.   Comparison 5 OLANZAPINE vs ATYPICAL ANTIPSYCHOTICS, Outcome 14
Mental state: 9. Negative symptoms change data at 6 months (SANS, high score=poor).

Study or subgroup

Treatment

Control

Lecrubier 1999

N

64

Mean(SD)

12.1 (5.2)

N

67

Mean(SD)

12.1 (5.2)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

100%

0[-1.78,1.78]

Favours Treatment

-10

-5

0

5

10

Favours Control

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

170

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Treatment

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

Total ***

64

67

100%

0[-1.78,1.78]

Heterogeneity: Not applicable

Test for overall effect: Not applicable

Favours Treatment

-10

-5

0

5

10

Favours Control

Analysis 5.15.   Comparison 5 OLANZAPINE vs ATYPICAL ANTIPSYCHOTICS, Outcome
15 Mental state: 10. Positive symptoms (PANSS, endpoint, high score=poor).

Study or subgroup

Treatment

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

5.15.1 by 8 weeks

Conley 2001

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=0.42(P=0.67)

144

144

18.6 (5.9)

134

134

18.3 (5.9)

100%

100%

0.3[-1.09,1.69]

0.3[-1.09,1.69]

5.15.2 3-12 months

Littrell 1999

Thomas 1998 (HGBU)

Subtotal ***

15.6 (7.2)

14.8 (6.3)

12

32

44

Heterogeneity: Tau2=24.87; Chi2=8.65, df=1(P=0); I2=88.44%

Test for overall effect: Z=0.93(P=0.35)

5.15.3 over 12 months

Jones 1998 (P022)

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=0.4(P=0.69)

12.5 (5.6)

21

21

8.2 (1.8)

14.9 (4.5)

11.9 (4.5)

12

30

42

21

21

47.62%

52.38%

100%

7.4[3.2,11.6]

-0.1[-2.81,2.61]

3.47[-3.87,10.81]

100%

100%

0.62[-2.43,3.67]

0.62[-2.43,3.67]

Favours Treatment

-10

-5

0

5

10

Favours Control

Analysis 5.16.   Comparison 5 OLANZAPINE vs ATYPICAL ANTIPSYCHOTICS, Outcome 16 Mental
state: 11. Positive symptoms (various scales, endpoint, high score=poor, skewed data).

Study

Intervention

Mean

SD

N

Mental state: 11. Positive symptoms (various scales, endpoint, high score=poor, skewed data)

Beuzen 1998 (HGCF)

Beuzen 1998 (HGCF)

Martin 2002

Martin 2002

Wang 2003

Wang 2003

Tran 1997 (HGBG)

Tran 1997 (HGBG)

Olanzapine

Clozapine

Olanzapine

Amisulpride

Olanzapine

Risperidone

Olanzapine

Risperidone

as measured by BPRS - by 18 weeks

8.16

8.40

5.29

5.07

as measured by PANSS - by 6 to 8 weeks

-9.9

-10.8

6.07

7.35

as measured by PANSS at 28 weeks

15.35

15.55

7.3

7.3

5.03

5.98

7.74

6.60

89

87

186

186

31

31

166

165

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

171

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 5.17.   Comparison 5 OLANZAPINE vs ATYPICAL ANTIPSYCHOTICS, Outcome 17 Mental
state: 12. Depression - by 8 weeks (Hamilton or MADRS rating scale, high score=poor, skewed data).

Mental state: 12. Depression - by 8 weeks (Hamilton or MADRS rating scale, high score=poor, skewed data)

Study

Intervention

Mean

SD

Conley 2001

Conley 2001

Martin 2002

Martin 2002

Olanzapine

Risperidone

Olanzapine

Amisulpride

8.3

7.4

-6.3

-6.0

6.0

5.4

7.7

8.8

189

188

186

186

Analysis 5.18.   Comparison 5 OLANZAPINE vs ATYPICAL ANTIPSYCHOTICS, Outcome
18 Mental state: 13. Depression - by 18 weeks (MADRS, high score=poor, skewed data).

Study

Intervention

mean

SD

Mental state: 13. Depression - by 18 weeks (MADRS, high score=poor, skewed data)

Martin 2002

Martin 2002

Olanzapine

Amisulpride

-6.3

-6.0

7.7

8.8

186

186

N

N

Analysis 5.19.   Comparison 5 OLANZAPINE vs ATYPICAL
ANTIPSYCHOTICS, Outcome 19 Leaving the study early: 1. Any reason.

Treatment

n/N

Control

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Study or subgroup

5.19.1 by 8 weeks

Chan 2003

Chen 2003

Conley 2001

Corrigan 2004

Jeste 2003

Kelly 2003

Martin 2002

Ritchie 2003

Simpson 2004

Tran 1997 (HGBG)

Wang 2002

Wang 2003

Subtotal (95% CI)

4/30

0/30

45/189

24/93

17/88

3/8

42/188

4/34

49/133

36/172

0/30

0/61

1056

4/30

0/34

54/188

84/286

24/87

0/5

39/189

10/32

66/136

28/167

2/33

0/61

1248

7/15

37/90

33/74

8/21

36/70

2/10

71/188

119/156

Total events: 224 (Treatment), 311 (Control)

Heterogeneity: Tau2=0.01; Chi2=10.04, df=9(P=0.35); I2=10.4%

Test for overall effect: Z=1.64(P=0.1)

5.19.2 by 3-12 months

Altamura 1999 (HGBQ)

Beuzen 1998 (HGCF)

Bitter 2004 (HGCK)

Jones 1998 (P022)

Lecrubier 1999

Malyarov 1999

Martin 2002

McQuade 2003

0/13

30/90

30/76

10/21

75/140

0/15

64/189

116/161

favours treatment

0.1

0.2

0.5

1

2

5

10

favours control

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

1.62%

18.96%

15.23%

8.37%

0.35%

15.39%

2.4%

25.33%

12.04%

0.3%

1[0.28,3.63]

Not estimable

0.83[0.59,1.16]

0.88[0.6,1.3]

0.7[0.41,1.21]

4.67[0.29,75.02]

1.08[0.74,1.59]

0.38[0.13,1.08]

0.76[0.57,1.01]

1.25[0.8,1.95]

0.22[0.01,4.39]

Not estimable

100%

0.87[0.74,1.03]

0.12%

5.94%

6.12%

1.83%

10.87%

0.11%

11.16%

34.6%

0.08[0,1.22]

0.81[0.55,1.19]

0.89[0.61,1.29]

1.25[0.62,2.53]

1.04[0.79,1.37]

0.14[0.01,2.6]

0.9[0.68,1.18]

0.94[0.83,1.08]

172

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Treatment

n/N

Control

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Study or subgroup

Naber 2001 (HGBF)

Thomas 1998 (HGBU)

Tran 1997 (HGBG)

Subtotal (95% CI)

36/57

15/32

70/172

966

35/57

21/33

88/167

881

Total events: 446 (Treatment), 457 (Control)

Heterogeneity: Tau2=0; Chi2=11.05, df=10(P=0.35); I2=9.52%

Test for overall effect: Z=1.97(P=0.05)

5.19.3 over 12 months

Littrell 1999

Meltzer (InterSept)

Subtotal (95% CI)

2/12

187/490

502

1/12

192/490

502

Total events: 189 (Treatment), 193 (Control)

Heterogeneity: Tau2=0; Chi2=0.39, df=1(P=0.53); I2=0%

Test for overall effect: Z=0.29(P=0.78)

10.15%

4.38%

14.72%

100%

1.03[0.77,1.37]

0.74[0.47,1.16]

0.77[0.61,0.97]

0.91[0.82,1]

0.48%

99.52%

100%

2[0.21,19.23]

0.97[0.83,1.14]

0.98[0.84,1.14]

favours treatment

0.1

0.2

0.5

1

2

5

10

favours control

Analysis 5.20.   Comparison 5 OLANZAPINE vs ATYPICAL ANTIPSYCHOTICS,
Outcome 20 Leaving the study early: 2. Due to lack of efficacy.

Treatment

n/N

Control

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Study or subgroup

5.20.1 by 8 weeks

Conley 2001

Corrigan 2004

Jeste 2003

Martin 2002

Ritchie 2003

Simpson 2004

Subtotal (95% CI)

Total events: 40 (Treatment), 67 (Control)

Heterogeneity: Tau2=0.2; Chi2=8.04, df=5(P=0.15); I2=37.85%

Test for overall effect: Z=0.25(P=0.8)

5.20.2 by 3-12 months

Bitter 2004 (HGCK)

McQuade 2003

Thomas 1998 (HGBU)

Tran 1997 (HGBG)

Subtotal (95% CI)

4/76

0/1

6/32

17/172

281

Total events: 27 (Treatment), 31 (Control)

Heterogeneity: Tau2=0; Chi2=1.36, df=2(P=0.51); I2=0%

Test for overall effect: Z=0.68(P=0.5)

5/189

4/93

1/88

16/188

3/34

11/133

725

2/188

37/286

3/87

11/189

2/32

12/136

918

3/74

0/1

11/33

17/167

275

10.51%

20.24%

6.18%

27.37%

9.61%

26.1%

100%

10.99%

31.21%

57.8%

100%

2.49[0.49,12.66]

0.33[0.12,0.91]

0.33[0.03,3.11]

1.46[0.7,3.07]

1.41[0.25,7.91]

0.94[0.43,2.05]

0.93[0.51,1.69]

1.3[0.3,5.6]

Not estimable

0.56[0.24,1.34]

0.97[0.51,1.84]

0.85[0.52,1.37]

5.20.3 over 12 months

Jones 1998 (P022)

Subtotal (95% CI)

Total events: 1 (Treatment), 4 (Control)

Heterogeneity: Not applicable

1/21

21

4/21

21

100%

100%

0.25[0.03,2.05]

0.25[0.03,2.05]

Favours Treatment

0.1

0.2

0.5

1

2

5

10

Favours Control

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

173

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Treatment

n/N

Control

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Test for overall effect: Z=1.29(P=0.2)

Favours Treatment

0.1

0.2

0.5

1

2

5

10

Favours Control

Analysis 5.21.   Comparison 5 OLANZAPINE vs ATYPICAL ANTIPSYCHOTICS,
Outcome 21 Adverse events: 1. Anticholinergic effects - specific symptoms.

Study or subgroup

Treatment

n/N

Control

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

5.21.1 constipation by 6 to 8 weeks

Casey 2003

Wang 2003

Subtotal (95% CI)

5/65

7/61

126

12/60

13/61

121

Total events: 12 (Treatment), 25 (Control)

Heterogeneity: Tau2=0; Chi2=0.26, df=1(P=0.61); I2=0%

Test for overall effect: Z=2.33(P=0.02)

42.67%

57.33%

100%

0.38[0.14,1.03]

0.54[0.23,1.26]

0.47[0.25,0.89]

6/90

90

17/90

90

100%

100%

0.35[0.15,0.85]

0.35[0.15,0.85]

59/490

490

131/490

490

100%

100%

0.45[0.34,0.6]

0.45[0.34,0.6]

5.21.2 constipation - by 18 weeks

Beuzen 1998 (HGCF)

Subtotal (95% CI)

Total events: 6 (Treatment), 17 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=2.31(P=0.02)

5.21.3 constipation - by 2 years

Meltzer (InterSept)

Subtotal (95% CI)

Total events: 59 (Treatment), 131 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=5.57(P<0.0001)

5.21.4 dizziness by 6 to 8 weeks

Casey 2003

Conley 2001

Wang 2003

Subtotal (95% CI)

3/65

27/189

6/61

315

7/60

26/188

22/61

309

Total events: 36 (Treatment), 55 (Control)

Heterogeneity: Tau2=0.53; Chi2=8.08, df=2(P=0.02); I2=75.25%

Test for overall effect: Z=1.34(P=0.18)

5.21.5 dizziness - by 18 weeks

Beuzen 1998 (HGCF)

Bitter 2004 (HGCK)

Subtotal (95% CI)

7/90

7/76

166

30/90

10/74

164

Total events: 14 (Treatment), 40 (Control)

Heterogeneity: Tau2=0.39; Chi2=3.13, df=1(P=0.08); I2=68.08%

Test for overall effect: Z=1.76(P=0.08)

5.21.6 diizziness - by 2 years

24.94%

40.82%

34.24%

100%

0.4[0.11,1.46]

1.03[0.63,1.7]

0.27[0.12,0.63]

0.52[0.2,1.35]

52.68%

47.32%

100%

0.23[0.11,0.5]

0.68[0.27,1.7]

0.39[0.14,1.11]

Meltzer (InterSept)

72/490

140/490

100%

0.51[0.4,0.66]

Favours treatment

0.1

0.2

0.5

1

2

5

10

Favours control

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

174

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Treatment

n/N

Control

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Subtotal (95% CI)

490

490

100%

0.51[0.4,0.66]

Total events: 72 (Treatment), 140 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=5.11(P<0.0001)

5.21.7 dry mouth by 6 to 8 weeks

Conley 2001

Wang 2002

Wang 2003

Subtotal (95% CI)

42/189

21/188

8/30

5/61

280

9/33

6/61

282

Total events: 55 (Treatment), 36 (Control)

Heterogeneity: Tau2=0.11; Chi2=3.41, df=2(P=0.18); I2=41.34%

Test for overall effect: Z=1.04(P=0.3)

50.28%

30.39%

19.33%

100%

1.99[1.23,3.23]

0.98[0.43,2.21]

0.83[0.27,2.59]

1.35[0.76,2.41]

5.21.8 dry mouth by 18 weeks

Beuzen 1998 (HGCF)

Subtotal (95% CI)

Total events: 25 (Treatment), 14 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=1.94(P=0.05)

5.21.9 dry mouth - by 2 years

Meltzer (InterSept)

Subtotal (95% CI)

Total events: 56 (Treatment), 37 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=2.05(P=0.04)

25/90

90

14/90

90

100%

100%

1.79[0.99,3.21]

1.79[0.99,3.21]

56/490

490

37/490

490

100%

100%

1.51[1.02,2.25]

1.51[1.02,2.25]

5.21.10 did not report improvement in libido - by 4 weeks

Ritchie 2003

Subtotal (95% CI)

24/34

34

29/32

32

Total events: 24 (Treatment), 29 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=2.01(P=0.04)

5.21.11 rhinitis - by 6 to 8 weeks

Casey 2003

Conley 2001

Svestka 2003

Subtotal (95% CI)

2/65

31/189

1/21

275

8/60

30/188

8/21

269

Total events: 34 (Treatment), 46 (Control)

Heterogeneity: Tau2=1.13; Chi2=7.4, df=2(P=0.02); I2=72.96%

Test for overall effect: Z=1.3(P=0.19)

100%

100%

0.78[0.61,0.99]

0.78[0.61,0.99]

30.74%

44.75%

24.51%

100%

0.23[0.05,1.04]

1.03[0.65,1.63]

0.13[0.02,0.91]

0.39[0.09,1.61]

5/90

90

3/90

90

100%

100%

1.67[0.41,6.77]

1.67[0.41,6.77]

5.21.12 rhinitis - by 18 weeks

Beuzen 1998 (HGCF)

Subtotal (95% CI)

Total events: 5 (Treatment), 3 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=0.71(P=0.47)

5.21.13 salivation - by 6 weeks

Favours treatment

0.1

0.2

0.5

1

2

5

10

Favours control

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

175

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Wang 2003

Subtotal (95% CI)

Treatment

n/N

Control

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

0/61

61

22/61

61

100%

100%

0.02[0,0.36]

0.02[0,0.36]

Total events: 0 (Treatment), 22 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=2.68(P=0.01)

5.21.14 salivation by 18 weeks

Beuzen 1998 (HGCF)

Bitter 2004 (HGCK)

Subtotal (95% CI)

14/90

5/76

166

58/90

9/74

164

Total events: 19 (Treatment), 67 (Control)

Heterogeneity: Tau2=0.15; Chi2=1.86, df=1(P=0.17); I2=46.12%

Test for overall effect: Z=3.03(P=0)

66.74%

33.26%

100%

0.24[0.15,0.4]

0.54[0.19,1.54]

0.32[0.15,0.67]

5.21.15 salivation by 2 years

Meltzer (InterSept)

Subtotal (95% CI)

Total events: 41 (Treatment), 240 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=11.3(P<0.0001)

41/490

490

240/490

490

100%

100%

0.17[0.13,0.23]

0.17[0.13,0.23]

5.21.16 urinary incontinence - by 2 years

Meltzer (InterSept)

Subtotal (95% CI)

19/490

490

42/490

490

Total events: 19 (Treatment), 42 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=2.95(P=0)

5.21.17 vision abnormalities - by 8 weeks

Conley 2001

Subtotal (95% CI)

19/189

189

12/188

188

Total events: 19 (Treatment), 12 (Control)

Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%

Test for overall effect: Z=1.28(P=0.2)

5.21.18 vision abnormalities by 2 years

Meltzer (InterSept)

Subtotal (95% CI)

1/490

490

0/490

490

Total events: 1 (Treatment), 0 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=0.67(P=0.5)

100%

100%

0.45[0.27,0.77]

0.45[0.27,0.77]

100%

100%

1.57[0.79,3.15]

1.57[0.79,3.15]

100%

100%

3[0.12,73.46]

3[0.12,73.46]

Favours treatment

0.1

0.2

0.5

1

2

5

10

Favours control

Analysis 5.22.   Comparison 5 OLANZAPINE vs ATYPICAL ANTIPSYCHOTICS, Outcome
22 Adverse events: 2a. Extrapyramidal - needing anticholinergic medication.

Study or subgroup

5.22.1 by 8 weeks

Treatment

n/N

Control

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Favours Treatment

0.2

0.5

1

2

5

Favours Control

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

176

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Treatment

n/N

Control

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Study or subgroup

Chan 2003

Conley 2001

Jeste 2003

Simpson 2004

Svestka 2003

Subtotal (95% CI)

4/30

84/189

30/88

20/133

5/21

461

16/30

97/188

35/87

34/136

13/21

462

Total events: 143 (Treatment), 195 (Control)

Heterogeneity: Tau2=0.08; Chi2=10.4, df=4(P=0.03); I2=61.54%

Test for overall effect: Z=2.49(P=0.01)

5.22.2 by 3 to 12 months

Beuzen 1998 (HGCF)

Tran 1997 (HGBG)

Subtotal (95% CI)

6/90

34/172

262

16/90

55/167

257

Total events: 40 (Treatment), 71 (Control)

Heterogeneity: Tau2=0; Chi2=0.92, df=1(P=0.34); I2=0%

Test for overall effect: Z=3.32(P=0)

9.46%

32.52%

25.3%

20.97%

11.75%

100%

0.25[0.09,0.66]

0.86[0.7,1.06]

0.85[0.58,1.25]

0.6[0.37,0.99]

0.38[0.17,0.89]

0.64[0.46,0.91]

14.75%

85.25%

100%

0.38[0.15,0.91]

0.6[0.41,0.87]

0.56[0.4,0.79]

Favours Treatment

0.2

0.5

1

2

5

Favours Control

Analysis 5.23.   Comparison 5 OLANZAPINE vs ATYPICAL
ANTIPSYCHOTICS, Outcome 23 Adverse events: 2b. Extrapyramidal - any.

Study or subgroup

Treatment

n/N

Control

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

5.23.1 any extrapyramidal event by 8 weeks

Conley 2001

Jeste 2003

Svestka 2003

Wang 2002

Subtotal (95% CI)

37/189

31/88

6/21

1/30

328

45/188

32/87

15/21

2/33

329

Total events: 75 (Treatment), 94 (Control)

Heterogeneity: Tau2=0.04; Chi2=4.39, df=3(P=0.22); I2=31.59%

Test for overall effect: Z=1.55(P=0.12)

5.23.2 any extrapyramidal event by 3-12 months

Tran 1997 (HGBG)

Subtotal (95% CI)

32/172

172

52/167

167

Total events: 32 (Treatment), 52 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=2.62(P=0.01)

40.57%

39.54%

17.76%

2.13%

100%

0.82[0.56,1.2]

0.96[0.65,1.42]

0.4[0.19,0.83]

0.55[0.05,5.76]

0.76[0.54,1.08]

100%

100%

0.6[0.41,0.88]

0.6[0.41,0.88]

Favours treatment

0.1

0.2

0.5

1

2

5

10

Favours control

Analysis 5.24.   Comparison 5 OLANZAPINE vs ATYPICAL ANTIPSYCHOTICS, Outcome 24 Adverse
events: 2c. Extrapyramidal - parkinsonism ESRS (endpoint, high score=poor, skewed data).

Adverse events: 2c. Extrapyramidal - parkinsonism ESRS (endpoint, high score=poor, skewed data)

Study

Intervention

Mean

by 8 weeks

SD

N

Conley 2001

Olanzapine

3.8

4.6

145

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

177

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Adverse events: 2c. Extrapyramidal - parkinsonism ESRS (endpoint, high score=poor, skewed data)

Study

Intervention

Mean

SD

N

Conley 2001

Risperidone

Jones 1998 (P022)

Jones 1998 (P022)

Olanzapine

Risperidone

by 1 year

4.2

1.19

3.24

4.9

1.86

2.84

133

21

21

Analysis 5.25.   Comparison 5 OLANZAPINE vs ATYPICAL ANTIPSYCHOTICS,
Outcome 25 Adverse events: 2d. Extrapyramidal - specific symptoms.

Study or subgroup

Treatment

n/N

Control

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

5.25.1 akathisia - by 3 to 12 months

Beuzen 1998 (HGCF)

Bitter 2004 (HGCK)

Kern 2001

Tran 1997 (HGBG)

Subtotal (95% CI)

9/90

10/76

9/127

17/172

465

10/90

4/74

13/128

18/167

459

Total events: 45 (Treatment), 45 (Control)

Heterogeneity: Tau2=0.02; Chi2=3.32, df=3(P=0.35); I2=9.51%

Test for overall effect: Z=0.11(P=0.91)

22.7%

13.77%

24.66%

38.87%

100%

0.9[0.38,2.11]

2.43[0.8,7.42]

0.7[0.31,1.57]

0.92[0.49,1.72]

0.98[0.64,1.49]

5.25.2 akathisia - by 2 years

Meltzer (InterSept)

Subtotal (95% CI)

Total events: 52 (Treatment), 32 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=2.25(P=0.02)

52/490

490

32/490

490

100%

100%

1.63[1.07,2.48]

1.63[1.07,2.48]

5.25.3 dyskinetic movements - by 8 weeks

Jeste 2003

Subtotal (95% CI)

19/88

88

27/87

87

Total events: 19 (Treatment), 27 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=1.4(P=0.16)

5.25.4 dyskinetic movements - by 3 to 12 months

Beuzen 1998 (HGCF)

Tran 1997 (HGBG)

Subtotal (95% CI)

5/90

4/172

262

4/90

5/167

257

Total events: 9 (Treatment), 9 (Control)

Heterogeneity: Tau2=0; Chi2=0.26, df=1(P=0.61); I2=0%

Test for overall effect: Z=0.03(P=0.98)

5.25.5 new parkinsonism - by 3 to 12 months

Beuzen 1998 (HGCF)

Tran 1997 (HGBG)

Subtotal (95% CI)

7/90

22/172

262

9/90

37/167

257

Total events: 29 (Treatment), 46 (Control)

Heterogeneity: Tau2=0; Chi2=0.3, df=1(P=0.58); I2=0%

Test for overall effect: Z=2.22(P=0.03)

100%

100%

0.7[0.42,1.15]

0.7[0.42,1.15]

50.6%

49.4%

100%

1.25[0.35,4.5]

0.78[0.21,2.84]

0.99[0.4,2.46]

20.75%

79.25%

100%

0.78[0.3,2]

0.58[0.36,0.94]

0.61[0.4,0.94]

Favours Treatment

0.1

0.2

0.5

1

2

5

10

Favours Control

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

178

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Treatment

n/N

Control

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

5.25.6 restlessness - by 6 weeks

Wang 2003

Subtotal (95% CI)

Total events: 2 (Treatment), 2 (Control)

Heterogeneity: Not applicable

Test for overall effect: Not applicable

5.25.7 tardive dyskinesia

Beuzen 1998 (HGCF)

Subtotal (95% CI)

Total events: 6 (Treatment), 4 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=0.65(P=0.52)

5.25.8 tremor - by 6 to 8 weeks

Jeste 2003

Wang 2003

Subtotal (95% CI)

2/61

61

6/90

90

2/61

61

4/90

90

23/88

3/61

149

25/87

12/61

148

Total events: 26 (Treatment), 37 (Control)

Heterogeneity: Tau2=0.65; Chi2=3.91, df=1(P=0.05); I2=74.42%

Test for overall effect: Z=0.96(P=0.34)

100%

100%

1[0.15,6.87]

1[0.15,6.87]

100%

100%

1.5[0.44,5.14]

1.5[0.44,5.14]

59.3%

40.7%

100%

0.91[0.56,1.47]

0.25[0.07,0.84]

0.54[0.15,1.91]

Favours Treatment

0.1

0.2

0.5

1

2

5

10

Favours Control

Analysis 5.26.   Comparison 5 OLANZAPINE vs ATYPICAL ANTIPSYCHOTICS, Outcome
26 Adverse events: 3. Treatment emergent adverse events -by 4 to 8 weeks.

Study or subgroup

Casey 2003

Jeste 2003

Simpson 2004

Treatment

n/N

Control

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

48/65

61/88

95/133

47/60

62/87

115/136

22.97%

23.91%

53.12%

0.94[0.77,1.15]

0.97[0.8,1.18]

0.84[0.74,0.96]

Total (95% CI)

286

283

100%

0.9[0.82,0.98]

Total events: 204 (Treatment), 224 (Control)

Heterogeneity: Tau2=0; Chi2=1.77, df=2(P=0.41); I2=0%

Test for overall effect: Z=2.28(P=0.02)

Favours treatment

0.1

0.2

0.5

1

2

5

10

Favours control

Analysis 5.27.   Comparison 5 OLANZAPINE vs ATYPICAL ANTIPSYCHOTICS, Outcome 27 Adverse events: 4. Other:.

Study or subgroup

5.27.1 agitation - by 8 weeks

Conley 2001

Jeste 2003

Subtotal (95% CI)

Treatment

n/N

Control

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

40/189

24/88

277

29/188

35/87

275

49.85%

50.15%

100%

1.37[0.89,2.12]

0.68[0.44,1.04]

0.96[0.48,1.93]

Total events: 64 (Treatment), 64 (Control)

Favours treatment

0.1

0.2

0.5

1

2

5

10

Favours control

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

179

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Treatment

n/N

Control

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Heterogeneity: Tau2=0.2; Chi2=5.21, df=1(P=0.02); I2=80.81%

Test for overall effect: Z=0.11(P=0.92)

5.27.2 agitation - by 18 to 26 weeks

Beuzen 1998 (HGCF)

Kern 2001

Subtotal (95% CI)

10/90

8/127

217

4/90

15/128

218

Total events: 18 (Treatment), 19 (Control)

Heterogeneity: Tau2=0.93; Chi2=4.7, df=1(P=0.03); I2=78.72%

Test for overall effect: Z=0.13(P=0.9)

5.27.3 anxiety - by 6 to 8 weeks

Casey 2003

Conley 2001

Subtotal (95% CI)

3/65

23/189

254

7/60

20/188

248

Total events: 26 (Treatment), 27 (Control)

Heterogeneity: Tau2=0.3; Chi2=2.15, df=1(P=0.14); I2=53.44%

Test for overall effect: Z=0.45(P=0.65)

5.27.4 anxiety - by 18 to 26 weeks

Beuzen 1998 (HGCF)

Kern 2001

Subtotal (95% CI)

5/90

5/127

217

5/90

22/128

218

Total events: 10 (Treatment), 27 (Control)

Heterogeneity: Tau2=0.79; Chi2=3.61, df=1(P=0.06); I2=72.31%

Test for overall effect: Z=1.06(P=0.29)

5.27.5 asthenia - by 4 weeks

Casey 2003

Subtotal (95% CI)

Total events: 3 (Treatment), 4 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=0.5(P=0.62)

5.27.6 asthenia - by 18 weeks

Beuzen 1998 (HGCF)

Bitter 2004 (HGCK)

Subtotal (95% CI)

3/65

65

2/90

9/76

166

Total events: 11 (Treatment), 17 (Control)

Heterogeneity: Tau2=0; Chi2=0.94, df=1(P=0.33); I2=0%

Test for overall effect: Z=1.11(P=0.27)

4/60

60

6/90

11/74

164

46.79%

53.21%

100%

2.5[0.81,7.68]

0.54[0.24,1.22]

1.1[0.25,4.97]

34.04%

65.96%

100%

0.4[0.11,1.46]

1.14[0.65,2.01]

0.8[0.3,2.14]

46.63%

53.37%

100%

1[0.3,3.34]

0.23[0.09,0.59]

0.46[0.11,1.94]

100%

100%

0.69[0.16,2.97]

0.69[0.16,2.97]

21.39%

78.61%

100%

0.33[0.07,1.61]

0.8[0.35,1.81]

0.66[0.32,1.37]

5.27.7 asthenia - by 2 years

Meltzer (InterSept)

Subtotal (95% CI)

Total events: 24 (Treatment), 47 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=2.77(P=0.01)

24/490

490

47/490

490

100%

100%

0.51[0.32,0.82]

0.51[0.32,0.82]

5.27.8 decrease in white blood cells - 4 weeks

Wang 2003

Subtotal (95% CI)

0/61

61

0/61

61

Favours treatment

0.1

0.2

0.5

1

2

5

10

Favours control

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Not estimable

Not estimable

180

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Treatment

n/N

Control

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Total events: 0 (Treatment), 0 (Control)

Heterogeneity: Not applicable

Test for overall effect: Not applicable

5.27.9 decrease in white blood cells - by 18 to 26 weeks

Beuzen 1998 (HGCF)

Bitter 2004 (HGCK)

Subtotal (95% CI)

1/90

0/76

166

5/90

2/74

164

Total events: 1 (Treatment), 7 (Control)

Heterogeneity: Tau2=0; Chi2=0, df=1(P=0.99); I2=0%

Test for overall effect: Z=1.82(P=0.07)

5.27.10 decrease in white blood cells - by 2 years

Meltzer (InterSept)

Subtotal (95% CI)

17/490

490

39/490

490

Total events: 17 (Treatment), 39 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=2.93(P=0)

5.27.11 diabetes mellitus - by 2 years

Meltzer (InterSept)

Subtotal (95% CI)

34/490

490

27/490

490

66.84%

33.16%

100%

0.2[0.02,1.68]

0.19[0.01,3.99]

0.2[0.03,1.13]

100%

100%

0.44[0.25,0.76]

0.44[0.25,0.76]

100%

100%

1.26[0.77,2.05]

1.26[0.77,2.05]

Total events: 34 (Treatment), 27 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=0.92(P=0.36)

5.27.12 dyspepsia - by 4 weeks

Casey 2003

Subtotal (95% CI)

Total events: 11 (Treatment), 11 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=0.21(P=0.84)

5.27.13 dyspepsia - by 2 years

Meltzer (InterSept)

Subtotal (95% CI)

Total events: 53 (Treatment), 77 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=2.24(P=0.03)

5.27.14 fever - by 18 weeks

Beuzen 1998 (HGCF)

Subtotal (95% CI)

Total events: 1 (Treatment), 5 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=1.48(P=0.14)

5.27.15 flu syndrome - by 18 weeks

Beuzen 1998 (HGCF)

Bitter 2004 (HGCK)

Subtotal (95% CI)

Total events: 11 (Treatment), 13 (Control)

11/65

65

11/60

60

100%

100%

0.92[0.43,1.97]

0.92[0.43,1.97]

53/490

490

77/490

490

100%

100%

0.69[0.5,0.95]

0.69[0.5,0.95]

1/90

90

3/90

8/76

166

5/90

90

5/90

8/74

164

100%

100%

0.2[0.02,1.68]

0.2[0.02,1.68]

30.41%

69.59%

100%

0.6[0.15,2.44]

0.97[0.39,2.46]

0.84[0.39,1.82]

Favours treatment

0.1

0.2

0.5

1

2

5

10

Favours control

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

181

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Treatment

n/N

Control

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Heterogeneity: Tau2=0; Chi2=0.32, df=1(P=0.57); I2=0%

Test for overall effect: Z=0.44(P=0.66)

5.27.16 headache - 4 to 8 weeks

Casey 2003

Conley 2001

Jeste 2003

Subtotal (95% CI)

9/65

32/189

22/88

342

15/60

41/188

30/87

335

Total events: 63 (Treatment), 86 (Control)

Heterogeneity: Tau2=0; Chi2=0.6, df=2(P=0.74); I2=0%

Test for overall effect: Z=2.25(P=0.02)

5.27.17 headache - 18 to 26 weeks

Bitter 2004 (HGCK)

Kern 2001

Subtotal (95% CI)

12/76

17/127

203

10/74

22/128

202

Total events: 29 (Treatment), 32 (Control)

Heterogeneity: Tau2=0; Chi2=0.67, df=1(P=0.41); I2=0%

Test for overall effect: Z=0.43(P=0.66)

4/21

21

1/61

61

5/65

65

17/21

21

5/61

61

9/60

60

5.27.18 hyperprolactinaemia - by 6 weeks

Svestka 2003

Subtotal (95% CI)

Total events: 4 (Treatment), 17 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=3.13(P=0)

5.27.19 increased transaminase - by 6 weeks

Wang 2003

Subtotal (95% CI)

Total events: 1 (Treatment), 5 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=1.49(P=0.14)

5.27.20 nausea - by 4 weeks

Casey 2003

Subtotal (95% CI)

Total events: 5 (Treatment), 9 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=1.26(P=0.21)

5.27.21 nausea - by 18 to 26 weeks

Beuzen 1998 (HGCF)

Kern 2001

Subtotal (95% CI)

14.62%

47.3%

38.08%

100%

0.55[0.26,1.17]

0.78[0.51,1.18]

0.73[0.46,1.15]

0.72[0.54,0.96]

36.12%

63.88%

100%

1.17[0.54,2.54]

0.78[0.43,1.4]

0.9[0.57,1.44]

100%

100%

0.24[0.1,0.58]

0.24[0.1,0.58]

100%

100%

0.2[0.02,1.66]

0.2[0.02,1.66]

100%

100%

0.51[0.18,1.44]

0.51[0.18,1.44]

1/90

8/127

217

10/90

23/128

218

21.91%

78.09%

100%

0.1[0.01,0.77]

0.35[0.16,0.75]

0.27[0.09,0.75]

Total events: 9 (Treatment), 33 (Control)

Heterogeneity: Tau2=0.21; Chi2=1.34, df=1(P=0.25); I2=25.26%

Test for overall effect: Z=2.49(P=0.01)

5.27.22 nausea - by 2 years

Meltzer (InterSept)

Subtotal (95% CI)

60/490

490

90/490

490

100%

100%

0.67[0.49,0.9]

0.67[0.49,0.9]

Favours treatment

0.1

0.2

0.5

1

2

5

10

Favours control

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

182

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Treatment

n/N

Control

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Total events: 60 (Treatment), 90 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=2.63(P=0.01)

5.27.23 pain - by 4 weeks

Casey 2003

Subtotal (95% CI)

Total events: 7 (Treatment), 11 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=1.18(P=0.24)

5.27.24 postural hypotension - by 18 weeks

Bitter 2004 (HGCK)

Subtotal (95% CI)

Total events: 7 (Treatment), 8 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=0.33(P=0.74)

5.27.25 SGPT increased - by 4 weeks

Casey 2003

Subtotal (95% CI)

Total events: 5 (Treatment), 0 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=1.58(P=0.11)

5.27.26 sweating - by 18 weeks

Beuzen 1998 (HGCF)

Subtotal (95% CI)

Total events: 2 (Treatment), 5 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=1.11(P=0.27)

5.27.27 tachycardia - by 6 weeks

Wang 2003

Subtotal (95% CI)

Total events: 1 (Treatment), 18 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=2.86(P=0)

5.27.28 tooth disorder

Beuzen 1998 (HGCF)

Subtotal (95% CI)

Total events: 0 (Treatment), 4 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=1.48(P=0.14)

5.27.29 vomiting - by 4 weeks

Casey 2003

Subtotal (95% CI)

Total events: 3 (Treatment), 8 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=1.62(P=0.1)

7/65

65

7/76

76

5/65

65

2/90

90

1/61

61

0/90

90

3/65

65

11/60

60

8/74

74

0/60

60

5/90

90

18/61

61

4/90

90

8/60

60

100%

100%

0.59[0.24,1.42]

0.59[0.24,1.42]

100%

100%

0.85[0.33,2.23]

0.85[0.33,2.23]

100%

100%

10.17[0.57,180.04]

10.17[0.57,180.04]

100%

100%

0.4[0.08,2.01]

0.4[0.08,2.01]

100%

100%

0.06[0.01,0.4]

0.06[0.01,0.4]

100%

100%

0.11[0.01,2.03]

0.11[0.01,2.03]

100%

100%

0.35[0.1,1.24]

0.35[0.1,1.24]

Favours treatment

0.1

0.2

0.5

1

2

5

10

Favours control

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

183

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Treatment

n/N

Control

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

5.27.30 vomiting - by 18 weeks

Beuzen 1998 (HGCF)

Subtotal (95% CI)

Total events: 4 (Treatment), 5 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=0.34(P=0.73)

5.27.31 vomiting - by 2 years

Meltzer (InterSept)

Subtotal (95% CI)

Total events: 55 (Treatment), 90 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=3.1(P=0)

4/90

90

5/90

90

100%

100%

0.8[0.22,2.88]

0.8[0.22,2.88]

55/490

490

90/490

490

100%

100%

0.61[0.45,0.83]

0.61[0.45,0.83]

Favours treatment

0.1

0.2

0.5

1

2

5

10

Favours control

Analysis 5.28.   Comparison 5 OLANZAPINE vs ATYPICAL ANTIPSYCHOTICS, Outcome 28 Adverse
events: 8. Simpson and Angus Scale - by 2 months (endpoint, high score=poor, skewed data).

Adverse events: 8. Simpson and Angus Scale - by 2 months (endpoint, high score=poor, skewed data)

Study

Intervention

mean

SD

N

Martin 2002

Martin 2002

Olanzapine

Amisulpride

0.21

0.24

0.36

0.40

185

186

Analysis 5.29.   Comparison 5 OLANZAPINE vs ATYPICAL ANTIPSYCHOTICS, Outcome 29 Adverse events:
9. Yale Brown Obsessive Compulsive Scale - by 6 weeks (endpoint, high score=poor, skewed da.

Adverse events: 9. Yale Brown Obsessive Compulsive Scale - by 6 weeks (endpoint, high score=poor, skewed da

de Haan 2002

de Haan 2002

Study

Olanzapine

Risperidone

Analysis 5.30.   Comparison 5 OLANZAPINE vs ATYPICAL
ANTIPSYCHOTICS, Outcome 30 Adverse events: 10. Sleep problems.

Study or subgroup

Treatment

n/N

Control

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

5.30.1 insomnia by 6 to 8 weeks

Conley 2001

Wang 2003

Subtotal (95% CI)

35/189

3/61

250

45/188

0/61

249

Total events: 38 (Treatment), 45 (Control)

Heterogeneity: Tau2=1.34; Chi2=2.17, df=1(P=0.14); I2=53.89%

Test for overall effect: Z=0.36(P=0.72)

5.30.2 insomnia by 18 to 26 weeks

72.25%

27.75%

100%

0.77[0.52,1.15]

7[0.37,132.7]

1.43[0.2,10.09]

Favours treatment

0.1

0.2

0.5

1

2

5

10

Favours control

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

184

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Kern 2001

Subtotal (95% CI)

Treatment

n/N

Control

n/N

14/127

127

41/128

128

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

100%

100%

0.34[0.2,0.6]

0.34[0.2,0.6]

Total events: 14 (Treatment), 41 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=3.77(P=0)

5.30.3 insomnia - by 2 years

Meltzer (InterSept)

Subtotal (95% CI)

Total events: 168 (Treatment), 107 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=4.26(P<0.0001)

5.30.4 somnolence by 6 to 8 weeks

168/490

490

107/490

490

100%

100%

1.57[1.28,1.93]

1.57[1.28,1.93]

Casey 2003

Conley 2001

Wang 2002

Wang 2003

Subtotal (95% CI)

16/65

73/189

7/31

16/61

346

Total events: 112 (Treatment), 130 (Control)

Heterogeneity: Tau2=0.17; Chi2=11.43, df=3(P=0.01); I2=73.76%

Test for overall effect: Z=1.24(P=0.22)

5.30.5 somnolence by 18 to 26 weeks

Beuzen 1998 (HGCF)

Bitter 2004 (HGCK)

Kern 2001

Subtotal (95% CI)

12/90

8/76

37/127

293

Total events: 57 (Treatment), 55 (Control)

Heterogeneity: Tau2=0.63; Chi2=13.93, df=2(P=0); I2=85.65%

Test for overall effect: Z=0.3(P=0.76)

13/60

69/188

20/32

28/61

341

22/90

15/74

18/128

292

21.86%

32.15%

20.28%

25.71%

100%

33.52%

31.06%

35.43%

100%

1.14[0.6,2.16]

1.05[0.81,1.36]

0.36[0.18,0.73]

0.57[0.35,0.94]

0.74[0.45,1.2]

0.55[0.29,1.03]

0.52[0.23,1.15]

2.07[1.25,3.44]

0.86[0.33,2.28]

5.30.6 somnolence - by 2 years

Meltzer (InterSept)

Subtotal (95% CI)

Total events: 131 (Treatment), 231 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=6.39(P<0.0001)

131/490

490

231/490

490

100%

100%

0.57[0.48,0.67]

0.57[0.48,0.67]

Favours treatment

0.1

0.2

0.5

1

2

5

10

Favours control

Study or subgroup

5.31.1 4 to 8 weeks

Casey 2003

Wang 2002

Wang 2003

Analysis 5.31.   Comparison 5 OLANZAPINE vs ATYPICAL
ANTIPSYCHOTICS, Outcome 31 Adverse events: 6. Weight gain.

Treatment

n/N

Control

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

9/65

9/31

5/31

5/60

8/32

12/31

29.7%

36.9%

33.39%

1.66[0.59,4.68]

1.16[0.51,2.62]

0.42[0.17,1.04]

Favours treatment

0.1

0.2

0.5

1

2

5

10

Favours control

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

185

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Treatment

n/N

Control

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Subtotal (95% CI)

127

123

100%

0.92[0.42,2.02]

Total events: 23 (Treatment), 25 (Control)

Heterogeneity: Tau2=0.27; Chi2=4.43, df=2(P=0.11); I2=54.87%

Test for overall effect: Z=0.21(P=0.83)

5.31.2 3 to 12 months

Beuzen 1998 (HGCF)

Bitter 2004 (HGCK)

Kern 2001

Subtotal (95% CI)

6/90

13/76

37/127

293

6/90

11/74

9/128

292

Total events: 56 (Treatment), 26 (Control)

Heterogeneity: Tau2=0.53; Chi2=8.16, df=2(P=0.02); I2=75.48%

Test for overall effect: Z=1.16(P=0.25)

28.24%

35.37%

36.38%

100%

1[0.34,2.98]

1.15[0.55,2.4]

4.14[2.09,8.23]

1.76[0.68,4.59]

5.31.3 over 12 months

Meltzer (InterSept)

Subtotal (95% CI)

Total events: 278 (Treatment), 161 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=7.22(P<0.0001)

278/490

490

161/490

490

100%

100%

1.73[1.49,2]

1.73[1.49,2]

Favours treatment

0.1

0.2

0.5

1

2

5

10

Favours control

Analysis 5.32.   Comparison 5 OLANZAPINE vs ATYPICAL
ANTIPSYCHOTICS, Outcome 32 Adverse events: 7. Weight gain.

Study or subgroup

Treatment

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

5.32.1 by 3-12 months

Lecrubier 1999

Thomas 1998 (HGBU)

Tran 1997 (HGBG)

Subtotal ***

72.9 (13.6)

89.3 (23.4)

80.9 (19.4)

70

32

166

268

70

32

165

267

71.9 (14.1)

81.6 (16.8)

78.7 (15.5)

Heterogeneity: Tau2=0; Chi2=1.42, df=2(P=0.49); I2=0%

Test for overall effect: Z=1.52(P=0.13)

37.23%

7.87%

54.9%

100%

1.03[-3.56,5.62]

7.71[-2.28,17.7]

2.16[-1.62,5.94]

2.18[-0.63,4.98]

5.32.2 over 12 months

Jones 1998 (P022)

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=1.84(P=0.07)

84.8 (17.7)

22

22

74.7 (18.8)

22

22

100%

100%

10.09[-0.68,20.86]

10.09[-0.68,20.86]

Favours Treatment

-10

-5

0

5

10

Favours Control

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

186

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 5.33.   Comparison 5 OLANZAPINE vs ATYPICAL ANTIPSYCHOTICS,
Outcome 33 Adverse events: 8. Weight - by 8 weeks (change data).

Study or subgroup

Treatment

Control

Chan 2003

Conley 2001

Ritchie 2003

Total ***

Mean(SD)

3 (3.5)

3.9 (5)

2.8 (1.8)

N

26

189

19

234

Mean(SD)

1.2 (3.2)

2 (3.7)

2.1 (1.4)

N

26

188

15

229

Heterogeneity: Tau2=0.16; Chi2=2.86, df=2(P=0.24); I2=30.12%

Test for overall effect: Z=3.47(P=0)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

16.89%

46.34%

36.77%

1.74[-0.06,3.54]

1.88[0.99,2.77]

0.7[-0.38,1.78]

100%

1.42[0.62,2.23]

Favours treatment

-10

-5

0

5

10

Favours control

Analysis 5.34.   Comparison 5 OLANZAPINE vs ATYPICAL ANTIPSYCHOTICS, Outcome
34 Quality of life: 1. QOL total - by 3 to 12 months(endpoint, high score=good).

Study or subgroup

Treatment

Control

Tran 1997 (HGBG)

Total ***

Heterogeneity: Not applicable

Test for overall effect: Z=0.75(P=0.46)

Mean(SD)

62 (27.3)

N

118

118

Mean(SD)

59.6 (22.7)

N

122

122

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

100%

2.42[-3.93,8.77]

100%

2.42[-3.93,8.77]

Favours treatment

-10

-5

0

5

10

Favours control

Analysis 5.35.   Comparison 5 OLANZAPINE vs ATYPICAL ANTIPSYCHOTICS, Outcome
35 Quality of life: 2. QLS total by 3 to 12 months (endpoint, high score=good).

Study or subgroup

Treatment

Control

Lecrubier 1999

Thomas 1998 (HGBU)

Total ***

N

Mean(SD)

N

Mean(SD)

53.3 (25.4)

83.4 (11.9)

53

32

85

50.7 (20.6)

89.4 (24.3)

58

29

87

Heterogeneity: Tau2=14.84; Chi2=1.67, df=1(P=0.2); I2=40.13%

Test for overall effect: Z=0.32(P=0.75)

Mean Difference

Random, 95% CI

Weight

Mean Difference

53.58%

46.42%

Random, 95% CI

2.6[-6.05,11.25]

-6[-15.76,3.76]

100%

-1.39[-9.8,7.01]

Favours treatment

-10

-5

0

5

10

Favours control

Analysis 5.36.   Comparison 5 OLANZAPINE vs ATYPICAL ANTIPSYCHOTICS,
Outcome 36 Service outcome:1. Discharged from hospital - by 8 weeks.

Study or subgroup

Treatment

n/N

Control

n/N

Martin 2002

94/108

95/106

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

100%

0.97[0.88,1.07]

Total (95% CI)

108

106

100%

0.97[0.88,1.07]

Favours treatment

0.5

0.7

1

1.5

2

Favours control

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

187

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Treatment

n/N

Control

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Total events: 94 (Treatment), 95 (Control)

Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%

Test for overall effect: Z=0.59(P=0.56)

Favours treatment

0.5

0.7

1

1.5

2

Favours control

Analysis 5.37.   Comparison 5 OLANZAPINE vs ATYPICAL ANTIPSYCHOTICS, Outcome
37 Service outcome: 2. Hospitalisation for imminent risk of suicide - by 2 years.

Study or subgroup

Treatment

n/N

Control

n/N

Meltzer (InterSept)

128/490

100/490

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

100%

1.28[1.02,1.61]

Total (95% CI)

490

490

100%

1.28[1.02,1.61]

Total events: 128 (Treatment), 100 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=2.11(P=0.04)

Favours treatment

0.1

0.2

0.5

1

2

5

10

Favours control

Analysis 5.38.   Comparison 5 OLANZAPINE vs ATYPICAL ANTIPSYCHOTICS,
Outcome 38 Service outcome: 3. Increase in level of surveillance - by two years.

Study or subgroup

Treatment

n/N

Control

n/N

Meltzer (InterSept)

57/490

41/490

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

100%

1.39[0.95,2.04]

Total (95% CI)

490

490

100%

1.39[0.95,2.04]

Total events: 57 (Treatment), 41 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=1.69(P=0.09)

Favours treatment

0.1

0.2

0.5

1

2

5

10

Favours control

Comparison 6.   OLANZAPINE vs ATYPICAL ANTIPSYCHOTICS FOR PEOPLE WITH TREATMENT RESISTANT ILLNESS

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

1 Death - by 18 weeks

2 Global effect: No clinically impor-
tant response - by 18 weeks

2.1 as measured by CGI

1

2

2

180

330

Risk Ratio (M-H, Random, 95%
CI)

0.0 [0.0, 0.0]

Risk Ratio (M-H, Random, 95%
CI)

Subtotals only

Risk Ratio (M-H, Random, 95%
CI)

0.89 [0.73, 1.08]

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

188

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

2

2

2.2 as measured by Kane criteria

3 Mental state: 1. No important clini-
cal response - by 18 weeks (20% de-
crease in PANSS)

4 Mental state: 2. BPRS total - by 18
weeks (endpoint, high score=poor,
skewed data)

5 Mental state: 3. PANSS total - by 18
weeks (endpoint, high score=poor)

1

6 Mental state: 4. Negative symp-
toms - by 18 weeks (BPRS, endpoint,
high score=poor, skewed data)

7 Mental state: 5. Negative symp-
toms - by 18 weeks (PANSS, end-
point, high score=poor)

8 Mental state: 6. Positive symptoms
- by 18 weeks (BPRS, endpoint, high
score=poor, skewed data)

9 Leaving the study early. Any rea-
son

9.1 by 8 weeks

9.2 by 3-12 months

10 Leaving the study early. due to
lack of efficacy - by 18 weeks

11 Adverse events: 1. HAS - by 18
weeks (change, high score=poor)

12 Adverse events: 2. AIMS - by 18
weeks (change, high score=poor)

13 Adverse events: 3. Simpson and
Angus Scale - by 18 weeks (change,
high score=poor)

14 Adverse events: 4. Anticholinergic
effects - by 18 weeks

14.1 constipation

1

4

1

3

2

1

1

1

2

1

330

330

176

176

457

13

444

330

137

139

139

180

Risk Ratio (M-H, Random, 95%
CI)

0.97 [0.80, 1.17]

Risk Ratio (M-H, Random, 95%
CI)

1.00 [0.68, 1.49]

Other data

No numeric data

Mean Difference (IV, Random,
95% CI)

0.03 [-8.07, 8.13]

Other data

No numeric data

Mean Difference (IV, Random,
95% CI)

-0.75 [-2.94, 1.44]

Other data

No numeric data

Risk Ratio (M-H, Random, 95%
CI)

0.98 [0.81, 1.19]

Risk Ratio (M-H, Random, 95%
CI)

4.67 [0.29, 75.02]

Risk Ratio (M-H, Random, 95%
CI)

0.97 [0.80, 1.18]

Risk Ratio (M-H, Random, 95%
CI)

1.32 [0.65, 2.70]

Mean Difference (IV, Random,
95% CI)

0.40 [-2.30, 3.10]

Mean Difference (IV, Random,
95% CI)

0.30 [-0.58, 1.18]

Mean Difference (IV, Random,
95% CI)

-0.10 [-1.56, 1.36]

Risk Ratio (M-H, Random, 95%
CI)

Subtotals only

Risk Ratio (M-H, Random, 95%
CI)

0.35 [0.15, 0.85]

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

189

 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

14.2 dry mouth

14.3 dizziness

14.4 headache

14.5 rhinitis

14.6 salivation

15 Adverse events: 5. Extrapyrami-
dal - by 18 weeks

15.1 akathisia

15.2 dyskinesia

15.3 new parkinsonism

15.4 tardive dyskinesia

16 Adverse events: Other - by 18
weeks

16.1 agitation - by 18 weeks

16.2 anxiety

16.3 asthenia

16.4 backpain

16.5 decrease in white blood cells

16.6 fever

16.7 flu syndrome

1

2

2

1

2

2

2

1

1

1

2

1

1

2

1

1

1

2

180

330

330

180

330

330

180

180

180

180

180

330

150

180

180

330

Risk Ratio (M-H, Random, 95%
CI)

1.67 [0.94, 2.95]

Risk Ratio (M-H, Random, 95%
CI)

0.39 [0.14, 1.11]

Risk Ratio (M-H, Random, 95%
CI)

1.67 [0.82, 3.38]

Risk Ratio (M-H, Random, 95%
CI)

1.67 [0.41, 6.77]

Risk Ratio (M-H, Random, 95%
CI)

0.40 [0.13, 1.21]

Risk Ratio (M-H, Random, 95%
CI)

Subtotals only

Risk Ratio (M-H, Random, 95%
CI)

1.38 [0.53, 3.64]

Risk Ratio (M-H, Random, 95%
CI)

1.25 [0.35, 4.50]

Risk Ratio (M-H, Random, 95%
CI)

0.78 [0.30, 2.00]

Risk Ratio (M-H, Random, 95%
CI)

1.5 [0.44, 5.14]

Risk Ratio (M-H, Random, 95%
CI)

Subtotals only

Risk Ratio (M-H, Random, 95%
CI)

2.5 [0.81, 7.68]

Risk Ratio (M-H, Random, 95%
CI)

1.0 [0.30, 3.34]

Risk Ratio (M-H, Random, 95%
CI)

0.66 [0.32, 1.37]

Risk Ratio (M-H, Random, 95%
CI)

2.43 [0.80, 7.42]

Risk Ratio (M-H, Random, 95%
CI)

0.2 [0.02, 1.68]

Risk Ratio (M-H, Random, 95%
CI)

0.2 [0.02, 1.68]

Risk Ratio (M-H, Random, 95%
CI)

0.84 [0.39, 1.82]

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

190

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

16.8 nausea

16.9 postural hypotension

16.10 somnolence

16.11 sweating

16.12 tooth disorder

16.13 vomiting

16.14 weight gain

1

1

2

1

1

1

2

180

150

330

180

180

180

330

Risk Ratio (M-H, Random, 95%
CI)

0.10 [0.01, 0.77]

Risk Ratio (M-H, Random, 95%
CI)

0.85 [0.33, 2.23]

Risk Ratio (M-H, Random, 95%
CI)

0.54 [0.32, 0.88]

Risk Ratio (M-H, Random, 95%
CI)

0.40 [0.08, 2.01]

Risk Ratio (M-H, Random, 95%
CI)

0.11 [0.01, 2.03]

Risk Ratio (M-H, Random, 95%
CI)

0.8 [0.22, 2.88]

Risk Ratio (M-H, Random, 95%
CI)

1.10 [0.60, 2.03]

Analysis 6.1.   Comparison 6 OLANZAPINE vs ATYPICAL ANTIPSYCHOTICS FOR
PEOPLE WITH TREATMENT RESISTANT ILLNESS, Outcome 1 Death - by 18 weeks.

Study or subgroup

Beuzen 1998 (HGCF)

Total (95% CI)

Total events: 0 (Treatment), 0 (Control)

Heterogeneity: Not applicable

Test for overall effect: Not applicable

Treatment

n/N

Control

n/N

0/90

90

0/90

90

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Not estimable

Not estimable

Favours Treatment

0.1

0.2

0.5

1

2

5

10

Favours Control

Analysis 6.2.   Comparison 6 OLANZAPINE vs ATYPICAL ANTIPSYCHOTICS FOR PEOPLE WITH TREATMENT
RESISTANT ILLNESS, Outcome 2 Global effect: No clinically important response - by 18 weeks.

Study or subgroup

6.2.1 as measured by CGI

Beuzen 1998 (HGCF)

Bitter 2004 (HGCK)

Subtotal (95% CI)

Treatment

n/N

Control

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

45/90

41/76

166

55/90

41/74

164

54.87%

45.13%

100%

0.82[0.63,1.07]

0.97[0.73,1.3]

0.89[0.73,1.08]

Total events: 86 (Treatment), 96 (Control)

Heterogeneity: Tau2=0; Chi2=0.75, df=1(P=0.39); I2=0%

Test for overall effect: Z=1.22(P=0.22)

Favours Treatment

0.5

0.7

1

1.5

2

Favours Control

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

191

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Treatment

n/N

Control

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

6.2.2 as measured by Kane criteria

Beuzen 1998 (HGCF)

Bitter 2004 (HGCK)

Subtotal (95% CI)

56/90

32/76

166

60/90

29/74

164

Total events: 88 (Treatment), 89 (Control)

Heterogeneity: Tau2=0; Chi2=0.41, df=1(P=0.52); I2=0%

Test for overall effect: Z=0.36(P=0.72)

76.05%

23.95%

100%

0.93[0.75,1.16]

1.07[0.73,1.58]

0.97[0.8,1.17]

Favours Treatment

0.5

0.7

1

1.5

2

Favours Control

Analysis 6.3.   Comparison 6 OLANZAPINE vs ATYPICAL ANTIPSYCHOTICS FOR PEOPLE WITH TREATMENT RESISTANT
ILLNESS, Outcome 3 Mental state: 1. No important clinical response - by 18 weeks (20% decrease in PANSS).

Study or subgroup

Beuzen 1998 (HGCF)

Bitter 2004 (HGCK)

Total (95% CI)

Treatment

n/N

Control

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

37/90

24/76

166

43/90

18/74

164

62.35%

37.65%

0.86[0.62,1.19]

1.3[0.77,2.18]

100%

1[0.68,1.49]

Total events: 61 (Treatment), 61 (Control)

Heterogeneity: Tau2=0.04; Chi2=1.74, df=1(P=0.19); I2=42.67%

Test for overall effect: Z=0.02(P=0.98)

Favours Treatment

0.5

0.7

1

1.5

2

Favours Control

Analysis 6.4.   Comparison 6 OLANZAPINE vs ATYPICAL ANTIPSYCHOTICS FOR PEOPLE WITH TREATMENT RESISTANT
ILLNESS, Outcome 4 Mental state: 2. BPRS total - by 18 weeks (endpoint, high score=poor, skewed data).

Study

Intervention

Mean

SD

N

Mental state: 2. BPRS total - by 18 weeks (endpoint, high score=poor, skewed data)

Beuzen 1998 (HGCF)

Beuzen 1998 (HGCF)

Olanzapine

Clozapine

27.16

27.05

17.10

14.93

89

87

Analysis 6.5.   Comparison 6 OLANZAPINE vs ATYPICAL ANTIPSYCHOTICS FOR PEOPLE WITH TREATMENT
RESISTANT ILLNESS, Outcome 5 Mental state: 3. PANSS total - by 18 weeks (endpoint, high score=poor).

Study or subgroup

Treatment

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Beuzen 1998 (HGCF)

89

82.6 (29.1)

87

82.6 (25.7)

Weight

Mean Difference

Random, 95% CI

100%

0.03[-8.07,8.13]

Total ***

89

87

100%

0.03[-8.07,8.13]

Heterogeneity: Not applicable

Test for overall effect: Z=0.01(P=0.99)

Favours Treatment

-10

-5

0

5

10

Favours Control

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

192

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 6.6.   Comparison 6 OLANZAPINE vs ATYPICAL ANTIPSYCHOTICS FOR
PEOPLE WITH TREATMENT RESISTANT ILLNESS, Outcome 6 Mental state: 4.
Negative symptoms - by 18 weeks (BPRS, endpoint, high score=poor, skewed data).

Mental state: 4. Negative symptoms - by 18 weeks (BPRS, endpoint, high score=poor, skewed data)

Study

Intervention

Mean

SD

N

Beuzen 1998 (HGCF)

Beuzen 1998 (HGCF)

Olanzapine

Clozapine group

5.15

5.28

3.22

2.57

89

87

Analysis 6.7.   Comparison 6 OLANZAPINE vs ATYPICAL ANTIPSYCHOTICS FOR PEOPLE WITH TREATMENT RESISTANT
ILLNESS, Outcome 7 Mental state: 5. Negative symptoms - by 18 weeks (PANSS, endpoint, high score=poor).

Study or subgroup

Treatment

Control

Beuzen 1998 (HGCF)

Total ***

Mean(SD)

22 (7.6)

N

89

89

Mean(SD)

22.8 (7.2)

N

87

87

Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%

Test for overall effect: Z=0.67(P=0.5)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

100%

-0.75[-2.94,1.44]

100%

-0.75[-2.94,1.44]

Favours Treatment

-10

-5

0

5

10

Favours Control

Analysis 6.8.   Comparison 6 OLANZAPINE vs ATYPICAL ANTIPSYCHOTICS FOR
PEOPLE WITH TREATMENT RESISTANT ILLNESS, Outcome 8 Mental state: 6.
Positive symptoms - by 18 weeks (BPRS, endpoint, high score=poor, skewed data).

Mental state: 6. Positive symptoms - by 18 weeks (BPRS, endpoint, high score=poor, skewed data)

Study

Intervention

Mean

SD

N

Beuzen 1998 (HGCF)

Beuzen 1998 (HGCF)

Olanzapine

Clozapine

8.16

8.40

5.29

5.07

89

87

Analysis 6.9.   Comparison 6 OLANZAPINE vs ATYPICAL ANTIPSYCHOTICS FOR PEOPLE
WITH TREATMENT RESISTANT ILLNESS, Outcome 9 Leaving the study early. Any reason.

Study or subgroup

6.9.1 by 8 weeks

Kelly 2003

Subtotal (95% CI)

Total events: 3 (Treatment), 0 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=1.09(P=0.28)

6.9.2 by 3-12 months

Beuzen 1998 (HGCF)

Bitter 2004 (HGCK)

Naber 2001 (HGBF)

Subtotal (95% CI)

Treatment

n/N

Control

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

3/8

8

0/5

5

0.47%

0.47%

4.67[0.29,75.02]

4.67[0.29,75.02]

36/90

30/76

36/57

223

37/90

33/74

35/57

221

29.15%

25.7%

44.68%

99.53%

0.97[0.68,1.39]

0.89[0.61,1.29]

1.03[0.77,1.37]

0.97[0.8,1.18]

Total events: 102 (Treatment), 105 (Control)

Heterogeneity: Tau2=0; Chi2=0.4, df=2(P=0.82); I2=0%

Favours treatment

0.1

0.2

0.5

1

2

5

10

Favours control

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

193

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Treatment

n/N

Control

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Test for overall effect: Z=0.28(P=0.78)

Total (95% CI)

231

226

100%

0.98[0.81,1.19]

Total events: 105 (Treatment), 105 (Control)

Heterogeneity: Tau2=0; Chi2=1.61, df=3(P=0.66); I2=0%

Test for overall effect: Z=0.2(P=0.84)

Test for subgroup differences: Chi2=1.22, df=1 (P=0.27), I2=17.87%

Favours treatment

0.1

0.2

0.5

1

2

5

10

Favours control

Analysis 6.10.   Comparison 6 OLANZAPINE vs ATYPICAL ANTIPSYCHOTICS FOR PEOPLE WITH TREATMENT
RESISTANT ILLNESS, Outcome 10 Leaving the study early. due to lack of efficacy - by 18 weeks.

Study or subgroup

Beuzen 1998 (HGCF)

Bitter 2004 (HGCK)

Total (95% CI)

Treatment

n/N

Control

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

12/90

4/76

166

9/90

3/74

164

76.37%

23.63%

1.33[0.59,3.01]

1.3[0.3,5.6]

100%

1.32[0.65,2.7]

Total events: 16 (Treatment), 12 (Control)

Heterogeneity: Tau2=0; Chi2=0, df=1(P=0.98); I2=0%

Test for overall effect: Z=0.78(P=0.44)

Favours treatment

0.1

0.2

0.5

1

2

5

10

Favours control

Analysis 6.11.   Comparison 6 OLANZAPINE vs ATYPICAL ANTIPSYCHOTICS FOR PEOPLE WITH TREATMENT
RESISTANT ILLNESS, Outcome 11 Adverse events: 1. HAS - by 18 weeks (change, high score=poor).

Study or subgroup

Treatment

Control

Bitter 2004 (HGCK)

Total ***

Heterogeneity: Not applicable

Test for overall effect: Z=0.29(P=0.77)

Mean(SD)

-2.3 (8.9)

N

68

68

N

69

69

Mean(SD)

-2.7 (7.1)

Mean Difference

Random, 95% CI

Weight

Mean Difference

100%

100%

Random, 95% CI

0.4[-2.3,3.1]

0.4[-2.3,3.1]

Favours treatment

-10

-5

0

5

10

Favours control

Analysis 6.12.   Comparison 6 OLANZAPINE vs ATYPICAL ANTIPSYCHOTICS FOR PEOPLE WITH TREATMENT
RESISTANT ILLNESS, Outcome 12 Adverse events: 2. AIMS - by 18 weeks (change, high score=poor).

Study or subgroup

Treatment

Control

Bitter 2004 (HGCK)

Total ***

Heterogeneity: Not applicable

Mean(SD)

-0.6 (2.5)

N

69

69

N

70

70

Mean(SD)

-0.9 (2.8)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

100%

0.3[-0.58,1.18]

100%

0.3[-0.58,1.18]

Favours treatment

-10

-5

0

5

10

Favours control

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

194

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Treatment

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

Test for overall effect: Z=0.67(P=0.51)

Favours treatment

-10

-5

0

5

10

Favours control

Analysis 6.13.   Comparison 6 OLANZAPINE vs ATYPICAL ANTIPSYCHOTICS FOR PEOPLE WITH TREATMENT RESISTANT
ILLNESS, Outcome 13 Adverse events: 3. Simpson and Angus Scale - by 18 weeks (change, high score=poor).

Study or subgroup

Treatment

Control

Bitter 2004 (HGCK)

Total ***

Heterogeneity: Not applicable

Test for overall effect: Z=0.13(P=0.89)

Mean(SD)

-3 (4.8)

N

69

69

Mean(SD)

-2.9 (3.9)

N

70

70

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

100%

-0.1[-1.56,1.36]

100%

-0.1[-1.56,1.36]

Favours treatment

-10

-5

0

5

10

Favours control

Analysis 6.14.   Comparison 6 OLANZAPINE vs ATYPICAL ANTIPSYCHOTICS FOR PEOPLE WITH
TREATMENT RESISTANT ILLNESS, Outcome 14 Adverse events: 4. Anticholinergic effects - by 18 weeks.

Study or subgroup

6.14.1 constipation

Beuzen 1998 (HGCF)

Subtotal (95% CI)

Treatment

n/N

Control

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

6/90

90

17/90

90

100%

100%

0.35[0.15,0.85]

0.35[0.15,0.85]

Total events: 6 (Treatment), 17 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=2.31(P=0.02)

6.14.2 dry mouth

Beuzen 1998 (HGCF)

Subtotal (95% CI)

Total events: 25 (Treatment), 15 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=1.76(P=0.08)

25/90

90

15/90

90

100%

100%

1.67[0.94,2.95]

1.67[0.94,2.95]

6.14.3 dizziness

Beuzen 1998 (HGCF)

Bitter 2004 (HGCK)

Subtotal (95% CI)

7/90

7/76

166

Total events: 14 (Treatment), 40 (Control)

Heterogeneity: Tau2=0.39; Chi2=3.13, df=1(P=0.08); I2=68.08%

Test for overall effect: Z=1.76(P=0.08)

6.14.4 headache

Beuzen 1998 (HGCF)

Bitter 2004 (HGCK)

Subtotal (95% CI)

Total events: 19 (Treatment), 11 (Control)

7/90

12/76

166

30/90

10/74

164

3/90

8/74

164

52.68%

47.32%

100%

0.23[0.11,0.5]

0.68[0.27,1.7]

0.39[0.14,1.11]

28.58%

71.42%

100%

2.33[0.62,8.74]

1.46[0.63,3.37]

1.67[0.82,3.38]

Favours treatment

0.1

0.2

0.5

1

2

5

10

Favours control

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

195

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Treatment

n/N

Control

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Heterogeneity: Tau2=0; Chi2=0.35, df=1(P=0.56); I2=0%

Test for overall effect: Z=1.42(P=0.15)

6.14.5 rhinitis

Beuzen 1998 (HGCF)

Subtotal (95% CI)

Total events: 5 (Treatment), 3 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=0.71(P=0.47)

6.14.6 salivation

Beuzen 1998 (HGCF)

Bitter 2004 (HGCK)

Subtotal (95% CI)

5/90

90

3/90

90

100%

100%

1.67[0.41,6.77]

1.67[0.41,6.77]

14/90

7/76

166

58/90

9/74

164

56.15%

43.85%

100%

0.24[0.15,0.4]

0.76[0.3,1.93]

0.4[0.13,1.21]

Total events: 21 (Treatment), 67 (Control)

Heterogeneity: Tau2=0.51; Chi2=4.45, df=1(P=0.03); I2=77.53%

Test for overall effect: Z=1.62(P=0.1)

Favours treatment

0.1

0.2

0.5

1

2

5

10

Favours control

Analysis 6.15.   Comparison 6 OLANZAPINE vs ATYPICAL ANTIPSYCHOTICS FOR PEOPLE WITH
TREATMENT RESISTANT ILLNESS, Outcome 15 Adverse events: 5. Extrapyramidal - by 18 weeks.

Study or subgroup

6.15.1 akathisia

Beuzen 1998 (HGCF)

Bitter 2004 (HGCK)

Subtotal (95% CI)

Treatment

n/N

Control

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

9/90

10/76

166

10/90

4/74

164

56.76%

43.24%

100%

0.9[0.38,2.11]

2.43[0.8,7.42]

1.38[0.53,3.64]

Total events: 19 (Treatment), 14 (Control)

Heterogeneity: Tau2=0.24; Chi2=1.94, df=1(P=0.16); I2=48.5%

Test for overall effect: Z=0.66(P=0.51)

6.15.2 dyskinesia

Beuzen 1998 (HGCF)

Subtotal (95% CI)

Total events: 5 (Treatment), 4 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=0.34(P=0.73)

6.15.3 new parkinsonism

Beuzen 1998 (HGCF)

Subtotal (95% CI)

Total events: 7 (Treatment), 9 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=0.52(P=0.6)

6.15.4 tardive dyskinesia

Beuzen 1998 (HGCF)

Subtotal (95% CI)

5/90

90

7/90

90

6/90

90

4/90

90

9/90

90

4/90

90

100%

100%

1.25[0.35,4.5]

1.25[0.35,4.5]

100%

100%

0.78[0.3,2]

0.78[0.3,2]

100%

100%

1.5[0.44,5.14]

1.5[0.44,5.14]

Favours treatment

0.1

0.2

0.5

1

2

5

10

Favours control

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

196

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Treatment

n/N

Control

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Total events: 6 (Treatment), 4 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=0.65(P=0.52)

Favours treatment

0.1

0.2

0.5

1

2

5

10

Favours control

Analysis 6.16.   Comparison 6 OLANZAPINE vs ATYPICAL ANTIPSYCHOTICS FOR PEOPLE
WITH TREATMENT RESISTANT ILLNESS, Outcome 16 Adverse events: Other - by 18 weeks.

Study or subgroup

Treatment

n/N

Control

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

6.16.1 agitation - by 18 weeks

Beuzen 1998 (HGCF)

Subtotal (95% CI)

Total events: 10 (Treatment), 4 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=1.6(P=0.11)

6.16.2 anxiety

Beuzen 1998 (HGCF)

Subtotal (95% CI)

Total events: 5 (Treatment), 5 (Control)

Heterogeneity: Not applicable

Test for overall effect: Not applicable

6.16.3 asthenia

Beuzen 1998 (HGCF)

Bitter 2004 (HGCK)

Subtotal (95% CI)

10/90

90

5/90

90

2/90

9/76

166

Total events: 11 (Treatment), 17 (Control)

Heterogeneity: Tau2=0; Chi2=0.94, df=1(P=0.33); I2=0%

Test for overall effect: Z=1.11(P=0.27)

6.16.4 backpain

Bitter 2004 (HGCK)

Subtotal (95% CI)

Total events: 10 (Treatment), 4 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=1.56(P=0.12)

6.16.5 decrease in white blood cells

Beuzen 1998 (HGCF)

Subtotal (95% CI)

Total events: 1 (Treatment), 5 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=1.48(P=0.14)

6.16.6 fever

Beuzen 1998 (HGCF)

Subtotal (95% CI)

10/76

76

1/90

90

1/90

90

4/90

90

5/90

90

6/90

11/74

164

4/74

74

5/90

90

5/90

90

100%

100%

2.5[0.81,7.68]

2.5[0.81,7.68]

100%

100%

1[0.3,3.34]

1[0.3,3.34]

21.39%

78.61%

100%

0.33[0.07,1.61]

0.8[0.35,1.81]

0.66[0.32,1.37]

100%

100%

2.43[0.8,7.42]

2.43[0.8,7.42]

100%

100%

0.2[0.02,1.68]

0.2[0.02,1.68]

100%

100%

0.2[0.02,1.68]

0.2[0.02,1.68]

Favours treatment

0.1

0.2

0.5

1

2

5

10

Favours control

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

197

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Treatment

n/N

Control

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Total events: 1 (Treatment), 5 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=1.48(P=0.14)

6.16.7 flu syndrome

Beuzen 1998 (HGCF)

Bitter 2004 (HGCK)

Subtotal (95% CI)

3/90

8/76

166

Total events: 11 (Treatment), 13 (Control)

Heterogeneity: Tau2=0; Chi2=0.32, df=1(P=0.57); I2=0%

Test for overall effect: Z=0.44(P=0.66)

6.16.8 nausea

Beuzen 1998 (HGCF)

Subtotal (95% CI)

Total events: 1 (Treatment), 10 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=2.22(P=0.03)

6.16.9 postural hypotension

Bitter 2004 (HGCK)

Subtotal (95% CI)

Total events: 7 (Treatment), 8 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=0.33(P=0.74)

6.16.10 somnolence

Beuzen 1998 (HGCF)

Bitter 2004 (HGCK)

Subtotal (95% CI)

1/90

90

7/76

76

12/90

8/76

166

Total events: 20 (Treatment), 37 (Control)

Heterogeneity: Tau2=0; Chi2=0.01, df=1(P=0.92); I2=0%

Test for overall effect: Z=2.46(P=0.01)

6.16.11 sweating

Beuzen 1998 (HGCF)

Subtotal (95% CI)

Total events: 2 (Treatment), 5 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=1.11(P=0.27)

6.16.12 tooth disorder

Beuzen 1998 (HGCF)

Subtotal (95% CI)

Total events: 0 (Treatment), 4 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=1.48(P=0.14)

6.16.13 vomiting

Beuzen 1998 (HGCF)

Subtotal (95% CI)

Total events: 4 (Treatment), 5 (Control)

2/90

90

0/90

90

4/90

90

5/90

8/74

164

10/90

90

8/74

74

22/90

15/74

164

5/90

90

4/90

90

5/90

90

30.41%

69.59%

100%

0.6[0.15,2.44]

0.97[0.39,2.46]

0.84[0.39,1.82]

100%

100%

0.1[0.01,0.77]

0.1[0.01,0.77]

100%

100%

0.85[0.33,2.23]

0.85[0.33,2.23]

60.76%

39.24%

100%

0.55[0.29,1.03]

0.52[0.23,1.15]

0.54[0.32,0.88]

100%

100%

0.4[0.08,2.01]

0.4[0.08,2.01]

100%

100%

0.11[0.01,2.03]

0.11[0.01,2.03]

100%

100%

0.8[0.22,2.88]

0.8[0.22,2.88]

Favours treatment

0.1

0.2

0.5

1

2

5

10

Favours control

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

198

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Treatment

n/N

Control

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Heterogeneity: Not applicable

Test for overall effect: Z=0.34(P=0.73)

6.16.14 weight gain

Beuzen 1998 (HGCF)

Bitter 2004 (HGCK)

Subtotal (95% CI)

6/90

13/76

166

6/90

11/74

164

31.21%

68.79%

100%

1[0.34,2.98]

1.15[0.55,2.4]

1.1[0.6,2.03]

Total events: 19 (Treatment), 17 (Control)

Heterogeneity: Tau2=0; Chi2=0.04, df=1(P=0.83); I2=0%

Test for overall effect: Z=0.31(P=0.76)

Favours treatment

0.1

0.2

0.5

1

2

5

10

Favours control

Comparison 7.   OLANZAPINE vs ATYPICAL ANTIPSYCHOTICS FOR FIRST EPISODE

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

1 Mental state: 1. No important clinical re-
sponse - by 6 weeks (50% decrease in PANSS
total score)

2 Adverse events: 1. Extrapyramidal - need-
ing anticholinergic medication - by 6 weeks

3 Adverse events: 2. Exprapyramidal - any -
by 6 weeks

4 Adverse events: 3. Anticholinergic effects -
rhinitis - by 6 weeks

5 Adverse events: 4. hyperprolactinaemia -
by 6 weeks

1

1

1

1

1

42

42

42

42

42

Risk Ratio (M-H, Ran-
dom, 95% CI)

0.83 [0.30, 2.31]

Risk Ratio (M-H, Ran-
dom, 95% CI)

Risk Ratio (M-H, Ran-
dom, 95% CI)

Risk Ratio (M-H, Ran-
dom, 95% CI)

Risk Ratio (M-H, Ran-
dom, 95% CI)

0.38 [0.17, 0.89]

0.40 [0.19, 0.83]

0.13 [0.02, 0.91]

0.24 [0.10, 0.58]

Analysis 7.1.   Comparison 7 OLANZAPINE vs ATYPICAL ANTIPSYCHOTICS FOR FIRST EPISODE, Outcome
1 Mental state: 1. No important clinical response - by 6 weeks (50% decrease in PANSS total score).

Study or subgroup

Svestka 2003

Total (95% CI)

Treatment

n/N

Control

n/N

5/21

21

6/21

21

Total events: 5 (Treatment), 6 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=0.35(P=0.73)

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

100%

0.83[0.3,2.31]

100%

0.83[0.3,2.31]

Favours Treatment

0.5

0.7

1

1.5

2

Favours Control

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

199

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 7.2.   Comparison 7 OLANZAPINE vs ATYPICAL ANTIPSYCHOTICS FOR FIRST EPISODE,
Outcome 2 Adverse events: 1. Extrapyramidal - needing anticholinergic medication - by 6 weeks.

Study or subgroup

Svestka 2003

Total (95% CI)

Treatment

n/N

Control

n/N

5/21

21

13/21

21

Total events: 5 (Treatment), 13 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=2.24(P=0.02)

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

100%

0.38[0.17,0.89]

100%

0.38[0.17,0.89]

Favours Treatment

0.2

0.5

1

2

5

Favours Control

Analysis 7.3.   Comparison 7 OLANZAPINE vs ATYPICAL ANTIPSYCHOTICS FOR
FIRST EPISODE, Outcome 3 Adverse events: 2. Exprapyramidal - any - by 6 weeks.

Study or subgroup

Svestka 2003

Total (95% CI)

Treatment

n/N

Control

n/N

6/21

21

15/21

21

Total events: 6 (Treatment), 15 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=2.47(P=0.01)

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

100%

0.4[0.19,0.83]

100%

0.4[0.19,0.83]

Favours treatment

0.1

0.2

0.5

1

2

5

10

Favours control

Analysis 7.4.   Comparison 7 OLANZAPINE vs ATYPICAL ANTIPSYCHOTICS FOR FIRST
EPISODE, Outcome 4 Adverse events: 3. Anticholinergic effects - rhinitis - by 6 weeks.

Study or subgroup

Svestka 2003

Total (95% CI)

Treatment

n/N

Control

n/N

1/21

21

8/21

21

Total events: 1 (Treatment), 8 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=2.05(P=0.04)

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

100%

0.13[0.02,0.91]

100%

0.13[0.02,0.91]

Favours treatment

0.1

0.2

0.5

1

2

5

10

Favours control

Analysis 7.5.   Comparison 7 OLANZAPINE vs ATYPICAL ANTIPSYCHOTICS FOR
FIRST EPISODE, Outcome 5 Adverse events: 4. hyperprolactinaemia - by 6 weeks.

Study or subgroup

Svestka 2003

Total (95% CI)

Treatment

n/N

Control

n/N

4/21

21

17/21

21

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

100%

0.24[0.1,0.58]

100%

0.24[0.1,0.58]

Favours treatment

0.1

0.2

0.5

1

2

5

10

Favours control

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

200

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Treatment

n/N

Control

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Total events: 4 (Treatment), 17 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=3.13(P=0)

A D D I T I O N A L   T A B L E S

Favours treatment

0.1

0.2

0.5

1

2

5

10

Favours control

Table 1.   Olanzapine versus typical antipsychotics: Study size and number of reports 

Study tag

Participants

Published reports

Unpublished re-
ports

Tollefson (HGAJ)1997

Beasley 1997

Beasley 1996a

HGFH (Korea) 1998

Conley 1998a

Bernardo 2001

HGCU (Taiwan) 1998

HGBJ (Finland)

Jones 1998

Loza 1999

HGDV (Morocco) 1999

HGCJ (Hong Kong) 1998

HGBL 1997

HGCQ (Turkey) 2000

Altamura 1999

Avasti 2001

Barak 2002

Chang 2003

Chaudry 2003

Conley 1998

1996

431

267

104

84

27

54

46

65

41

40

31

30

30

24

27

20

62

276

84

143

16

35

1

5

1

3

2

10

2

0

5

0

3

1

1

1

1

1

7

1

2

1

2

1

1

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

201

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Table 1.   Olanzapine versus typical antipsychotics: Study size and number of reports  (Continued)

de Hann 2003

Esel 2001

He 2003

Ishigooka 2001

Jakovljevic1999 HGCH

Lieberman 2003 (HGDH)

Lima 2003 (HGHS)

Malyarov 1999

Namjoshi 2002

Rosenheck 2003(HGFI)

W H A T ' S   N E W

24

29

80

182

60

263

197

43

364

309

2

1

1

4

11

28

3

1

4

3

1

Date

Event

Description

12 December 2012

Amended

Comment added, see Published notes.

H I S T O R Y

Protocol first published: Issue 1, 1998
Review first published: Issue 3, 1998

Date

Event

Description

13 April 2011

Amended

Contact details updated.

5 August 2009

Amended

Contact details updated.

31 October 2008

Amended

Converted to new review format.

C O N T R I B U T I O N S   O F   A U T H O R S

Lorna Duggan - searching, study selection, data extraction and assimilation, report writing and updating.

Mark Fenton - searching, study selection, data extraction and assimilation, report writing and updating.

Roland Dardennes - protocol development, searching, study selection.

Ahmed El-Dosoky - protocol development, searching.

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

202

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Saroja Indran - protocol development, searching.

John Rathbone - study selection, data extraction and assimilation, report writing (update 2004).

D E C L A R A T I O N S   O F   I N T E R E S T

Lorna  Duggan  -  has  attended  functions  sponsored  by  Lundbeck,  Janssen,  Pfizer,  Bristol  Myers  Squibb  and  Zeneca  and  has  accepted
sponsorship from Eli Lilly for internal flights in the United States.

Mark Fenton - has led Janssen, Lilly and Zeneca sponsored workshops for clinicians.

Ahmed El-Dosoky - has participated in Eli Lilly sponsored research (Loza 1999 (HGDT)).

John Rathbone - no known conflicts of interest.

The Cochrane Schizophrenia Group editorial base in Leeds has received general support funding from Eli Lilly during the years 1996-1999
(see  Group  Module).  This,  along  with  some  funds  from  other  pharmaceutical  companies,  is  used  to  support  any  ongoing  work  of  the
editorial base and is not linked to any particular review (annual report available on request).

S O U R C E S   O F   S U P P O R T

Internal sources

• Centre Hospitalier Sainte-Anne, France.
• Behman Hospital, Egypt.
• University Kebangsaan, Malaysia.
• St Andrew's Hospital, UK.

External sources

• NHS Centre for Reviews and Dissemination, York, UK.

N O T E S

Cochrane Schizophrenia Group internal peer review complete (see Module).
External peer review scheduled.

It has been drawn to our attention that there are parts of the data of this review that may need correction (1). All comments relate to the
placebo comparison and, so far in our investigations, we have found no substantive issue that changes conclusions. Reviewers interested in
a new review covering this specific comparison are welcome to contact the editorial base. Amendments to this review will be made shortly.

1. Hutton P, Morrison AP, Yung AR, Taylor PJ, French P, Dunn G. Effects of drop-out on efficacy estimates in five Cochrane reviews of popular
antipsychotics for schizophrenia. Acta Psychiatr Scand. 2012 Jul;126(1):1–11.

I N D E X   T E R M S

Medical Subject Headings (MeSH)

Antipsychotic Agents  [*therapeutic use];  Benzodiazepines  [*therapeutic use];  Olanzapine;  Psychotic Disorders  [drug therapy]; 
Randomized Controlled Trials as Topic;  Schizophrenia  [*drug therapy]

MeSH check words

Humans

Olanzapine for schizophrenia (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

203
